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1.1   Biotechnology  
The field of biotechnology originates from the overlapping areas of biology, chemistry 
and process engineering and is defined as “the technical application of biological systems or 
parts thereof to provide products and services to meet human needs” [1]. It should contribute 
towards sustainable production of various materials, using renewable raw materials and 
biological systems, in a process performed without the formation of waste and where 
byproducts should be recycled. Therefore, the design of such processes remains a challenge 
to biotechnology. These processes involve the use of living cells or enzymes for the 
biotechnological production of added-value products, which is also known as applied 
biocatalysis. The application of enzymes started with the production of bread, cheese, juice 
and beer but their application in a more scientific environment has grown in less than a 
century with the production of more complex molecules like fine chemicals and 
pharmaceuticals [1]. Overcoming the demand for new products and the development of new 
sustainable production processes for existing products has become the most important 
incentive for the development of biocatalysts and enzyme technology.  
Applied biocatalysis started with the ancient manufacture and preservation of food 
and alcoholic drinks. The first report of a biotechnological process was made by the 
Sumarians 6000 years ago in a document which describes the technique of brewing [2]. Beer 
and wine manufacture was economically so important in Mesopotamia and Egypt that it 
became a major source of tax revenue [2]. With the development of modern natural science 
during the eighteenth and nineteenth centuries, biotechnology began to develop a more 
scientific basis. It started in 1833 with Payen and Persoz reporting the production of dextrin 
and sugars [3], followed two decades later by the proposal of so called  “organized and 
unorganized soluble ferments” (enzymes), involved in processes (catalysis) of degradation. 
Lavoisier and Gay-Lussac elaborated also quantitative correlations for alcoholic 
fermentation, without giving explanations for the described process [4]. In 1857 Wagner 
defined the nitrogen-containing organic substance (unorganized) and the living body 
(organized) as responsible for the fermentation processes [5]. Consequently, in 1878 Kühne 
named these classes of substances enzymes [1].  
 
1.2   Enzymes as catalysts 
At the end of the nineteenth century, Emil Fisher described the term specificity using 
the famous “lock and key” concept for the hydrolysis of α- or β-methyl-D-glucoside by invertin 
and emulsin, respectively. He postulated that the “geometrical form of the (enzyme) molecule 
concerning its asymmetry corresponds to that of the natural hexoses” [1, 6]. Afterwards, the 
protein nature of enzymes was postulated by Fisher in 1894 but not until Eduard Buchner 
successfully demonstrated three years later the preparation of a cell-free pressed juice from 
yeast cells that transformed sugar into alcohol and carbon dioxide, the consideration of 
enzymes as proteins was a huge controversy [7]. Buchner postulated in 1897 that enzyme 
catalysis, including complex phenomena such as alcoholic fermentation, was a chemical 
process not necessarily related to the presence and action of living cells, which  means not 
requiring a vis vitalis [7]. With Pasteur´s work the scientific debate on the nature of 
fermentation was settled in favor of the role of living microorganisms. In his paper about 
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lactic acid fermentation, he concluded the biological concept of fermentation and the practice 
of inoculation. Spectacularly, he could unravel the mystery of generatio spontanea 
(spontaneous generation of living organisms). In 1860, Pasteur took an expedition to high 
altitude mountains, the Alps and the glacier Mer de Glace, to demonstrate the existence of 
germ free air, in contrast to air under normal conditions carrying germs causing the 
fermentations [4]. Following Pasteur and Koch´s success in the identification of agents 
causing diseases and establishing pure cultures, pharmaceutical companies developed 
vaccines and tested substances with antimicrobial properties [4]. 
After 1950 a large number of enzymes were found, purified and characterized helping 
to develop enzyme technology towards washing processes, starch processing and cheaper 
raw materials for sweeteners. Also new techniques for enzyme immobilization were 
established, promoting the application of enzymes in industrial scale, for example in the 
production of high-fructose corn syrups (HFCS) using starch as raw material and glucose 
isomerase as catalyst [1, 8]. Still today, the glucose isomerase is used in immobilized form 
for the production of HFCS with yields of ~15000 kg HFCS kg-1 enzyme [1] [9]. Further 
examples of main industrial enzyme processes with free or immobilized enzymes as 
biocatalysts are listed in Table 1.1. 
Table 1.1 Products produced in large quantities (tons year
-1
) by different companies with 
enzymes or cells as biocatalysts. Table adapted from Buchholz et al. [1] 
 
Product Enzyme/designed cells 
Free or immobilized 
isolated enzyme or cell 
Companies 
>10 000 000 t a
-1
  
HFCS Amylase Free Several 
 Glucoamylase Free  
 Glucose isomerase Immobilized  
Ethanol (gasoline additive) Amylase Free Several 
 Glucoamylase Free  
 Hemicellulases Free  
    
>100 000 t a
-1
  
Acrylamide Nitrilase in resting cells Immobilized resting Nitto, DSM 
Cocoa butter Lipase Immobilized Fuji Oil, 
Unilever 
Polylactic acid Designed cells  Cargill-Dow, 
Polymers LLC, 
Dupont 
    
>10 000 t a
-1
  
6-Aminocephalosporanic 
acid 
Penicillin amidase Immobilized Several 
Lactose free milk or whey β-galactosidase lactase Free or immobilized Several 
    
>1000 t a
-1 
Aminocephalosporanic 
acid 
Engineered 
Cephalosporin C amidase 
Immobilized Novartis 
Aspartame Thermolysin Immobilized Toso, DSM 
(S)-Aminoacids Aminoacylase Free Degussa, 
Tanabe 
    
1000 to >10 t a
-1
 
Amoxicillin Penicillin amidase Immobilized DSM 
Insulin Carboxypeptidase B Free Novo Nordisk 
 Lysyl Free Sanofi 
 Trypsin Free Eli Lilly 
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1.3   Why use Biotransformations? Bio- vs. Chemocatalysis 
Since the 18th century, organic chemistry has a continuous and fruitful development 
providing methods required for almost any synthesis, even though they are ecologically and 
economically often still unfavorable. On the other hand, the enzymatic toolbox for organic 
synthesis is much younger and not routinely used by synthetic organic chemists. The reason 
is the low availability of strains and enzymes, since a broad strain library is a key factor for 
biotransformations in industry [10]. Additionally, product inhibition, stability, solubility of 
reactants and when needed the regeneration of cofactors are well known limitations. 
There are two main reasons why biotransformations are used. Firstly, the ability of 
microorganisms to produce large amounts of biomass and a huge variety of different 
enzymes in short time is an advantage in contrast to the production and purification of 
chemocatalysts which often require several time consuming steps. Microorganisms are also 
able to grow under varying conditions and on a great variety of substrates. The second main 
reason is the high chemo-, regio- and enantioselectivity of enzymes which is more difficult to 
achieve in chemical catalyses. On the other hand, enzyme stability, low catalytic rates and 
restricted conditions for the use of enzymes as catalysts are well-known limitations in 
biotransformations [9, 11]. Clearly, the choice between a biotransformation and a chemical 
process will depend on the commercial performance of the selected synthetic strategy for a 
specific target. There are well established chemical technologies for introducing chirality into 
a molecule where enzymes might not be competitive. As an example, the asymmetric 
hydrogenation of olefins, ketones and enamines is well established using chiral chemical 
catalysts [9, 11]. On the other hand, biotransformations will be useful in cases where there is 
no (simple) chemical solution. For example, enantioselective transaminases could be an 
attractive alternative for preparing α- and β-amino acids or chiral amines. In this way, the 
necessity of protective groups is avoided which is one of the main disadvantages of the 
current asymmetric hydrogenation of unsaturated β-amino acids [12]. Furthermore, bio-
oxidations can be very effective biotransformations compared with chemical methods, 
especially if molecular oxygen is used as the oxidant. An interesting example is the 
enzymatic direct oxidation of a methyl group to a carboxylic acid function, for which a 
chemically transformation would require several steps [13]. Besides biooxidations, also C-C 
coupling reactions belong to the area of chemistry with a high need for biocatalytic options. 
An example of this approach involves the use of thiamine diphosphate (ThDP)-dependent 
enzyme from Yersinia pseudotuberculosis , which catalyses the formation of tertiary alcohols 
via intermolecular crossed aldehyde-ketone carboligation [14].  
However, the question is not always if the chemical or the biocatalytic approach in the 
synthesis of a target molecule is better suited. Several examples for the combination of 
chemo- and biocatalytic steps in the synthesis of fine chemicals and pharmaceuticals exist 
already. This is especially true for dynamic kinetic resolution processes involving an 
enzymatic kinetic resolution of a chiral substrate. Here, the racemization of the unwanted 
enantiomer is usually performed chemically proving that the combination of enzymatic and 
chemical steps can be of great advantage. One example is the production of optically active 
amines by combination of a reduction reaction performed by palladium catalyst, followed by 
kinetic resolution by acetylation of the desired amine using Candida antartica B lipase as 
catalyst [15]. The mechanism of racemization consists of a combination of chemical 
dehydrogenation with palladium of the non-desired amine enantiomer and readdition of 
hydrogen to the formed imine while acylation of the desired chiral amine by CAL-B catalysis 
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takes place. Thus, complete conversion of the prochiral ketoxime to one acylated amine 
enantiomer can be achieved (Figure 1.1). 
 
 
 
Figure 1.1 Dynamic kinetic resolution for the synthesis of optically active amines by a 
combination of chemo- and biocatalysis. Data adapted from Choi et al. [15] 
 
 
1.4   Oxidative enzymes: general aspects 
Oxidoreductases enzymes are classified as EC.1 according to the Enzyme 
Commission (EC from IUPAC- International Union of Pure and applied chemistry-), category 
which contains nowadays more than 6000 enzymes (http://www.brenda-
enzymes.org/information/all_enzymes.php4). These enzymes are involved in oxidation-
reduction reactions in which electrons are transferred from one molecule to another., e.g. 
oxidation-reduction of alcohol functions. In order to perform these reactions, oxidoreductases 
often use (in)organic cofactors which are normally shielded by the polypeptide backbone of 
the enzyme and modulate their selectivity, redox potential, reactivity, stability and inhibition-
resistance [16]. Common cofactors are the so called coenzymes, which usually are tightly 
bound to the enzyme, for example pyridine cofactors such as nicotine adenine dinucleotide 
phosphate (NAD(P)H) or nicotine adenine dinucleotide (NADH), in addition to flavin 
derivatives such as riboflavin, flavin mononucleotide (FMN), flavin adenine dinucleotide 
(FAD), In addition, other cofactors used by oxidoreductases are metal-ions (Cu, Fe, Mo, Fe-
S), pyrroloquinoline (PPQ) or molecule complexes containing metal-ions (protoporphyrin – 
heme groups) which are covalently bound via cysteine or histidine residues to the enzyme, 
also called prosthetic groups (Figure 1.2) [16, 17].  
According to Xu et al., oxidoreductases can be classified in four groups with respect 
to their sequence or three-dimensional structure, signature reaction and/or cofactor 
dependency: (i) oxidases, (ii) peroxidases, (iii) dehydrogenases/ reductases and (iv) 
oxygenases/ hydroxylases [16][18]. Oxidases catalyze the irreversible oxidation of a 
substrate using molecular oxygen (O2, cheap and bio-renewable oxidant) as the electron 
acceptor, which is thereby reduced to water or hydrogen peroxide [19]. Peroxidases can 
catalyze hetero-atom oxidations and epoxidations and use hydrogen peroxide or organic 
hydroperoxides as oxidizing agent to re-oxidize their catalytically active prosthetic group [19]. 
Dehydrogenases catalyze the reversible oxidation of a substrate by transferring hydride ions 
from the substrate to an acceptor, usually NAD(P)+. Important examples are alcohol 
dehydrogenases (ADHs) and amino acid dehydrogenases, which are currently applied in 
industry [18]. The last group, oxygenases and hydroxylases, catalyze the insertion of oxygen  
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Figure 1.2 Examples of cofactors used by oxidoreductases. Including flavin derivatives such as 
riboflavin, flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD) and the heme b prosthetic 
group. 
 
atom(s) into an organic substrate using molecular oxygen (O2) as oxygen donor. This group 
of enzymes can be divided into two subgroups, where the catalyst introduces either one or 
both oxygen atoms from molecular oxygen into the substrate, called monooxygenases and 
dioxygenases, respectively [19]. 
External monooxygenases use NADH or NADPH to provide electrons for catalysis 
(Scheme 1.1). In contrast, internal monooxygenases use the substrate itself as reducing 
agent [20]. An example of external monooxygenases is the so called Baeyer-Villiger 
monooxygenase found only in bacteria and fungi [18]. They catalyze e.g. the conversion of 
ketones into the corresponding esters or lactones using molecular oxygen [21] as well as the 
oxidation of aldehydes and heteroatoms such as sulfur, nitrogen, boron, or phosphorous [18]. 
One example is the Bayer-Villiger oxidation of 2-(2´-acetoxyethyl)cyclohexanone (a) by MO2 
from P. putida NCIMB 10007 applied in the synthesis of (R)-(+)-lipoic acid (b), a bioactive 
compound used in the treatment of hepatitis, pancreatitis, and induced carcinomas (Figure 
1.3.A) [22, 23]. Another group of external monooxygenases are cytochrome P450 
monooxygenases. The most studied P450 nowadays is the self-sufficient P450 BM3 from 
Bacillus megaterium, a soluble complex composed of a FAD-FMN-containing reductase and 
a hemoprotein domain in one polypeptide chain [24]. A double mutant of P450BM-3 was 
shown to produce (+)-nootkatone (f), a high value sesquiterpene used in the flavor and 
fragrance industry (Figure 1.3.B). 
One group of dioxygenases are Rieske non-heme iron dioxygenases. These 
enzymes are usually involved in the degradation of aromatic compounds by the formation of 
stereospecific cis-dihydrodiols in a regiospecific manner. They are multicomponent systems 
consisting of a reductase that obtains electrons from NAD(P)H, usually a Rieske ferredoxin 
shuttling the electrons and an oxygenase component that performs the catalysis. Most 
biocatalytic reactions described in literature were performed using toluene dioxygenase  
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Figure 1.3 Examples of oxygenase catalyzed reactions. A: Bayer Villiger oxidation of 2-(2´-
acetoxyethyl) cyclohexanone (a) by MO2 from Peusomonas putida NCIMB 10007 applied in the 
synthesis of (R)-(+)-lipoic acid (c) B: Asymmetric oxidation of (+)-valencene (d) to produce (+)-
nootkatone (f) using engineered P450BM-3 monooxygenase from Bacillus megaterium. C: Cis-
dihydroxylation of mono-substituted benzenes catalyzed by toluene dioxygenase from Pseudomonas 
putida F1. Data adapted from Schallmey et al. [18] 
 
(TDO) from Pseudomonas putida F1 for the cis-hydroxylation of substituted benzenes and 
bicyclic arenes (Figure 1.3.C) [18]. 
 
1.5   Cytochrome P450 monooxygenases as powerful biocatalysts 
1.5.1 General aspects 
One of the most characterized and used monooxygenases in biotransformations are 
the cytochrome P450 (CYP or P450) systems (E.C 1.14.x.y). Today more than 20000 P450 
sequences are known (http://drnelson.uthsc.edu/CytochromeP450.html). Members are 
identified by the abbreviation CYP followed by a number denoting the enzymes family. P450s 
belonging to the same family share more than 40 % sequence identity. Furthermore, a letter 
behind the family number designates the subfamily (>55 % sequence identity) and an 
additional number represents the individual enzyme within the subfamily. P450s are 
widespread in nature, e.g. they can be found in mammalian tissue and organs as well as in 
plants, bacteria, yeast and insects [20]. Cytochrome P450s received their name (1950s) due 
to their spectral properties exhibiting a typical absorption maximum at 450 nm for the 
reduced carbon monooxide-bound complex (P450 stands for pigment at 450 nm) [25]. The 
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prosthetic group present in P450s is the heme b (iron protoporphyrin IX, Figure 1.2) and the 
P450 function strictly depends on the heme environment and the substrate [20]. In 1963, 
Estabrook et al. demonstrated for the first time the catalytic role for the pigment in the C-21 
hydroxylation of 17-hydroxyprogesterone by adrenal cortex microsomes [26].  
It is now known, that P450s have two main functional roles [27]. One is the 
metabolism of xenobiotics (compounds exogenous to the organism) as a protective role of 
degradation by increasing their solubility to facilitate excretion. One example would be the 
degradation of herbicides by plant P450s [27]. Secondly, P450 monooxygenases can be 
involved in the synthesis of critical signaling molecules used for control of development and 
homeostasis [27]. Nevertheless, they are involved in several functions, as in mammals e.g., 
P450s are involved in the synthesis of steroid hormones and the conversion of 
polyunsaturated fatty acids to biologically active molecules besides metabolism of 
xenobiotics.  
Several reviews exist which highlight the chemical diversity of P450-catalyzed 
reactions. In particular, Sono et al. listed twenty different ones including the hydroxylation of 
hydrocarbons, epoxidation of alkenes, N-, S- and O-dealkylations as well as heteroatom 
oxidations, among others. Additionally, more uncommon P450-catalyzed reactions were 
reported by Guengerich et al. (Figure 1.4) [20][28][29]. 
 
Figure 1.4 Summary of the diverse catalyzed reactions performed by P450s. X: -C, -N, -S. 
Summary taken from Bornscheuer et al. [11]. 
1.5.2 Chemistry of oxygen activation: the catalytic cycle 
Judging from the vast number of diverse reactions catalyzed by P450 enzymes, the 
following question arises: How is the protein able to perform these different reactions using 
the same catalytic cycle? The general cytochrome P450 catalytic mechanism was reported 
first in the early 1980s by White et al. where the mechanism of oxygen-oxygen bond 
cleavage in the heme peroxo intermediate was described [27, 28, 30–34]. However, it was 
not until the 1990s that the mechanism of oxygen activation got deciphered, employing the 
well-studied P450cam (CYP101) from the soil bacterium Pseudomonas putida, an enzyme 
that converts camphor to 5-exo-hydroxycamphor [35–41]. 
The catalytic cycle, shown in Figure 1.5, starts with a water molecule as the sixth 
ligand at the heme iron. This distal ligand is trans to the proximal cysteinate (1). When the 
substrate binds in the active site, this water molecule is displaced leaving a vacant 
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coordination site at the iron (2) that will ultimately be available for dioxygen binding; the 
substrate is now bound to the enzyme near the distal region of the heme cavity. Depending 
on the P450 and/or the substrate, the spin state of the protein can change from low spin (LS) 
to high spin (HS) in the substrate-bound complex. In this way, the redox potential changes 
(becomes more positive) allowing the first electron transfer from the cofactor, usually 
NAD(P)H, to occur (3). It was demonstrated for certain P450 systems that the spin shift is not 
mandatory for the electron transfer to occur, therefore it is difficult to generalize the 
mechanism of P450 monooxygenases [42]. In the following step, molecular oxygen binds to 
the reduced iron (FeII) generating an oxy-P450 complex (5a-b), which is the last relatively 
stable and well-characterized intermediate in this cycle [43][44]. After this step, very few 
direct measurements have been possible due to the high reactivity and lack of accumulation 
of the next intermediates in kinetic studies. Reduction of the oxy-P450 complex through a 
second electron transfer from the cofactor results in formation of the peroxo-ferric 
intermediate (6), usually the limiting step of the cycle. Afterwards, protonation at the distal 
oxygen atom (7) occurs with subsequent heterolytic cleavage of the O-O-bond and formation 
of compound I (8) and water. Finally the substrate gets oxygenated to form a product-P450 
complex. A lot of discussion exists in literature regarding the action of compound I in 
substrate hydroxylation. One theory is the hydrogen abstraction mechanism described by 
Groves et al., referred to as oxygen rebound, where a proton is abstracted from the substrate 
first to complete the reaction by radical recombination, as shown in Figure 1.6 [28, 45]. 
Consequently, the product is released regenerating the ferric heme (resting state 1) and 
allowing the next catalytic cycle to begin. 
Several oxygen atom donors (such as alkyl peroxides, hydrogen peroxide, peracids, 
sodium chlorite, sodium periodate and iodobenzene) can be used directly to form compound 
I without the need for NAD(P)H and O2, which are required in the normal catalytic cycle. 
These oxygen atom donors can directly react with 2 via a short circuit path to generate 
oxygenated products (Figure 1.5) [30, 31, 44]. On the other hand, uncoupling of electron 
transfer and substrate oxygenation can often occur under physiological conditions, leading to 
unproductive pathways without product formation. The first unproductive shunt (Figure 1.5) 
occurs via autooxidation of oxy-ferrous P450 (5a) with release of superoxide. However, this 
shunt rarely occurs since the second electron transfer (formation of 6) is usually much faster 
than the autooxidation [20]. The second unproductive pathway is the peroxide shunt, where 
protonation of the unprotonated oxygen in intermediate 7 releases hydrogen peroxide 
generating state 2 again. In this case, no oxygenated product is formed although NAD(P)H 
and O2 are consumed in a 1:1 ratio [20, 44, 46, 47]. 
The third possibility for uncoupling is the oxidase shunt, where a two-electron 
reduction and double protonation of the oxo-group in 8 yields a second water molecule. 
Again, no oxygenated product is formed but NAD(P)H and O2 are consumed in a ratio 2:1 
[20, 44, 46, 47] Possible causes of the uncoupling were studied in detail for cytochrome 
P450cam. Based on crystal structure analysis of P450cam-complexes with various camphor 
analogs as well as generated mutants with modified active sites, the uncoupling was 
attributed to the high substrate mobility in the active site and the presence of excess water 
near the heme iron [20]. 
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Figure 1.5 Catalytic cycle of cytochrome P450 monooxygenases. R-H and R-OH represent 
substrate and product, respectively. The prosthetic heme group is abbreviated as a parallelogram with 
nitrogen at the corners. State 4 represents the reduced, carbon monoxide-bound P450 complex, 
responsible for the characteristic absorbance maximum at 450 nm. States from 6 to 8 are hypothetical 
intermediates, whose structures have not been yet established [27]. Autooxidation, peroxide and 
oxidase unproductive shunt pathways are marked with doted arrows. Data collected from Denisov et 
al. and Sono et al. [20, 27]. 
 
 
 
 
Figure 1.6 Oxygen rebound mechanism. Compound I (8) abstracts a hydrogen atom and then 
completes the hydroxylation reaction by radical recombination. Data taken from Groves et al.[45]. 
 
 
 
Introduccion 
 
C
h
a
p
te
r 
1
: 
C
y
to
c
h
ro
m
e
 P
4
5
0
 m
o
n
o
o
x
y
g
e
n
a
s
e
s
 a
s
 p
o
w
e
rf
u
l 
b
io
c
a
ta
ly
s
ts
 
11 
 
1.5.3 Structure of P450s  
Sequence identities between members of different P450 families are usually only 
around 20 %. Nevertheless, their general topography and structural fold are highly 
conserved. The structural core of P450s is formed by a four-helix boundle composed of three 
parallel helices (D,L and I) and one anti-parallel helix (E) [48]. In P450s, the heme prosthetic 
group is bound to the enzyme through ligation of the heme iron by a cysteine thiolate 
(conserved) that defines the proximal side of the heme. On the distal side (opposite to the 
thiolate) the active site is located. Based on the crystal structure of P450cam (CYP101A1), a 
standard secondary structure nomenclature for P450s was described by Poulos et al. [35] 
and adopted until today for the structure analysis of other P450s. As observed in Figure 1.7., 
the active site of P450cam is bordered to the north by helix I (yellow), to the west by helix B´ 
(light blue) as well as the B-C loop, to the south by residues of the β3 sheet (orange) and to 
the east by the β5 sheet (red). Access of solvent molecules into the active site is hindered by 
a cap formed by the F and G helices and the F-G loop (green) [49].  
 
Figure 1.7 Protein structure of P450cam (PDB: 2CPP) with D-camphor bound in the active site. 
Secondary structure elements are labeled according to Poulos et al.[35] and colour coded: N-terminus 
(blue) to C-terminus (red) [49]. 
 
On the other hand, the most variable regions are represented by the flexible substrate 
recognition sequences (SRS) giving rise to the remarkable substrate scope as well as regio- 
and stereoselectivity of P450s [50]. It is important to consider the structure of P450s as 
flexible dynamic arrangements, which can change depending on the presence of substrate 
and the oxidation state of the heme iron [49]. 
Binding of substrate to the cytochrome P450 is a complex process, since it triggers 
the change of the heme-iron spin state from LS to HS inducing a change in the redox 
potential from ca. -300 to ca. 100 mV [27]. In the resting state (FeIII) the rather low negative 
redox potential of the FeIII/ FeII couple (usually in the range from -400 to -170 mV) is 
maintained by the presence of a negatively charged proximal thiolate ligand (cysteine 
residue) and by the coordination of a water molecule as the sixth ligand. In this way, the LS 
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state of the ferric iron is stabilized. The loss of this sixth ligand of the heme iron upon 
substrate binding thermodynamically destabilizes the ferric state, and the midpoint potential 
of the heme shifts to positive values. As a result, the stronger the ability of the substrate to 
perturb the water ligation to the ferric heme, the more pronounced is the resulting positive 
shift of the redox potential facilitating the heme reduction [27].  
 
1.5.4 Structural organization of cytochrome P450s  
Although some P450s do not require any other protein component to successfully 
achieve the reductive activation of molecular oxygen [51], the majority of P450s depend on 
the interaction with one or more redox partners delivering electrons to the heme iron. In most 
cases, the ultimate reducing agent supplying electrons for the catalytic cycle is the cofactor 
NAD(P)H with a midpoint potential of -320 mV [27]. Thus, substrate-P450 complexes do not 
exhibit the necessary redox potential to accept electrons directly from NAD(P)H and 
therefore require the assistance of electron transfer components (ETCs). 
After the discovery of the first bacterial P450 system, P450cam [52, 53] it was found 
that in this enzyme system the electrons needed for the reaction are transferred from the 
cofactor NADH via a FAD-containing reductase (putidaredoxin reductase, PdR) and an iron-
sulfur cluster-containing protein of the [2Fe-2S] type (putidaredoxin, Pdx) to the 
monooxygenase (Figure 1.8.A). Thus, the electron transfer system was found to be 
analogous to adrenodoxin reductase (AdR) and adrenodoxin (Adx), previously described for 
adrenal mitochondrial P450 systems (Figure 1.8.B) [54]. Consequently, most bacterial three-
component P450 systems and mitochondrial P450s, both consisting of a FAD-containing 
reductase, a ferrodoxin and the P450 itself, are classified as class I P450 systems [55]. In 
contrast to the soluble bacterial P450 systems, in eukaryotes only the ferrodoxin is a soluble 
protein of the mitochondrial matrix, whereas the reductase and the P450 are membrane 
associated and membrane bound to the inner mitochondrial membrane, respectively [55]. 
   
Figure 1.8 Structural organization of cytochrome P450 systems. Class I: (A) bacterial three-
component system and (B) mitochondrial three-component system. Class VIII: (C) bacterial self-
sufficient P450 systems consisting of a CPR-P450 fusion protein. Scheme adapted from Hannemann 
et al. [55]. 
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Class I of P450 systems is only one out of 10 different classes defined by 
Hannemann et al. [55]. Another example of a bacterial three-component P450 is P450cin 
(CYP176A1), a class III P450, utilizing a flavodoxin as the second mediator instead of a 
ferredoxin. Hence, in contrast to the class I system, the electrons are transferred from the 
FAD to the heme via FMN and not via an iron-sulfur cluster. Furthermore, class VIII P450s 
(also called self-sufficient P450s) constitute P450 fusion proteins with the heme domain 
fused to a eukaryotic-like diflavin reductase (cytochrome P450 reductase, CPR) in a single 
polypeptide chain (Figure 1.8.C) [55]. The most well-known example is P450 BM3 from 
Bacillus megaterium (CYP102A1), which consists of a heme-containing monooxygenase that 
is connected by a short protein linker to a diflavin reductase domain containing besides the 
heme each one equivalent of the cofactors FAD and FMN [56, 57]. 
Although all P450s belonging to the same class share significant structural homology, 
it is known that often the ferrodoxin components of two different P450 systems cannot 
efficiently substitute for each other in functional assays [58]. However, the ETCs of novel 
P450s are in many cases not known and, thus, the heterologous reconstitution with other, 
well-known ETC represents an alternative approach for the biotechnological application of 
P450s. There are several successful examples of such artificial systems reported in 
literature. One is the use of eukaryotic AdR and Adx in combination with bacterial CYP106A2 
from Bacillus megaterium in the bioconversion of steroid derivatives [59]. Another interesting 
example is the work of Agematu et al., where 213 different bacterial P450s were applied 
together with PdR and Pdx from Pseudomonas putida as ETC for the hydroxylation of 
testosterone [60]. Other redox partners used in combination with P450s are spinach 
ferredoxin and ferredoxin reductase [61] as well as flavodoxin and flavodoxin reductase from 
Citrobacter braakii [62]. Also, the flavodoxin and NADPH- dependent flavodoxin reductase 
from E. coli are commonly used [63, 64]. Recently, also bacterial class I P450s were 
expressed in E. coli as soluble and functionally active fusion proteins with the reductase 
domain of P450RhF from Rhodococcus sp. [65, 66]. 
 
1.6   Biotechnological application of cytochrome P450s  
Cytochrome P450 monooxygenases are used in the synthesis of important 
pharmaceutical intermediates due to their synthetic potential on a vast variety of substrates 
[67]. In particular, their ability to hydroxylate non-activated carbon atoms, their high selectivity 
and the possibility to heterologously express them and improve or change their activity, 
stability as well as selectivity by genetic engineering techniques makes them promising 
candidates in biotechnological applications. Furthermore, they also replace hazardous and 
expensive chemicals, save on energy and resources, create novel functionalities and 
reduced impact on the environment. Despite their impressive synthetic potential, P450s have 
drawbacks which often limit their biotechnological use due to their complexity, instability, low 
catalytic activity and, in most cases, the need of stoichiometric amounts of an external 
cofactor, commonly NAD(P)H.  
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1.6.1 P450 biocatalysis using isolated enzymes or whole cells  
To apply cytochrome P450s in biotechnology the cofactor has to be used in catalytic 
quantities and regenerated in situ to make the reaction economically feasible. An efficient 
way to regenerate the cofactor is the use of whole cell (WC) catalysis, where the host’s own 
metabolism will recycle the cofactor in expense of a cheap added energy source, for 
example glucose. An alternative method is the use of isolated enzyme where the 
regeneration is carried out by the addition of a co-enzyme and a cheap co-substrate. In 
general, there are no specific rules indicating which strategy is preferred since both methods 
have their advantages and disadvantages. Although, the use of isolated enzymes often 
allows a better control over the reaction the need of an additional enzyme and a co-substrate 
for cofactor regeneration will make the entire process more cost expensive. On the other 
hand whole cell catalysis is much simpler, cheaper and enzymes are significantly more 
stable in the protected cell environment. In contrast, substrate uptake and unwanted side 
reactions are important limitations of this WC approach. Further advantages and 
disadvantages of both strategies are summarized in Table 1.2.  
 
Table 1.2 Isolated enzyme vs. whole cell (WC) catalysis. Advantages and disadvantages in the use 
of isolated enzyme and whole cells in biocatalysis. Data taken from Schallmey et al.[18]. 
 
Cell free extract (CFE) catalysis Whole cell (WC) catalysis 
Advantages Disadvantages Advantages Disadvantages 
    
Better reaction control 
(e.g. pH). No side 
reactions 
Addition of co-factor 
regeneration system 
necessary 
Simple and reduced costs Unwanted side reactions 
    
No limitation in 
substrate and product 
transport 
Many enzymes not 
commercially available in 
pure form or purification 
necessary 
Cofactor regeneration 
employing the cells 
metabolism 
Substrate uptake limitation. 
Energy is required to transport 
substrate or product across the 
membrane 
    
Higher substrate and 
product concentration 
tolerance 
 No enzyme isolation and 
purification 
Substrate or product inhibition 
possible 
 
1.6.2 Cofactor regeneration  
In general, the reduced cofactors are more expensive than their respective oxidized 
forms. Employing a rough estimation of prices, NADPH has a cost of 400000 € and NADH of 
28000 € per mol, whereas the oxidized forms have a cost of 9000 and 15000 € per mol, 
respectively (http://www.applichem.com). Hence, many options for cofactor regeneration 
have been developed in order to overcome this limitation. 
 
In all cases, the use of a co-substrate is required leading to the formation of a co-product 
which has to be separated from the desired product during work up. A simple solution is to 
apply a cofactor regeneration system that leads to the formation of a volatile co-product such 
as acetone through oxidation of the co-substrate isopropanol by an alcohol dehydrogenase 
[68]. Usually, in situ removal of the volatile co-product will drive the desired reaction towards 
completion. A commonly applied alternative is the use of formate dehydrogenase (FDH) from 
Candida boidinii which irreversibly converts sodium formate to carbon dioxide. This cofactor 
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regeneration system is applied by Degussa in the industrial production of L-tert-leucine [68–
70]. In 2002, a very promising enzyme, a phosphite dehydrogenase (PtxD) which oxidizes 
phosphite to phosphate, was reported by Vrtis et al. Besides NAD+, the enzyme also accepts 
NADP+ for the reaction although less effective [71]. Thus, during cofactor regeneration 
applying PtxD the phosphite buffer used as reaction medium is simply converted into a 
phosphate buffer in a nearly irreversible process. Furthermore, the co-product phosphate 
does not inhibit PtxD even at high concentrations [71]. A recent application was successfully 
shown by Watanabe et al., where PTxD was incorporated into an artificial hetero-trimetric 
complex of P450cam, PdR and Pdx for the hydroxylation of D-camphor, creating a phosphite-
driven self-sufficient P450 complex [72].  
Such a cofactor regenerating enzyme can be also applied in whole-cell approaches. 
Thus, the co-enzyme is coexpressed in the cell together with an enzyme for the desired 
reaction, generating a metabolism-independent catalyst. An example is the coexpression of 
an alcohol dehydrogenase from Lactobacillus brevis together with CYP106A2 from Bacillus 
megaterium and AdR and Adx as electron transfer partners for the conversion of steroids 
hormones [73]. 
Enzymes for NADPH regeneration are less common than their NADH-dependent 
counterparts. Therefore, research has focused on the identification and generation of 
efficient NADPH regeneration systems. One strategy is based on the use of naturally 
occurring NADPH-dependent enzymes such as alcohol dehydrogenases (ADH) (e.g., an 
ADH from Thermoanaerobium brockii [68]), glucose-6-phosphate-dehydrogenases [68] and 
glucose dehydrogenases [74]. On the other hand, the already described FDH [68, 75] and 
PtxD [76] were engineered to accept NADP+ instead of NAD+. A different approach is to 
directly engineer the cofactor specificity of the production enzyme from NADPH to NADH 
since the latter is cheaper and more stable [68]. As an example, this strategy was applied for 
P450 BM3 from Bacillus megaterium (CYP102A1) in the hydroxylation of cyclohexane 
resulting in an overall reduction of the process costs by 20 % [77]. 
Strategies for recycling of the oxidized cofactor NAD(P)+ are less developed than 
those for NAD(P)H (Table 1.3). The requirement for NAD(P)+ regeneration is based, e.g., on 
the use of alcohol dehydrogenases to resolve racemic mixtures of chiral alcohols by kinetic 
resolution or in the synthesis of ketones that are difficult to prepare chemically. For example, 
regeneration of NADP+ from NADPH can be achieved using glutamate dehydrogenase in the 
reduction of α-ketoglutarate to L-glutamate [68]. Additionally, NAD+ can be recycled from 
NADH by using NADH oxidases from Lactobacillus sanfranciscensis and Borrelia burgdorferi 
with the formation of H2O as a co-product [78, 79]. 
Another potentially powerful technology is the electrochemical recycling of reduced 
and oxidized forms of pyridine nucleotide cofactors. Although this approach does not require 
a secondary enzyme and co-substrate, thus not producing any co-product, it is still a limited 
strategy today. Obstacles such as the necessity of high overpotentials, electrode fouling, and 
dimerization of the cofactor have already been successfully overcome with the development 
of e.g. biosensors with surface modifications [80] to avoid electrode fouling, and membranes 
surrounding the electrode [81] or electron deposition [68, 82] in order to retain the enzyme or 
cofactor close to the electrode. However, the need for much larger electrode surfaces and 
the costs related to scale-up are still a challenge for their application in preparative 
electrochemical reactors [68]. 
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Table 1.3 Commonly used enzyme systems for the regeneration of cofactors NAD(P)
+
 and 
NAD(P)H. DH: dehydrogenase. Data taken from Schallmey et al. [18] and Van der Donk et al. [68]. 
Cofactor  Main reaction co-enzyme co-substrate co-product 
NAD(P)+ 
 
Alcohol DH 
  
   
Lactate DH 
  
   
Glutamate DH 
  
   
NADH oxidase O2 H2O / H2O2 
     
NAD(P)H 
 
Alcohol DH 
  
   
Formate DH HCOO
-
 CO2 
   
Phosphite DH 
  
   
Glucose DH 
(R=H) or 
glucose-6-
phosphate  DH 
(R=P)   
 
 
1.6.3 Industrial applications of cytochrome P450 monooxygenases 
Enzyme-catalyzed redox reactions represent one third of all commercialized 
enzymatic processes and from these approximately one half comprise oxidation reactions 
[83]. Enantiospecific oxyfunctionalisations such as hydroxylations (mono- and di-
hydroxylations) and epoxidations represent 54 % and 14 %, respectively, of the biocatalytic 
oxidation reactions applied in industry (Figure 1.9) [83]. Usually, industrial processes using 
oxygenases are based on whole cell catalysis since the regeneration of oxidized cofactors 
has not reached the development stage for commercial implementation yet.  
The usually broad substrate specificity of cytochrome P450 monooxygenases combined with 
a high versatility of the catalyzed reactions make these enzymes attractive catalysts for 
application in the synthesis of different pharmaceuticals as well as bioremediation purposes 
[83]. As just mentioned, the use of cytochrome P450 enzymes in industrial processes is 
restricted to whole-cell catalysis so far [84]. Technical examples include the hydroxylation of 
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alkanes for the production of dicarboxylic acids, the biotransformation of steroid hormones, 
as well as the hydroxylation of important aromatic precursors [84]. A well-established 
commercial application of P450 monooxygenases is the oxyfunctionalization of steroid 
hormones such as the 11β-hydroxylation of Reichstein S to hydrocortisone with Curvularia 
sp. at a scale of ~100 tons per year (by Bayer Schering Pharma, Germany) [85, 86]. Further 
examples are the conversion of progesterone to cortisone by Rhizopus sp. developed in the 
1950s by Pharmacia and Upjohn (now Pfizer) [87, 88] and the production of pravastatin (a 
potent cholesterol lowering agent) by Daiichi Sankyio (Toky, Japan) and Bristol- Myers 
Squibb (New York, NU) using Mucor hiemalis (Figure 1.10) [18, 89]. 
 
Figure 1.9 Distribution of different types of oxidation reactions in industrial biocatalysis. Data 
taken from Liese et al. [83]. 
 
 
Figure 1.10 Industrial-scale applications of cytochrome P450 monooxygenases. Production of 
hydrocortisone using P450 from Curvularia sp. by Bayer Schering Pharma and production of 
pravastatin by selective hydroxylation of compactin using P450 from Mucor hiemalis by Daiichi Sankyo 
(Japan) and Bristol-Myers Squibb (US) is shown. Data taken from Schallmey et al. [18]. 
 
mono- 
hydroxylation 
40% 
dihydroxylation 
14% 
Baeyer-Villiger 
oxidation 
5% 
epoxidation 
14% 
desaturation 
5% 
alcohol/ amine 
oxidation 
22% 
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P450s are also involved in the synthesis of new anticancer drugs. Since these drugs 
are naturally only available in limited quantities from their biological sources, synthetic routes 
are required. An example is the synthesis of Taxol, which involves an initial in vivo step 
performed by recombinant yeast expressing the taxoid 10β-hydroxylase (CYP725A1) and a 
cytochrome P450 reductase from Taxus cuspidate [90]. Furthermore, the biocatalytic 
production of perillyl alcohol, another anticancer drug, from limonene can be performed by a 
cytochrome P450 alkane hydroxylase isolated from Mycobacterium sp. which is 
recombinantely expressed in Pseudomonas putida. Thus, a volumetric productivity of 6.8 g/L 
was achieved using a whole-cell process [91]. 
The best known application of P450 monooxygenases in the field of bioremediation is 
the use of naturally occurring enzymes for the degradation of environmentally harmful 
compounds such as insecticides and pesticides, among other agrochemicals. Rylott et al. 
reported a cytochrome P450 monooxygenase called P450 XplA which is involved in the 
microbial metabolism of the military explosive hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). 
Genes coding for this enzyme were found in several microbial genera exhibiting nearly 
complete sequence identities. However, P450 XplA was only detected in microorganisms at 
RDX-contaminated sites suggesting a rapid dissemination of the gene since the introduction 
of RDX into the environment 50 years ago. The authors suggested that transgenic plants 
expressing xplA could provide a low cost sustainable remediation strategy for contaminated 
military areas [92]. 
 
1.7   P450s for steroid production  
As described before, the application of cytochrome P450s in the synthesis of steroid 
hormones is of high importance for the pharmaceutical industry. In fact, the remarkable 
ability of P450s to catalyze the hydroxylation of non-activated carbon atoms in a regio- and 
stereoselective manner facilitates the functionalization of steroids avoiding in this way the 
use of protecting groups and several time-consuming chemical steps. Therefore, research 
focussing on steroid hydroxylation by P450s has attracted the interest of scientists for 
several decades. Today, about 300 approved steroid drugs are known and are ranked 
among the most commercialized medical products representing the second largest category 
next to antibiotics [93, 94]. Bureik and Bernhardt reported in 2007 an annual production of 
steroid drugs exceeding one million tons with a worldwide market of US$10 billion [95]. 
 
1.7.1 Steroids: general aspects 
Hormonal steroids are terpenoid lipids with a specific structure containing a gonane 
skeleton, which consists of four cycloalkane rings and two additional methyl groups at 
positions 10β and 13β, respectively (Figure 1.11). Other classes of steroids such as 
cardioactive steroid lactones and bile acids differ from hormonal steroids by the 
arrangements of the rings. Steroid compounds have been identified in many living systems 
such as plants (e.g., phytosterols, diosgenin, brassinosteroids), insects (e.g., ecdysteroids), 
vertebrates (e.g., cholesterol; corticosteroids such as glucocorticoids and mineralocorticoids; 
sex hormones such as androgens and estrogens; bile acids; vitamin D; neurosteroids) and 
lower eukaryotes such as yeasts and fungi (e.g., ergosterol; ergosteroids) [94, 96].  
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A                                                             B 
 
Figure 1.11 General steroid structure. A: Androstane containing three cyclohexane rings (A-C) and 
a cyclopentane ring (D). B: Four rings of androstane in trans configuration. 
In humans, steroidogenesis is the process in which biologically active steroid 
hormones are synthesized from cholesterol (Figure 1.12). Five different steroid classes can 
be identified depending on the receptor to which those hormones bind: progestagens 
(skeleton with 21 carbons), androgens (19 carbons), estrogens (18 carbons), 
mineralocorticoids (21 carbons) and glucocorticoids (21 carbons) [97]. Regulation 
determining the type of steroid to be produced is mediated by many enzymes, which are 
classified as cytochrome P450 monooxygenases present in mitochondria and the 
endoplasmic reticulum, as well as hydroxysteroid dehydrogenases (HSDs) belonging either 
to the aldo-keto reductase or short-chain dehydrogenase/reductase family. The first and rate-
limiting step in steroidogenesis is the conversion of cholesterol to pregnenolone, involving 
the cleavage of the cholesterol side-chain by P450scc (CYP11A1). Starting from 
pregnenolone, many others progestagens (pregnanes) are synthesized by P450s and HSDs. 
These groups of steroid hormones are involved in maintaining pregnancy (pro-gestational), 
although they are also present in many phases of the menstrual cycle. Androgens are steroid 
hormones that are also derived from cholesterol (via progestagen derivatives) and which are 
involved in the development and maintenance of male characteristics such as 
spermatogenesis. The most known ones are testosterone, dihydrotestosterone and 
androstenedione [98]. They serve as precursors for the synthesis of estrogens, primary 
female sex hormones, which are used as part of oral contraceptives, in estrogen 
replacement therapies and in some cases for the treatment of prostate cancer [99]. 
Furthermore, the last two group of steroid hormones that are produced from cholesterol (via 
progestagen derivatives) are mineralocorticoids and glucocorticoids such as aldosterone and 
cortisol, respectively [98]. Aldosterone acts on the kidneys providing active reabsorption of 
sodium and secretion of potassium, thus affecting the retention of water with a final increase 
in blood pressure. Cortisol, also known as hydrocortisone, increases blood sugar levels 
through gluconeogenesis and also suppresses the immune system acting as anti-
inflammatory agent [98]. 
Besides the already mentioned ones, further natural roles of steroid hormones are the 
regulation of cholesterol levels, control of fertility and menopause [100–104], as well as 
cardiovascular and neuroprotective functions [105–110]. Furthermore, they are also involved 
in tissue differentiation and cell proliferation, regulation of signal transduction pathways and 
quorum sensing  cell-to-cell communication processes [111–115]. Additionally, various 
activities of steroid drugs are reported. They are generally used as anti-tumor, anti-
inflammatory, anti-microbial, anti-viral, anti-fungal, anti-estrogenic, anti-convulsant and anti-
allergy agents [94, 96]. For example, they are used to treat hormone-dependent forms of  
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Figure 1.12 Human steroidogenesis. Major steroid hormones synthesized from cholesterol are 
shown, such as progestagens (yellow), mineralocorticoids (violet), glucocorticoids (green, partially 
overlapped with mineralocorticoids), androgens (blue) and estrogens (red). Enzymes in blue 
correspond to mitochondrial enzymes; enzymes in black are located in the endoplasmic reticulum. 
Parts of the structures indicated in red show the changes in the molecule compared to the precursors. 
Data reported by Boron et al. [116] [117]. 
Introduccion 
 
C
h
a
p
te
r 
1
: 
P
4
5
0
s
 f
o
r 
s
te
ro
id
 p
ro
d
u
c
ti
o
n
 
21 
 
breast and prostate cancer, certain forms of colon cancer, obesity, diabetes, rheumatoid 
arthritis, hypertension, asthma, eczema, metabolic disorders, neurodegenerative diseases, 
central nervous system disorders, gynecopathy, anaphylactic shock, and prevention and 
treatment of an infection by HIV [94, 96]. 
 
1.7.2 Structure-activity relationship 
The physiological activity of steroids directly depends on their structure, type, number 
and position of functional groups attached to the core as well as the oxidation state of the 
rings. For example, the presence of an oxygen functionality at C11(β) of the steroid core is 
crucial for anti-inflammatory activity and the 17β-hydroxyl group determines the androgenic 
properties of steroids [94, 96] More examples of structure-activity relationships in steroids are 
given in Table 1.4. Fragkaki et al. reviewed the structure-activity relationship of several 
anabolic androgenic steroids (AAS, testosterone derivatives) by studying their binding to the 
androgen receptor (AR) [118]. The aim was to generate different AAS derivatives by 
modifying the testosterone structure in order to obtain AAS with a stronger anabolic but less 
androgenic effect to reduce unwanted side-effects. Additionally, the desired steroid effect can 
be prolonged, e.g., by esterification of the 17β-hydroxyl group, making it more lipophilic and 
thus increasing its retention in fat tissue [118].  
In general, steroid analogues are favored compared to their naturally occurring 
counterparts due to several therapeutic advantages, such as an increased potency (e.g. 
better interaction with their respective receptors), longer half-lives in the blood stream, 
simpler delivery methods and reduced side effects [119]. However, their synthesis is a real 
challenge for traditional chemistry, where the introduction of functional groups, such as 
hydroxyl groups or double bonds, in a regio- and stereoselective manner becomes a limiting 
step. Therefore, the combination of traditional chemistry techniques and enzymatic catalysis 
has become the preferred methodology for steroid synthesis in the pharmaceutical industry.  
 
1.7.3 Synthesis of steroid drugs traditional chemistry in combination with biocatalysis. 
The production of steroid hormones is one of the best examples for the successful 
application of microorganisms in the pharmaceutical industry [96]. The complex structure of 
steroids requires multi-step synthetic schemes, which often involve the preparation of 
intermediates with protected groups followed by de-protection, limiting in this way the overall 
process yield and making it expensive and time consuming. Furthermore, chemical synthesis 
involves the use of hazardous compounds not only in regard to human health but also to the 
environment. In contrast, microbial steroid conversions are performed under mild conditions 
(temperature and pressure) which allow the development of simpler manufacturing 
processes. However, several limitations such as lower purity and productivities have to be 
overcome here as well. Generally, as already mentioned, whole cell catalysis is the method 
of choice for the enzymatic steps in industrial steroid synthesis [94, 119]. 
Kramli and Horvath reported in 1947 for the first time the 7α-hydroxylation of 
cholesterol by Proactinomyces roseus [120]. In the 1950s, Upjohn Company and Squibb 
reported at the same time the 11α-hydroxylation of progesterone by Rhizopus arrhizus and 
Aspergillus niger, respectively. This hydroxylated steroid was used as an intermediate in the 
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synthesis of cortisone, although the 11β-hydroxy configuration is required for the biological 
activity of corticosteroids. Thus, inversion of the configuration was necessary which was 
successfully achieved by chemical oxidation and further reduction. The introduction of this 
enzymatic step reduced the number of required steps in the synthesis of corticosteroid 
hormones derivatives by 10 in contrast to the synthetic chemical route developed by Merck 
(Germany), where 31 steps were necessary to obtain 1 g of cortisone from 615 kg of 
deoxycholic acid. Thus, the microbial hydroxylation reduced the price of cortisone from U$S 
200 to U$S 6 per gram [119]. 
Highlighted by this example, the importance of introducing more enzymatic steps into 
the synthesis of steroid derivatives becomes evident. However, only a few P450s involved in 
steroid synthesis are deeply characterized since most of the bioconversions of steroids and 
sterols are performed using whole microorganisms or their respective cell free extract (only 
on lab scale), resulting also in the formation of side products. Since the 1980s, the use of 
microorganisms for the synthesis of steroid derivatives has been reviewed, focusing mainly 
on steroid hydroxylations, Δ1 dehydrogenation and sterol side-chain cleavage [94, 121–126]. 
In particular, Donova et al. reported the use of actinobacteria as the most prominent and 
efficient biocatalysts for steroid biotransformations [126]. Diverse reactions are catalyzed by 
actinobacteria including dehydrogenations, oxidations of hydroxyl groups (3β-OH and 17β-
OH), double bond isomerization (Δ5 to Δ4), double bond hydrogenation (e.g. Δ1 and Δ4), 
reduction of keto groups to alcohols (17C and 20C), deacetylation (21C-OAc) and 
hydroxylation at various positions such as 9α, 6β, 11α/β, 14α, 16α, as well as complete or 
partial degradation of the side-chain and other reactions [121, 122, 124, 125, 127]. 
Nowadays, almost all positions of the steroid core can be functionalized by microbial 
enzymes. The most well-known hydroxylation positions of industrial importance and obtained 
with high yields and controlled costs are 11α, 11β, 15α and 16α [119, 126]. Other positions 
that have a high potential for industrial exploitation are 7α, 9α and 17α [126]. 
 
1.7.4 Bacterial P450s for steroid hydroxylation 
Hydroxylation is one of the most important reactions for steroid functionalization since 
hydroxylated steroids often exhibit a higher biological activity in comparison to their less-
polar analogs. In addition, their toxicity and secretion from the cell are also affected. Steroid 
hydroxylation in eukaryotes and prokaryotes is carried out by cytochrome P450 
monooxygenases exclusively [126]. Because of their natural role in steroid synthesis, today a 
larger number of eukaryotic P450s (mainly mammalian enzymes) capable of steroid 
hydroxylation are known as compared to prokaryotic ones. However, the biotechnological 
use of eukaryotic P450 monooxygenases is significantly hampered by the fact that they are 
membrane bound within the cells and often show low catalytic activities [55]. In contrast, 
bacterial P450s are soluble enzymes that can usually be overexpressed to very high 
amounts allowing much higher productivities in biotransformations. Despite that fact, only a 
very limited number of reported bacterial cytochrome P450 monooxygenases are able to 
perform selective steroid hydroxylations [73].  
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Table 1.4 Structure-activity relationship of steroids. Modification of the steroid hormone structure 
(e.g. through hydroxylation, alkylation or oxidation) at specific positions facilitates the synthesis of 
steroid drugs exhibiting different biological activities. 
 
Modification of the 
parent compound 
Parent compound 
Biological 
activity/application 
Ref. 
    
C1- and C2-alkylation Testosterone Favors anabolic activity [118, 128] 
    
C2-oxygenation Testosterone Favors anabolic activity [118] 
    
C3-keto group Testosterone Enhances androgenic activity [118] 
    
H5α isomer Testosterone Enhances androgenic activity [118, 129] 
    
C7α-alkylation Testosterone Favors anabolic activity [118] 
    
C7α-hydroxylation Dehydroepiandrostero
ne and pregnelone 
Useful in the treatment of certain 
cancer types, increase of 
immune response, anti-obesity 
agent and anti-glucocorticoid 
action 
[119] 
    
C7α-methylation 19-nor-17α-hydroxy-4-
androstenes 
Enhances androgenic activity [118] 
    
C11-hydroxylation deoxycortisone Anti-inflammatory activity [94, 96] 
,
[119]
 
    
C15α-hydroxylation 13-ethyl-4-gonene-
3,17-dione 
Contraceptive activity [119] 
    
C15β-hydroxylation Finasteride Treatment of prostate cancer [96, 119] 
    
C16α-hydroxylation Progestagens Increases glucocorticoid activity [119] 
    
C17α-alkylation Testosterone Favors anabolic activity [118] 
    
C17β-hydroxylation Testosterone Androgenic properties [94, 96] 
    
17-OH group Testosterone Enhances androgenic activity [118, 130] 
    
17-OH oxidation Testosterone Reduces androgenic activity [118, 131] 
    
17-OH esterification Testosterone Favors anabolic activity [118] 
    
C19 removal Testosterone Reduces androgenic activity [118, 132, 
133] 
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Although many bacterial species are reported in literature to carry out hydroxylation of 
various steroids, the genes coding for the respective CYPs are often not known and the 
enzymes usually have been only poorly characterized [96, 125, 126, 134]. The most 
prominent example of a bacterial P450 acting on steroids is the class I CYP106A2 from 
Bacillus megaterium, an enzyme able to hydroxylate several steroid substrates in 15β-
position [95]. In a recent work, Zehentgruber et al. reported an impressive productivity of 5.5 
g L-1 d-1 for 15β-hydroxylation of testosterone and progesterone through coexpression of 
CYP106A2 and the electron transfer partners AdR and Adx together with an alcohol 
dehydrogenase from Lactobacillus brevis for cofactor regeneration [73]. 
In 2006, Agematu et al. published a study where several bacterial P450s were 
evaluated for their ability to hydroxylate testosterone using PdR and Pdx from Pseudomonas 
putida as electron transfer components in whole cell catalyses [60]. Out of 213 bacterial 
P450s tested, only 24 converted testosterone. One of them was CYP154C5, which was able 
to hydroxylate testosterone in a highly regio- and stereoselective manner producing 16α-
hydroxytestosterone with an overall conversion >10 %. Similarly, CYP110D1 from Nostoc sp. 
was found to oxyfunctionalise testosterone with high selectivity yielding only one product with 
hydroxylation at 15β position. Furthermore, CYP200A1 from Bradyhizobium japonicum and 
CYP127A3 from Mesorhizobium loti were reported to hydroxylate testosterone at position 11 
with β orientation, a well-known position of industrial importance. However, in these cases 
also side-products such as 2β- and 17-hydroxytestosterone were formed in lower yields [60].  
1.7.5 Engineering of P450s for steroid hydroxylation 
Protein engineering has become the method of choice to generate enzymes with new 
or improved functions, for the conversion of non-natural substrates, or to enhance their 
stability at elevated temperatures, non-biological pH conditions and in unconventional media 
such as organic solvents, ionic liquids (ILs) or deep eutectic solvents [135]. There are two 
major strategies for the improvement of an enzyme by protein engineering. The first is 
rational protein design which requires the availability of the three-dimensional structure or a 
homology model of the enzyme in order to identify the type and position of improving amino 
acid exchanges, which are introduced by site-directed mutagenesis [11]. Another approach is 
the so-called directed evolution which involves either random mutagenesis of the whole gene 
encoding the catalyst (e.g. by error prone PCR) or recombination of gene fragments of 
homologous enzymes. This type of mutagenesis resembles an in vitro version of Darwinian 
evolution. Afterwards the generated libraries are usually assayed using high-throughput 
screening technologies to identify improved variants [136]. For both approaches the gene 
encoding the enzyme as well as a suitable expression system are prerequisites. 
Directed evolution also provides the tools to develop a catalyst with a new function, in 
this case, e.g., for steroid hydroxylation. An example is the study of Lewis et al., where it was 
shown that the substitution of leucine to alanine at position 437 of P450BM3 from Bacillus 
megaterium (CYP102A1) enlarges its active site and generates a catalyst which, in contrast 
to the wild type [137], is now able to convert trimethyl estriol, a steroid compound. Based on 
these results Lewis et al. developed a mutant F1 (four mutations compared to the wild type) 
which is able to hydroxylate progesterone and testosterone derivatives at position C2 with α-
orientation [138]. One year later, Kille et al. performed an iterative combinatorial active-site 
saturation test where several aminoacid residues (next or near the binding pocket) of 
P450BM3 were randomized and the resulting focused libraries were screened for activity 
and/or selectivity [139]. An improved mutant at one site was then used as a template to 
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perform saturation mutagenesis at another site and this process was repeated until the 
desired improvement of the catalyst was reached. As basis for their strategy, the single 
mutant F87A, already able to hydroxylate testosterone yielding a 1:1 mixture of 2β- and 15β-
hydroxytestosterone, was used. As a result, mutants KSA-2 (R471I/T491I/Y511I/F87A) and 
KSA-14 (R47I/T49F/A82M/F87A) were found to selectively hydroxylate testosterone yielding 
either 2β- or 15β-hydroxytestosterone with 94 % and 96 % conversion, respectively. 
A combination of directed evolution techniques, such as site-saturation mutagenesis 
(SSM, where, ideally, all 21 aminoacids are introduced at a given position by using 
customized degenerated oligonuclotides) [83] and rational protein design were applied to 
CYP106A2 from Bacillus megaterium in a study by Nguyen et al. in order to change the 
enzyme’s regioselectivity. The authors accomplished an impressive increase in 
regioselectivity from 28 % up to 81 % for hydroxylation of progesterone at C11 position using 
the double mutant A89N/A395I [140]. Also eukaryotic P450s were engineered, such as 
CYP2D6 which is one of the major human drug metabolizing enzymes that only poorly 
metabolizes testosterone (atypical substrate) producing 6β-hydroxytestosterone [141]. In the 
study by Geier et al. the influence of two active site residues (216 and 483) of CYP2D6 was 
analyzed by generating the 400 possible combinatorial mutants and their expression in 
Pichia pastoris. As a result, mutant E216Q/F483G exhibited higher steroid hydroxylase 
activity than the wild type, with a hydroxylation rate for testosterone as high as for the 
conversion of the standard substrate bufuralol (6.8 min-1). Furthermore, the regioselectivity of 
the enzyme was changed since in this case the 2β-hydroxylated product was mainly 
obtained. 
 
1.8   Aim and outline of the thesis 
The main objective of this thesis was an in depth characterization of CYP154C5 from 
Nocardia farcinica in the bioconversion of steroid compounds to explore its potential for 
application in industrial-scale steroid hydroxylation. This P450 monooxygenase was selected 
out of the 24 bacterial enzymes reported by Agematu et al. due to its remarkably high 
selectivity in the production of 16α-hydroxytestosterone [60]. The incorporation of a 16-
hydroxyl group in the steroid backbone is of high relevance for the pharmaceutical industry 
for the synthesis of highly potent glucocorticoids. 
In a first step, a recombinant expression system for CYP154C5 from Nocardia 
farcinica, together with Pdx and PdR from Pseudomonas putida as electron transfer partners 
was developed employing Escherichia coli as the host strain. Furthermore, the regio- and 
stereoselectivity of CYP154C5 towards other steroid substrates (Figure 1.13) was 
determined and an optimized reaction system for steroid hydroxylation employing the 
artificial three-component system was developed. The obtained results are summarized in 
chapter 2 of this thesis. Furthermore, relevant characteristics of the purified three-
component system composed of CYP154C5, PdR and Pdx were determined. This included 
the determination of dissociation constants (KD) as a measure of the affinity of CYP154C5 
towards the different steroids (1-6), as well as turnover numbers and coupling efficiencies. 
Additionally, the crystal structure of CYP154C5 in the presence of steroids 1-6 was 
elucidated in collaboration with Konrad Herzog and Dr. Kurt Hoffmann from the Fraunhofer 
Institute IME in Aachen. Results are reported in chapter 3 of this thesis. 
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Based on the solved crystal structure, the active site of CYP154C5 was analyzed 
carefully in order to identify key residues involved in substrate binding and, thus, the 
enzyme’s high regio- and stereoselectivity. In a first approach, identified residues were 
exchanged by site-directed mutagenesis and the resulting mutants were characterized 
regarding substrate binding, activity and selectivity. In a second approach, further steroid 
substrates were tested that should potentially lead to a different orientation in the enzyme’s 
active site and, hence, to the incorporation of the hydroxyl group at a different position by WT 
CYP154C5. For that, steroid substrates 7-11 were selected (Figure 1.13). Respective results 
are summarized in chapter 4.  
Finally, chapter 5 describes the results obtained in a collaborative project with Bayer 
Schering Pharma on the bioconversion of four pharmaceutically important steroid substrates 
(2, 4, 14, 15) using the bacterial P450 monooxygenases CYP106A2 from Bacillus 
megaterium and CYP110D1 from Nostoc sp. Additionally, conversion of substrates 14 and 
15 was also tested with CYP154C5.  
In chapter 6, the work described in this thesis is summarized, conclusions and future 
prospects are given.  
 
Figure 1.13 Substrates tested in bioconversions with bacterial P450 monooxygenases. 
Substrates 1-15 were tested with wild type CYP154C5 as catalyst, substrates 1-6 were additionally 
tested with CYP154C5 mutants. Substrates 2, 4, 14 and 15 were also tested with CYP106A2 and 
CYP110D1 as catalysts. 
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2.1Abstract 
 
We have studied a bacterial P450 monooxygenase, CYP154C5 from Nocardia 
farcinica IFM 10152, which was previously described to convert testosterone, in order to 
investigate its activity and selectivity in bioconversions of different androstane and pregnane 
steroids. CYP154C5 was coexpressed in Escherichia coli together with putidaredoxin and 
putidaredoxin reductase (Pdx and PdR) from Pseudomonas putida as redox partners for 
electron transfer and applied in bioconversions of pregnenolone (1), dehydroepiandrosterone 
(2), progesterone (3), androstenedione (4), testosterone (5) and nandrolone (6). Structure 
elucidation of the formed products revealed a high regio- and stereoselectivity for 
CYP154C5, yielding in all cases the corresponding 16-hydroxylated steroid. Application of 
whole cells carrying the three components (P450, Pdx and PdR) in steroid 
biotransformations resulted in significantly higher conversions and productivities compared to 
reactions using cell-free extracts.  Additionally, considerably higher substrate loads (up to 15 
mM) were tolerated by the use of β-hydroxypropyl-cyclodextrin in whole-cell catalysis. 
Furthermore, turnover numbers (TON) were determined for the six different steroids using 
whole cells. Testosterone was found to be the worst substrate with a TON of only 0.8 min-1, 
while progesterone and pregnenolone were converted the fastest resulting in TON of 3.3 min-
1. Using this enzyme, 16-hydroxylated steroids, which are important precursors for the 
synthesis of high value steroidal drugs can be selectively produced on preparative scale with 
TTN (µmol substrate consumed µmol-1 CYP154C5) exceeding 2000 and productivities of 
several grams per liter a day. 
 
2.2   Introduction 
Cytochrome P450 monooxygenases (CYPs) catalyze the selective oxidation of 
(unactivated) C-H bonds using molecular oxygen. Thus, P450 monooxygenases are applied 
in the pharmaceutical industry for the regio- and stereoselective hydroxylation of steroid 
compounds – a reaction that can be hardly achieved by chemical methods – to form highly 
valuable steroid hormones like glucocorticoids, mineralocorticoids and sexual hormones [1, 
2]. In general, their application in industry is restricted to whole cell catalysis since P450s are 
typically complex systems usually involving more than one protein and often including 
membrane-associated proteins [3, 4]. However, besides whole-cell catalysis, also isolated 
enzymes could be used. Both approaches offer their specific advantages but entail also 
certain drawbacks. Whole-cell catalysis is the simpler and cheaper approach since no 
enzyme isolation and purification steps are needed. Furthermore, one of the most important 
features of whole-cell catalysis is that the cells’ metabolism can be utilized for cofactor 
regeneration. On the other hand, the use of WC can lead to unwanted side reactions by cell-
innate enzymes, substrate or product inhibition as well as a substrate uptake limitation. 
Some of these issues can be overcome, for example by the use of detergents which will 
permeabilize the cell membrane enhancing the substrate uptake [5], or the use of a biphasic 
system with an organic solvent as second phase which can function as a substrate and 
product reservoir to reduce possible toxicity effects or to increase the solubility of highly 
hydrophobic substrates [6]. On the other hand, the application of isolated enzyme offers the 
advantage that user-defined conditions can be easily applied, no side reactions will occur 
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and usually higher substrate and product concentration are tolerated. In contrast, the 
requirement for an additional cofactor regeneration system is a common limitation that has to 
be overcome. However, many different cofactor regenerating enzymes are already available 
[7, 8]. Additionally, not many enzymes are commercially available in an isolated form. 
Although on industrial scale the application of whole-cells in P450-catalyzed reactions might 
be preferred, they do not necessarily lead to a more efficient process. For example, 
Zehentgruber et al. reported the use of CFE containing CYP106A2 from Bacillus megaterium 
together with bovine adrenodoxin and adrenodoxin reductase as electron transfer partners in 
steroid conversions. The authors could already achieve a six-fold faster conversion by using 
CFE instead of whole cells which was mainly attributed to a substrate uptake limitation in 
case of the whole-cell system. Additionally, the coexpression of an alcohol dehydrogenase 
from Lactobacillus brevis for cofactor regeneration resulted in a 18-fold increase in 
conversion due to a higher cofactor regeneration capacity [9]. 
Because of their natural role in steroid synthesis, today a lot more eukaryotic CYPs 
capable of steroid hydroxylation are known compared to prokaryotic ones. However, the 
biotechnological use of eukaryotic P450 monooxygenases is limited by the fact that they are 
membrane bound within the cells, and show only low catalytic activities [10]. In contrast, 
bacterial CYPs are very often soluble enzymes that usually can be overexpressed to very 
high amounts allowing much higher productivities in biotransformations. Nevertheless, only a 
few bacterial cytochrome P450 monooxygenases are known to perform selective steroid 
hydroxylations [9],[11]. In a recent study, Agematu et al. examined a library consisting of 213 
different bacterial CYPs for their ability to convert testosterone [11]. Of these 213 enzymes 
only 24 turned out to be active on this substrate (Figure 2.1), exhibiting also different regio- 
and stereoselectivities. One of these active P450 monooxygenases is CYP154C5 from 
Nocardia farcinica IFM 10152. Agematu et al. reported that this enzyme was able to convert 
100 µM testosterone selectively into 16α-hydroxytestosterone using whole cell catalysis with 
an overall conversion >10 % [11].  
 
 
Figure 2.1 Summary of bacterial P450s able to selectively hydroxylate testosterone (5). Data 
summarized from Donova et al. and Agematu et al. [11, 12]. 
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Nocardia farcinica is a human pathogen causing a disease called nocardiosis on lung, 
central nervous system, brain and cutaneous tissues. The bacterium belongs to the phylum 
of Actinobacteria and is naturally found in soils. The complete genome of N. farcinica IFM 
10152 was recently sequenced revealing the presence of 21 genes coding for putative 
cytochrome P450 monooxygenases, of which two were shown to hydroxylate steroids [13]. 
For its activity, the enzyme needs additional electron transfer components delivering 
electrons from the cofactor NAD(P)H to the heme of the monooxygenase. Since the natural 
electron transfer partners of CYP154C5 are not known, electron transfer components of 
other CYP systems have to be used as substitutes. Thus it was shown before that 
putidaredoxin (Pdx) and putidaredoxin reductase (PdR) from the P450cam system of 
Pseudomonas putida [11][14] as well as the reductase domain of P450RhF (CYP116B2) 
from Rhodococcus sp. NCIMB 9784 [15] can be applied as surrogate electron transfer 
partners required for CYP154C5 activity. 
Steroids are structurally derived from the four-ring system sterane and vary in the 
presence of functional groups and the oxidation state of the rings. The type, number and 
position of functional groups in the steroid backbone directly influence the physiological 
activity (such as the control of distinct aspects of cell proliferation, tissue differentiation and 
quorum sensing) [12]. Therefore, the regio- and stereoselective introduction of functional 
groups, such as hydroxylations, is important for the development of new steroid drugs for a 
wide range of therapeutic applications, namely as anti-inflammatory, immunosuppressive, 
progestational, diuretic, anabolic or contraceptive agents. Today, about 300 approved steroid 
drugs are known and they represent the second largest category of marketed medical 
products next to antibiotics [12]. Current studies in microbial steroid hydroxylation involve the 
search for novel biocatalysts capable of performing oxyfunctionalisations at positions 7α, 9α, 
11α, 11β, 16α and 17α [12, 16, 17]. Oxyfunctionalisation at position 11 is important for anti-
inflammatory steroid drugs such as cortisol, whereas 16-hydroxylated steroids are 
important intermediates in the synthesis of highly active glucocorticoids [2]. Thus, the 
identification and biocatalytic characterization of bacterial cytochrome P450 
monooxygenases able to hydroxylate steroids of different structure at the specified positions 
in a highly regio- and stereoselective fashion is of high importance for the pharmaceutical 
industry. Furthermore, a detailed analysis of optimal reaction parameters is crucial in order to 
develop efficient processes for the large-scale production of hydroxylated steroids using 
cytochrome P450s. 
Based on the initial findings of Agematu et al., this chapter reports the 
characterization and catalytic potential of CYP154C5 from N. farcinica IFM 10152 for its 
application in regio- and stereoselective steroid hydroxylations as well as the optimization 
and up-scaling of respective biocatalytic reactions using different androstanes and 
pregnanes as substrates (Figure 2.2).  
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Figure 2.2 Selected steroids applied in biocatalytic reactions with CYP154C5. The substrates 
were selected due to their different functionalization at positions C3 and C17 and the conformational 
differences caused by a double bond either at position C4 or C5 as well as their commercial 
availability. 
 
2.3   Materials and methods 
2.3.1 Materials 
Pregnenolone, testosterone, progesterone and cholesterol were purchased from 
Sigma-Aldrich (Taufkirchen, Germany). Dehydroepiandrosterone, androstenedione, 
nandrolone, 16α-hydroxypregnenolone, 16α-hydroxyprogesterone, 16α-hydroxydehydro-
epiandrosterone and 16α-hydroxyandrostenedione were purchased from Steraloids Inc. 
(Newport, USA).  
Cytochrome c from horse heart, formate dehydrogenase from Candida boidinii, N-
methyl-trimethylsilyltrifluoroacetamide activated I (MSTFA) and hydroxypropyl β-cyclodextrin 
were purchased from Sigma Aldrich (Taufkirchen, Germany). Roti-quant for Bradford assay 
was purchased from Roth (Karlsruhe, Germany). All solvents and chemicals necessary for 
the experiments were obtained from Roth or Sigma-Aldrich (Taufkirchen, Germany) and 
used without further purification. 
 
2.3.1.1 Bacterial strains and plasmids 
The Escherichia coli TOP10 strain (Invitrogen, Carlsbad, CA, USA) was used for 
genetic manipulations, while E. coli C43 (DE3) (Lucigen, Middleton, WI, USA) was used for 
expressions.  
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Plasmid pACYC-Duet1 was purchased from Novagen (EMD Biosciences, San Diego, 
CA, USA) while the broad host-range expression vector pIT2-MCS was prepared as 
described elsewhere [18]. Plasmid pKNL031_M17 from a genomic library of Nocardia 
farcinica containing the gene of CYP154C5 (nfa53110, GenBank: NC_006361) was kindly 
provided by Jun Ishikawa (National Institute of Infectious Diseases, Japan). Preparation of 
plasmid pACYCcamAB for coexpression of putidaredoxin reductase (CamA) and 
putidaredoxin (CamB) from Pseudomonas putida was described elsewhere [18]. 
 
2.3.2 Methods 
2.3.2.1 Cloning of cyp154c5 from Nocardia farcinica 
The gene of CYP154C5 was amplified by PCR from vector pKNL031_M17 using 
primers NF-P-NdeI-FW: 5′-AAAAAAAACATATGAACGCCTGCCCCCATTCGG-3′ and NF-P-
HindIII-RV: 5′-TTTTTTAAGCTTCACCTGCCCAGGTGGATGGG-3′. Thereby restriction sites 
NdeI and HindIII were introduced for subsequent cloning of cyp154C5 into vector pIT2-MCS. 
The resulting vector was named pIT2cyp154C5.  
 
2.3.2.2 Recombinant expression in E.coli  
2.3.2.2.1 Expression of Escherichia coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) in 
shake flask scale 
Small scale expression of CYP154C5 was performed in a 2 L flask. As first step, LB 5 
mL liquid media supplemented with tetracycline (10 µg/mL) and  chloramphenicol (25 µg/mL) 
was inoculated from a -80°C DMSO stock of Escherichia coli C43 (DE3) (pIT2cyp154c5) 
(pACYCCamAB). After incubating overnight at 37°C and 250 rpm, a 500 mL TB culture 
supplemented with tetracycline (10 µg/mL), chloramphenicol (25 µg/mL) and 0.1 % v/v of 
trace element solution was inoculated with 1 % v/v from the pre-culture and incubated at 
37°C and 250 rpm. At OD600 ~ 1 the system was induced with IPTG (200 µg/mL) and δ-
aminolevulinic acid (84 µg/mL) was added as a precursor for the heme synthesis. After 48 
hours of expression at 30°C and 250 rpm the cells were harvested (4424 x g, 4°C for 15 
min), washed with 50 mM potassium phosphate buffer pH 7.4, centrifuged (4424 x g, 4°C for 
15 min)  and the pellet directly used for biocatalysis. 
 
2.3.2.2.2 Expression of Escherichia coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) at 
10 L bioreactor scale. 
E. coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) was used for coexpression of 
CYP154C5 together with CamA (PdR) and CamB (Pdx) in one host. For that, 5 mL liquid LB 
media (10 g/L tryptone, 5 g/L yeast extract and 10 g/L NaCl) supplemented with tetracycline 
(10 µg/mL final concentration) and chloramphenicol (25 µg/mL final conc.) was inoculated 
from a frozen stock of E. coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB). After overnight 
incubation at 37°C and 250 rpm (Bench top shaker Certomat Sartorius, Göttingen, 
Germany), a 200 mL TB preculture (12 g/L tryptone, 24 g/L yeast extract, 4 mL glycerol, 2.3 
g/L KH2PO4 and 12.9 g/L K2HPO4) supplemented with tetracycline (10 µg/mL) and 
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chloramphenicol (25 µg/mL) was inoculated with 1 % v/v of the overnight culture and 
incubated for 24 h under the same conditions. Finally a 16 L fermentor (Bioreactor Biostat 
MD Sartorius, Göttingen, Germany) containing 9.8 L of TB media supplemented with 
tetracycline (10 µg/mL), chloramphenicol (25 µg/mL) and 0.1 % v/v trace element solution 
(0.50 g/L of CaCl2.2H2O, 0.18 g/L of ZnSO4.7H2O, 0.10 g/L of MnSO4.H2O, 20.10 g/L of Na2-
EDTA, 16.70 g/L of FeCl3.6H2O, 0.16 g/L of CuSO4.5H2O and 0.18 g/L of CoCl2.6H2O) was 
inoculated with 2 % v/v preculture. The pH was set to 7.0 and adjusted during the expression 
with 5 M KOH and H3PO4 solutions. Dissolved oxygen was controlled with a pO2 electrode. 
Foam formation was controlled using commercial Antifoam from Sigma. At an optical density 
(OD600) of 1 the system was induced with isopropyl β-D-1-thiogalactopyranoside (IPTG, 200 
µg/mL final conc.) and δ-aminolevulinic acid (84 µg/mL final conc.) was added as a precursor 
for heme synthesis. After 24 hours of expression at 30°C and 300 rpm the cells were 
harvested by centrifugation (4424 x g, 4°C for 15 min) (Sorvall RC-6 Thermo Fischer 
Scientific, Wilmington, USA), washed with 50 mM potassium phosphate buffer pH 7.4 (6.98 
g/L K2HPO4 and 1,35 g/L KH2PO4), centrifuged (4424 x g, 4°C for 15 min) (centrifuge 5810 R 
Eppendorf, Hamburg, Germany) and the pellets were stored at -20°C. 
 
2.3.2.2.3 Expression of Escherichia coli C43 (DE3) (pACYCcamAB) 
E. coli C43 (DE3) (pACYCcamAB) the camA and camB gene but not the gene of 
CYP154C5 was used as control strain in bioconversions. In this case, expression was 
performed according to the procedure described for E. coli C43 (DE3) (pIT2cyp154C5) 
(pACYCcamAB) in 500 mL scale with two modifications: only chloramphenicol (25 µg/mL) 
was used for selective growth and δ-aminolevulinic acid was not added during the 
expression.  
 
2.3.2.3 SDS-PAGE 
SDS-PAGE was carried out according to Schägger et al. adjusted to the Mini 
PROTEAN® Tetra Cell (Bio-Rad).[19] Samples were prepared via normalization of the cell 
amount, OD600  ~ 10 adjusted in a final volume of 500 µL of 50 mM potassium phosphate 
buffer pH 7.4, and the resuspended cells were lysed by sonication (5 cycles of 30 seconds 
pulse with each 45 seconds pause, 40-% of amplitude (Ultrasonic Homogenizator MS73/UW 
200, Sonoplus HD 200, Bandelin). After centrifugation at 20.238 x g (centrifuge Eppendorf 
5424, Hamburg, Germany) for 5 minutes, 10 µL of supernatant were mixed with 3.5 µL of 
loading dye (50 mM Tris HCl pH 6.8, 10 % (v/v) glycerol, 2 % (w/v) SDS, 0.10 % (w/v) 
bromophenol blue and 100 mM dithiothreitol) and incubated at 95°C for 5 min. The remaining 
pellet was resuspended in 500 µL of 50 mM potassium phosphate buffer pH 7.4. Afterwards, 
10 µL of the resuspended pellet was mixed with 3.5 µL of loading dye and incubated at 95°C 
for 5 to 10 min. In all cases, 8 µL of sample was loaded onto the gel and gels were run at 90 
V for 10 min, followed by another 60 min at 150 V. 
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2.3.2.4 Enzyme assays 
Assays were measured with cell lysate obtained from frozen cells of E. coli C43 (DE3) 
(pIT2-cyp154C5) (pACYCcamAB). Cells were resuspended in 50 mM potassium phosphate 
buffer pH 7.4 in order to reach an optical density of 40 and phenylmethylsulfonyl fluoride 
(PMSF, 17 µg/mL final conc.) was added as protease inhibitor. Cell disruption was performed 
in an EmulsiFlex-Homogenizer (Avestin, Germany) with 5 cycles of 1500 psi. After 
centrifugation (17,696 x g, 4°C for 45 min) (Sorvall RC-6 Thermo Fischer Scientific, 
Wilmington, USA) the resulting CFE was immediately used for the assays. CYP154C5 
concentration was determined by CO-difference spectroscopy (CO-lecture bottle station 
Sigma Aldrich, Steinheim, Germany) and calculated based on the absorbance maximum of 
CO-bound CYP154C5 at 450 nm (ε450= 91 mM
-1 cm-1) using a Cary 50 Varian 
spectrophotometer, (see appendix section 3.1) [20]. The activity of the electron transfer 
components (ETC) Pdx and PdR in CFE was determined by the cytochrome c reduction 
assay, monitoring the increase in absorbance at 550 nm of reduced cytochrome c (ε450= 19.1 
mM-1 cm-1) [21]. Protein concentration was determined by the Bradford assay measured in a 
BioPhotometer Plus Eppendorf (Hamburg, Germany) [22]. 
 
2.3.2.5 Analytical-scale bioconversions  
2.3.2.5.1 Whole-cell bioconversions 
In case of whole-cell bioconversions, frozen or fresh cells of E. coli C43 (DE3) 
(pIT2cyp154c5) (pACYCcamAB) overexpressing Pdx, PdR and CYP154C5 were 
resuspended in 50 mM potassium phosphate buffer pH 7.4 to the desired final OD600. All 
bioconversions were carried out in 1 mL scale at 30°C and 250 rpm (Bench top shaker 
Certomat Sartorius, Göttingen, Germany) with addition of glucose (0.54 mg/mL final conc.) 
for cofactor regeneration. Substrate stock solutions of steroids were prepared in 36 % (w/v) 
hydroxypropyl-β-cyclodextrin (CYD) solubilized in ddH2O. For substrates 2 and 5, stocks of 
100 mM were prepared whereas only 50 mM stocks could be used for substrates 1, 3-4 and 
6. From the prepared stocks, the respective amounts were added to the reactions in order to 
achieve final steroid concentrations of 0.5 to 15 mM. Hence, the ratio between substrate and 
hydroxypropyl-β-cyclodextrin stayed constant in each reaction. The molar ratio CYD: steroid 
is 2.6:1 and 5.2:1 for steroids -2, 5 and 1, 3-4, 6, respectively. Control reactions were carried 
out in parallel with E. coli C43 (DE3) (pACYCcamAB) which contained only Pdx and PdR. 
After 20 hours of reaction the bioconversions and controls were extracted for subsequent 
HPLC and GC analysis. For that, the complete sample was extracted twice with ethyl acetate 
(700 µL and 500 µL) and once with chloroform (500 µL), the organic phases were combined, 
dried with sodium sulphate, centrifuged 20.238 x g (Eppendorf centrifuge 5424, Hamburg, 
Germany) for 30 seconds and the solvent was removed under reduced pressure.  
 
2.3.2.5.2 Cell-free extract bioconversions 
In case of bioconversions using cell-free extract (CFE), frozen or fresh cells of E. coli 
C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) were resuspended in 50 mM potassium 
phosphate buffer pH 7.4 and PMSF (17 µg/mL final conc.) was added as protease inhibitor. 
Cell disruption was performed in an EmulsiFlex-Homogenizer (Avestin, Germany) with 5 
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cycles of 1500 psi. After centrifugation (17,696 x g, 4°C for 45 min) the resulting CFE was 
immediately used for bioconversions. In 1 mL scale bioconversions, NADH (36 µg/ mL final 
conc.) was used as electron donor, sodium formate (10 mg/mL final conc.) and formate 
dehydrogenase from Candida boidinii (Sigma Aldrich, 0.5 U/mL final activity) were added as 
NADH regeneration system in bioconversions. Steroid substrates were added as stock 
solutions in 36 % (w/v) hydroxypropyl-β-cyclodextrin in ddH2O as described for whole-cell 
reactions. After 24 hours of reaction at 30°C and 250 rpm (Bench top shaker Certomat 
Sartorius, Göttingen, Germany), the bioconversions and controls were extracted as 
described for the whole-cell system. 
 
2.3.2.6 Preparative-scale bioconversions and product purification 
Preparative-scale bioconversions were carried out in 100-200 ml of 50 mM potassium 
phosphate buffer pH 7.4 using resting whole cells of E. coli C43 (DE3) (pIT2cyp154c5) 
(pACYCcamAB) (from frozen stock) at 30°C and 250 rpm (Bench top shaker Certomat 
Sartorius, Göttingen, Germany), with the addition of glucose (0.54 mg/mL) in shake flasks. In 
all cases, resting cells with an optical density of 38 to 40 were used which is equivalent to 
approximately 3 µM CYP154C5 and an ETC activity of 1.1 U/mg of total protein, as 
determined by CO-difference spectra and cytochrome c assay, respectively. Substrate stock 
solutions were prepared in 36 % (w/v) hydroxypropy-β-cyclodextrin in ddH2O. In general 2 
mM substrate concentration was used, except for progesterone (3) and testosterone (5) 
where 4 and 1 mM were applied, respectively.  After 22-24 h of reaction, the complete 
reaction volume was extracted twice with ethyl acetate (50 and 40 mL) and once with 
chloroform (30 mL), the organic phases were combined, dried with sodium sulphate and the 
solvent removed under reduced pressure. Hydroxylated steroid products were afterwards 
purified by silica gel column chromatography (silica gel 60; 0.2-0.5 mm; Roth) with a gradient 
of ethyl acetate in n-heptane to pure ethyl acetate (starting with ethyl acetate:n-heptane 
ratios of 6:4 for pregnenolone (1), 4:6 for dehydroepiandrosterone (2), 9:1 for progesterone 
(3) and testosterone (5) 7:3 for androstenedione (4) and 95:5 for nandrolone (6)) as mobile 
phase.  
Larger scale bioconversions (700 mL volume) were carried out with progesterone (3) 
and testosterone (5) as substrates in a 2 L fermentor (2 L-Bioreactor Biostat MD Sartorius, 
Göttingen, Germany). Frozen E. coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) cells were 
resuspended in 50 mM potassium phosphate buffer pH 7.4 to reach an optical density of 
approximately 40 and 30 for bioconversion of 3 and 5, respectively. The stirring speed was 
adjusted to 300 rpm and pH was set to 7.0 and adjusted during the bioconversion with 5 M 
KOH and H3PO4 solutions; dissolved oxygen was controlled with a pO2 electrode. Substrate 
stock solutions were prepared in methanol (1.4 % v/v methanol final conc.).The initial 
concentration of 3 and 5 for the biocatalyses were 0.3 and 4 mM, respectively. In particular 
for testosterone bioconversion, substrate and glucose were fed every 3 hours during the first 
6 hours of catalysis (0.33 mM and 0.54 mg/mL, respectively) reaching 1 mM and 1.62 mg/mL 
final concentrations, respectively. After 24 h of reaction at 30°C, the complete reaction 
volume was extracted twice with ethyl acetate (240 and 180 mL) and once with chloroform 
(150 mL). The organic phases were combined, dried with sodium sulphate, centrifuged at 
20.238 x g (Eppendorf centrifuge 5424, Hamburg, Germany) for 30 seconds and the solvent 
was removed under reduced pressure. 
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2.3.2.7 Repetitive batch bioconversions 
Frozen E. coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) cells were resuspended in 
50 mM potassium phosphate buffer pH 7.4 to an optical density (OD600) of 40. This cell 
density of frozen cells was equivalent to a P450 concentration of 3 µM and a specific activity 
of the ETC of 1.1 U/mg of total protein, as determined by CO-difference spectra and 
cytochrome c assay, respectively. The conversion of 1 mM progesterone (3) was carried out 
in 10 mL scale for 2 h at 30°C and 250 rpm with the addition of 30 mM glucose for cofactor 
regeneration. The substrate stock solution of 50 mM progesterone (3) was prepared in 36 % 
(w/v) of hydroxypropyl-β-cyclodextrin in ddH2O. During the bioconversion, samples were 
taken every 30 minutes and analyzed by HPLC. At the end of the first cycle, cells were 
separated from the reaction by centrifugation (4424 x g, 4°C for 15 min), washed with 50 mM 
potassium phosphate buffer pH 7.4, centrifuged again (4424 x g, 4°C for 15 min) and 
resuspended in the same buffer to an OD600 of 40. Additionally, 30 mM glucose and 1 mM 
progesterone were added to start the second cycle. This procedure was repeated to achieve 
a total of four repetitive batches. 
 
2.3.2.8 Turnover numbers  
Frozen or fresh E. coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) cells were 
resuspended in 50 mM potassium phosphate buffer pH 7.4 to an optical density (OD600) of 
40. This cell density of frozen cells was equivalent to a P450 concentration of 3 µM and a 
specific activity of the ETC of 1.0 U/mg of total protein (4.5 U/mL), as determined by CO-
difference spectra and cytochrome c assay, respectively. In the case of fresh cells an OD600 
of 40 was equivalent to 3 µM P450 and a specific activity of ETC of 1.6 U/mg (12 U/mL). All 
bioconversions were carried out at 25 mL scale in shake flasks for 26 h at 30°C and 250 rpm 
with addition of 30 mM glucose for cofactor regeneration. Substrate stock solutions were 
prepared in 36 % (w/v) hydroxypropyl-β-cyclodextrin in ddH2O. In all cases 2 mM initial 
steroid concentration was used. During bioconversions, samples were taken every hour for 
subsequent HPLC or GC analysis. For that, 1 mL of reaction was extracted and the sample 
prepared for HPLC or GC analysis (section 2.3.2.10). Turnover numbers were calculated 
based on substrate consumption and for the period of time where the highest substrate 
consumption rate was observed (generally between 60 and 240 minutes of bioconversion, 
except for testosterone (5) and nandrolone (6) were the period between 180 and 360 
minutes was used). In the case of TONs using fresh cells, the maximum TON was 
determined for the time period between 240 and 420 minutes. All bioconversions were done 
in triplicate. 
 
2.3.2.9 Thin layer chromatography (TLC) 
Bioconversions of all substrates were analyzed by TLC using Polygram Sil G/UV 254 
plates (stationary phase), phosphomolybdic acid solution (25 g/L phosphomolybdic acid, 10 
g/L Ce(SO4)2, 8 % v/v of 98 % H2SO4 in ddH2O) for staining and a mixture of ethyl acetate 
and n-heptane (8:2) as mobile phase.  
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2.3.2.10 GC and HPLC analyses  
In the case of pregnenolone (1) and dehydroepiandrosterone (2) the solid residues 
were redissolved in chloroform containing 30 mM cholesterol as internal standard since it 
was previously demonstrated that CYP154C5 cannot convert cholesterol (not published 
data). The samples were analyzed on a GC2010 gas chromatograph (Shimadzu; Duisburg, 
Germany) equipped with an OPTIMA 17ms column (Macherey-Nagel, Düren, Germany) with 
a linear gradient starting at 250°C and heating with 10°C/min until 300°C. Injector and 
detector temperature were set to 350 and 300°C, respectively. Substrates and products were 
detected by flame ionization detector (FID). Both substrates, pregnenolone (1) and 
dehydroepiandrosterone (2), eluted at a retention time of 9.69 min and 7.94 min, 
respectively, whereas their products eluted at 9.27 (7) and 10.18 min (8), respectively.  
The dried residues of bioconversions with progesterone (3), androstenedione (4), 
testosterone (5) and nandrolone (6) were dissolved in acetonitrile:ddH2O (60:40) and injected 
on a high performance liquid chromatograph (HPLC, Beckmann Coulter) equipped with a 
Nucleosil 100-5 C18, 250 x 4,5 mm column at 50°C.  Acetonitrile:ddH2O (60:40) was used as 
mobile phase with a flow rate of 1 mL/ min. Detection of substrates and their respective 
products was performed by UV absorbance at 230 (3 and 3A), 254 (5 and 5A), and 245 nm 
(4, 6, 4A1 and 6A1). The substrates eluted at 9.42 (3), 6.68 (4), 7.73 (5), and 5.93 (6) min, 
whereas the main products were detected at 4.95 (3A), 4.47 (4A1), 4.12 (5A) and 3.95 (6A1) 
min. Secondary products of androstenedione (4) and nandrolone (6) eluted at 5.68 (4A2) and 
5.22 min (6A2), respectively. In all cases conversions were calculated based on substrate 
consumption.  
 
2.3.2.11 GC-MS and NMR analyses 
Preliminary product identification was performed with a gas chromatograph - mass 
spectrometer (GC-MS-QP2010S, Shimadzu, Duisburg, Germany) equipped with an OPTIMA 
17ms (products 2A, 3A, 5A and 6A1) (Macherey-Nagel, Düren, Germany) or Supreme 5ms 
(products 1A and 4A) column (CS Chromatographie Service, Langerwehe, Germany) with a 
linear gradient starting at 250°C and heating with 10°C/min until 300°C. Injector, interface 
and ion source were set to 300, 300 and 200°C respectively. For products 1A, 4A1 and 5A 
derivatization using N-Methyl-N-(trimethylsilyl) trifluoroacetamide activated I (MSTFA) was 
necessary to facilitate GC-MS analysis. Thus, after extraction and solvent removal, the solid 
residue was dissolved in 100 µL MSTFA and incubated at 65°C for 20 min before injection.  
Structure elucidation of formed products (1A-6A) was performed by 1H, 13C, COSY 
and HSQC NMR analysis on a Bruker AV400 instrument (1H-NMR 400MHz and 13C-NMR 
100MHz). Measurement of product standards 1A-4A and structure elucidation of product 
6A1 was performed by 1H, 13C, COSY, HSQC and NOESY NMR on a Bruker AV600 (1H-
NMR 600MHz and 13C-NMR 150MHz). In all cases deuterated chloroform was used as 
solvent with TMS as internal standard except for product 1A were deuterated DMSO with 
TMS was used. Chemical shifts (δ) are given in ppm and coupling constant (J) in Hz (see 
supplementary data section 2.4).  
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2.3.2.11.1 Experimental data of products 
2.3.2.11.1.1 16α-hydroxypregnenolone (1A)  
1H-NMR (400 MHz, DMSO): δ 5.27 (1H, d, J= 4.7, 6-H), 4.70 (1H, d, J= 4.9, 20-OH), 4.62 
(1H, d, J= 4.5, 3-OH), 4.52 (1H, m, 16β-H), 3.26 (1H, m, 3α-H), 2.43 (1H, d, J= 6.6, 17α-H), 
2.19-2.03 (5H, m, 4αβ-H and 21-Me), 1.90 (2H, m, 7-H and 12-H), 1.77 (1H, d, J= 13.5, 1-H), 
1.68 (1H, d, J= 12.0, 2-H), 1.60-1.28 (9H, m, 2-H, 7-H, 8-H, 12-H, 14-H and 15-H), 1.06-0.88 
(5H, m, 1-H, 14-H and 19-Me), 0.54 (3H, s, 18-Me). 13C-NMR (100 MHz, DMSO): δ 208.0 
(C20), 141.3(C5), 120.2 (C6), 73.0 (C17), 70.4 (C16), 69.9 (C3), 53.7 (C14), 49.5 (C9), 44.2 
(C13), 42.2 (C4), 38.0 (C12), 36.8 (C1), 36.1 (C10), 35.6 (C15), 31.7 (C7), 31.4 (C8), 31.2 
(C2), 31.0 (C21), 20.2 (C11), 19.1 (C19) and 14.1 (C18). 1H-NMR and 13C NMR data is 
consistent with data obtained for the respective standard.  
Molecular weight of derivatised product: 551.5 g/ mol; GC-MS: Retention time: 16.9 min. M+: 
550; m/z (%): 550 (1), 549 (1), 533 (4), 458 (6), 231 (85), 147 (15), 131 (12), 117 (33), 73 
(100). 
 
2.3.2.11.1.2 16α-hydroxydehydroepiandrosterone (2A) 
1H-NMR (400 MHz, CDCl3): δ 5.37 (1H, d, J= 5.3. 6-H), 4.38 (1H, d, J= 7.8, 16β-H), 3.54 (1H, 
m, 3α-H), 2.37-2.20 (2H, m,4α-H, 4β-H), 2.07 (1H, m, 7α-H), 2.02-1.80 (5H, m, 1β-H, 2α-H, 
15α-H, 15β-H), 1.73-1.33 (9H, m, 7β-H, 8β-H, 11α-H,  2β-H, 11β-H, 12β-H, 12α-H), 1.16-
0.94 (8H, m, 1α-H, 9α-H), 1.92 (5H, m), 1.04 (3H, s, 18-CH3), 0.99 (3H, s, 19-CH3). 
13C-NMR 
(100 MHz, CDCl3): δ 140.0 (5-C), 120.9 (6-C), 71.6 (3-C), 71.3 (16-C), 50.1 (9-C), 48.6 (14-
C), 47.4 (13-C), 42.2 (4-C), 37.1 (1-C), 36.6 (10-C), 31.5 (2-C), 31.5 (8-C), 31.2 (7-C), 30.6 
(12-C), 30.4 (15-C), 20.0 (11-C), 19.4 (19-C), 13.9 (18-C). ). 1H-NMR and 13C-NMR data is 
consistent with data obtained for the respective standard.  
Molecular weight: 304.4 g/ mol; GC-MS: Retention time: 8.5 min. M+: 304; m/z (%): 304 (68), 
286 (39), 271 (29), 214 (39), 199 (79), 91 (91), 79 (78), 55 (71), 41 (100). 
 
2.3.2.11.1.3 16α-hydroxyprogesterone (3A) 
1H-NMR (400 MHz, CDCl3): δ 5.67 (1H, s, 4-H), 4.78 (1H, t, J= 7.0, 16β-H), 2.48 (1H, d, J= 
6.5, 17-H), 2.42-2.19 (4H, m, 2α-H, 2β-H, 6α-H,  6β-H), 2.11 (3H, s, 21-Me), 1.11 (3H, s, 19-
Me), 2.01-1.91 (2H, m, 1β-H, 12β-H), 1.81-1.44 (9H, m, 1α-H, 7β-H, 8-H, 11α-H, 12α-H, 14-
H, 15α-H, 15β-H), 1.37 (1H, dq, Jq = 12.7, Jd = 4.2, 11β-H), 1.11 (3H, s, 19-Me), 0.61 (3H, s, 
19-Me). 13C-NMR (100 MHz, CDCl3): δ 123.0 (C4), 72.5 (C17), 70.9 (C16), 52.7 (C14), 52.5 
(C9), 37.5 (C13), 34.6(C12), 34.2 (C15), 34.1 (C1), 32.9 (C6), 31.7 (C2), 30.7(C21), 30.7 (C7), 
19.6 (C11), 16.3 (C19), 13.4 (C18). 
1H-NMR and 13C NMR data is consistent with data obtained 
for the respective standard.   
Molecular weight: 330.5 g/ mol GC-MS: Retention time: 15.8 min. M+: 330.  m/z (%): 330 (1), 
312 (11), 297 (6), 269 (10), 231 (26), 100 (32), 91 (25), 55 (23), 43 (100).  
2.3.2.11.1.4 16α-hydroxyandrostenedione (4A1) 
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1NMR (400 MHz, CDCl3): δ 5.69 (1H, s, 4-H), 4.33 (1H, d, J= 7.9, 16β-H), 2.45-2.23 (5H, m, 
2αH, 2βH, 6αH, 6βH), 2.01-1.89 (2H, m, 1βH, 15βH), 1.90 -1.76 (3H, m, 7βH, 12βH, 15αH), 
1.71-1.60 (3H, m, 1αH, 8βH, 11αH), 1.52-1.27 (4H, m, 11βH, 12αH, 14αH), 1.14 (3H, s, 19-
CH3),  1.05 (1H, dq, Jq = 12.3, Jd = 4.5, 6αH), 0.95 (4H, m, 9αH, 18-CH3). 
13C-NMR (100 
MHz, CDCl3): δ 217.7 (17-C), 198.2 (3-C), 168.9 (5-C), 123.3 (4-C), 70.2 (16-C), 52.3 (9-C), 
46.7 (14-C), 46.4 (13-C), 37.6 (10-C), 34.6 (8-C), 34.1 (1-C), 32.9 (2-C), 31.4 (6-C), 30.0 (12-
C), 29.5 (7-C), 29.4 (15-C), 18.9 (11-C), 16.4 (19-C), 13.0 (18-C). 1H-NMR and 13C NMR data 
is consistent with data obtained for the respective standard.  
Molecular weight of derivatized product: 521 g/ mol, GC-MS: Retention time: 16.4 min. M+: 
521; m/z (%): 521 (0.2), 518 (7), 503 (13), 245 (2), 147 (7), 129 (2), 75 (9), 73 (100), 45 (7). 
 
2.3.2.11.1.5 16α-hydroxytestosterone (5A) 
1H-NMR (400 MHz, CDCl3): δ 5.67 (1H, s, 4-H), 4.09 (1H, t, J= 6.4, 16β-H), 3.45 (1H, d, J= 
5.5, 17-H), 1.12 (3H, s, 19-Me), 0.75 (3H, s, 18-Me). NMR data was consistent with 
previously published data.[23] As already described elsewhere[11], CYP154C5 hydroxylates 
regio- and enantioselectively at position C-16 obtaining the 16-α-hydroxytestosterone.  
Molecular weight of derivatized product 523 g/mol; Retention time: 16.3 min. M+: 523; m/z 
(%): 523 (6), 521 (43), 520 (100), 430 (4), 325 (6), 197 (5), 147 (9), 73 (94), 45 (5). 
 
2.3.2.11.1.6 16α-hydroxynandrolone (6A1) 
1H-NMR (600 MHz, CDCl3): δ 5.85 (1H, s, 4-H), 4.15 (1H, m, 16β-H), 3.53 (1H, d, J= 5.74, 
17-H), 2.49 (1H, dt, Jd= 14.8, Jt= 3.0, 6β-H), 2.42 (1H, m, 2-H), 2.31-2.23 (3H, m, 1-H, 2-H, 
6α-H), 2.10 (1H, m, 9-H), 1.88-1.78 (4H, m, 7α-H, 11β-H, 12β-H, 15β-H), 1.61-1.50 (2H, m, 
1-H, 15α-H), 1.43-1.16 (6H, m, 8β-H, 11α-H, 12α-H, 14α-H), 1.08 (1H, dq, Jq= 13.5, Jd= 4.0, 
7β-H), 0.89 (1H, m, 9α-H), 0.84 (3H, s, 18-CH3). 
13C-NMR (150 MHz, CDCl3): δ 200.2 (3-C), 
166.8 (5-C), 124.7 (4-C), 89.7 (17-C), 78.3 (16-C), 49.5 (9-C),  47.5 (14-C), 43.6 (13-C), 42.6 
(10-C), 39.9 (8-C), 36.5 (12-C), 36.3 (2-C), 35.4 (6-C), 33.6 (15-C), 30.6 (7-C), 26.5 (1-C), 
25.7 (11-C), 12.2 (18-C). 1H-NMR and 13C NMR data is consistent with data obtained for the 
respective standard.  
Molecular weight: 290.4 g/ mol, GC-MS: Retention time: 10.7 min, M+: 290, m/z (%): 290 
(100), 261 (15), 213 (20), 138 (50), 91 (39), 79 (36), 67 (46), 55 (51), 41 (64). 
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2.4   Results 
2.4.1 Cloning and recombinant expression of CYP154C5 
The gene of CYP154C5 was amplified from vector pKNL031_M17 from a genomic 
library of N. farcinica IFM 10152 [13] using PCR and cloned into the broad host-range vector 
pIT2-MCS, which contains an IPTG-inducible trc promoter and a tetracycline resistance gene 
[18]. Putidaredoxin and putidaredoxin reductase from P. putida DSM50198 served as 
electron transfer components in bioconversions [14]. For efficient coexpression of all three 
proteins in one host, E. coli C43(DE3) a mutant of E. coli BL21(DE3) was used [24]. 
Employing E. coli as a host for P450 expression and biocatalysis offers the advantage that E. 
coli naturally does not contain any endogenous P450 enzyme which could result in 
background activity. Protein expression was induced by IPTG addition and δ-aminolevulinic 
acid was added for enhanced heme synthesis. Additionally, trace element solution was used 
to supplement the media especially with iron. Protein production at 10 L fermentor scale 
resulted in a higher expression level compared to shake flasks (0.5 L). In particular, 
expression of the redox partners Pdx and PdR was more efficient whereas the amount of 
P450 obtained was rather equal. The obtained specific activity of the electron transfer 
components (ETC activity) was in the range of 1.1 to 1.4 U/mg total protein at fermentor 
scale in comparison to only 0.6 to 0.8 U/mg obtained in shake flasks. With regard to P450 
expression, approximately 2.4 mg of CYP154C5 per g of wet cells (corresponding to 45 mg 
CYP154C5 per liter culture and 1.7 % CYP154C5 of total soluble protein) were produced 
during 24 h cultivation in the bioreactor. Figure 2.3 shows the expression of CYP154C5, PdR 
and Pdx over time by SDS-PAGE. Protein bands corresponding to the expected molecular 
weight were found mostly in soluble form. 
 
Figure 2.3 Recombinant expression of E.coli C43 (DE3) (pIT2CYP154C5) (pACYCcamAB) in 0.5 
L scale shake flask. Several samples were taken over time and normalized by the cell amount. The 
protein bands of CYP154C5 (~45KDa), PdR (~45KDa) and Pdx (~11KDa) are marked by arrows [M: 
marker; lines 1 to 5: soluble fractions and lines 6 to 10: pellet fractions after cell disruption and 
centrifugation; lines1 and 6: before induction; 2 and 7: 3 h after induction; 3 and 8: 20 h after induction; 
4 and 9: 27 h after induction; 5 and 10: 43 h after induction]. The fermentation was performed for 24 
hours at 30°C, using TB media, supplemented with trace element solution (0.1 % v/v), -aminolevulinic 
acid (84 µm/mL), chloramphenicol (25 µm/mL) and tetracycline (10 µm/mL). IPTG was added to 
induce protein expression. 
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2.4.2 Steroid conversions on analytical scale: whole cells versus cell-free extract 
In order to identify optimal reaction conditions for steroid transformations using 
CYP154C5, bioconversions employing resting whole cells (WC) or cell-free extract (CFE) of 
E. coli C43(DE3) (pIT2cyp154C5) (pACYCcamAB) were compared. Figure 2.4 gives an 
overview of both catalytic systems. In bioconversions using whole cells, glucose was added 
to enable cofactor (NADH) regeneration by the cell metabolism. In the case of CFE 
reactions, formate dehydrogenase from Candida boidinii together with sodium formate as 
cosubstrate was applied to efficiently regenerate NADH giving only CO2 as a byproduct. 
Additionally, the influence of increasing concentrations of steroid substrate (0.5 to 8 mM for 
substrates 1, 2, 5 and 6; 0.5 to 15 mM for substrates 3 and 4) was investigated in both 
systems. In whole-cell reactions, an OD600 of 40 was used, which is equivalent to 3 µM 
CYP154C5 and an ETC activity of 9 U/mL (corresponding to a specific activity of 1.4 U/mg of 
total protein) determined by analysis of the cell-free extract after cell disruption. In the case of 
CFE, 3 µM P450 and 6 U/mL (0.8 U/mg total protein) ETC activity were employed. Since the 
three proteins were coexpressed in one host (for the whole-cell biocatalyst as well as the 
CFE), only the level of one of them was kept constant in the biocatalytic reactions (3 µM 
CYP154C5 in this case). As controls, either whole cells or CFE of E. coli C43(DE3) 
(pACYCcamAB), not expressing the cytochrome P450, were employed in steroid 
biotransformations. Conversions were determined by GC or HPLC based on substrate 
depletion and total turnover numbers (TTN, µmol of substrate consumed per µmol of 
CYP154C5 present in the reaction mixture) were calculated. Additionally, TLCs of reactions 
and controls were performed in order to identify the products formed for all tested reactions 
(see appendix section 2.3). 
 
 
 
Figure 2.4 Steroid hydroxylation by CYP154C5, PdR and Pdx in reactions employing whole 
cells (WC, A) and cell free extract (CFE, B). A: Glucose was added in order to regenerate the 
cofactor (NADH) using the E.coli´s own metabolism. B: Formate dehydrogenase from Candida boidinii 
was added in order to convert sodium formate with the concomitant regeneration of the cofactor and 
formation of CO2 as a byproduct. 
 
For all tested substrates application of whole cells resulted in higher conversions and 
higher TTN than cell-free extract (Figures 2.5 and 2.6). In all cases, except for testosterone 
(5), the difference in conversion and TTN between whole cells and CFE increases with 
increasing substrate concentration. Hence, the whole-cell biocatalytic system is especially 
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more suitable for reactions with high initial steroid concentrations. Highest TTN were 
obtained for progesterone (3, TTN = 2440) and androstenedione (4, TTN = 3341) for 10 and 
15 mM substrate concentration, respectively, using whole cells. In contrast, TTN in steroid 
transformations using CFE hardly exceeded 1000. However, it has to be stressed that 
despite the high TTN full substrate conversion was not achieved within 20 h reaction time 
using high initial substrate concentrations (≥ 8mM). In the control reactions with E. coli C43 
(DE3) (pACYCcamAB) not expressing CYP154C5, no product formation was observed (see 
appendix section 3.2.1). Comparing reactions of the different substrates using whole cells, 
substrates 1, 2, 3 and 4 are fully converted for initial steroid concentrations of up to 4 mM, 
whereas conversions of substrates 5 and 6 are already significantly reduced at substrate 
concentrations above 0.5 mM. Hence, achieved TTN for 5 and 6 are also significantly lower 
as compared to steroids 1-4. 
Additionally, the influence of cell density on the performance of the whole-cell 
biocatalytic reactions was investigated. For that, E. coli cells containing CYP154C5, Pdx and 
PdR were resuspended to obtain OD600 of 20, 30, 40 and 60 and tested in bioconversions 
with up to 8 mM 1, 3 and 5. For all substrates, an optical density of 40 yielded the highest 
conversions especially at initial substrate concentrations of ≥ 4 mM (Figure 2.7). Other than 
expected, product formation was not further increased in whole-cell reactions with OD600 of 
60. This might be attributed to an insufficient oxygen input and distribution in reactions with 
high cell mass since oxygen availability plays an important role in monooxygenase-catalyzed 
reactions [25]. 
 
Figure 2.5 Comparison of whole cells (WC) and cell-free extract (CFE) of E. coli C43 (DE3) 
(pIT2cyp154C5) (pACYCcamAB) in steroid bioconversions. Results are given as conversions (%) 
obtained in biotransformations of pregnenolone (1), dehydroepiandrostendione (2), progesterone (3), 
androstenedione (4), testosterone (5) and nandrolone (6) using different initial substrate 
concentrations. All reactions were carried out in 50 mM potassium phosphate buffer pH 7.4 at 30°C for 
20 h. Substrates were added as stock solutions in 36 % (w/v) hydroxypropyl β-cyclodextrin in ddH2O.  
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Figure 2.6 Comparison of whole cells (WC) and cell-free extract (CFE) of E. coli C43 (DE3) 
(pIT2cyp154C5) (pACYCcamAB) in steroid bioconversions. Results are given as total turnover 
numbers (TTN, µmol of substrate consumed per µmol of CYP154C5 present in the reaction) obtained 
in biotransformations of pregnenolone (1), dehydroepiandrostendione (2), progesterone (3), 
androstenedione (4), testosterone (5) and nandrolone (6) using different initial substrate 
concentrations. All reactions were carried out in 50 mM potassium phosphate buffer pH 7.4 at 30°C for 
20 h. Substrates were added as stock solutions in 36 % (w/v) hydroxypropyl β-cyclodextrin in ddH2O.  
 
 
Figure 2.7 Whole-cell catalysis of androstenedione (4) applying different optical densities. All 
reactions were carried out in 50 mM potassium phosphate buffer pH 7.4 at 30°C for 20 h. The 
substrate was added as stock solution in 36% (w/v) hydroxypropyl β-cyclodextrin in ddH2O. Cofactor 
regeneration was achieved by addition of 0.54 mg/mL glucose. 
 
While resting cells proved to be superior to CFE bioconversions if comparable P450 
concentrations were applied, the influence of different P450 concentrations in reactions with 
CFE was also investigated. Thus, CFE conversions with different P450 concentrations were 
performed for progesterone (3) and testosterone (5) using also different substrate 
concentrations (from 0.5 to 8 mM). For this, concentrated CFE was diluted with different 
volumes of buffer in order to obtain 0.5, 5, and 18 µM final P450 concentration. The specific 
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activity of the electron transfer components PdR and Pdx remained constant at 0.4 U/mg 
total protein (corresponding to 3.2 U per µmol CYP154C5). As expected, the more enzyme 
present in the reaction mixture the more substrate was converted (Figure 2.8). At the same 
time the obtained TTNs decreased significantly with increasing enzyme concentration. Thus, 
highest TTNs were achieved when using only 0.5 µM P450. However, the absolute amount 
of hydroxylated steroid that can be produced at such low enzyme concentration is still low. 
Thus, for a preparative-scale reaction where high product yields are aspired, application of a 
higher P450 concentration would be required. Furthermore, the addition of more NADH and 
FDH for cofactor regeneration in the CFE reactions did not increase conversion further (data 
not shown). Thus, the cofactor regeneration system is not limiting the performance of the 
P450 system in the reactions with CFE even if high P450 concentrations are applied. 
 
 
Figure 2.8 Steroid bioconversions with cell-free extract (CFE) of E. coli C43 (DE3) 
(pIT2cyp154C5) (pACYCcamAB) employing different CYP154C5 concentrations. Reactions with 
different concentrations of progesterone (3) and testosterone (5) were performed in 50 mM potassium 
phosphate buffer pH 7.4 at 30°C for 24 h. Sodium formate (10 mg/mL) and formate dehydrogenase 
from Candida boidinii (FDH, 0.5 U/mL) were used for cofactor regeneration (NADH, 50 µM). 
Substrates were added as stock solutions in 36 % (w/v) hydroxypropyl β-cyclodextrin in ddH2O. 
 
When comparing the results obtained for 18 µM CYP154C5 using CFE (Figure 2.8) 
and those obtained in whole-cell bioconversions (OD = 40) of all steroids applying 3 µM 
CYP154C5 (Figure 2.6), whole cells outperform reactions with CFE. Similar product amounts 
could be achieved in whole-cell reactions, although six times lower P450 concentrations 
were used in comparison to CFE reactions. Hence, also significantly higher TTN can be 
obtained in whole-cell bioconversions (Figure 2.9). Therefore, whole cells overexpressing the 
three proteins (CYP154C5, Pdx and PdR) and directly regenerating NADH within the E. coli 
metabolism proved to be more efficient for the production of hydroxylated steroids compared 
to CFE and were thus chosen for preparative-scale reactions. 
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Figure 2.9 Comparison of TTN achieved in steroid bioconversions by E. coli C43 (DE3) 
(pIT2cyp154C5) (pACYCcamAB) using cell-free extract containing 18 µM CYP154C5 (blue) and 
whole cells containing 3 µM CYP154C5 (OD = 40, green). Reactions with different concentrations of 
pregnenolone (1), dehydroepiandrostendione (2),  progesterone (3), androstendione (4), testosterone 
(5) and nandrolone (6) were performed in 50 mM potassium phosphate buffer pH 7.4 at 30°C for 24 h. 
Sodium formate (150 µM) and  FDH from Candida boidinii (FDH, 0.5 U/mL) were used for cofactor 
regeneration (NADH, 50 µM). Whole cell reactions were carried out in 50 mM potassium phosphate 
buffer pH 7.4 at 30°C for 20 h with addition of glucose (30 mM) for cofactor regeneration. Substrates 
were added as stock solutions in 36 % (w/v) hydroxypropyl β-cyclodextrin in ddH2O. 
 
2.4.3 Steroid conversions on preparative scale  
 After optimization of important parameters for bioconversion of the different 
substrates on analytical scale, best conditions for each steroid were chosen for scale-up. 
Thus, an optical density of 40 and 2 mM substrate concentration were chosen for the whole 
cell bioconversions, except for substrates 3 and 5 where 4 and 1 mM substrate concentration 
were employed, respectively. In this way, sufficient amounts of products could be prepared 
and purified by column chromatography. Afterwards, product structures were elucidated by 
employing one- and two-dimensional NMR techniques in order to determine the regio- and 
stereoselectivity of CYP154C5.  
Preliminary product identification was performed with a gas chromatograph-mass 
spectrometer. In order to facilitate GC-MS analysis of products 1A, 4A and 5A derivatization 
using activated MSTFA was necessary. GC-MS analysis of all steroid products indicated the 
addition of an oxygen atom to the respective substrate (see appendix section 3.3) In order to 
identify the position and orientation of hydroxylation in products 1A-6A, 1- and 2-dimensional 
NMR data (1H, 13C, COSY, HSQC and NOESY) were analyzed and compared with the 
respective data of 16-hydroxylated standards (except for products 5A where no standard 
was purchased and 6A1 where no standard was available) (see appendix section 2.4). For 
products 1A, 3A, 5A and 6A1, the coupling constant (J) between 16β-H and 17α-H was the 
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key to confirm the orientation (α and/ or β) of hydroxylation to be 16. In contrast, for 
products 2A and 4A1 the JHβ15-Hβ16 was analyzed (Table 2.1). 
 
Table 2.1 Chemical shifts (δ) and coupling constants (J) determined from 
1
H-NMR and 
13
C-NMR 
data of steroid products 1A-6A1 formed by CYP154C5. Corresponding data of the standards are 
shown in brackets. 
a
 no standards were purchased  
 
Since no standard of 6A1 is commercially available, structure elucidation of this 
product was not possible based on a comparison of NMR data with that of a respective 
standard. Thus, as a first step, the 1H-NMR spectra of product and substrate were compared. 
The triplet signal at 3.77 ppm in the substrate spectrum corresponding to 17α-H changed to a 
doublet at 3.52 ppm in the product 1H-NMR spectrum. This is the first indication of 
hydroxylation at position C16, since a hydroxyl group cannot be introduced at the other 
neighboring carbon (position C13). Furthermore, in the HSQC spectrum of 6A1 (Figure 
2.10.B), the proton signal at 4.15 ppm is coupling with a carbon signal at 89.7 ppm. These 
chemical shifts indicate the presence of a hydroxyl group at the mentioned carbon. Therefore 
the proton signal is assigned as 16-H. Additionally, the COSY spectrum (Figure 2.10.C) 
shows a correlation between 16-H and 17α-H, and 16-H with 15β-H, confirming once more 
hydroxylation at position C16. In the NOESY spectrum (Figure 2.10.D) coupling between 16-
H and 17α-H is not observed whereas the coupling between 16-H and 15β-H is still present, 
indicating that 16-H is actually 16β-H. Hence, it can be concluded that CYP154C5 selectively 
hydroxylates nandrolone (6) at position 16 with α-orientation.  
As a result, an exceptionally high regio- and stereoselectivity was found for 
CYP154C5 in steroid conversions of 1–6 always yielding the corresponding 16α-
hydroxylated products (1A–6A, Figure 2.11). Only in the case of androstenedione (4) and 
nandrolone (6), small amounts of a secondary product were formed. However, the amounts 
were so low that they could be easily removed by column chromatography purification. As 
mentioned before, 16α-hydroxylation of testosterone (5) by CYP154C5 had already been 
demonstrated by Agematu et al. on analytical scale and was now confirmed for five other 
steroid substrates by our NMR results [11]. 
Product C16 δC 
(ppm) 
16-H δH 
(ppm) 
JHβ15-Hβ16 
(Hz) 
JHβ16-Hα17 
(Hz) 
(1A) 16α-hydroxypregnenolone 72.5 (71.0) 4.79 (5.53)  6.8 (6.5) 
     
(2A) 16α-hydroxydehydroepiandrosterone 71.3 (71.3) 4.38 (4.40) 7.8 (8.4)  
     
(3A) 16α-hydroxyprogesterone 70.9 (73.7) 4.78 (4.87)  7.0 (6.5) 
     
(4A1) 16α-hydroxyandrostenedione 70.2 (71.2) 4.33 (4.41) 7.9 (8.3)  
     
(5A) 16α-hydroxytestosterone
a 
 4.09  6.4 
     
(6A1) 16α-hydroxynandrolone
a
 78.3 4.15 multiplet  
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Figure 2.10 Structure elucidation of product 6A1. A: Structure of product 6A1. B: HSQC showing 
the correlation between 16β-H and the respective carbon 16, C: COSY showing the coupling between 
16β-H with 15β-H and 17α-H, D: NOESY confirming the α-hydroxylation where 16β-H couples with 18-
CH3 and 15β-H but not with 15-H.E: GC-MS spectrum showing the molecular ion of 6A1 with m/z= 
290 ([M]
+ 
of 6
 
+16). 
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Figure 2.11 Bioconversion of steroids 1-6 by the three component system composed of 
CYP154C5, Pdx and PdR. Product (1A-6A1) structures were determined by one and two-dimensional 
NMR techniques.  
 
Conversions and TTN achieved on preparative-scale were similar to the results of the 
analytical-scale biotransformations. Hence, scale up did not negatively influence the 
performance of the whole-cell biocatalyst. Substrates 1, 2, 3 and 4 were fully converted 
within 24 h of reaction whereas only one third and one half of the initial substrate 
concentration of 5 and 6, respectively, were hydroxylated. Furthermore, isolated yields of the 
purified steroid products under non-optimized conditions ranged between 70-80 % (40-130 
mg hydroxylated steroid).  
Later, the preparative-scale conversions of progesterone and testosterone were also 
tested in a 2 L bioreactor with controlled pH and dissolved oxygen. In case of progesterone 
(3), 4 mM substrate was added to 700 mL resuspended cells with an optical density of 40 in 
phosphate buffer containing 30 mM glucose for cofactor regeneration. After 22 h of reaction 
another 30 mM glucose were added to the bioreactor. As can be seen from Figure 2.12.A 
progesterone (3) is initially consumed with a high rate (1.3 µmol substrate consumed min-1 
µmol-1 CYP154C5) accompanied by an acidification of the reaction medium, and thus base 
addition, most likely due to formation of organic acids upon glucose consumption. 
Additionally, dissolved oxygen stayed close to zero suggesting the presence of metabolically 
active E.coli cells. After five hours of reaction, the E. coli cells started to consume the formed 
organic acids again as can be concluded from the addition of acid to the reaction medium in 
order to keep the pH constant at pH 7.00. At approx. 12 h of reaction, the dissolved oxygen 
increased reaching a maximum of 75 % between 17 to 22 h. This is most likely attributed to 
the complete consumption of the carbon source. Hence, also progesterone was most 
probably not converted anymore since no cofactor regeneration could occur. Addition of 
fresh glucose solution to the reaction at 22 h (indicated by an arrow, Figure 2.12.A) caused 
again a dramatic decrease of dissolved oxygen (to zero), but led only to a further slight 
increase in progesterone conversion. After 25 h of reaction only 60 % 3 were converted to 
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product (3A; 630 mg and 68 % isolated yield). Hence, the conversion and TTN (773) 
achieved in the bioreactor are 2-fold lower than the results obtained in shake flask 
experiments (Figure 2.6). However, the performance of the whole-cell biocatalyst could be 
still significantly enhanced by further optimizing the reactions conditions in the bioreactor.  
 
 
Figure 2.12 Whole cell catalysis of progesterone (3, A) and testosterone (5, B) by CYP154C5, 
PdR and Pdx in a 2 L bioreactor. Bioreactor parameters such as dissolved oxygen, the volumes of 
added acid and base as well as substrate consumption are depicted over time. All reactions were 
performed at 30°C for 25 h. A: Bioconversion of 4 mM progesterone (3) by whole cell catalysis with an 
OD600 of 40 and addition of 21 mmol glucose. The arrow indicates the addition of another 9 mmol 
glucose. B: Bioconversion of testosterone (5) using an OD600 of 30. Each arrow indicates the 
individual addition of 231 nmol substrate 5 and 21 mmol glucose. 
 
When the testosterone conversion was scaled up in the bioreactor under controlled 
pH and dissolved oxygen, additionally a pulsed substrate and glucose feeding was employed 
to keep the testosterone concentration below a possible inhibitory level. Since  conversion of 
5, either by WC or CFE, was significantly hampered at testosterone concentrations of 1 mM 
and higher, the steroid was this time added in three portions (0, 3 and 6 h of reaction) of 
each 231 nmol (corresponding to 0.33 mM) resulting in an overall testosterone concentration 
of 1 mM. (Figure 2.12.B). Similarly, 21 mmol of glucose (~30 mM) were concomitantly added 
each time for cofactor regeneration. This carbon source is metabolized generating acids 
which cause a decrease in pH. As a consequence, base solution was added to maintain the 
pH stable at 7.00. Since three times more glucose was added in the testosterone reaction in 
comparison to the progesterone conversion, also the addition of more base was necessary in 
the first case (Figure 2.12.A-B). Despite the substrate feeding conditions in the bioreactor, 
the productivity of the biotransformation was not improved but similar results as in shake 
flask experiments were achieved. Overall, only 30 % of the added substrate 5 was converted 
to product in the bioreactor resulting in a rather low TTN of 100. Maybe also the formed 
product 5A exerts a certain inhibitory or toxic effect limiting the overall product yield. In this 
case the use of a biphasic system allowing an in situ extraction of the formed product could 
be a solution [26]. 
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2.4.5 Reaction kinetics of the resting whole-cell system 
In order to characterize the performance of the whole-cell system further, turnover 
numbers (TON, µmol of substrate consumed per min per µmol CYP154C5) for all six steroid 
substrates were determined. In this way the efficiency of the catalytic system for the different 
substrates could be analyzed and compared. Bioconversions on 25 ml scale using whole 
cells of E. coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) were performed with an optical 
density of 40 (corresponding to 3 µM CYP154C5 and a specific activity of ETC of 1.0 U/mg of 
total protein, 4.5 U/mL) and 2 mM substrate concentration. Samples were taken every hour 
in order to quantify the amount of consumed substrate in the reaction. As can be observed in 
Figure 2.13, the substrate conversion rate differs significantly depending on the steroid 
substrate. Substrates 1, 2, 3 and 4 reached full conversion within the first 4-6 hours of 
reaction, whereas in bioconversions of 5 and 6 roughly only 50 % of the substrate was 
converted within the first 8 hours. This results in space-time yields of the whole-cell system of 
2.7, 3.0, 4.0, 3.6, 0.9 and 1.5 g L-1 d-1 for steroid products 1A, 2A, 3A, 4A1, 5A and 6A1, 
respectively.  
 
Figure 2.13 Turnover number (TON) determination for whole cells of E. coli C43 (DE3) 
(pIT2cyp154C5) (pACYCcamAB) in steroid biotransformations. TTN and conversion of A: 
pregnenolone (1) and testosterone (5), and B: progesterone (3) over time are given. All 
bioconversions were carried out in 50 mM potassium phosphate buffer pH 7.4 at 30°C for 20 h with an 
optical density of 40 and glucose for cofactor regeneration (0.54 mg/mL). Substrates were added as 
stock solutions in 36 % (w/v) hydroxypropyl-β-cyclodextrin in ddH2O. Reactions were performed in 
triplicate. 
 
 Surprisingly, the conversion of some steroids, especially pregnenolone (1), was rather 
low during the first hour (Figure 2.13.A). Thus, in order to determine the highest rates of 
steroid conversion by the whole-cell system, TON were calculated starting at two hours of 
reaction (0 and 1 h data points were not included in the calculation). As expected, 5 and 6 
gave the lowest TON, approximately 1 µmol of substrate was consumed per minute per µmol 
of CYP154C5. In contrast, 1 and 3 gave a 3-fold higher TON in comparison to 5 and 6 (Table 
2.2).  
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Table 2.2 Calculated TON for whole-cell bioconversions of E. coli C43 (DE3) (pIT2cyp154C5) 
(pACYCCamAB) and the six different steroid substrates. Values represent mean values of 
triplicate measurements. 
 
Substrate TON (µmol substrate consumed 
min-1 µmol-1 CYP154C5) 
1 Pregnenolone 3.28 ± 0.05 
2 Dehydroepinadrosterone 2.90 ± 0.17 
3 Progesterone 3.33 ± 0.10 
4 Androstenedione 2.15 ± 0.03 
5 Testosterone 0.82 ± 0.01 
6 Nandrolone 1.24 ± 0.15 
 
Since for all bioconversions cells were used which had been stored at -20°C before 
use, the question was if freezing and thawing of the cells had an impact on the reaction 
kinetics. Thus, bioconversions of the six substrates (1-6) were repeated under the same 
conditions but using fresh cells overexpressing CYP154C5, Pdx and PdR. Surprisingly, in 
this case the results indicate a more pronounced “lag phase” as obtained for frozen cells, 
which was now even observable for all substrates (Figure 2.14). Depending on the substrate, 
this delay in conversion lasted between two to five hours before conversion rates increased. 
Thus, an overall longer reaction time was necessary to achieve the same conversion and 
TTN.  
 
2.4.6 Repetitive batch bioconversions 
Additionally, the possibility to recycle the whole-cell catalyst in the conversion of 
progesterone (3) was tested. Thus, bioconversions on 25 ml scale using frozen cells of E. 
coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) were performed with an optical density of 
40 and 30 mM glucose for cofactor regeneration. In order to observe full conversion in a 
short period of time, an initial substrate concentration of only 1 mM was applied. After 2 h of 
reaction the cells were harvested, washed and resuspended again in buffer to start the 
second cycle with the addition of 30 mM glucose and 0.5 mM substrate as described for the 
first round. In total, four cycles were run with the same batch of cells. Samples were taken 
every 30 minutes and the substrate consumption was determined (Figure 2.15). As a result, 
after 1.5 h full conversion was achieved in the first cycle. However, a dramatic decrease of 
the overall conversion was already observed in the second cycle, where only 12 % 
conversion was obtained, followed by 7 % conversion in the third cycle and no conversion in 
the last round. Thus, the tested conditions are not suitable for the repeated use of the whole-
cell catalyst in consecutive cycles for steroid hydroxylation.  
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Figure 2.14 Comparison of whole cell biocatalyses using fresh and frozen cells of E. coli C43 
(DE3) (pIT2cyp154C5) (pACYCcamAB). Fresh cells containing CYP154C5, PdR and Pdx were 
washed after expression and resuspended to an OD600 of 40 in 50 mM potassium phosphate buffer pH 
7.4 (equivalent to 3 µM CYP154C5 and a specific activity of ETC of 1.6 U/mg of total protein). Whole-
cell conversions with frozen cells were performed with a batch of cells which had been frozen and 
thawn before use. Cells were also resuspended to OD600 of 40 (equivalent to 3 µM CYP154C5 and a 
specific activity of ETC of 0.7 U/mg of total protein) in buffer. In both cases 30 mM glucose and 2 mM 
substrate, dissolved in 36 % (w/v) hydroxypropyl--cyclodextrin in water, were added. 
 
Figure 2.15 Reuse of the whole-cell catalyst in repetitive batches of progesterone 
hydroxylation. For each cycle E. coli C43 (DE3) (pIT2CYP154C5) (pACYCcamAB) cells  
resuspended to OD600 of 40 in 50 mM potassium phosphate buffer pH 7.4 (corresponding to 3 µM 
CYP154C5 and a specific activity of ETC of 1.1 U/ mg of total protein) were incubated for 2 h at 30°C 
after addition of 0.5 mM progesterone (3) and 30 mM glucose. 
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2.5   Discussion 
 Industrial steroid synthesis involves sophisticated chemical and enzymatic steps 
including the selective incorporation of hydroxyl groups in the steroid backbone. For this 
reason, cytochrome P450 monooxygenases, which are able to directly hydroxylate non-
activated carbon atoms, are attractive enzymes for the production of steroid hormones in the 
pharmaceutical industry. In the present chapter, the recombinant expression and 
characterization of bacterial CYP154C5 for the regio- and stereoselective hydroxylation of 
different steroid compounds is reported. Since the natural electron transfer partners of this 
P450 are unknown, Pdx and PdR from P. putida were employed to supply CYP154C5 with 
the necessary electrons for catalysis. It had been shown earlier by Agematu et al. that Pdx 
and PdR can be applied as surrogate redox partners for this P450 [11]. Using a two-plasmid 
system the three different proteins, CYP154C5, Pdx and PdR, were coexpressed in soluble 
and active form in E. coli yielding good levels of CYP154C5 (approximately 2 % of total 
protein) and sufficient activity of the electron transfer components (up to 1.4 U/mg of total 
protein).  
 Applying this three-component system in bioconversions of six different steroid 
substrates (1-6) we could show that CYP154C5 exhibits excellent regio- and stereoselectivity 
not only for testosterone but also for all other tested steroids always producing exclusively 
16-hydroxylated steroids 1A-6A. Such a high specificity in the hydroxylation of various 
steroids carrying different functional groups and differing in the position of double bonds is 
remarkable since often more than one product is formed for the same steroid substrate by a 
P450 monooxygenase [9, 11, 27, 28] and regioselectivities even vary with change of the 
steroid substrate ([9, 28] and chapter 5 of this thesis). With CYP154C5 only in the case of 4 
and 6 low quantities of a secondary product were observed in whole-cell transformations, 
which were not formed using purified proteins (see Chapter 4 of this thesis). Hence, they 
might not be direct products of CYP154C5 catalysis. Steroid hydroxylation in 16-position 
was also described in literature for a P450 monooxygenase from Streptomyces 
roseochromogenes NCIB 10984 as well as CYP123 from Rhodococcus erythropolis PR4 and 
CYP110A1 from Nostoc sp. PCC7120 [11, 29]. However, reported steroid hydroxylation 
activities were rather low (e.g. 1.18 mmol progesterone converted per hour per mmol P450 
for the enzyme from S. roseochromogenes) [29] and further oxyfunctionalisation of the 
product at additional positions was reported. In contrast and under the described reaction 
conditions, the here obtained TON with CYP154C5 are already by a factor of 40 to 160 
higher depending on the used steroid substrate.  
 Comparing the efficiency of steroid bioconversions using either resting whole cells or 
cell-free extract of E. coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) clearly revealed an 
advantage of the whole-cell system, especially at high initial substrate concentrations. Not 
only significantly higher steroid concentrations (up to 15 mM) were still efficiently converted 
using whole cells, also substantially higher TTN and product yields could be achieved 
applying only low P450 concentrations. Thus, space-time yields of several grams of 
hydroxylated steroid per liter and day could be obtained. However, when comparing both 
systems it has to be taken into account that in the case of CFE reactions (i) a different 
cofactor regeneration system was used and (ii) the applied ETC activity was slightly lower as 
compared to the whole-cell system. Nevertheless we could prove that NADH regeneration by 
formate dehydrogenase and sodium formate in the CFE system was not limiting the overall 
performance of the P450 reaction. Furthermore, the slightly lower ETC activity alone can also 
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not account for the significantly reduced conversions and product yields of the CFE system 
as compared to whole cells since similar product yields for both systems could only be 
obtained using six times higher P450 concentration and three times higher volumetric ETC 
activity in CFE reactions as compared to whole cells. Hence, the experimental results clearly 
prove the superior performance of our whole-cell system over reactions using CFE. In 
contrast, Zehentgruber et al. reported that the use of crude cell extract (CCE) of 
recombinantly expressed CYP106A2 from Bacillus megaterium in E. coli together with bovine 
adrenodoxin and adrenodoxin reductase as redox partners resulted in significantly higher 
initial reaction rates (9.6 U15β-Prog glyphilisate
-1) as compared to whole cells in testosterone and 
progesterone bioconversions. However, the authors applied only low substrate 
concentrations (0.5 mM) since activity decreased significantly at higher steroid 
concentrations. On the other hand, the selectivity of their P450 system decreased to 80 % 
when using cell free extract in comparison to whole cells due to unwanted formation of 
secondary hydroxylation products [9].  
 
Furthermore, an optical density of 40 in our whole cell catalytic system was found to 
be the optimum under the tested conditions, since an OD of 60 resulted already in lower 
conversion. This might be attributed to an insufficient oxygen input and distribution in 
reactions with high cell mass since oxygen availability plays an important role in 
monooxygenase-catalyzed reactions [25]. Additionally, freezing and thawing of the cells prior 
to bioconversion resulted in a faster reaction. This is most likely due to an improved 
substrate uptake since steroids cannot be actively transported into the cells but have to 
diffuse through the membrane [30]. Therefore, freezing and thawing contributes to cell 
permeabilization and thus facilitates substrate uptake. However, the reuse of cells in 
biotransformations over several rounds was not possible since a dramatic decrease in 
steroid conversion was already observed in the second cycle. It has to be stressed that 
partially permeabilized cells were applied in this experiment since the employed cells had 
also been frozen and thawn before use. Thus, the required cofactor NADH or other low 
molecular weight compounds, e.g. metabolites in glycolysis or the TCA cycle important for 
cofactor regeneration, might have been lost during the washing steps. Hence, the use of 
fresh and thus intact cells might result in a better performance in repetitive cycles of steroid 
hydroxylation. On the other hand, the coexpression of a cofactor regenerating enzyme 
enabling a cofactor regeneration independent of the cell metabolism might be advantageous.  
 In literature, generally only low initial steroid concentrations (<1 mM) are applied in 
biotransformations of steroids using bacterial or eukaryotic P450 systems (whole-cell as well 
as isolated enzyme approaches). This might be explained by the very low solubility of 
steroids in aqueous solution [31], typically low rates of the applied P450s or the possible 
inhibitory (or even toxic) effect of steroids for microbial cells and enzymes [32]. The low 
solubility of steroids is usually overcome by the use of a co-solvent such as methanol. 
Furthermore, the use of hydroxypropyl--cyclodextrin for the solubilization of steroids in 
aqueous solution was also reported [33–36]. Thereby, the cyclodextrin derivative offers the 
advantage that even high steroid concentrations are efficiently dissolved in the aqueous 
reaction media. In contrast, comparably high amounts of methanol, exhibiting a destabilizing 
effect on enzymes and cells, would be necessary to achieve the same [5]. Nevertheless, for 
potential industrial applications productivities of several grams per liter are required, 
emphasizing the need for biocatalytic systems that efficiently hydroxylate steroids with high 
rates and achieve high product titers [12]. Our E. coli-based whole-cell biocatalyst containing 
CYP154C5, Pdx and PdR still efficiently hydroxylated steroids at concentrations of 4 mM or 
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higher. Thus, productivities of 2-3 g/L could be achieved in case of pregnenolone (1), 
dehydroepiandrosterone (2), progesterone (3) and androstendione (4). The use of 
hydroxypropyl--cyclodextrin in our reactions clearly facilitated the solubilization and thus 
conversion of the required steroid amounts without exhibiting any destabilizing effects on 
cells or enzymes. Only for testosterone (5) and nandrolone (6) much lower yields were 
obtained at initial steroid concentrations of 1 mM or higher. Likewise also the measured TON 
for the two steroids using our whole-cell system was by a factor of 2-3 lower compared to the 
other steroids. This might be due to a different substrate specificity of the enzyme or even an 
inhibitory effect of the two steroids at higher concentrations. Structurally, testosterone (5) and 
nandrolone (6) are very similar, both carrying a hydroxyl group at carbon 17, which might 
explain the similar behavior. Bioconversion of testosterone (5) in a bioreactor with controlled 
pH and oxygen as well as substrate feeding to keep overall testosterone concentrations low 
did also not result in a higher productivity. Instead, it decreased two-fold as compared to 
shake-flask conversions. However, an optimization of the reaction conditions in the 
bioreactor was not carried out and would be required first. Furthermore, it has to be stressed 
that in this bioreactor experiment methanol was used as cosolvent instead of hydroxypropyl-
-cyclodextrin to dissolve the steroid substrate. Hence, the decreased productivity could also 
result from the lower solubility of 5 in the aqueous reaction medium with addition of only 1 % 
methanol as compared to a complete dissolution using hydroxypropyl--cyclodextrin. This 
should be investigated in further experiments in the future. 
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3.1   Abstract 
Cytochrome P450 CYP154C5 from Nocardia farcinica exhibits a remarkably high 
regio- and stereoselectivity in the hydroxylation of various steroid molecules, such as 
pregnenolone (1), dehydroepiandrosterone (2), progesterone (3), androstenedione (4), 
testosterone (5) and nandrolone (6), yielding exclusively the respective 16α-hydroxylated 
steroid. The enzyme’s crystal structure in presence of the six different steroid substrates was 
solved, showing the typical helix-rich P450 structure. Interestingly, the asymmetric unit was 
found to be composed of two protein molecules that are covalently linked via a disulphide 
bond. In all obtained CYP154C5-steroid complexes, the steroid substrate is orientated in the 
active site with its C16 pointing towards the heme group. Additionally, the steroid molecule is 
slightly shifted above the heme, so that hydroxylation can only occur from the α-face of the 
substrate explaining the high selectivity of this P450 in steroid hydroxylation. Interestingly, 
the steroid substrates fit almost perfectly in the active site of CYP154C5 since the 
hydrophobic steroid core as well as the polar regions at both ends of the molecule are 
perfectly mimicked by the enzyme’s substrate binding pocket. Due to the high hydrophobicity 
of the steroid substrates and the enzyme’s active site, substrate binding was found to be 
mainly entropically driven. Careful inspection of the structures further revealed that residues 
Q398 and to a less extent Q239 were observed to play important roles for substrate 
orientation in the active site as they form hydrogen bonds (either directly or via water 
molecules) with the respective hydroxyl-, keto- or acetyl- substituents at positions C17 and 
C3 of the steroid molecule. Furthermore, bioconversions of substrates 1-6 were carried out 
employing purified CYP154C5, putidarodoxin and putidarodoxin reductase from 
Pseudomonas putida in order to determine the efficiency of the purified three-component 
system. Thus, turnover numbers (TONs), coupling efficiencies and dissociation constants 
(KD) were determined. Results showed remarkably tight binding of the steroids by CYP154C5 
due to KD values in the nanomolar range, and coupling efficiencies between 40 and 86 % 
depending on the used substrate. Although no significant structural differences were 
observed between the six different CYP154C5-steroid complexes, some steroid-specific 
enzyme-substrate interactions could be identified which likely play a role in substrate binding 
and hence influence also the efficiency of the catalytic system.  
 
3.2   Introduction 
 
Cytochrome P450 monooxygenases (CYPs) are highly interesting, heme-containing 
enzymes as they are involved in many physiologically important reactions such as the 
detoxification of xenobiotics, the synthesis of secondary metabolites or drug metabolism [3]. 
Furthermore, they are promising biocatalysts due to their remarkable ability to directly 
hydroxylate non-activated carbon atoms simply using molecular oxygen from air. Besides 
hydroxylation, CYPs were shown to catalyze a range of chemically diverse reactions such as 
epoxidations, dealkylations, dehalogenations and heteroatom oxidations amongst others. 
The enzymes are found in eukaryotes and prokaryotes mainly as multi-component systems 
containing, besides the monooxygenase, one or two redox partners for electron transfer from 
the cofactor NAD(P)H to the heme iron.  
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One industrially very important application of cytochrome P450 monooxygenases is 
the regio- and stereoselective hydroxylation of steroid compounds in the pharmaceutical 
industry for the synthesis of highly valuable steroid hormones such as glucocorticoids, 
mineralocorticoids and sexual hormones. Today, many more eukaryotic CYPs are known to 
carry out this reaction due to their natural involvement in steroid synthesis. In consequence, 
also more crystal structures of eukaryotic P450 monooxygenases were solved so far carrying 
a steroid molecule in the active site. In contrast, only the crystal structures of two bacterial, 
steroid-converting CYPs  CYP125A1 (PDB: 2X5W) [4] and CYP142A2 (PDB: 2YOO) [5] 
both originating from mycobacteria  with steroid bound in the active site can be found in the 
PDB. This is in so far surprising as eukaryotic CYPs are typically membrane-bound while 
prokaryotic CYPs are soluble enzymes. Hence, the latter also seem to be more promising for 
industrial application due to easy overexpression and facilitated protein engineering for the 
generation of improved variants.  
Very recently, a novel bacterial cytochrome P450 monooxygenase from Nocardia 
farcinica, CYP154C5, was identified to hydroxylate various pregnans and androstans with 
exceptionally high regio- and stereoselectivity yielding only the corresponding 16-
hydroxylated steroids as products [6]. The enzyme belongs to class I three-component P450 
monooxygenases requiring a ferredoxin reductase and a ferredoxin as redox partners for 
catalysis. Using putidaredoxin (Pdx) and putidaredoxin reductase (PdR) from Pseudomonas 
putida as surrogate electron transfer partners together with CYP154C5 [7, 8], a highly 
efficient, Escherichia coli-based whole-cell biocatalyst was generated for preparative-scale 
steroid hydroxylations achieving productivities of 1-4 g L-1 d-1 depending on the converted 
substrate. Thus, CYP154C5 constitutes a promising biocatalyst for the future production of 
16-hydroxylated steroids and could serve as a template for protein engineering experiments 
in order to generate variants with changed but still exclusive selectivity. Though exhibiting 
always the same high regio- and stereoselectivity in the conversion of pregnenolone (1), 
dehydroepiandrosterone (2), progesterone (3), androstenedione (4), testosterone (5) and 
nandrolone (6) (Figure 3.1), also significant differences in the reaction rates were observed 
for CYP154C5 which cannot be explained without structural insights into steroid binding and, 
thus, the crystal structure of this enzyme. 
Of the CYP154 family of P450 monooxygenases the crystal structures of two CYPs, 
namely CYP154A1 (1ODO) and CYP154C1 (1GWI) from Streptomyces coelicolor A3(2), 
were reported so far revealing significant differences in their active sites [9, 10]. The most 
intriguing difference is the 180° flip of the heme orientation in the active site of CYP154A1 
compared to most other CYP structures. CYP154C1 was reported to hydroxylate various 
macrolactones while CYP154A1 catalyses the cyclisation of a dipentaenone molecule [9]. 
Both enzyme structures, however, were only obtained without substrate bound in the active 
site impeding the generation of a reliable homology model for CYP154C5. Furthermore, 
although belonging to the same subfamily of P450 monooxygenases, CYP154C1 and 
CYP154C5 share only 54 % sequence identity on protein level. Hence, in order to identify 
structural determinants for the high regio- and stereoselectivity of CYP154C5 in steroid 
hydroxylations and to facilitate the generation of CYP154C5 variants with improved activity or 
altered selectivity by protein engineering, elucidation of its crystal structure with substrate 
bound in the active site is essential. Therefore, protein crystallization trials were performed 
yielding high-resolution structures of four CYP154C5-steroid complexes with pregnenolone 
(1), progesterone (3), androstenedione (4) and testosterone (5) bound in the active site. 
Based on these crystal structures, the exclusive selectivity of CYP154C5 can be explained 
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and likely reasons for differences in steroid binding affinity as well as conversion of 1-6 by 
this P450 are given. 
 
 
Figure 3.1 Bioconversion of steroids 1-6 by the three component system composed of 
CYP154C5, Pdx and PdR. In all cases, 16-monohydroxylated products (1A-6A) of pregnenolone (1), 
dehydroepiandrosterone (2), progesterone (3), androstenedione (4), testosterone (5) and nandrolone 
(6) are obtained [6]. 
 
3.3   Materials and methods 
3.3.1 Materials 
Pregnenolone, testosterone, progesterone and cholesterol were purchased from 
Sigma-Aldrich, Germany. Dehydroepiandrosterone, androstenedione and nandrolone were 
purchased from Steraloids Inc., USA. All solvents and chemicals necessary for the 
experiments were obtained from Applichem Roth, or Sigma-Aldrich. 
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Cytochrome c from horse heart, formate dehydrogenase from Candida boidinii, 
superoxide dismutase from bovine erythrocytes, catalase from bovine liver and 
hydroxypropyl β-cyclodextrin were purchased from Sigma Aldrich (Taufkirchen, Germany). 
Roti-quant for Bradford assay was purchased from Roth (Karlsruhe, Germany). All solvents 
and chemicals necessary for the experiments were obtained from Roth or Sigma-Aldrich 
(Taufkirchen, Germany) and used without further purification. 
 
3.3.1.1 Bacterial strains and plasmids 
The Escherichia coli TOP10 strain (Invitrogen, Carlsbad, CA, USA) was used for 
storage and genetic manipulations, while E. coli C43 (DE3) (Lucigen, Middleton, WI, USA) 
was used for expressions.  
Plasmid pACYC-Duet1 was purchased from Novagen (EMD Biosciences, San Diego, 
CA, USA) while the broad host-range expression vector pIT2-MCS was prepared as 
described elsewhere [11]. Plasmid pKNL031_M17 from a genomic library of Nocardia 
farcinica containing the gene of CYP154C5 (nfa53110, GenBank: NC_006361) was kindly 
provided by Jun Ishikawa (National Institute of Infectious Diseases, Japan). Plasmid 
pET28a(+) was purchased from Novagen (EMD Biosciences, San Diego, CA, USA).  
Preparation of plasmids pACYCcamA for expression of putidaredoxin reductase 
(CamA or PdR) and pACYCcamB for expression of putidaredoxin (CamB or Pdx) from 
Pseudomonas putida in E. coli was described elsewhere [11]. The gene of CYP154C5 was 
cloned into vector pIT2-MCS as previously described [6]. Afterwards, CYP154C5 was 
subcloned from pIT2cyp154C5 into vector pET28a(+) using restriction sites NdeI and HindIII. 
The resulting plasmid was named pET28cyp154C5. Expression of CYP154C5 from vector 
pET28cyp154C5 results in a fusion protein with N-terminal His-tag. 
 
3.3.2 Methods 
3.3.2.2 Recombinant expression in E. coli 
3.3.2.2.1 Expression of Escherichia coli C43 (DE3) (pIT2cyp154C5) at 10 L bioreactor 
scale 
E. coli C43 (DE3) was used as host in order to express CYP154C5 without his-tag 
from vector pIT2cyp154C5 for crystallization studies. For that, 5 mL liquid LB media (10 g/L 
of tryptone, 5 g/L of yeast extract, 10 g/L of NaCl) supplemented with tetracycline (10 µg/mL 
final concentration) was inoculated from a frozen stock of E. coli C43 (DE3) (pIT2cyp154C5). 
After overnight incubation at 37°C and 250 rpm (Bench top shaker Certomat Sartorius, 
Göttingen, Germany), a 200 mL TB preculture supplemented with tetracycline (10 µg/mL) 
was inoculated with 1 % v/v of the overnight culture and incubated for 24 h under the same 
conditions. Finally a 15 L fermenter (Bioreactor Biostat MD Sartorius, Göttingen, Germany) 
containing 9.8 L of TB media supplemented with tetracycline (10 µg/mL) and 0.1 % v/v of 
trace element solution (0.5 g/L of CaCl2.2H2O, 0.18 g/L of ZnSO4.7H2O, 0.10 g/L of 
MnSO4.H2O, 20.10 g/L of Na2-EDTA, 16.70 g/L of FeCl3.6H2O, 0.16 g/L of CuSO4.5H2O and 
0.18 g/L of CoCl2. 6H2O) was inoculated with 2 % v/v of preculture. The pH was set to 7.0 
and adjusted during the expression with 5 M KOH and H3PO4 solutions. Dissolved oxygen 
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was controlled with a pO2 electrode. At OD600 = 1 the system was induced with isopropyl β-
D-1-thiogalactopyranoside (IPTG, 100 µg/mL final conc.) and δ-aminolevulinic acid (84 
µg/mL final conc.) was added as a precursor for heme synthesis. After 6 hours of induction 
glycerol feeding was started with 0.1 g/min, after 24 hours of induction the feeding was 
doubled (0.2 g/min) and finally after 30 hours of induction feeding of 0.4 g/min was applied 
until the end of the fermentation process.  After 48 hours of expression at 30°C and 300 rpm 
the cells were harvested by centrifugation (4424 x g, 4°C for 15 min) (Sorvall RC-6 Thermo 
Fischer Scientific, Wilmington, USA), washed with 50 mM potassium phosphate buffer pH 
7.4, centrifuged (4424 x g, 4°C for 15 min) (centrifuge 5810 R Eppendorf, Hamburg, 
Germany) and the pellets stored at -20°C. 
 
3.3.2.2.2 Expression of Escherichia coli C43 (DE3) (pET28cyp154C5) at 5 L bioreactor 
scale 
The expression of CYP154C5 with N-terminal his-tag was performed in a 5 L 
fermenter (Bioreactor Biostat MD Sartorius, Göttingen, Germany) according to the protocol 
described for E. coli C43 (DE3)(pIT2cyp154C5) with the following modifications: kanamycin 
(50 µg/mL final conc.) was used as antibiotic instead of tetracycline, IPTG with 200 µg/mL 
final concentration was added to induce expression and no glycerol feeding was performed. 
 
3.3.2.2.3 Expression of Escherichia coli C43 (DE3) (pACYCcamA) and Escherichia coli 
C43 (DE3) (pACYCcamB) in shake flasks 
The expression of PdR was performed in a 2 L shake flask. For that, 5 mL liquid LB 
media supplemented with chloramphenicol (25 µg/mL final conc.) was inoculated from a 
frozen stock of E. coli C43 (DE3)(pACYCcamA). After overnight incubation at 37°C and 250 
rpm, a 200 mL TB preculture supplemented with chloramphenicol (25 µg/mL) and 0.1 % v/v 
of trace element solution was inoculated with 1 % v/v of the overnight culture and incubated 
at 37°C, 250 rpm until OD600 = 1 was reached. Then the system was induced with IPTG (200 
µg/mL final conc.). After 48 h of incubation at 30°C and 250 rpm the cells were harvested by 
centrifugation (4424 x g, 4°C for 15 min) washed with 50 mM potassium phosphate buffer pH 
7.4, centrifuged again and the pellets stored at -20°C. For Pdx expression the same 
procedure as described for PdR was used employing strain E. coli C43 (DE3) 
(pACYCcamB). 
 
3.3.2.3 Protein purification 
3.3.2.3.1 Purification of CYP154C5 with N-terminal His-tag  
Approximately 10 g of wet cells of E. coli C43 (DE3) (pET28cyp154C5), containing 
over expressed CYP154C5 from N. farcinica with N-terminal his-tag, were resuspended in 80 
mL of 50 mM potassium phosphate buffer pH 7.4 and PMSF (phenylmethylsulfonyl fluoride, 
17 µg/mL final conc.) was added in order to avoid protease degradation. Cell disruption was 
performed by French Press (EmulsiFlex-Homogenizer, Avestin) with 5 cycles of 1500 psi. 
Cell debris was removed by centrifugation at 17696 x g, 4°C for 45 minutes and the 
supernatant was filtered through 0.2 µm pore size filters. 
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The purification of CYP154C5 via N-terminal his-tag was performed in 2 steps. In all 
cases the characteristic red-brown colour of the protein due to the presence of the iron-
containing heme prosthetic group indicated the presence of the P450 monooxygenase. First, 
the supernatant containing active P450 was loaded on a 120 mL Q-Sepharose FF column 
(GE Healthcare) equilibrated with 20 mM potassium phosphate buffer pH 7.4. The column 
was then washed with the same buffer before elution of the target protein with a linear 
gradient of 0-500 mM KCl in 20 mM potassium phosphate buffer pH 7.4. Fractions containing 
CYP154C5 were combined and loaded on a 20 mL HisTrap HP column (GE Healthcare) 
equilibrated with 500 mM KCl in 50 mM potassium phosphate buffer pH 7.4. The column was 
then washed with 50 mM potassium phosphate buffer pH 7.4 containing 20 mM imidazol and 
500 mM KCl in order to remove all unbound protein. Afterwards, the target protein was eluted 
with 250 mM imidazol in 50 mM potassium phosphate buffer pH 7.4 and 500 mM KCl. 
Fractions containing the P450 monooxygenase were combined and concentrated by 
ultrafiltration using Amicon centrifugal tubes (Millipore) with 30 kDa cutoff. Size exclusion 
chromatography PD10 columns (GE Healthcare) and 50 mM potassium phosphate buffer pH 
7.4 were employed to desalt the protein solution. Additionally, dialysis of the protein solution 
in 50 mM potassium phosphate buffer pH 7.4 was performed overnight at 4°C in order to 
remove all traces of imidazol. Finally 10 % v/v glycerol was added to the pure protein solution 
and stored at -20°C.  
 
3.3.2.3.2 Purification of CYP154C5 without His-tag 
Pelleted cells of CYP154C5-producing E. coli C43 (DE3) (pIT2cyp154C5) were 
resuspended in 20 mM MES buffer, pH 6.5 containing 2 mM DTT. Typical protease inhibitors 
were added and cell disruption was carried out by initial lysozyme treatment followed by 
sonication on ice. The resulting cell lysate was centrifuged at 40000 x g, 4°C for 45 min to 
remove all cell debris. Liquid chromatography was performed for CYP154C5 purification 
using as first step a Q Sepharose FF column (GE Healthcare) equilibrated with 20 mM MES 
buffer, pH 6.5 containing 2 mM DTT. The column was then washed with the same buffer 
before elution of the target protein with a linear gradient of 0-1 M KCl in 20 mM MES buffer, 
pH 6.5 containing 2 mM DTT. Fractions containing CYP154C5 were combined and loaded 
onto a Mono Q HR1010 column (GE Healthcare) and the same elution protocol was 
followed. Afterwards, the fractions containing CYP154C5 were combined and loaded onto a 
TSK PHENYL column (Tosoh Bioscience) equilibrated with 20 mM MES buffer, pH 6.5 
containing 2 mM DTT and 1 M (NH4)2SO4. The target protein was eluted with a linear 
gradient of 1-0 M (NH4)2SO4 in 20 mM MES, 2 mM DTT buffer pH 6.5. Finally, the collected 
fractions containing CYP154C5 were loaded onto a HiLoad 16/60 Superdex 75 gel filtration 
column (GE Healthcare) equilibrated with 20 mM MES buffer, pH 6.5 containing 100 mM KCl 
and 2 mM DTT and eluted using the same buffer. 
The purity of CYP154C5 was monitored by SDS-PAGE under nonreducing conditions 
with alkylation of the samples prior to electrophoresis by incubation of 2 µL protein solution in 
10 µL 100 mM NH4HCO3, 25 mM iodoacetamide for 30 min in the dark [12, 13]. Gels were 
washed in MiliQ H2O and stained in a sensitive Coomassie Brilliant Blue 250G solution [14]. 
The total mass of previously C4 ZipTip® (Millipore) desalted CYP154C5 solution was 
measured using a Q-TOF2 mass spectrometer (Micromass). DLS measurements of 1µL 
protein droplets under paraffin oil were carried out using an in-house self-constructed light 
scattering device. 
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3.3.2.3.3 Purification of PdR  
Approximately 10 g of wet cells of E. coli C43 (DE3) (pACYCcamA) containing over-
expressed PdR from P. putida were resuspended in 80 mL of 50 mM potassium phosphate 
buffer pH 7.4 and cell disruption was performed as previously described for CYP154C5 (with 
his-Tag) purification. The purification of PdR (45 kDa) was performed in two steps. In all 
cases the characteristic yellow colour indicated the PdR-containing fractions due to the 
presence of the FAD cofactor. As first step, purification was performed using a 120 mL Q-
Sepharose FF ion exchange column equilibrated with 50 mM potassium phosphate buffer pH 
7.4. The protein was eluted with a 1 L gradient of 0-500 mM KCl in 50 mM potassium 
phosphate buffer pH 7.4 (buffer A), with a flow of 6 mL/min. PdR protein eluted at 
approximately 60 % buffer A. All yellow fractions which showed on SDS-PAGE the 
respective PdR band at 45 kDa (see appendix section 4.3) were combined and concentrated 
using a 30 kDa cut-off Amicon centrifugal tube. In the second step, the concentrated PdR 
fraction was adjusted to 1.5 M KCl concentration and loaded on a 50 mL Phenyl-Sepharose 
FF hydrophobic interaction column equilibrated with 1.5 M KCl in 50 mM potassium 
phosphate buffer pH 7.4. The target protein was eluted with a 500 mL gradient of 1.5 to 0 M 
KCl in 50 mM potassium phosphate buffer pH 7.4 (buffer B). PdR eluted at approximately 70 
% of buffer B. The respective fractions were combined and concentrated in a 30 kDa cut-off 
Amicon centrifugal tube. Size exclusion chromatography PD10 columns (GE Healthcare) 
were employed to remove KCl traces that were still present in the protein sample. Finally 10 
% v/v glycerol was added to the pure protein and stored at -20°C. 
 
3.3.2.3.4 Purification of Pdx  
Approximately 10 g of wet cells of E. coli C43 (DE3) (pACYCcamB) containing over-
expressed Pdx from P. putida were resuspended in 80 mL of 50 mM potassium phosphate 
buffer pH 7.4 and cell disruption was performed as previously described for CYP154C5 
purification via N-terminal his-tag. In the first step a 120 mL ion exchange Q-Sepharose FF 
column was used and Pdx (11 KDa) was eluted with the same gradient system as described 
for PdR. All brown fractions, due to the presence of an iron-sulfur cluster in Pdx, were 
combined (with previous SDS-PAGE confirmation, see appendix section 3.2) and Pdx was 
further purified by ultrafiltration with a 30 kDa cut-off membrane. Thereby, larger proteins 
could be removed. Afterwards, 10 kDa cut-off Amicon centrifugal tubes were used to highly 
concentrate the protein. Size exclusion chromatography PD10 columns (GE Healthcare) and 
50 mM potassium phosphate buffer pH 7.4 were employed to desalt the protein solution. 
Finally 10 % v/v glycerol was added to the pure protein and stored at -20°C. 
 
3.3.2.4 SDS-PAGE and enzyme assays 
Unless otherwise specified SDS-PAGE was carried out according to Schägger et al. 
adjusted to the Mini PROTEAN® Tetra Cell (Bio-Rad) [15]. Samples were prepared and ran 
as described in chapter 2 (section 2.3.2.3) of this thesis.  
P450 concentration was determined by CO-difference spectra and calculated based 
on the absorbance maximum of CO-bound P450 at 450 nm (ε450=91 mM
-1 cm-1) using a Cary 
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50 (Varian) spectrophotometer [16]. The concentrations of pure Pdx and PdR were 
determined at 455 nm (ε455=10.4 mM
-1 cm-1) and 454 nm (ε455=10.0 mM
-1 cm-1), respectively 
[17]. The activity of the electron transfer components (ETC) Pdx and PdR in a mixture 
containing a ratio of PdR:Pdx of 3:16 was determined by cytochrome c reduction assay, 
monitoring the increase in absorbance at 550 nm of reduced cytochrome c (ε450=19.1 mM
-1 
cm-1) in a mixture containing a ratio of PdR:Pdx equal to 3:16 [18]. Protein concentration was 
determined by Bradford assay [19]. 
 
3.3.2.5 Dissociation constants (KD) 
Dissociation constants of CYP154C5 for the six different steroids were determined by 
spectroscopic measurements upon titration of purified enzyme with increasing steroid 
concentrations [20]. Thus, purified CYP154C5 stock was diluted with 50 mM potassium 
phosphate buffer pH 7.4 in order to reach 3 µM final enzyme concentration. To this mixture, 
substrate was added in concentrations from 0 to 100 µM. Therefore, three different substrate 
stock solutions of 0.1, 0.5 and 1 mM in 0.1- 4.5 % (w/v) hydroxypropyl--cyclodextrin in 
ddH2O (see appendix section 3.3) were prepared. The absorbance spectra of each sample 
were measured in a Cary 50 Spectrophotometer (Varian) in the range between 300 and 500 
nm at 30°C. As a blank, 3 µM P450 in 50 mM potassium phosphate buffer pH 7.4 with 
addition of an equivalent amount of buffer instead of substrate solution was used. Each 
sample was prepared and measured in duplicate. By plotting the resulting absorbance 
difference (Abs396nm – Abs419nm) against the applied substrate concentration and fitting the 
data using Matlab software with the tight binding equation [21], KD values for the different 
steroids were obtained. 
 
3.3.2.6 Turnover numbers  
Pure PdR, Pdx and CYP154C5 dissolved in 50 mM potassium phosphate buffer pH 
7.4 stocks were employed for the turnover number determination. In all cases 3 µM of 
CYP154C5, 3 µM of PdR, 16 µM of Pdx were applied in conversions of 2 mM steroid 
substrates (1-6) in 50 mM potassium phosphate buffer pH 7.4 at 30!C. Thus, the activity of 
the electron transfer components was 2.9 U/mL. In order to regenerate the confactor NADH 
(50 µM), formate dehydrogenase from Candida boidinii (0.5 U/mL) and sodium formate (150 
mM) were applied. Additionally, catalase from bovine liver (300 U/mL) was added to the 
reaction to degrade the possibly formed hydrogen peroxide.Steroid stock solutions of 5 mM 
concentration were prepared in 1.8 - 4.5 % (w/v) hydroxypropyl-β-cyclodextrin in ddH2O (see 
appendix section 3.3). Samples were taken over time, extracted and analysed by HPLC or 
GC in order to calculate the TONs based on substrate consumption over time. For that, 0.5 
mL of reaction was extracted twice with ethyl acetate (300 µL and 250 µL) and once with 
chloroform (300 µL), the organic phases were combined, dried with sodium sulfate and the 
solvent was removed under reduced pressure. Each reaction was made in duplicate. 
 
3.3.2.7 NADH oxidation rate and coupling efficiency 
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NADH depletion during bioconversions of steroids by CYP154C5, Pdx and PdR was 
monitored in a spectrophotometer at 340 nm (ε340 = 6.22 mM
-1 cm-1). Reactions of 0.7 mL 
total volume contained 0.4 µM purified P450, 0.4 µM purified PdR, 14 µM purified Pdx, 600 
U/mL catalase from bovine liver, 200 U/mL superoxide dismutase (SOD), 200 µM NADH and 
1 mM of the respective steroid (5 mM stock in 1.8 - 4.5 % w/v of hydroxypropyl-β-cyclodextrin 
in ddH2O -see appendix section 3.3) in 50 mM potassium phosphate buffer pH 7.4. After the 
NADH was completely consumed, 0.5 mL reaction mixture was extracted as described for 
the turnover number determination and further analyzed by HPLC and GC in order to 
determine the conversion. 
 
3.3.2.8 HPLC and GC analysis 
Substrate consumption and product formation in bioconversions of steroids using 
CYP154C5 together with Pdx and PdR were measured by GC (steroids 1 and 2) and HPLC 
(steroids 3-6). In the case of pregnenolone (1) and dehydroepiandrosterone (2) the solid 
residues were redissolved in chloroform containing 30 mM cholesterol as internal standard 
since it was previously demonstrated that CYP154C5 cannot use cholesterol as substrate 
(not published data). These samples were analyzed on a GC2010 gas chromatograph 
(Shimadzu; Duisburg, Germany) equipped with an OPTIMA 17ms column (Macherey-Nagel, 
Düren, Germany) with a linear gradient starting at 250°C and heating with 10°C/min until 
300°C. Injector and detector temperature were set to 350 and 300°C respectively. Substrates 
and products were detected by flame ionization detector (FID). Both substrates, 1 and 2, 
were eluted with a retention time of 9.69 min and 7.94 min respectively, whereas their 
products (1A and 2A) eluted at 9.27 and 10.18 min respectively. The dried residues of 
bioconversions with progesterone (3), androstenedione (4) testosterone (5) and nandrolone 
(6) were dissolved in acetonitrile: water (60:40) and injected on ultra-fast liquid 
chromatograph (UFLC, Prominence, Shimadzu) equipped with a C18, 250 x 4.5 mm column 
(CS Chromatographie Service, Germany) at 50°C. Acetonitrile: water (60:40) was used as 
mobile phase with a flow rate of 1.2 mL/min. Detection of substrates and their respective 
products was performed by UV absorbance at 242 nm. The substrates were eluted at 10.70 
(3), 6.34 (4), 6.08 (5) and 5.51 (6) min, whereas the products were detected at 4.23 (3A), 
3.93 (4A), 4.47 (5A) and 3.29 (6A) min. In all cases the conversions were calculated based 
on substrate consumption.  
 
3.3.2.9 Thermal shift 
All thermal shift experiments were carried out in a MyiQ2® RT-PCR thermal cycler 
(BIORAD), using film sealed 96-well plates and a filter set for λex = 485 nm and λem = 530 nm. 
Each single reaction had a volume of 50 µL and contained 0.15 mg/mL (~ 3.3 µM) 
CYP154C5, 12 mM MES, 60 mM KCl, 1.2 mM DTT or TCEP and 5x SYPRO® orange. 
Melting data were recorded from a stepwise temperature gradient of 0.5°C steps from 25°C 
to 95°C. CYP154C5 melting curves with the steroid hormones pregnenolone (1), 
dehydroepiandrosterone (2), progesterone (3), androstenedione (4), testosterone (5), 
nandrolone (6) and were recorded. The hormones were dissolved in 100 % DMSO to get 
stock solutions of 200 µM (2, 3, 5 and 6) or 100 µM (1 and 4). Thermal data of CYP154C5 
were collected at different molar equivalent (eqv) concentrations of hormone compared to the 
CYP154C5 concentration, namely 0, 1, 2, 4 and 8 eqv for 2, 3, 5 and 6 and 0, 0.5, 1, 2 and 4 
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eqv of 1 and 4 due to their lower solubility. The mentioned relative hormone concentrations 
correspond to absolute DMSO concentrations of 0, 1.6, 3.2, 6.4 and 12.8 % (v/v), 
respectively. 
 
3.3.2.10 Crystallization and data collection 
All crystallization experiments were carried out as sitting drop vapor diffusion 
experiments with droplets of 2.0 µL and reservoirs of 250 µL in crystallization plates from 
TAORAD. Crystallization droplets were created of 1.0 µL protein solution and crystallization 
condition respectively. During the crystallization experiments the six steroid hormones 
mentioned above were used. Stock solutions of hormones were prepared in 100 % DMSO 
with concentrations of 100 mM for 2, 3, 5 and 6 and 50 mM for 1 and 4. All solutions used for 
crystallization experiments were filtered (0.22 µm diameter) before usage. Steroid hormones 
were added from the stock solutions to the pure protein solution prior to filtration. Diffracting 
crystals were obtained within a “window” of crystallization conditions containing 0.2-0.3 M 
MgCHO2, pH 6.0-6.5 in the presence of 0.5-2 equivalents steroid substrate.  
For X-ray crystallography, the loop-mounted crystals were equilibrated for several 
seconds in solutions of 0.3 M magnesium formate pH 6.5 enriched with increasing 
concentrations of glycerol as cryoprotective agent and were flash-frozen at 100 K in a liquid 
nitrogen stream. Near-complete X-ray data sets were collected using a Bruker FR591 
rotating anode X-ray generator and a Mar345dtb detector. Diffraction data were processed 
using iMOSFLM [22], analysed regarding their symmetry using Pointless and scaled with 
SCALA [23], both from the CCP4-suite [24]. 
 
3.3.2.11 Structure determination, refinement and modelling 
The structures of CYP154C5 were solved by molecular replacement approach using 
CCP4’s MolRep [25]. For CYP154C5 in complex with pregnenolone the structure of 
CYP154C1 [9], PDB entry 1GWI, was processed with CCP4’s Chainsaw [26] and used as 
model for the molecular replacement. The fully solved CYP154C5-pregnenolone structure 
was then taken as molecular replacement model for all the other CYP154C5 structures. All 
the structures were iteratively refined by manual inspection of the electron density with 
WinCoot 0.7 [27] and refinement with Refmac5 [28]. Refinement to convergence was carried 
out with isotropic B-values and using TLS parameters initially computed using the TLSMD-
webserver [29, 30]. Alternative conformations were modelled for a number of side chains and 
occupancies were adjusted manually for some atoms. Coordinates and structure factors 
have been deposited in the Protein Data Bank under accession codes 4J6B, 4J6C, 4J6D and 
4JBT. A model for the substrate free open CYP154C5 conformation was built based on the 
A-chain of CYP154C1 in 1GWI by manually fitting the CYP154C5 residues and backbone 
into the electron density reported for 1GWI. 
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3.4   Results 
3.4.1 Protein expression and purification 
Expression of CYP154C5 in E. coli from vector pIT2cyp154C5 yields protein without 
his-tag fusion, which was used for crystallization. Additionally, cyp154C5 was subcloned into 
plasmid pET28a(+), containing a T7 promoter and a kanamycin resistance gene. Expression 
of CYP154C5 from vector pET28cyp154C5 results in a fusion protein with N-terminal his-tag, 
facilitating its purification for biochemical characterization purposes. Putidaredoxin reductase 
(camA) and putidaredoxin (camB) from Pseudomonas putida DSM50198 served as electron 
transfer components in bioconversions [7] and were separately expressed using vector 
pACYC [6]. In all cases, protein expression was induced by IPTG addition. Additionally, -
aminolevulinic acid was added for enhanced heme synthesis when expressing CYP154C5. 
Its production from E. coli C43(DE3) (pIT2cyp154C5) at 15 L fermentor scale with controlled 
oxygen supply,  pH and glycerol feeding after 48 h cultivation resulted in high expression 
levels. After several purification steps, 162 mg CYP154C5 L-1 culture (12 mg of CYP154C5 
per g of wet cells -gwc-) were obtained in highly pure form for crystallization trials. Moreover, 
146 mg L-1 culture (~14 mg gwc
-1) and 27 mg L-1 culture (~1.6 mg gwc
-1) of purified PdR and 
Pdx were obtained, respectively. The three proteins used for biochemical characterization 
exhibited in each case more than 90 % purity (see appendix section 3.2). 
 
3.4.2 Overall structure of CYP154C5 
Initial crystallization trials with substrate free CYP154C5 yielded no crystals. Upon 
introduction of steroid substrates into the crystallization screening process, diffracting 
crystals were obtained for CYP154C5 with all six steroids mentioned above. However, 
datasets of publishing quality could be recorded only for CYP154C5 complexes with 
pregnenolone (1, 4J6B with 2.2 Å resolution), progesterone (3, 4J6C with 1.9 Å resolution), 
androstenedione (4, 4JBT with 2.2 Å resolution) and testosterone (5, 4J6D with 2.4 Å 
resolution). The respective statistics of data collection and structure refinement are given in 
Konrad Herzog´s master thesis [2]. CYP154C5’s overall structure is characterized by the 
helix-rich cytochrome P450 monooxygenase fold as shown in Figure 3.2.A for the A-chain of 
CYP154C5 with progesterone. On the bottom of the active site a heme B molecule is bound 
to the typically conserved residues His99, Arg103, Arg297, Tyr320, His355 and Cys357. The 
active site bound steroid molecule is surrounded by a narrow channel with a small surface 
opening. Despite the strong hydrophobicity of steroids, the channel opening is not 
extensively surrounded by hydrophobic patches that could facilitate an initial substrate 
surface association and subsequent entering of the active site channel by the steroid (Figure 
3.2.B).  
 
Enzyme-substrate-complex structure of CYP154C5 shed light on the modes of selective 
steroid hydroxylation 
 
C
h
a
p
te
r 
3
: 
R
e
s
u
lt
s
 
79 
 
 
Figure 3.2 Structure of CYP154C5 in complex with progesterone (3). A: P450-steroid complex is 
shown as a ribbon model with P450 helix numbering. B: The water accessible surface is observed and 
coloured by the residues Kyte-Doolite hydrophobicity. Figure taken from Herzog [2]. 
 
The different CYP154C5 structures exhibit all an asymmetric unit formed of two 
CYP154C5 molecules. Interestingly, the two molecules are covalently linked via a Cys4(A)-
Cys4(B) disulphide bond and surrounded by adjacent Mg2+-coordination sites forming crystal 
contacts with neighbouring asymmetric units (Figure 3.3). This covalent interaction seems to 
be crucial for successful crystallization, as trials with the his-tagged variant of CYP154C5 
failed. With Cys4 being located on a highly flexible N-terminal loop (Figure 3.2.A, dark blue), 
the dimerization constrains the loop’s opportunities of thermal motion and thus strongly 
increases the overall stability of CYP154C5. Nevertheless the N-terminal loop region seems 
to have a relatively high remaining flexibility, as electron density could be observed for the 
disulphide bond only in the CYP154C5 structures with testosterone (5), 
dehydroepiandrosterone (2) and nandrolone (6). 
RMSD values of the different structures, as determined by Konrad Herzog in his 
Master thesis [2], demonstrated that structural differences between the CYP154C5-steroid-
complexes are small. Except for the “self-alignments” (chains A and B of the same structure) 
the active site RMSDs are generally lower than the overall RMSDs, showing a structural 
conservation of the residues directly involved in ligand binding. The higher active site RMSDs 
for the “self-alignments” can be explained by chain specific structural differences in the 
asymmetric unit being required for the formation of crystal contacts. The overall and active 
site RMSD between pregnenolone (1) and progesterone (3) are much smaller than those 
between pregnenolone (1) or progesterone (3) and the other two steroids. This could be 
explained by an adaption of CYP154C5 to the larger steroids pregnenolone (1) and 
progesterone (3) that share an acetyl-substituent at position C17, while androstenedione (4) 
and testosterone (5) possess a smaller C17-oxygen substituent. 
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Figure 3.3 Disulphide dimerization site in the CYP154C5-testosterone structure.  Flexible N-
terminal loops (light blue) are connected via Cys4. Adjacent Mg
2+
 coordination sites from crystal 
contacts with other neighbouring CYP154C5 molecules in the unit cell. Figure taken from Herzog [2]. 
 
3.4.3 Active-site architecture 
The co-crystallized steroids share an overall structure of two peripheral polar groups 
(hydroxyl- or carbonyl-group) and the typical, strongly hydrophobic steroid core (Figure 3.1). 
This architecture is also observed in CYP154C5’s active site, forming a cavern with two 
oppositely located polar regions that delimit a flat central hydrophobic “tube” (Figure 3.4.A). 
The imitation of the steroids polarity distribution and the flattened substrate channel shape 
allow an initial rough orientation of the steroid molecule within the active site. Thereby, the 
steroids bind in a position where C16 is directly facing the heme iron (Figure 3.4.A) which 
explains the exclusive regioselectivity of this enzyme that has been observed in 
bioconversions of steroids 1-6 ([6] and Chapter 2 of this thesis). Additionally, CYP154C5’s 
high stereoselectivity is caused by the orientation of the flat hydrophobic tube relative to the 
heme. As the substrate binding site is not centred above the heme iron, the steroid molecule 
is shifted towards the heme carboxyl groups (Figure 3.4.A middle). Consequently the 
catalytic heme-bound oxygen radical can attack the steroid’s C16 only from the α-face, so 
that CYP154C5 catalyzes exclusively α-hydroxylation of the investigated steroids. 
The residues forming the active site of CYP154C5 are visualized in Figure 3.5. 
Several aromatic and aliphatic residues, namely Val87, Met84, Phe92, Phe179, Phe180, 
Ala240, Ala243, Ala244, Val291 and Leu294, form a flat hydrophobic tube around the 
substrate and pre-position it via steric and hydrophobic interactions. Residue Gln398, as it 
forms a hydrogen bond with the steroid’s C17 oxygen substituent-, seems to stabilize the 
pre-oriented substrate in the position which would allow C16-hydroxylation. Gln398’s 
configuration is stabilized via a network of hydrogen bonds with Thr397 and several water 
molecules bound to the backbone peptides of the loop/β-strand region between the α-helices 
K and K’ (Figure 3.2.A, yellow). On the opposite site of Gln398 an additional polar surface 
zone is established by Gln239. At least for the two larger steroids pregnenolone (1) and 
progesterone (3) this polar region is contributing to substrate binding via water mediated 
hydrogen bonding networks between Gln239 and O3. Even if those waters are not visible in 
the structures with androstenedione (4, 4JBT) and testosterone (5, 4J6D), most probably due 
to the lower data quality of these structures, it can be expected that equivalent hydrogen 
bonding networks will exist there as well, as this polar region forms the entrance of the 
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observed substrate channel and is therefore in contact with the aqueous solvent outside the 
protein (Figure 3.5). 
 
 
Figure 3.4 Active site of CYP154C5. A: Three perspectives of the active site with progesterone (3) 
and heme. The active site’s surface is calculated from 4J6C and coloured by hydrophobicity.B: 
Superposition of active site residues surrounding progesterone (3, cyan) and androstenedione (4, 
magenta). C: Superposition of active site residues surrounding progesterone (3, cyan) and 
pregnenolone (1, brown).Figure taken from Herzog [2]. 
 
As indicated by the similar active site RMSD values [2] and as demonstrated by 
selected superpositions depicted in Figure 3.4.B-C, the conformation of the CYP154C5 
active site is strongly conserved. However, steroid substrates containing an acetyl group at 
position C17, such as pregnenolone (1) and progesterone (3), showed a slightly different 
orientation as compared to the C17- hydroxyl/keto-substituted steroids (4 and 5). As 
observed in Figure 3.4.A, the superposition of CYP154C5’s active site with progesterone (3) 
and androstenedione (4) depicts the similarity in orientations of the steroid surrounding 
amino acids. However, the steroid orientation is significantly different depending on the C17-
substituent. In order to maintain the crucial hydrogen bond between Gln398 and the larger 
side chain at position C17 of the steroid molecule, these bulkier substrates are slightly 
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rotated along the C10-C19-bond in a way that the distance between C16 and the catalytic 
iron atom is not significantly affected in comparison to C17-hydroxyl/carbonyl- substituted 
steroids (Table 3.1).  
 
Figure 3.5 Schematic 2D-representation of CYP154C5’s active site architecture in complex with 
A: pregnenolone (1), B: dehydroepiandrosterone (2), C: progesterone (3), D: androstenedione (4), E: 
testosterone (5) and D: nandrolone (6). Hydrogen bonds are represented by blue dashed lines with 
the respective distances in Å. Green circle segments indicate hydrophobic interactions. Figure 
adapted from Herzog [2]. 
 
3.4.4 CYP154C5-steroid interactions 
In order to allow a detailed and well-founded analysis of the small CYP154C5-steroid 
interaction differences, additional experiments were carried out to determine the dissociation 
constants (KD) for each steroid and to elucidate possible ligand induced enzyme stabilization 
via protein melting temperatures (Tm) determined by differential scanning fluorimetry (DSF) 
[31, 32]. The KD determination for P450 monooxygenases is based on an optically 
measurable spin shift of the heme iron upon substrate binding. In absence of substrate, P450 
enzymes contain a water molecule as the sixth ligand at the heme iron, which exhibits a low-
spin (LS) configuration with an absorbance maximum at approximately 420 nm. Upon 
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substrate addition, the water molecule is removed by substrate binding in the active site and 
coordination to the heme iron. This causes a shift of the iron atom to a high-spin (HS) 
configuration which, in type I spectral changes, involves a shift of the absorbance maximum 
to approximately 390 nm [20]. The more substrate is added to the enzyme, the bigger the 
peak-to-trough difference in absorbance (A) gets between P450 with high spin iron (A390) 
and P450 with low spin iron (A420) until saturation is reached. From these data, binding 
constants can be estimated by plotting A against the substrate concentration and fitting of 
the data. In case of CYP154C5, a steroid concentration-dependent shift from 419 to 386 nm 
in the presence of the six steroid substrates occurred. Furthermore, the quadratic tight 
binding equation [33, 34] had to be used for fitting of the resulting data due to very low KD 
values in a range of only 10-100 nM (see appendix section 3.4). DSF measurements clearly 
revealed a CYP154C5 stabilization upon steroid binding although the stabilizing effect of 
nandrolone and pregnenolone was significantly lower as for the other steroid substrates. 
Obtained KD and Tm values for CYP154C5 with the six steroids are graphed in Figure 3.6.  
 
 
Figure 3.6 KD and Tm values for CYP154C5-steroid complexes. A: nandrolone (6); B: 
pregnenolone (1); C: progesterone (3); D: testosterone (5); E: androstenedione (4); F: 
dehydroepiandrosterone (2). KD values were determined at 30°C for the monomeric His-tagged 
CYP154C5. KD error bars show the 95 % parameter confidence intervals from the curve fitting. Tm 
data points measured at Csteroid = CCYP154C5. Horizontal dotted lines represent the Tm values of 
substrate free CYP154C5. Tm values taken from Herzog [2]. 
DSF measurements further revealed multiple melting events for CYP154C5-
substrate-mixtures, which could be assigned to a monomeric and a dimeric CYP154C5 
species by combinatorial cross-validation with additional experimental results (Figure 3.7). 
The dimeric CYP154C5 can be assumed to be the covalently linked disulphide dimer that 
has been found in the crystal structures (Figure 3.3). Dimerization via disulphide bond 
formation seems to be enforced by DMSO, which has been described to be a mild oxidant for 
thiol compounds and which has been used in crystallization trials as well as in the DSF 
measurements for dissolving the steroids [35–39]. Generally, the dimeric forms were found to 
be much more stable than the monomeric CYP154C5 in all DSF experiments, thus proofing 
the importance of fixing the N-terminal loop for successful CYP154C5 crystallization. 
However, in the reducing environment of the cytosol it can be assumed that only the 
monomeric form of CYP154C5 will exist and that the dimeric form likely has no physiological 
meaning. 
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Figure 3.7 Melting curves (red) and first derivatives (blue) from CYP154C5 thermal shift 
experiments. A: Pure enzyme with DTT. B: Pure enzyme with TCEP. C: Enzyme with 1 eqv. 
testosterone (5), DMSO and TCEP. Figure taken from Herzog [2]. 
 
3.4.5 Steroid hydroxylation kinetics 
In order to further characterize the catalytic system, turnover numbers (TON) and 
coupling efficiencies were determined in the conversion of 1-6 by the purified three-
component P450 system. In this way the efficiency of the catalytic system for the different 
substrates could be analyzed and compared. TONs were determined by calculating the 
highest rates of substrate consumption (by HPLC or GC) during the first hours of reaction. 
Bioconversions of 2 mM substrate using purified CYP154C5, PdR and Pdx were performed 
employing 3 µM CYP154C5 and a volumetric activity of the electron transfer components, 
PdR and Pdx, of 2.9 U/mL at 30°C for 24 h. Results demonstrated that the conversion rates 
differ significantly depending on the steroid used. Substrates 1, 2, 3 and 4 were fully 
converted within the first 2-6 hours of reaction (Figure 3.8), whereas in bioconversions of 5 
and 6 roughly only 70 % of the substrate was converted within 6 h. As expected, these gave 
the lowest TON, approximately 1.4 µmol of 6 were consumed per minute per µmol of 
CYP154C5 (Table 3.1). In contrast, progesterone 3 gave the best TON, 4-fold higher than 
that of substrate 5. This resulted in a productivity of up to 7.7 g 16α-hydroxyprogesterone 
(3A) per liter and day when using the purified three-component system. For steroid products 
1A, 2A, 4A, 5A and 6A productivities of 4.0, 6.8, 3.1, 1.4 and 1.4 g per liter and day could be 
obtained.  
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Figure 3.8 Bioconversions of steroid substrates by purified CYP154C5, PdR and Pdx. 
Conversion of pregnenolone (1), dehydroepiandrosterone (2), progesterone (3), androstenedione (4), 
testosterone (5) and nandrolone (6) were performed in 50 mM potassium phosphate buffer pH 7.4 at 
30°C for 24 h. Each reaction contained 3 µM CYP154C5, 3 µM PdR, 16 µM Pdx, 0.5 U/mL formate 
dehydrogenase from Candida boidinii, 150 mM of sodium formate, 300 U/mL catalase from bovine 
liver, 200 U/mL superoxide dismutase from from bovine erythrocytes, 50 µM NADH and 2 mM of the 
respective steroid in 50 mM potassium phosphate buffer pH 7.4. Substrates were added as stock 
solutions in 36 % (w/v) hydroxypropyl β-cyclodextrin in ddH2O. 
 
NADH oxidation rates and more importantly coupling efficiencies (%) are essential 
parameters to be determined in order to study the efficiency of the catalytic system as a 
function of the used steroid substrate. The NADH oxidation rate reflects the velocity with 
which the cofactor NADH is oxidized by the ferrodoxin reductase in presence of the other 
components in the catalytic system. In contrast, the coupling efficiency represents the 
percentage of electrons taken from the cofactor NADH which are indeed used for product 
formation, steroid hydroxylation in this case. Using 0.4 µM CYP154C5, 0.4 µM PdR and 14 
µM Pdx (ratio of 1:1:35), the conversion of 1 mM steroid 1-6 was determined at 30°C. As a 
result, progesterone (3) caused the highest NADH oxidation rate among all tested 
substrates, followed by pregnenolone (1) and androstenedione (4) whereas lower NADH 
oxidation rates were observed when substrates 2, 5 and 6 were applied (Table 3.1). In 
addition, all reactions generally revealed coupling efficiencies below 100 % which indicates a 
loss of electrons during catalysis. However, with coupling efficiencies around 80 % for 
dehydroepiandrosterone (2), progesterone (3) and androstenedione (4), the reactions can be 
still considered to be well coupled since artificial redox partners were used together with 
CYP154C5. In contrast, pregnenolone (1), testosterone (5) and particularly nandrolone (6) 
resulted in lower coupling efficiencies with the lowest one for nandrolone showing only 40 % 
coupling efficiency. 
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Table 3.1 Turnover numbers, NADH oxidation rates and coupling efficiencies using purified 
CYP154C5, PdR, Pdx and the six different steroid substrates [pregnenolone (1), 
dehydroepiandrosterone (2), progesterone (3), androstenedione (4), testosterone (5) and nandrolone 
(6)]. Results represent mean values of duplicate measurements. Additionally, characteristic active site 
distances are given. 
Substrate 
TON 
(min
-1
) 
NADH oxidation rate* 
(min
-1
) 
Coupling 
Efficiency 
(%) 
Average Fe-
C16 distance 
(Å) 
Average Q398-
O17/20 distance 
(Å) 
      
1  4.47 ± 0.36 9.42 ± 0.07 68 ± 1 4.31 2.93 
2  5.10 ± 0.11 6.25 ± 0.33 86 ± 5 4.33 2.89 
3  5.70 ± 0.22 15.10 ± 0.06 84 ± 3 4.51 2.84 
4 3.14 ± 0.06 9.19 ± 0.14 83 ± 1 4.22 2.94 
5  1.55 ± 0.23 6.01 ± 0.00 62 ± 5 4.88 2.91 
6  1.33 ± 0.10 6.98 ± 0.04 40 ± 7 4.33 3.21 
*initial rates 
 
3.5   Discussion 
 
As previously shown by us, CYP154C5 from N. farcinica exhibits high regio- and 
stereoselectivity in the hydroxylation of several steroid molecules as indicated by the 
exclusive production of 16α-hydroxylated steroids [6]. With the elucidation of the enzyme’s 
crystal structure in presence of different steroid substrates (1-6) bound in the active site [2], 
the reason for this remarkable selectivity could be clarified. In all cases the carbon atom at 
position 16 of the steroid molecule is pointing towards the iron atom of the heme prosthetic 
group which explains the excellent regioselectivity of this enzyme. Moreover, the presence of 
the I-helix in the catalytic pocket causes a lateral shift of the substrate towards the carboxyl 
groups of the heme so that only the α face of the substrate is accessible for hydroxylation 
resulting in exclusive stereoselectivity.  
As expected, the conformation of CYP154C5´s active site is strongly conserved 
among the different enzyme-steroid complexes. In all cases a hydrogen bond between 
residue Gln398 and the oxygen substituent at position C17 of the steroid molecule is present. 
This H-bond is directly located next to target position of CYP154C5 for hydroxylation which 
suggests that the interaction with Gln398 might play an important role in substrate binding 
and orientation. On the opposite site of the steroid molecule, the oxyfunctional group at 
position C3 of 1 and 3 was observed to interact via water molecules with residue Gln239. 
Although from crystallographic data it is difficult to conclude the importance of this enzyme-
substrate interaction, Gln239 might play an important role in the process of steroid binding in 
the active site.  
In all cases a tight binding in the nanomolar range was obtained for CYP154C5 
towards the six steroid substrates (1-6). These results are in agreement with the high 
similarity in structure and hydrophobicity of the catalytic pocket and the steroid substrate 
which could lead to a high enzyme-substrate affinity. Moreover, this tight binding can be 
explained as a consequence of the steroid´s hydrophobicity which upon solvation in aqueous 
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solution results in a thermodynamically unfavorable entropy reduction of the surrounding 
water molecules. Therefore, substrate binding will lead to a release of these water molecules 
from the steroid´s solvation shell, as well as the release of water molecules from the 
hydrophobic active site, increasing in this way the overall entropy of the system. As a result 
and due to the large hydrophobic interaction interfaces between enzyme and steroid, the 
process of steroid binding can be assumed to be predominantly entropically driven [2]. 
Nevertheless, a reduced affinity for pregnenolone (1) and in more extent for nandrolone (6) 
was obtained in comparison to the other tested substrates. This can be explained based on 
CYP154C5’s structure. In case of nandrolone (6), this steroid is lacking a methyl group at 
position C10 which reduces the molecule surface and increases its water solubility at least by 
30% (as estimated by Konrad Herzog [2]). In consequence, this steroid could move more 
freely in the active site of CYP154C5 and due to its reduced hydrophobicity the main 
contributor for substrate binding is also reduced resulting in a higher KD and reduced thermal 
stability. Additionally, the lower affinity of CYP154C5 towards nandrolone (6) is further 
reduced due to a longer hydrogen bond between O17 and Q398 (Table 3.1). This lower 
binding affinity results also in a lower stabilization of the enzyme upon nandrolone (6) binding 
as indicated by a lower Tm value of CYP154C5 obtained with substrate 6. 
In contrast to nandrolone (6), the higher KD and lower Tm values obtained for 
pregnenolone (1) cannot be attributed to its water solubility and size. In this case, the weaker 
interaction could be attributed to other specific interactions such as the interaction of 
pregnenolone with residues Phe92 and the more distant Tyr176. Figure 3.10 depicts the 
superposition of pregnenolone (1) and androstenedione (4) and the orientation of residues 
Phe92 and Tyr176 in the active site. As observed, phenylalanine and tyrosine residues 
mediate important hydrophobic interactions with the steroid core. In the particular case of 
pregnenolone (1), the Phe92 ring is slightly rotated in comparison to Phe92 in the active site 
of the androstenedione (4) complex. This is most probably due to π-electron repulsion and 
steric interactions with the double bond of this particular substrate reducing in this way the 
hydrophobic interactions and thus contributing to a higher KD value. 
Considering the entrance size of the substrate channel in the CYP154C5-steroid 
crystal structures, it becomes evident that a dynamic binding process starting from a more 
open P450 conformation must occur. Otherwise the steroid substrate would not fit through 
the substrate channel opening present in the crystal structures to reach the enzyme’s active 
site (Figure 3.9.A). As previously described for other P450s, these enzymes preferentially 
exhibit an open or closed conformation in absence or presence of substrate, respectively. 
This was already demonstrated for the well-studied cytochrome P450 monooxygenase 
CYP101A1 (P450cam) from Pseudomonas putida [40, 41] as well as for CYP101D2 from 
Novosphingobium aromaticivorans [42] by crystallographic studies. However, some P450s 
also exhibit an equilibrium of open and closed conformation even in absence of substrate as 
in the case of EryK, a P450 from Saccharopolyspora erythraea, for which three different 
crystal structures, including two ligand-free forms and one in complex with its substrate 
erythromycin D, were obtained [43]. In 2003, Podust et al. published the crystal structure of 
CYP154C1 (1GWI), the closest homologue of CYP154C5 with solved crystal structure, which 
exhibits an open conformation in absence of substrate [9]. In order to support the theory of 
dynamic steroid binding for CYP154C5 and due to the fact that these two enzyme possess 
highly conserved residues in the active site (12 identical residues and nine highly similar 
exchanges), a CYP154C1-based model for the substrate free CYP154C5 structure was 
generated by Konrad Herzog [2]. As depicted in Figure 3.9.B, the model clearly 
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demonstrates that the active site of substrate-free CYP154C5 is exposed to the solvent and 
therefore allows the steroid to enter and to bind into the active site. In this prediction, the 
helices F and G are forced to adopt a more open conformation (as indicated by the red 
arrow). However, this open, solvent-exposed conformation is thermodynamically 
unfavourable due to the hydrophobic nature of the active site. Therefore, the core of 
CYP154C5 is compacted upon substrate binding increasing the hydrophobic interactions 
between substrate and enzyme. Consequently the thermal stability of the enzyme-substrate 
complex is increased as reflected by the DSF-derived Tm values. 
Based on the model of dynamic substrate binding proposed by Konrad Herzog, 
another possible reason can be found to explain the higher dissociation constant obtained for 
CYP154C5 with pregnenolone (1) in comparison to the other tested steroids. As observed in 
Figure 3.10, residue Tyr176 of the F helix mediates a hydrogen bonding network via water 
molecules with residues Gln239 and Ala243 of helix I. In the CYP154C5-pregnenolone 
crystal structure (brown), residue Tyr176 is rotated clockwise due to the changed interaction 
between Phe92 and the substrate, altering in consequence also the hydrogen bonding 
network between helices F and I. A conserved water molecule (red arrow, Figure 3.10) was 
observed in all crystal structure complexes except for the ones with nandorolone (6) 
(possibly due to low resolution) and pregnenolone (1). In contrast, in the CYP154C5-
pregnenolone complex the closed conformation is stabilized via an altered water network 
(red water molecules, Figure 3.10) which might lead to a reduced binding affinity for 1 and 
thus also a lower Tm value indicating a less compact protein core. 
In addition to substrate binding affinities, also turnover numbers and coupling 
efficiencies for steroid conversions by CYP154C5 were determined. For all tested steroid 
substrates, coupling efficiencies of less than 100 % were obtained revealing a (significant) 
loss of electrons from the cofactor NADH. However, taking into account that surrogate redox 
partners (Pdx and PdR from P. putida) were used for CYP154C5, obtained coupling 
efficiencies for progesterone (3), androstenedione (4) and dehydroepiandrosterone (2) are 
still rather high. Generally, the steroid-dependent trend of obtained coupling efficiencies 
corresponds with the previously described KD and Tm values, indicating a correlation between 
the steroid binding differences and the observed coupling efficiencies. In this context, the 
higher dissociation constants for pregnenolone (1) and nandrolone (6) can explain the lower 
coupling efficiencies obtained for these two steroids. The weaker binding of 1 and 6 could 
suggest that the substrates have more freedom to move in the active site of CYP154C5, thus 
increasing the time and probability for reduced Pdx to lose its electrons elsewhere. Only the 
value for testosterone (5) does not agree with this hypothesis. While the KD for 5 is lower 
than for pregnenolone (1), both coupling efficiencies are in the same range. This observation 
seems to be the result of an almost 10 % longer Fe-C16-distance for testosterone (5) 
compared to progesterone (3) (4.88 and 4.51 Å respectively (Table 3.1). This heme-
testosterone distance might be too long for a highly efficient radical attack by the reactive  
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Figure 3.9 A model for the dynamic process of steroid binding to CYP154C5’s active site. A: 
The closed conformation as observed in the crystal structures. B: The open conformation model of 
CYP154C5 based on the structure of CYP154C1 from 1GWI. C: The superposition of the closed 
conformation of CYP154C5 (beige) as well as the substrate bound open conformation model (cyan). 
All surfaces were calculated with a 1.7 Å probe radius to account for the averaged C-C-, C-N and C-O 
interactions. Figure adapted from Herzog [2]. 
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Figure 3.10 Superposition of the CYP154C5 A-chains with pregnenolone (1, brown) and 
androstenedione (4, orange) and the hydrogen bond network between steroid, Y176, Q239 and A243. 
The red arrow marks the conserved water molecule. Figure taken from Herzog [2]. 
 
iron-oxo complex, so that the reaction rate for C16-hydroxylation of testosterone is slowed 
down significantly. 
Although nandrolone (6) differs from 5 only in the absence of the methyl group at 
C10, its Fe-C16-distance is not increased. Nevertheless, steroids 5 and 6 are the less 
preferred substrates for the tested three-component system, resulting in the lowest TONs, 
coupling efficiencies and in case of nandrolone (6) the highest KD. A further contribution to 
their low TONs might be the additional hydrogen bonding network between the steroids’ O17, 
His293 and Gln398 (see Figure 3.5), as it might stabilize binding of the product and thus 
hampering product release. On the other hand, progesterone (3) seems to be the preferred 
of the tested substrates resulting in the highest TON, NADH oxidation rate, one of the 
highest coupling efficiencies and one of the lowest dissociation constants. 
Previously, we reported the use of resting whole cells in bioconversions of steroids 1-
6 using E. coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB) cells overexpressing CYP154C5, 
PdR and Pdx [6]. When comparing obtained space-time yields (STY) and TONs with the 
herein reported purified three-component system, it becomes obvious that the use of pure 
proteins leads to 2 fold higher TONs and productivities for all tested steroids except for 
product 6A, where no improvement was found. However, when comparing both systems it 
has to be taken into account that in the case of WC reactions cofactor regeneration was 
achieved by the cell metabolism with the sole addition of glucose, whereas FDH and sodium 
formate were added for cofactor regeneration in the purified three-component system. Thus, 
conversion rates in whole cell biotransformations seem to be limited by the cofactor 
regeneration system and/or substrate uptake into the cells. Steroid hydroxylation in 16α-
position was also described in literature for a P450 monooxygenase from Streptomyces 
roseochromogenes NCIB 10984, as well as CYP123 from Rhodococcus erythropolis PR4 
and CYP110A1 from Nostoc sp. PCC7120 [8, 44]. However, rather low TONs (e.g. 1.18 
mmol progesterone converted per hour per mmol P450 for the enzyme from S. 
roseochromogenes) with the use of cell free extract and further oxyfunctionalization of the 
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product at additional positions was reported. In contrast, the here obtained TON with purified 
CYP154C5 are by a factor of 70 to 290 higher depending on the used steroid substrate. 
In order to study if sub-optimal interactions between the non-natural electron transfer 
component Pdx and CYP154C5 could be a possible cause of the reduced coupling observed 
for the tested steroid substrates, a structural comparison was performed based on the 
crystallographic P450cam-Pdx complex (PDB: 4JX1) reported by Tripathi et al. [45]. Figure 
3.11 illustrates the residues, located in the interface between P450cam (orange) and Pdx 
(grey), which are involved in the specific interaction of these two proteins. For comparison, 
the crystal structure of CYP154C5 with pregnenolone (1, green) bound in the active site was 
superimposed with P450cam in order to analyse its particular interactions with Pdx. In 
general, the interaction surface of both P450s, CYP154C5 and P450cam, with Pdx are rather 
similar since both are positively charged. Additionally, some specific interactions between 
Pdx and P450cam could be also identified for CYP154C5. Residue Arg112 of P450cam was 
previously demonstrated to be directly involved in the electron transfer from reduced Pdx to 
P450cam via residue D38 of Pdx [45, 46]. In case of CYP154C5 this interaction is conserved 
and established via residue Arg103 of the P450. In contrast, the two other hydrogen bond 
interactions observed between P450cam and Pdx  N116(P450cam)-W106(Pdx) and 
E76(P450cam)-R66(Pdx)  are not completely conserved in CYP154C5. In this case, 
residues T107 and Q108 are interacting with W106 of Pdx and, more dramatically, the 
hydrogen bond between R66 of Pdx and E76 of P450cam cannot occur in CYP154C5 since 
residue E76 is replaced by T56 in CYP154C5. Structural alignment of the six CYP154C5-
steroid crystal structures revealed no significant differences between CYP154C5-Pdx 
interactions and thus differences in coupling efficiencies cannot be attributed to changed 
interactions with the ferrodoxin. Nevertheless, results obtained from this comparison might 
give an important basis to further improve the Pdx-CYP154C5 interaction and thus electron 
transfer by protein engineering. 
 
 
Figure 3.11 Superposition of CYP154C5 (green) with Pdx (grey) and P450cam (orange) 
complex. Residues involved in the interaction of P450cam with Pdx (4JX1) and the equivalents in 
CYP154C5 (4J6B) are depicted. 
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4.1   Abstract 
CYP154C5 from Nocardia farcinica is a P450 monooxygenase which converts a 
range of steroid compounds, such as pregnenolone (1), dehydroepiandrosterone (2), 
progesterone (3), androstenedione (4), testosterone (5) and nandrolone (6) with high regio- 
and stereoselectevity into the respective 16-hydroxylated products. Its crystal structure in 
presence of the six mentioned substrates was previously determined in order to identify key 
residues in the active site which could be involved in substrate binding and therefore also 
responsible for catalytic specificity of the P450 monooxygenase. In this chapter, two 
strategies were applied to understand the selectivity of CYP154C5 better. Firstly, the four key 
residues M84, F92 Q239 and Q398, which were identified to be involved in hydrophobic 
interactions as well as hydrogen bonding with the substrates, were exchanged to alanine by 
site directed mutagenesis. The four created single mutants were fully characterized for the 
conversion of substrates 1 to 6 by determining dissociation constants (KD), turnover numbers 
(TON), total turnover numbers (TTN) and coupling efficiencies using a three-component 
system consisting of purified CYP154C5 mutant as well as putidaredoxin and putidaredoxin 
reductase (Pdx and PdR, respectively) from Pseudomonas putida for electron transfer. 
Interestingly, with a single mutation in the active site a secondary hydroxylation product was 
obtained in the conversion of 3 by CYP154C5-F92A, thus, changing the selectivity of this 
enzyme. Additionally, the overall conversion of nandrolone (6) was increased 1.5-fold when 
mutant CYP154C5-Q239A was applied. Interestingly, the exchange of methionine by alanine 
at position 84 dramatically affected the conversion of all tested substrates. As a second 
strategy, CYP154C5 wild type was tested in the conversion of selected steroids (7-11) 
lacking key functional groups in their structure that could substantially affect substrate 
binding and therefore also catalytic efficiency and selectivity of the system. Interestingly, here 
the regioselectivity of CYP154C5 was completely changed when 5α-androstan-3-one (11) 
was used as substrate, producing in this case the 15α-hydroxylated product. Similarly, four 
different products were obtained when substrate 3-deoxydehydroepiandrosterone (10) was 
converted by CYP154C5 wild-type. Furthermore, steroid substrates with large substituents at 
position C17 (7 and 8) were not converted by CYP154C5. Additionally, the much smaller 
substrate β-ionone (12) was also selectively monohydroxylated by this enzyme.  
 
4.2   Introduction 
One of the most important uses of cytochrome P450 monooxygenases (P450s or 
CYPs) is their application in steroid synthesis due to their remarkable ability to catalyze the 
hydroxylation of non-activated carbon atoms [3, 4]. In this way, synthesis of drug metabolites 
and fine chemicals using CYPs in combination with traditional chemical approaches 
facilitates or enables the production of e.g. steroid drugs which could not be selectively 
produced by purely chemical strategies. Nowadays, well known biochemical processes are 
established in the pharmaceutical industries which combine chemical and biological steps 
(e.g. whole cell catalysis). However, there is often still the need for yield improvement, 
including the increase in hydroxylation specificity (e.g. fewer by-products), a change in 
selectivity to hydroxylate e.g. new sites in a known substrate or an adaptation of the enzyme 
to a new substrate [5]. In order to be able to do that, it is important to study protein-substrate 
interactions in the P450 monooxygenase.  
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This is usually done by means of protein engineering with mutagenesis at single 
active site residues. Furthermore, protein engineering also provides the tools to develop an 
enzyme catalyst with new characteristics. An example in the area of steroid hydroxylation is 
the study of Lewis et al., where it was shown that the substitution of leucine to alanine at 
position 437 in cytochrome P450BM3 from Bacillus megaterium (CYP102A1) enlarges its 
active site and generates a catalyst which, in contrast to the wild type [6], is now able to 
convert trimethyl estriol. Based on these results, Lewis et al. developed a mutant F1 (four 
mutations compared to the wild type) which is able to hydroxylate progesterone and 
testosterone derivatives at position C2 with α orientation [7]. One year later, Kille et al. 
performed an iterative combinatorial active-site saturation test where several amino acid 
residues (next or near the binding pocket) of P450BM3 were randomized generating focused 
libraries that were screened for activity and/or selectivity on steroids [8]. An improved mutant 
at one site was then used as a template to perform saturation mutagenesis at another site 
and this process was repeated until the desired improvement of the catalyst was reached. As 
starting point for their strategy the single mutant F87A, able to hydroxylate testosterone 
yielding a 1:1 mixture of 2β- and 15β-hydroxytestosterone, was used. As a result, mutants 
KSA-2 (R471I/T491I/Y511I/F87A) and KSA-14 (R47I/T49F/A82M/F87A) were found to 
selectively hydroxylate testosterone yielding the 2β- and 15β-hydroxytestosterone with 94 % 
and 96 % conversion, respectively. 
Furthermore, directed evolution can be used to improve the regioselectivity of an 
enzyme. As an example, a combination of site-saturation mutagenesis (SSM)[9] and rational 
protein design was applied to change the regioselectivity of CYP106A2 from Bacillus 
megaterium for the conversion of progesterone. In this way, Nguyen et al. accomplished an 
impressive increase in regioselectivity towards position C11 from 28 % up to 81 % by a 
double mutation (A89N/A395I) in this P450 [10]. 
Protein engineering of a given enzyme is significantly facilitated if structural 
information for the protein is available such as the crystal structure of the enzyme with bound 
substrate. The crystal structure of CYP154C5, a cytochrome P450 monooxygenase from 
Nocardia farcinica, was elucidated in the presence of six steroid substrates (1-6) (see 
chapter 3 of this thesis). This enzyme was shown to catalyze the regio- and stereoselective 
hydroxylation of six steroids (1-6) producing exclusively the 16α-hydroxylated products (see 
chapter 2 of this thesis). In Figure 4.1.A, the active site pocket of CYP154C5 is depicted, 
surrounded by 21 residues, namely L81, M84, V87, F92, Y176, F179, F180, I193, M196, 
Q239, A240, A243, A244, T248, V291, L294, L295, V395, T397 and Q398. The underlined 
aliphatic or aromatic residues are forming a hydrophobic “tube” which interacts with the 
highly hydrophobic steroid core. At both ends of this “tube” there are two oppositely polar 
regions which are involved in substrate-protein interactions. Here, two glutamine residues at 
positions 239 and 398 are situated forming hydrogen bonds with the hydroxyl or ketone 
functionalities of steroids at positions C3 and C17. The crystal structures of all CYP154C5-
substrate complexes explain the remarkably high regioselectivity of CYP154C5, since all 
tested steroids (1-6) bind in the active site with their C16 pointing towards the heme-iron. 
Furthermore, the steroid substrate is slightly shifted towards the carboxylic acid groups of the 
prosthetic group (Figure 4.1.B), which explains why only α-hydroxylated steroids are 
produced by this highly stereoselective enzyme.  
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Figure 4.1 Crystal structure of CYP154C5. A: Active site of the CYP154C5-pregnenolone complex. 
In grey are shown the heme prosthetic group and the substrate pregnenolone (1), in yellow and blue 
are residues given which surround the active site pocket. B: Active-site view showing that steroid 1 
above the heme is slightly shifted towards the carboxylic chains, thus exposing the  face for 
hydroxylation.  
 
In 2008, a homology model of CYP154C5 was already created by Dekker et al. based 
on the crystal structure of CYP154C1 A3(2) from Streptomyces coelicolor [11, 12]. The 
generated model was used for subsequent docking experiments with testosterone to identify 
the probable binding orientation of this steroid and possible residues in the active site of this 
P450 that are involved in substrate binding. In this way, five active-site residues were 
identified, rationally exchanged and the resulting mutants were tested in the hydroxylation of 
different steroid substrates. Thus, residues methionine 84 and glutamine 398 were already 
identified as important residues for substrate binding since significant changes in substrate 
specificity and activity could be detected for mutants M84A and Q398A. Based on these 
initial results together with the crystal structure of CYP154C5, site-directed mutagenesis of 
selected active-site residues was performed to get more detailed information on the enzyme-
substrate interactions with the final aim of tailoring CYP154C´s regio- and stereoselectivity. 
Furthermore, substrate engineering was chosen as approach to investigate the 
importance of specific substrate-enzyme interactions in CYP154C5 and to study the 
enzyme’s selectivity. As it was extensively discussed in chapter 3 of this thesis, CYP154C5 
forms hydrogen bonds with steroids that are oxyfunctionalized at positions C3 and C17, 
carrying in particular hydroxyl and keto-groups. Therefore, the use of steroids lacking one or 
both of these functional groups could result in inefficient or even a lack of binding and/or 
conversion. Moreover, a change in regio- or stereoselectivity of CYP154C5 could be the 
result of a different substrate positioning in the active site. 
In this chapter, both strategies, protein engineering by site-directed mutagenesis as 
well as substrate engineering, were followed to better understand the molecular basis for the 
high selectivity of CYP154C5 in the conversion of steroids and to tailor its regio- and 
stereoselectivity in the future. Thus, four CYP154C5 single mutants were created and 
characterized in detail in the conversion of steroid substrates 1-6 (Figure 4.2) using Pdx and 
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PdR from Pseudomonas putida as electron transfer proteins. Additionally, the same catalytic 
system but using wild type CYP154C5 was applied in the conversion of selected steroids 
lacking oxyfunctional groups at positions C3 and C17 (7, 9-11) or carrying much larger side 
chains at C17 (7 and 8) (Figure 4.2). Additionally, a norisoprenoid (12) and a sesquiterpene 
(13) (Figure 4.2) were tested as substrates of CYP154C5.  
 
 
Figure 4.2 Steroidal and non-steroidal substrates used in the characterization of CYP154C5 
mutants and wild type. Steroids such as pregnenolone (1), dehydroepiandrosterone (2), 
progesterone (3), androstenedione (4), testosterone (5) and nandrolone (6) were tested with 
CYP154C5 mutants whereas steroids finasteride (7), etiadienic acid ethyl ester (8), thioallocholane 
(9), 3-deoxydehydroepiandrosterone (10) and 5α-androstan-3-one (11) as well as β-ionone (12) and 
valencene (13) were tested with CYP154C5 wild type. 
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4.3   Materials and methods 
 
4.3.1 Materials 
4.3.1.1 Substrates and chemicals 
Pregnenolone, testosterone, progesterone, cholesterol, β-ionone and (+)-valencene 
were purchased from Sigma-Aldrich (Taufkirchen, Germany. Dehydroepiandrosterone, 
androstendione, nandrolone, finasteride, etiadienic acid ethyl ester, ethioallocholane, 3-
deoxydehydroepiandrostendione and 5-androstan-3-one were purchased from Steraloids 
Inc., (Newport, USA).  
Cytochrome c from horse heart, formate dehydrogenase from Candida boidinii, 
superoxide dismutase, catalase from bovine liver and hydroxypropyl β-cyclodextrine were 
purchased from Sigma Aldrich (Taufkirchen, Germany). Roti-quant for Bradford assay was 
purchased from Roth (Karlsruhe, Germany). NucleoSpin® Plasmid and NucleoSpin® PCR 
clean-up kits for purification of plasmid DNA and amplified DNA after PCR were purchased 
from Machery-Nagel (Düren, Germany). Pfu-Turbo Hotstart PCR Master Mix was obtained 
from Stratagene (California, US). All solvents and other chemicals required for the 
experiments were obtained from Roth or Sigma-Aldrich (Taufkirchen, Germany) and used 
without further purification. 
 
4.3.1.2 Bacterial strains and plasmids 
The Escherichia coli TOP10 (Invitrogen, Carlsbad, CA, USA) and Escherichia coli 
DH5 strains (Invitrogen, Carlsbad, CA, USA) were used for storage, while E. coli C43 (DE3) 
(Lucigen, Middleton, WI, USA) was used for recombinant gene expressions.  
Plasmid pACYC-Duet1 was purchased from Novagen (EMD Biosciences, San Diego, 
CA, USA) while the broad host-range expression vector pIT2-MCS was prepared as 
described elsewhere [13]. Plasmid pKNL031_M17 from a genomic library of Nocardia 
farcinica containing the gene of CYP154C5 (nfa53110, GenBank: NC_006361) was kindly 
provided by Jun Ishikawa (National Institute of Infectious Diseases, Japan). Plasmid 
pET28a(+) was purchased from Novagen (EMD Biosciences, San Diego, CA, USA). 
Preparation of plasmid pACYCcamAB for coexpression of putidaredoxin reductase (CamA) 
and putidaredoxin (CamB) from Pseudomonas putida was described elsewhere [13].  
The gene of CYP154C5 was cloned into vector pIT2-MCS and subcloned to 
pET28a(+) using restriction sites NdeI and HindIII. The resulting plasmid was named 
pET28cyp154C5. Expression of CYP154C5 from vector pET28cyp154C5 results in a fusion 
protein with N-terminal His-tag. 
 
4.3.2 Methods 
4.3.2.1 Production of CYP154C5 mutants  
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Mutants M84A and Q398A were prepared in a previous work by Maurits Dekker [11] 
and were kindly provided by Prof Schallmey, whereas mutants F92A and Q239A were 
prepared by QuikChange® site-directed mutagenesis using the Pfu-Turbo Hotstart PCR 
Master Mix according to the manufacturer’s instructions.  The PCR reactions contained each 
5 µM of forward and reverse primer and 10, 50 or 100 ng of pET28cyp154C5 template. The 
primers applied in the PCR reactions are listed in Table 4.1.  
 
Table 4.1 Applied QuikChange® primers for the generation of CYP154C5 mutants F92A and 
Q239A containing the optimal alanine codon of E. coli (underlined). Melting temperatures are 
also given. 
Primer Sequence (5´to 3´) Tm (°C) 
F92A fwd GGACCGCTCGATGGCCACCGTGGACGGC 88.6 
F92A rev GCCGTCCACGGTGGCCATCGAGCGGTCC 88.6 
Q239A fwd TGATCGGCAATCTCGCGGCGCTCGTCGCC 89.4 
Q239A rev GCGACGAGCGCCGCGAGATTGCCGATCAG 87.9 
 
The following temperature program was used for PCR: initial denaturation at 98°C for 
2 min, followed by 16 cycles of 30 s denaturation at 95°C, 1 min annealing at 55°C and 7 min 
elongation at 68°C. The methylated parental DNA was afterwards digested by adding 1 μL 
DpnI (NEB) and 6 µL NEBuffer 4 (NEB) to each reaction. The final volume was adjusted to 
60 μL with ddH2O and all PCR tubes were incubated for 3 h at 37°C. Afterwards the 
reactions were purified with the NucleoSpin Gel and PCR Clean-up kit and the isolated 
plasmids containing the different mutants were transformed into chemically competent E. coli 
DH5α cells. Correct introduction of the mutations was confirmed by sequencing at GATC 
Biotech (Germany) and final plasmids were transformed into electrocompetent E. coli C43 
(DE3) cells for protein expression. 
 
4.3.2.2 Transformation of chemically competent cells 
For transformation, 1 μL plasmid DNA (~20 ng) was added into a -80°C DMSO 
aliquot of chemically competent E. coli DH5α cells (prepared as previously described by 
Hanahan [14]) followed by incubation for 30 min on ice. DNA uptake was achieved by heat-
shock at 42°C for 1 min followed by 2 min incubation on ice. Subsequently, 300 μL of sterile 
SOC (Super Optimal broth with Catabolite repression) medium (preheated to 37°C) were 
added and the cells were incubated for 1 h at 37°C and 250 rpm. In order to select 
successful transformants, 50 and 100 μl of the cell suspension were streaked on two LB 
plates containing kanamycin (50 µg/mL) and incubated overnight at 37°C.  
 
4.3.2.3 Transformation of electrocompetent cells 
Electrocompetent E. coli C43 (DE3) cells, previously prepared as described by 
Alonso-Stepanova Lab [15] were thawed on ice, mixed with 1 μL plasmid DNA (~100 ng) and 
incubated for 1 min on ice. Afterwards, the cells were transferred into a prechilled 
electroporation cuvette (2 mm electrode gap, Peqlab, Erlangen, Germany) and placed into 
Exploring CYP154C5’s specificity by substrate and protein engineering 
 
C
h
a
p
te
r 
4
: 
M
a
te
ri
a
ls
 a
n
d
 m
e
th
o
d
s
 
102 
 
the electroporator where 1500 V were applied. Afterwards, 1 mL of preheated SOC media 
(37°C) was immediately added and the cells were transferred in a 1 mL reaction tube to 
incubate them for 1 h at 37°C and 250 rpm. To select successful transformants, the cells 
were spread on LB agar plates containing kanamycin (50 µg/mL) and incubated overnight at 
37°C. Stocks were prepared as described in the following section. 
 
4.3.2.4 Cryogenic storage of E.coli cells 
In order to produce frozen stocks of E. coli strains containing the respective plasmids, 
5 mL liquid LB media supplemented with kanamycin (50 µg/mL) was inoculated from the 
plates with one single colony. The culture was incubated overnight at 37°C and 250 rpm. 
After mixing 900 μL overnight culture with 68 μL DMSO and shock freezing in liquid nitrogen, 
the E. coli cells were stored at -80°C. 
 
4.3.2.5 Protein expression 
4.3.2.5.1 Expression of Escherichia coli C43 (DE3) (pET28cyp154C5) and mutants.  
As first step, 5 mL liquid LB media (10 g/L of tryptone, 5 g/L of yeast extract, 10 g/L of 
NaCl) supplemented with kanamycin (50 µg/mL final concentration) was inoculated from a -
80°C DMSO stock of E. coli C43 (DE3) containing pET28cyp154C5. After incubation 
overnight at 37°C and 250 rpm (Bench top shaker Certomat Sartorius, Göttingen, Germany), 
a 500 mL TB preculture (12 g/L of tryptone, 24 g/L of yeast extract, 4 mL glycerol, 2.3 g/L of 
KH2PO4 and 12.9 g/L of K2HPO4) supplemented with kanamycin (50 µg/mL) was inoculated 
with 1 % v/v overnight culture and incubated at 37°C and 250 rpm. At OD600 ~ 1 the culture 
was induced with isopropyl β-D-1-thiogalactopyranoside (IPTG, 200 µg/mL final conc.), δ-
aminolevulinic acid (84 µg/mL final conc.) was added as a precursor for the synthesis of the 
heme prosthetic group and 0.1 % v/v trace element solution (0.5 g/L of CaCl2.2H2O, 0.18 g/L 
of ZnSO4.7H2O, 0.10 g/L of MnSO4.H2O, 20.10 g/L of Na2-EDTA, 16.70 g/L of FeCl3.6H2O, 
0.16 g/L of CuSO4.5H2O and 0.18 g/L of CoCl2. 6H2O) was also added. After 48 hours of 
expression at 30°C and 300 rpm, the cells were harvested by centrifugation (4424 x g, 4°C 
for 15 min), washed with 50 mM potassium phosphate buffer pH 7.4, centrifuged again (4424 
x g, 4°C for 15 min) (centrifuge 5810 R Eppendorf, Hamburg, Germany) and the pellet was 
stored at -20°C until further use. The expression of CYP154C5 mutants was performed 
under the same conditions as described for wild type. 
 
4.3.2.5.2 Expression of Escherichia coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB). 
Small scale expression of CYP154C5 was performed in a 2 L flask following the same 
protocol as described in section 4.3.2.5.1 with the exception that chloramphenicol (25 µg/mL 
final conc.) and tetracycline (10 µg/mL final conc.) were applied as antibiotics instead of 
kanamycin. 
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4.3.2.5.3 Expression of Escherichia coli C43 (DE3) (pACYCcamA), Escherichia coli C43 
(DE3) (pACYCcamB) and Escherichia coli C43 (DE3) (pACYCcamAB). 
The expression of CamA (PdR) was performed in a 2L flask. As first step, 5 mL liquid 
LB media supplemented with chloramphenicol (25 µg/mL) was inoculated from a -80°C 
DMSO stock of Escherichia coli C43 (DE3) (pACYCcamA). After incubation overnight at 
37°C and 250 rpm (Bench top shaker Certomat Sartorius, Göttingen, Germany), a 500 mL 
TB preculture supplemented with chloramphenicol (25 µg/mL) was inoculated with 1 % v/v 
overnight culture and incubated at 37°C and 250 rpm. At OD600 ~ 1 the culture was induced 
with isopropyl β-D-1-thiogalactopyranoside (IPTG, 200 µg/mL final conc.) and 0.1 % v/v trace 
element solution was added. After 48 hours of expression at 30°C and 300 rpm, the cells 
were harvested by centrifugation (4424 x g, 4°C for 15 min), washed with 50 mM potassium 
phosphate buffer pH 7.4, centrifuged again (4424 x g, 4°C for 15 min) and the pellet was 
stored at -20°C until further use. 
Expression of Escherichia coli C43 (DE3) (pACYCcamB) and E. coli C43 (DE3) 
(pACYCcamAB) – the first used for recombinant expression of CamB (Pdx), latter used as 
control strain in bioconversions - were performed under the same conditions as described for 
CamA. 
 
4.3.2.6 Protein purification 
4.3.2.6.1 Purification of CYP154C5 and mutants via N-terminal His-tag  
Approximately 10 g of wet cells of E. coli C43 (DE3) (pET28cyp154C5) containing 
over-expressed CYP154C5 with N-terminal His-tag were resuspended in 80 mL 50 mM 
potassium phosphate buffer pH 7.4 and PMSF (phenylmethylsulfonyl fluoride, 17 µg/mL final 
conc.) was added as protease inhibitor. Cell disruption was performed by French Press 
(EmulsiFlex-Homogenizer, Avestin) with 5 cycles of 1500 psi. Cell debris was removed by 
centrifugation at 17696 x g, 4°C for 45 minutes and the supernatant was filtered through 0.2 
µm pore size filters. 
The purification of CYP154C5 via N-terminal His-tag was performed in 2 steps. In all 
cases the characteristic red-brown colour of the protein due to the presence of the iron-
containing heme prosthetic group indicated the presence of the P450 monooxygenase. First, 
the supernatant containing active P450 was loaded on a 120 mL Q-Sepharose FF column 
(GE Healthcare) equilibrated with 20 mM potassium phosphate buffer pH 7.4. The column 
was then washed with the same buffer before elution of the target protein with a linear 
gradient of 0-500 mM KCl in 20 mM potassium phosphate buffer pH 7.4. Fractions containing 
CYP154C5 were combined and loaded on a 20 mL HisTrap HP column (GE Healthcare) 
equilibrated with 500 mM KCl in 50 mM potassium phosphate buffer pH 7.4. The column was 
then washed with 50 mM potassium phosphate buffer pH 7.4 containing 20 mM imidazol and 
500 mM KCl in order to remove all unbound protein. Afterwards, the target protein was eluted 
with 250 mM imidazol in 50 mM potassium phosphate buffer pH 7.4 and 500 mM KCl. 
Fractions containing the P450 monooxygenase were combined and concentrated by 
ultrafiltration using Amicon centrifugal tubes (Millipore) with 30 kDa cutoff. Size exclusion 
chromatography PD10 columns (GE Healthcare) and 50 mM potassium phosphate buffer pH 
7.4 were employed to desalt the protein solution. Additionally, dialysis of the protein solution 
in 50 mM potassium phosphate buffer pH 7.4 was performed overnight at 4°C in order to 
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remove all traces of imidazol. Finally the solution was shock-frozen using liquid nitrogen and 
stored at -80°C.  
Purification of CYP154C5 mutants was performed as described for CYP154C5 wild 
type (see appendix section 4.3). 
 
4.3.2.6.2 Purification of PdR 
Approximately 10 g of wet cells of E. coli C43 (DE3) (pACYCcamA) containing over-
expressed PdR from P. putida were resuspended in 80 mL of 50 mM potassium phosphate 
buffer pH 7.4 and cell disruption was performed as previously described for CYP154C5 
purification. The purification of PdR (45 kDa) was also performed in two steps. In all cases 
the characteristic yellow colour indicated the PdR containing fractions due to the presence of 
the FAD cofactor. As first step, purification was performed using a 120 mL Q-Sepharose FF 
ion exchange column equilibrated with 50 mM potassium phosphate buffer pH 7.4. The 
protein was eluted with a 1 L gradient of 0-500 mM KCl in 50 mM potassium phosphate 
buffer pH 7.4 (buffer A), with a flow of 6 mL/min. PdR protein eluted at approximately 60 % 
buffer A. All yellow fractions which showed on SDS-PAGE the respective PdR band at 45 
kDa (see appendix section 3.2) were combined and concentrated using a 30 kDa cut-off 
Amicon centrifugal tube. In the second step, the concentrated PdR fraction was adjusted to 
1.5 M KCl concentration and loaded on a 50 mL Phenyl-Sepharose FF hydrophobic 
interaction column equilibrated with 1.5 M KCl in 50 mM potassium phosphate buffer pH 7.4. 
The target protein was eluted with a 500 mL gradient of 1.5 to 0 M KCl in 50 mM potassium 
phosphate buffer pH 7.4 (buffer B). PdR eluted at approximately 70 % of buffer B. The 
respective fractions were combined and concentrated in a 30 kDa cut-off Amicon centrifugal 
tube. Size exclusion chromatography PD10 columns (GE Healthcare) were employed to 
remove KCl traces that were still present in the protein sample. Finally, the PdR solution was 
shock-frozen using liquid nitrogen and stored at -80°C. 
 
4.3.2.6.3 Purification of Pdx 
Approximately 10 g of wet cells of E. coli C43 (DE3) (pACYCcamB) containing over-
expressed Pdx from P. putida were resuspended in 80 mL of 50 mM potassium phosphate 
buffer pH 7.4 and cell disruption was performed as previously described for CYP154C5 
purification. In the first step a 120 mL ion exchange Q-Sepharose FF column was used and 
Pdx (11 KDa) was eluted with the same gradient system as described for PdR. All brown 
fractions, due to the presence of an iron-sulfur cluster in Pdx, were combined (with previous 
SDS-PAGE confirmation, see appendix section 3.2) and Pdx was further purified by 
ultrafiltration with a 30 kDa cut-off membrane. Thereby, larger proteins could be removed. 
Afterwards, 10 kDa cut-off Amicon centrifugal tubes were used to highly concentrate the 
protein. Size exclusion chromatography PD10 columns (GE Healthcare) and 50 mM 
potassium phosphate buffer pH 7.4 were employed to desalt the protein solution. Finally, the 
Pdx solution was shock-frozen using liquid nitrogen and stored at -80°C. 
 
 
Exploring CYP154C5’s specificity by substrate and protein engineering 
 
C
h
a
p
te
r 
4
: 
M
a
te
ri
a
ls
 a
n
d
 m
e
th
o
d
s
 
105 
 
4.3.2.7 SDS-PAGE and enzyme assays 
SDS-PAGE was carried out according to Schägger et al. adjusted to the Mini 
PROTEAN® Tetra Cell (Bio-Rad) [16]. Samples were prepared and ran as described in 
chapter 2 (section 2.3.2.3) of this thesis.  
In cases were purified proteins (P450, PdR and Pdx) where employed for catalysis 
their respective concentration and activity were previously determined by the following 
assays. P450 concentration was determined by CO-difference spectra [17] and calculated 
based on the absorbance maximum of CO-bound P450 at 450 nm (ε450=91 mM
-1 cm-1) using 
a Cary 50 (Varian) spectrophotometer. The concentration of pure Pdx and PdR was 
determined at 455 nm (ε455=10.4 mM
-1 cm-1) and 454 nm (ε455=10.0 mM
-1 cm-1) respectively 
[18]. Afterwards, the activity of the purified electron transfer components (ETC) Pdx and PdR 
was determined by cytochrome c reduction assay, monitoring the  increase in absorbance at 
550 nm of reduced cytochrome c (ε450=19.1 mM
-1 cm-1) in a mixture containing a ratio of 
PdR:Pdx equal to 3:16 [19]. Additionally, all enzymes assays were also measured with cell 
lysate of the respective E. coli C43 (DE3) cells containing P450, PdR and Pdx before whole-
cell catalyses. For this, cells were resuspended in 50 mM potassium phosphate buffer pH 7.4 
in order to reach an optical density of 40 and phenylmethylsulfonyl fluoride (PMSF, 17 µg/mL 
final conc.) was added as protease inhibitor. Cell disruption was performed in an EmulsiFlex-
Homogenizer (Avestin, Germany) with 5 cycles of 1500 psi. After centrifugation (17,696 x g, 
4°C for 45 min) the resulting CFE was immediately used for the assays. P450 concentration 
and the activity of the ETC in the CFE were determined as previously described for the 
purified proteins. Total protein concentration was determined by Bradford assay [20].  
 
4.3.2.8 Dissociation constants (KD) 
Dissociation constants of CYP154C5 and CYP154C5 mutants for the different 
steroids were determined by spectroscopic measurements upon titration of purified P450 
with increasing steroid concentrations. Thus, purified CYP154C5 stock was diluted with 50 
mM potassium phosphate buffer pH 7.4 in order to reach 3 µM final enzyme concentration. 
To this mixture, substrate was added in concentrations from 0 to 100 µM. Therefore, three 
different substrate stock solutions of 0.1, 0.5 and 1 mM in 0.1-4.5 % (w/v) hydroxypropyl--
cyclodextrin in ddH2O (see appendix section 3.3) were prepared. The absorbance spectra of 
each sample were measured in a Cary 50 Spectrophotometer (Varian) in the range between 
300 and 500 nm at 30°C. As a blank, 3 µM P450 in 50 mM potassium phosphate buffer pH 
7.4 with addition of an equivalent amount of buffer instead of substrate solution was used. 
Each sample was prepared and measured in duplicate. By plotting the resulting absorbance 
difference (Abs396nm – Abs419nm) against the applied substrate concentration and fitting the 
data using Matlab software with the tight binding equation [21], KD values for the different 
steroids were obtained. 
 
4.3.2.9 Analytical scale bioconversions  
4.3.2.9.1 Whole cell catalysis 
In case of whole-cell bioconversions, frozen cells of E. coli C43 (DE3) 
(pIT2cyp154C5) (pACYCcamAB) overexpressing Pdx, PdR and CYP154C5 were 
resuspended in 50 mM potassium phosphate buffer pH 7.4 to the desired final OD600. All 
Exploring CYP154C5’s specificity by substrate and protein engineering 
 
C
h
a
p
te
r 
4
: 
M
a
te
ri
a
ls
 a
n
d
 m
e
th
o
d
s
 
106 
 
bioconversions were carried out in 1 mL scale at 30°C and 250 rpm with addition of glucose 
(0.54 mg/mL final conc.) for cofactor regeneration and 1 mM substrate, with the exception of 
substrates 12 and 13 were 10 mM were applied. Substrate stock solutions of steroids were 
prepared in 36 % w/v hydroxypropyl-β-cyclodextrin in water. In detail, stocks with a final 
concentration of 2.5; 3.2; 4.2; 4.1 and 4.2 mM for substrates finasteride (7), etiadienic acid 
ethyl ester (8); ethioallocholane (9); 3-deoxydehydroepiandrostendione (10) and 5-
androstan-3-one (11) were prepared, respectively. For β-ionone (12) and (+) valencene (13) 
each 1 M stocks solutions in DMSO were prepared. Control reactions were carried out in 
parallel with E. coli C43 (DE3) (pACYCcamAB) containing only Pdx and PdR. After 20 hours 
of reaction, the bioconversions were extracted for subsequent HPLC and GC analysis. For 
that, 500 µL of sample was extracted twice with ethyl acetate (300 µL and 250 µL) and once 
with chloroform (250 µL). The organic phases were combined, dried with sodium sulphate 
and the solvent was removed under reduced pressure. As an exception, conversions 
performed with steroid 8 were acidified with 2 M HCl previous to the extraction procedure. 
 
4.3.2.9.2 Cell free extract catalysis 
In case of bioconversions using cell-free extract (CFE), frozen cells of E. coli C43 
(DE3) (pIT2cyp154C5) (pACYCcamAB) were resuspended in 50 mM potassium phosphate 
buffer pH 7.4 and phenylmethylsulfonyl fluoride (17 µg/mL final conc.) was added as 
protease inhibitor. Cell disruption was performed in an EmulsiFlex-Homogenizer (Avestin, 
Germany) with 5 cycles of 1500 psi. After centrifugation (17,696 x g, 4°C for 45 min) the 
resulting CFE was immediately used for bioconversions. In 1 mL scale reactions, NADH (36 
µg/mL final conc.) was used as electron donor, sodium formate (10 mg/mL final conc.) and 
formate dehydrogenase from Candida boidinii (Sigma Aldrich, 0.5 U/mL final activity) were 
added for NADH regeneration. Steroid substrates were also added as stock solutions in 36 
% w/v hydroxypropyl-β-cyclodextrin in water (for more details see section 4.3.2.7.1). After 24 
hours of reaction at 30°C and 250 rpm, 500 µL reaction mixture was extracted as described 
for whole-cell catalysis. 
 
4.3.2.9.3 Catalysis using purified three-component system 
Stocks of pure PdR, Pdx and the P450 mutants in 50 mM potassium phosphate buffer 
pH 7.4 were employed in overnight conversions of steroids. Each reaction of 1 mL contained 
3 µM P450, 3 µM PdR, 16 µM Pdx, 0.5 U/mL formate dehydrogenase from Candida boidinii, 
150 mM sodium formate, 300 U/mL catalase from bovine liver, 50 µM NADH and 2 mM of 
the respective steroid substrate in 50 mM potassium phosphate buffer pH 7.4. Steroid stock 
solutions of 5 mM concentration were prepared in 1.8-4.5 % (w/v) hydroxypropyl-β-
cyclodextrin in ddH2O (see appendix section 3.3). All bioconversions were carried out at 
30°C and 250 rpm for 20 h. After that, 500 µL of each reaction was extracted twice with ethyl 
acetate (300 µL and 250 µL) and once with chloroform (300 µL), the organic phases were 
combined, dried with sodium sulphate and the solvent was removed under reduced pressure. 
Each reaction was performed in duplicate. 
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4.3.2.10 Turnover numbers  
Stocks of pure PdR, Pdx and CYP154C5 in 50 mM potassium phosphate buffer pH 
7.4 were employed for the determination of turnover numbers of the different CYP154C5 
mutants. Each reaction contained 3 µMP450, 3 µM PdR, 16 µM Pdx, 0.5 U/mL formate 
dehydrogenase from Candida boidinii (Sigma), 150 mM of sodium formate, 300 U/mL 
catalase from bovine liver, 50 µM NADH and 2 mM of the respective steroid (5 mM stock in 
1.8-4.5 % w/v hydroxypropyl-β-cyclodextrin in ddH2O - see appendix section 3.3) in 50 mM 
potassium phosphate buffer pH 7.4. All bioconversions were carried out at 5 mL scale for 8 h 
at 30°C and 250 rpm. During bioconversions, samples were taken at different time points for 
subsequent HPLC and GC analysis. For that, 0.5 mL of each reaction was extracted twice 
with ethyl acetate (300 µL and 250 µL) and once with chloroform (300 µL), the organic 
phases were combined, dried with sodium sulphate and the solvent was removed under 
reduced pressure. Turnover numbers were calculated based on substrate consumption and 
for the period of time where the highest substrate consumption rate was observed. Each 
reaction was made in duplicate. 
While performing preparative scale reactions using frozen cells of E. coli C43 (DE3) 
(pIT2cyp154C5) (pACYCcamAB) (according to section 4.3.2.9.1) samples were taken over 
time and TONs calculated as described in the previous paragraph.  
 
4.3.2.11 NADH oxidation rate and coupling efficiency 
NADH depletion during bioconversions of steroids by CYP154C5 mutants, Pdx and PdR 
was monitored in a spectrophotometer at 340 nm (ε340 = 6.22 mM
-1 cm-1). Reactions of 0.7 
mL total volume included 0.4 µM purified P450, 0.4 µM purified PdR, 14 µM purified Pdx, 600 
U/mL catalase from bovine liver, 200 U/mL superoxide dismutase (SOD), 200 µM NADH and 
1 mM of the respective steroid (5 mM stock in 1.8-4.5 % w/v of hydroxypropyl-β-cyclodextrin 
in ddH2O -see appendix section 3.3) in 50 mM potassium phosphate buffer pH 7.4. After the 
NADH was completely consumed, 0.5 mL reaction mixture was extracted as described for 
the turnover number determination and further analyzed by HPLC and GC in order to 
determine the conversion. 
 
4.3.2.12 Preparative scale bioconversions and product purification 
Preparative-scale bioconversions were carried out in 50 mM potassium phosphate 
buffer pH 7.4 in shake flasks using resting whole cells of E. coli C43 (DE3) (pIT2cyp154c5) 
(pACYCcamAB) (from frozen stock) at 30°C and 250 rpm (Bench top shaker Certomat 
Sartorius, Göttingen, Germany) with the addition of  glucose (0.54 mg/mL) for cofactor 
regeneration. In case of substrate 10, resting cells were resuspended in 100 mL buffer to 
OD600 ~ 36, equivalent to 2 µM CYP154C5 and an ETC activity of 5.6 U/mL (1.4 U/mg of total 
protein), as determined by CO-difference spectra and cytochrome c assay, respectively. 
Similarly, conversion of substrate 11 was performed using resting cells resuspended in 50 
mL buffer to OD600 ~ 40, equivalent to 3 µM CYP154C5 and an ETC activity of 11.8 U/mL 
(2.1 U/mg of total protein). Initial substrate concentrations of 1 mM (10) and 500 µM (11) 
were used; for that, stock solutions of substrates 10 and 11 were prepared in 36 % (w/v) 
hydroxypropyl-β-cyclodextrin (in ddH2O) and DMSO, respectively. After 22-24 h of reaction, 
the complete reaction volume was extracted twice with ethyl acetate (50 and 40 mL) and 
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once with chloroform, (30 mL), the organic phases were combined, dried with sodium 
sulphate and the solvent removed under reduced pressure. Hydroxylated steroid products 
were afterwards purified by silica gel column chromatography (silica gel 60; 0.2-0.5 mm; 
Roth) with a gradient of ethyl acetate in n-heptane to pure ethyl acetate starting with ethyl 
acetate:n-heptane ratio of 2:8, followed by 1:1, 7:3 and 8:2 as mobile phase in case of 
products derived from substrate 10. Purification of the reaction using substrate 11 was 
performed with a mixture of ethyl acetate:n-heptane of 1:1 as mobile phase. 
 
4.3.2.13 Thin layer chromatography (TLC) 
Bioconversions of all substrates were analyzed by TLC using Polygram Sil G/UV 254 
plates (stationary phase) and phosphomolybdic acid solution (25 g/L phosphomolybdic acid, 
10 g/L Ce(SO4)2, 8 % v/v of 98 % H2SO4 in ddH2O) for staining in addition to UV254nm 
detection. A mixture of ethyl acetate and n-heptane (8:2) was used as mobile phase, with the 
exceptions of substrates deoxydehydroepiandrosterone (10), 3α-androstan-3-one (11), β-
ionone (12) and (+) valencene (13) where a 1:1 mixture of ethyl acetate and n-heptane was 
used. Additionally, a 9:1.5:1 mixture of toluene: methanol: triethylamine was employed as 
mobile phase for substrate finasteride (7).  
 
4.3.2.14 GC and HPLC analyses 
In the case of pregnenolone (1), dehydroepiandrosterone (2), 3-deoxydehydroepi-
androsterone (10) and 5-androstan-3-one (11), the solid residues were redissolved in 
chloroform containing 30 mM cholesterol as internal standard. In case of substrates 
etiadienic acid ethyl ester (8) and ethioallocholane (9), samples were dissolved in pure 
chloroform. Samples were analyzed on a GC2010 gas chromatograph (Shimadzu) equipped 
with an OPTIMA 17ms column (Macherey-Nagel, Germany) with a linear gradient starting at 
250°C and heating with 10°C/min until 300°C, with the exception of substrate 9 were the 
gradient started at 230°C. Injector and detector temperature were set to 350 and 300°C 
respectively. Substrates and products were detected by FID. Substrates, pregnenolone (1), 
dehydroepiandrosterone (2), etiadienic acid ethyl ester (8), ethioallocholane (9), 3-
deoxydehydroepiandrosterone (10) and 5-androstan-3-one (11) were detected with a 
retention time of 9.69 min, 7.94 min, 9.36 min, 3.87 min, 4.97 min and 5.37 min, respectively, 
whereas their major products eluted at 9.27 (1A), 10.18 min (2A), 6.14 min (10A2) and 8.24 
min (11A2), respectively. In case of substrates finasteride (7), β-ionone (12) and (+) 
valencene (13), the solid residues were redissolved in chloroform. These samples were 
analyzed on a GC2010 equipped with a Supreme 5ms column (CS Chromatographie 
Service, Langerwehe, Germany). In case of finasteride (7), an isothermal program was ran at 
300°C for 20 min whereas a linear gradient starting at 40°C and heating with 10°C/min until 
300°C was applied for substrates 12 and 13. Injector and detector temperature were set to 
300°C. Substrates were eluted with retention times of 5.22 min (7), 15.36 min (12) and 15.59 
min (13), respectively. Product 12A was eluted with a RT of 17.65 min. 
The dried residues of bioconversions with progesterone (3), androstendione (4), 
testosterone (5) and nandrolone (6) were dissolved in acetonitrile: water (60:40) and injected 
on an ultra-fast liquid chromatograph (UFLC, Prominence, Shimadzu) equipped with a 
Nucleosil 100-5 C18, 250 x 4,5 mm column at 50°C.  Acetonitrile: water (60:40) was used as 
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mobile phase with a flow rate of 1.2 mL/ min. Detection of substrates and their respective 
products was performed by UV absorbance at 243 (5 and 5A) and 242 nm (3, 4, 6, 3A, 4A 
and 6A). The substrates were eluted at 5.93 min (5), 10.45 min (3), 6.35 min (4) and 5.39 
min (6), whereas the main products were detected at 3.23 min (5A), 4.35 min (3A), 5.60 min 
(3A*), 3.87 min (4A) and 3.26 min (6A). In all cases the conversions were calculated based 
on substrate consumption.  
 
4.3.2.15 GC-MS and NMR analyses 
Preliminary product identification was performed with a gas chromatograph - mass 
spectrometer (GC-MS-QP2010S, Shimadzu, Germany) equipped with an OPTIMA 17ms 
column (Macherey-Nagel, Germany) using a linear temperature gradient starting at 250°C 
and heating with 10°C/min to 300°C. Injector, interface and ion source temperature were set 
to 300, 300 and 200°C respectively. Structure elucidation of formed products was performed 
by 1H, 13C, COSY, HSQC and NOESY NMR analysis on a Bruker AV600 instrument (1H-
NMR 600MHz and 13C-NMR 150MHz) using deuterated chloroform as solvent with TMS as 
internal standard for all products except for product 10A2 were deuterated DMSO with TMS 
was used. Chemical shifts (δ) are given in ppm and coupling constant (J) in Hz. For further 
information see appendix section 4.6. 
 
4.3.2.15.1 16α-hydroxy-3-deoxydehydroepiandrosterone (10A2) 
 
1H-NMR (600 MHz, DMSO): δ 5.34 (1H, d, J= 5.6, 16-OH), 5.26 (1H, d, J=5.1, 6-H), 4.21 
(1H, dd, Jd= 8.4, Jd= 5.9, 16-βH), 2.22 (1H, m, 4-H), 2.05-1.95 (2H, m, 4-H and 7-H), 1.91 
(1H, dt, Jt= 13.7, Jd= 8.5, 15-H), 1.81 (1H, d, J= 12.7, 1-H), 1.73-1.51 (6H, m, 2-H, 3-H, 
8-H, 11-H, 12-H and 15-H), 1.50-1.43 (2H, m, 2-H and 14-H), 1.39 (1H, dq, Jq= 13.4, 
Jd= 4.6, 11-H), 1.31-1.21 (2H, m, 7-H, 12-H), 1.14 (1H, m, 3-H), 1.03-0.95 (5H, m, 1-H, 
9α-H and 19-Me), 0.86 (3H, m, 18-Me). 13C-NMR (150 MHz, DMSO): δ 118.9 (6-C), 70.6 (16-
C), 50.6 (9-C), 48.7 (14-C), 47.2 (13-C), 39.4 (1-C), 37.6 (10-C), 32.8 (4-C), 32.1 (7-C), 31.8 
(12-C), 31.3 (8-C), 30.5 (15-C), 27.9 (3-C), 22.5 (2-C), 19.8 (11-C), 19.7 (19-C), 14.3 (18-C). 
Molecular weight: 288 g/mol; GC-MS: Retention time: 6.0 min. M+: 288; m/z (%): 288 (100), 
201 (82), 216 (79), 145 (77), 41 (74), 91 (72), 105 (69), 79 (66), 55 (58), 159 (54), 121 (43). 
 
4.3.2.15.2 Unknown 3-deoxydehydroepiandrosterone product (10A3) 
Molecular weight: 346 g/mol, GC-MS: Retention time: 9.9 min, M+= 346, m/z (%) = 346 (9), 
328 (8), 268 (13), 253 (17), 199 (27.8), 157 (20), 145 (20), 91 (31), 55 (29), 43 (100). 
 
4.3.2.15.3 Unknown 3-deoxydehydroepiandrosterone product (10A4) 
Molecular weight: 288. g/mol; GC-MS: Retention time: 8.3 min, M+= 289, m/z (%) = 289 (72), 
213 (23), 199 (16), 145 (37), 121 (25), 108 (42), 91 (63), 79 (53), 55 (75), 43 (100). 
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4.3.2.15.4 Unknown 3-deoxydehydroepiandrosterone product (10A5) 
Molecular weight: 304 g/mol; GC-MS: Retention time: 8.6 min, M+= 304, m/z (%) = 304 (72), 
271 (69), 213 (82), 145 (76), 105 (100), 91 (100), 79 (80), 55 (74), 43 (88), 41 (89). 
 
4.3.2.15.5 15α-hydroxy-5α-androstan-3-one (11A2) 
1H-NMR (600 MHz, CDCl3): δ 4.50 (1H, m, 15β-H), 2.45-2.23 (2H, m, 2α-H, 2β-H), 2.29 (1H, 
t, Jt= 14.3, 4-H), 2.14-2.06 (2H, m, 4β-H, 16α-H), 2.04 (1H, dq, Jq= 6.8 Jd= 2.3, 1α-H), 1.77-
1.53 (8H, m, 5-H, 7-H, 11-H, 12-H, 17α-H, 17β-H), 1.44-1.25 (7H, m, 1β-H, 6α-H, 6β-H, 8-H, 
11-H, 12-H, 16β-H), 1.18 (1H, dd, Jd= 12.5 Jd= 5.9, 14α-H), 1.06-0.98 (4H, m, 7β-H, 19-CH3), 
0.85 (1H, m, 9α-H), 0.75 (3H, s, 18-CH3). 
13C-NMR (150 MHz, CDCl3): δ 211.2 (3-C), 71.7 
(15-C), 54.0 (9-C), 52 (14-C), 52 (16-C), 46.6 (5-C), 44.7 (4-C), 41.9 (13-C), 38.6 (1-C), 38.5 
(2-C), 38.2 (12-C), 37.3 (17-C), 35.8 (10-C), 35.2 (8-C), 31.9 (7-C), 28.9 (6-C), 21.1 (11-C), 
18.7 (19-C), 11.5 (18-C).  
Molecular weight: 290 g/mol; GC-MS: Retention time: 7.52 min. M+: 290; m/z (%): 290 (11), 
272 (41), 257 (65), 231 (76), 200 (50), 107 (57), 81 (71), 67 (74), 55 (100), 414 (93). 
 
4.3.2.15.6 4-hydroxy-β-ionone (12A) 
 
Molecular weight: 208 g/mol; GC-MS: Retention time: 18.33 min. M+: 208; m/z (%): 208 (16), 
193 (7), 137 (17), 134 (10), 123 (26), 109 (80), 95 (15), 91 (17), 55 (15), 43 (100). 
 
 
4.4   Results 
 
4.4.1 Mutagenesis, protein expression and purification 
Based on a detailed analysis of CYP154C5´s active site in presence of six different 
steroid substrates (1-6, see chapter 3 of this thesis), four residues were thought to play an 
important role in substrate binding in the active site. Thus, the gene cyp154c5 was 
individually mutated at the four different positions, namely M84, F92, Q239 and Q398 using 
QuikChange® site-directed mutagenesis in order to determinate their role in CYP154C5´s 
selectivity in steroid conversions. In particular, due to their involvement in hydrogen bond 
formation with oxyfunctionalities at positions C3 and C17 of the steroid molecule, residues 
Q239 and Q398 were exchanged to alanine, thus affecting the direct interaction between 
enzyme and substrate. Furthermore, residues in the hydrophobic substrate channel involved 
in hydrophobic interactions with the steroid core, such as M84 and F92, were also 
exchanged to alanine in order to analyze their importance in substrate binding. Figure 4.3 
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shows an overlay of the six crystal structures of CYP154C5-steroid complexes and the four 
residues in the active site which were mutated. Sequencing results after QuikChange® site-
directed mutagenesis showed the successful introduction of the four mutations without any 
unwanted gene modification. 
  
Figure 4.3 Superposition of the active sites of the six CYP154C5-steroid complexes. The overlay 
of substrates 1-6 bound in the active site of CYP154C5, surrounded by four key residues, namely 
M84, F92, Q239 and Q398, is depicted. 
 
Later on, the individual expression of CYP154C5 wild type and mutants M84A, F92A, 
Q239A and Q398A in E. coli C43 (DE3) was successfully achieved in 500 mL shake flasks. 
Similarly, expression of E. coli C43 (DE3) (pACYCcamA) and E. coli C43 (DE3) 
(pACYCcamB) was performed in order to obtain the electron transfer proteins PdR and Pdx 
from P. putida which are required to reconstitute the activity of CYP154C5 wild type and 
mutants. In all cases, protein expression was induced by IPTG addition and trace element 
solution was added to supplement the media especially with iron. Additionally, δ–
aminolevulinic acid was used for enhanced heme synthesis in the expression of the different 
P450s (for an SDS-PAGE gel see appendix section 4.2). After cell disruption, the individual 
proteins were purified by different chromatography steps including ion exchange, size-
exclusion and affinity chromatography, followed by ultrafiltration to concentrate the proteins, 
buffer exchange and dialysis (for CYP154C5, PdR and Pdx purification see appendix section 
3.2 and for CYP154C5 mutants see appendix section 4.3). As a result, the obtained amount 
of wild type CYP154C5 and its mutants as well as electron transfer components (ETC: PdR 
and Pdx) varied between 2-3 % of the total protein content. In particular, 27 mg of Pdx per 
liter of culture (~1.6 mg of protein per g of wet cell -gwc -) were obtained after purification, 
whereas 146 mg L-1 PdR (~14 mg gwc
-1), 162 mg L-1 CYP154C5 (~12 mg gwc
-1), 157 mg L-1 
CYP154C5-F92A (~9 mg gwc
-1) and 106 mg L-1 CYP154C5-Q239A (~6 mg gwc
-1) were 
isolated. Although the total amount of purified CYP154C5-M84A and CYP154C5-Q398A was 
not determined, the expression level of these mutants seemed to be equivalent to the 
expression level of CYP154C5 wild type (see SDS-PAGE in appendix section 4.2). 
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4.4.2 Characterization of CYP154C5 mutants in the hydroxylation of steroid substrates 
4.4.2.1 Dissociation constant  
In absence of substrate, P450 enzymes contain a water molecule as the sixth ligand 
at the heme iron, which exhibits a low-spin (LS) configuration with an absorbance maximum 
at approximately 420 nm. Upon substrate addition, the water molecule is removed by 
substrate binding in the active site and coordination to the heme iron. This causes a shift of 
the iron atom to a high-spin (HS) configuration which, in type I spectral changes, involves a 
shift of the absorbance maximum to approximately 390 nm. The more substrate is added to 
the enzyme, the bigger the peak-to-trough difference in absorbance (A) gets between P450 
with high spin iron (A390) and P450 with low spin iron (A420) until saturation is reached. From 
these data, dissociation constants (KD) can be estimated by plotting A against the substrate 
concentration and fitting of the data. In case of CYP154C5, the quadratic tight binding 
equation had to be used for fitting due to very low KD values [21, 22]. It was known that 
CYP154C5 wild type completely shifts from LS (420 nm) to HS (386 nm) upon addition of an 
excess of substrates 1 to 6 (see chapter 3). So the question was if the same still holds true 
for the CYP154C5 single mutants, which would be an indication of efficient steroid binding. 
For this reason, the spectral shifts of the four purified mutants were analysed for steroids 1-6. 
As a result, almost all combinations resulted in 100 % shift of CYP154C5 mutants from low 
spin to high spin. However, some mutants showed only a partial or no spectral shift upon 
substrate addition, even at high steroid concentration, and thus their KD was not determined 
(Table 4.2).  
 
Table 4.2 Dissociation constants (KD) of CYP154C5 mutants for steroid substrates 1-6. KD 
values were determined at 30°C for the His-tagged CYP154C5 mutants by tight-binding equation, 
except for mutant Q239A (*) where the Hill equation had to be used. All values are the result of 
duplicate measurements. 
-    no shift to high-spin heme observed 
-+ only partial shift to high-spin heme observed 
* data fitted using Hill equation 
 
As expected, all mutants generally exhibited lower substrate binding affinities (higher 
KD values) towards the six steroid substrates than the wild type. The only exception is mutant 
CYP154C5-Q398A with pregnenolone (1) and progesterone (3) for which KD values were 
obtained in the same order of magnitude as for wild type. In contrast, the affinity of 
 KD (nM) 
Substrates CYP154C5 
CYP154C5
-M84A 
CYP154C5
-F92A 
CYP154C5
-Q239A 
CYP154C5
-Q398A 
Pregnenolone (1) 45 ± 36 - -+ 1917 ± 89* 13 ± 36 
Dehydroepiandrosterone (2) <1  -+ 632 ± 72 1774 ± 84* 296 ± 91 
Progesterone (3) 5 ± 12 -+ 134 ± 32 1875 ± 92* 1 ± 71 
Androstenedione (4) 1 ± 12 2390 ± 992 337 ± 82 1796 ± 86* 393 ± 364 
Testosterone (5) 4 ± 17 5630 ± 946 1032 ± 73 1799 ± 85* 349 ± 89 
Nandrolone (6) 110 ± 52 - -+ 1841 ± 78* - 
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CYP154C5-Q398A was significantly reduced for substrates 2, 4, 5, while no shift to high-spin 
form was observed with nandrolone (6). 
In general, mutant CYP154C5-M84A exhibited the biggest differences in comparison 
to the wild type among all tested variants. Although androstenedione (4) and testosterone (5) 
induced still full shift of the heme iron towards high spin, approximately 1000-fold lower 
binding affinities than for the wild type were obtained. Additionally, mutation M84A strongly 
affected binding of pregnenolone (1) and nandrolone (6) since here no shifts of the heme iron 
towards high spin were observed while substrates 2 and 3 induced only partial shifts. 
Furthermore, the exchange of phenylalanine by alanine at position 92 affected the substrate 
binding of testosterone (5) for which a significantly lower affinity was obtained in comparison 
to the wild-type. This mutation affected also binding of pregnenolone (1) and nandrolone (6) 
since only partial spectral shifts were observed.  
Additionally, the data obtained in experiments using mutant CYP154C5-Q239A 
together with the six steroid substrates (1-6) had to be fitted using Hill equation since a 
reliable fitting using the tight-binding equation was not possible. For this reason, resulting KD 
values cannot be directly compared with KD values obtained for the wild type and the other 
mutants. Therefore, a simple comparison was performed in order to estimate if the affinity 
would be in the same range as for the wild-type. For this, the initial part of the binding titration 
curves (linear increase) were analysed and compared to those obtained for the wild type 
(see appendix section 4.6). The steeper the slope of the initial phase, the smaller should be 
the corresponding KD and consequently the tighter the binding. As a result, CYP154C5-
Q239A shows similar affinity towards substrates 1, 3, 4 and 5 as compared to wild type, 
whereas for substrate 6 a slightly higher affinity than that of wild-type was obtained. In 
contrast, results indicate a lower affinity of variant Q239A for dehydroepiandrosterone (2) 
than the wild-type. However, it has to be pointed out that the same trend was not observed 
for KD values obtained by fitting of the data using the Hill equation. Instead, resulting KD 
values hardly differ for the six substrates (Table 4.2).  
  
4.4.2.2 Conversion and turnover number (TON) determination  
 In order to analyse if the single mutations affected the performance of the catalytic 
system, composed of purified CYP154C5 mutant, PdR and Pdx, TONs were determined and 
compared to those obtained for wild-type P450. In all cases, 3 µM of P450, 3 µM PdR and 16 
µM Pdx were applied in conversions of 2 mM steroid substrates (1-6) in 50 mM potassium 
phosphate buffer pH 7.4 at 30°C. Thus, the activity of the electron transfer components was 
in the range of 1.0 and 1.6 U/mL, depending on the batch of purified PdR and Pdx that was 
used. In order to regenerate the cofactor NADH (50 µM), formate dehydrogenase from 
Candida boidinii (0.5 U/mL) and sodium formate (150 mM) were applied. Additionally, 
catalase was added to the reaction to degrade the possibly formed hydrogen peroxide. 
Samples were taken over time, extracted and analysed by GC or HPLC in order to calculate 
TONs based on substrate consumption over time. Additionally, overall conversions achieved 
after 24 h of reaction using mutants CYP154C5-F92A and CYP154C5-Q239A were 
calculated via substrate consumption and compared to those results obtained for the wild-
type under the same conditions (Figure 4.4.A). On the other hand, due to only low remaining 
amounts of purified protein, conversions using CYP154C5-M84A and CYP154C5-Q398A 
were only monitored until 8 h of reaction (Figure 4.4.B).  
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Figure 4.4 Comparison of achieved steroid conversions (%) of CYP154C5 wild-type and 
mutants. A: Conversion by mutants CYP154C5-F92A and CYP154C5-Q239A were calculated after 
24h of reaction and compared to wild-type results. B: Conversion by CYP154C5-M84A and 
CYP154C5-Q398A were determined after 8h of reaction and compared to wild-type results under the 
same conditions. All reactions contained 2 mM initial steroid concentration [substrates pregnenolone 
(1), dehydroepiandrosterone (2), progesterone (3), androstenedione (4), testosterone (5) and 
nandrolone (6)], 3 µM P450, 3 µM PdR, 16 µM Pdx, 50 µM NADH, 300 U/mL catalase, 0.5 U/mL FDH, 
150 mM sodium formate and were incubated at 30°C and 250 rpm. All measurements were performed 
in duplicate. 
 
 In almost all cases, conversion of the tested steroids resulted in the formation of 16α-
hydroxylated products. Only in the conversion of progesterone (3) by mutant CYP154C5-
F92A, formation of a second hydroxylation product was observed. GC-MS analysis gave a 
second product peak with a retention time of 8.8 min and m/z = 312 [M]+-2 which could 
correspond to progesterone hydroxylation followed by water elimination due to the GC-MS 
conditions (see appendix section 4.5.1). This proves that the presence of a phenylalanine at 
position 92 plays an important role in the correct positioning of progesterone (3) in the active 
site. The GC analytics employed to study conversions of substrates 1 and 2 does not allow 
the direct visualization of product peaks due to their high polarity. Nevertheless, thin layer 
chromatography (TLC) showed no formation of by-products in the conversion of 
pregnenolone (1), still confirming a high regio- and stereoselectivity of CYP154C5 mutants. 
However, formation of secondary products in conversions of dehydroepiandrosterone (2) 
cannot be ruled out, since no TLC was performed. 
 The exchange of residues M84 and Q398 had a larger effect on the P450´s catalytic 
activity than mutations F92A and Q239A. However, the conversion of all tested substrates by 
mutants M84A, F92A and Q398A was significantly decreased in comparison to wild-type 
conversions under the same conditions. On the other hand, the exchange of glutamine by 
alanine at position 239 did not negatively affect the overall conversion obtained after 24 h of 
reaction independent of the tested substrate. Surprisingly, nandrolone (6) was even fully 
converted by CYP154C5-Q239A in comparison to the wild-type for which a conversion of 
only 70 % was obtained under the same conditions. As expected, no conversion of 
nandrolone (6) could be observed when mutants CYP154C5-M84A and CYP154C5-Q398A 
were employed since no binding could be spectrophotometrically observed. Although 
CYP154C5-M84A did not show a spectral shift upon addition of pregnenolone (1), this 
substrate was still converted, however, with a 20-fold reduction in conversion (5 %) as 
compared to the wild-type. This result could suggest that a very tiny amount of CYP154C5-
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M84A indeed was shifted to high-spin state which could not be observed 
spectrophotometrically due to the detection limit of the applied spectrophotometer. In 
contrast, conversion of progesterone (3) was much less affected independent of the applied 
mutant since conversion values were still above 60 %. This result goes in hand with the still 
very low KD values and consequently high binding affinities determined with 3 for all mutants.  
In order to further study the activity of the different mutants, turnover numbers (TON, 
min-1) were determined by calculating the highest rates of substrate consumption (by HPLC 
or GC) during the first hours of reaction. Resulting TON of CYP154C5 mutants were 
afterwards compared to those obtained with the wild-type (Figure 4.5). In general, the 
conversion rate was high at the beginning and slowed down with increasing reaction time 
(data not shown)[1]. Here, most bioconversions stopped already after 4 to 5 hours of reaction 
before the steroid was completely consumed. Only variant Q239A was able to convert all six 
steroids completely. As expected, mutants M84A, F92A and Q398A exhibit dramatically 
decreased TONs in comparison to the wild-type, independent of the used substrate, while for 
mutation Q239A the TONs decreased to less extent. This decrease perfectly explains the 
lower overall conversions obtained for the mutants (Figure 4.4). Reactions resulted mostly in 
TONs below 50 % of respective wild-type values, with the exception of testosterone (5) and 
nandrolone (6) conversions by variants F92A and Q239A. Here, TONs were in a similar 
range as the wild-type values.  However, the respective TONs of CYP154C5 wild-type for 
these two steroids are already the smallest among the wild-type values. In contrast, variants 
M84A and Q398A exhibited even smaller TONs for substrates 1, 2 and 5 (around 0.6 min−1) 
or showed no convesion at all. Furthermore, conversion of pregnenolone (1) by CYP254C5-
M84A led to the lowest TON measured (0.23 min-1) which is in accordance with the obtained 
low conversion of 5 % after 8 h reaction time. However, a high TON is not automatically 
followed by high overall conversion. This is reflected in the conversion of substrates 5 and 6 
by CYP154C5-F92A where similar initial rates as for wild-type were obtained. Nevertheless, 
the overall conversion values achieved after 24 h were significantly lower. Furthermore, 
mutations F92A and Q239A did not affect the TON for nandrolone (6) conversion in 
comparison to wild-type. Although all CYP154C5 mutants still gave highest overall 
conversion in reactions with progesterone (3), the corresponding TON were still significantly 
reduced. In particular, 67 % conversion of 3 was obtained by CYP154C5-M84A within 8 h 
reaction time with a maximum rate of 2.5 min-1. In contrast, 82 % conversion was achieved 
within 8 h reaction time when CYP154C5-Q398A was applied exhibiting only a TON of 1.5 
min-1.  
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Figure 4.5 Comparison of turnover numbers (TON) of CYP154C5 mutants and wild-type. The 
turnover numbers (min
-1
) of CYP154C5-M84A, CYP154C5-F92A, CYP154C5-Q239A, CYP154C5-
Q398A and wild type were determined for substrates pregnenolone (1), dehydroepiandrosterone (2), 
progesterone (3), androstenedione (4), testosterone (5) and nandrolone (6) by conversion with purified 
three-component system. All reactions contained 2 mM steroid, 3 µM P450, 3 µM PdR, 16 µM Pdx, 50 
µM NADH, 300 U/mL catalase, 0.5 U/mL FDH and 150 mM sodium formate. All measurements were 
performed in duplicate. 
 
 
4.4.2.3 NADH oxidation rate and coupling efficiency determination  
 
 Many factors can influence the efficiency of delivering electrons from the cofactor, in 
this case NADH, to the cytochrome P450. One limitation could be the ability of PdR to 
oxidize NADH in presence of different substrates, Pdx and P450. This can be measured by 
monitoring the rate of NADH oxidation (min-1) at 340 nm in presence of each substrate in the 
three-component catalytic system. Additionally, it is important to have in mind that the ability 
of PdR to transfer the electrons onto oxidized Pdx and further the electron transfer from, Pdx 
to the P450 will also have an influence on the NADH oxidation rate. As expected, obtained 
results demonstrate that the four point mutations in CYP154C5 do not strongly affect the 
NADH oxidation rate in comparison to the wild-type P450 since all obtained rates are in the 
same range (Figure 4.6.A). However, the use of mutants CYP154C5-M84A and CYP154C5-
Q398A in the conversion of pregnenolone (1) and progesterone (3) caused a surprising 
decrease in NADH oxidation rate in comparison to the wild-type. These two substrates have 
structurally a large substituent at position C17 of the steroid core in common, which was 
shown to slightly modify the orientation of the substrate in the active site in comparison to the 
rest of the tested substrates.  Possibly, the redox potential of these variants in presence of 
substrates 1 or 3 might be slightly different in comparison to the wild-type as well as the other 
substrates and therefore electron transfer from Pdx to the P450 in consequence also the 
NADH oxidation rate could be affected.  As for wild type, progesterone (3) conversion 
generally resulted in highest NADH oxidation rates, in particular with mutants CYP154C5-
F92A and CYP154C5-Q239A, in comparison to the rest of the substrates.  
The efficiency of the catalytic system can also be negatively affected by uncoupling of 
cofactor consumption and substrate oxygenation. This means, NADH is oxidized and 
electrons are transferred to the P450 but no product is formed. To investigate this for the four 
CYP154C5 mutants, coupling efficiencies (%) were determined for the conversion of steroid 
substrates 1-6 and compared with those obtained for the wild-type. By adding 200 µM of 
NADH and 1 mM substrate to the catalytic system, a maximum theoretical substrate 
consumption of 200 µM could be expected equivalent to 100 % coupling efficiency. However, 
results shown in Figure 4.6.B confirm that the introduction of the four single mutations in 
CYP154C5 caused in most cases a decrease in coupling efficiency for conversion of all 
tested substrates. Exceptions are the conversion of nandrolone (6), where coupling 
efficiencies of mutants F92A and Q239A were not affected, as well as the conversion of 
testosterone (5) by mutants CYP154C5-Q239A and CYP154C5-Q398A. In contrast, mutant 
CYP154C5-M84A exhibited always the lowest coupling efficiency for all tested steroids. 
Although overall conversions of steroids obtained with mutant CYP154C5-Q239A showed no 
significant difference in comparison to the wild type, coupling efficiencies determined for this 
mutant were always lower. One exception was observed for the conversion of 
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dehydroepiandrosterone (2), where mutant Q239A exhibited a similar coupling efficiency as 
wild-type CYP154C5. Due to analytical errors, no duplicate reaction could be performed for 
the determination of the coupling efficiency of CYP154C5-F92A in the conversion of 2 and 
therefore it can only be roughly estimated to lie between 55 to 60 %. 
As previously shown in Figure 4.5, a 5- and 4-fold decrease in TON was obtained in the 
conversion of 3 by mutants CYP154C5-F92A and CYP154C5-Q398A, respectively, in 
comparison to the wild-type although rather high overall conversions (~ 80 %) were obtained 
in both cases. These reduced TONs are a direct consequence of significantly increased 
uncoupling leading to 3- and 2-fold lower coupling efficiencies, respectively, compared to wild 
type (Figure 4.6.B). Interestingly, coupling efficiencies of all mutants in the conversion of 
progesterone (3) were affected the most. 
 
 
Figure 4.6 Comparison of NADH oxidation rates and coupling efficiencies of CYP154C5 
mutants and wild type. The NADH oxidation rates (A) and coupling efficiencies (B) of CYP154C5, 
CYP154C5-M84A, CYP154C5-F92A, CYP154C5-Q239A and CYP154C5-Q398A were determined for 
substrates pregnenolone (1), dehydroepiandrosterone (2), progesterone (3), androstenedione (4), 
testosterone (5) and nandrolone (6) by conversion with purified three-component system. All reactions 
contained 1 mM steroid, 0.4 µM P450, 0.4 µM PdR, 14 µM Pdx, 200 µM NADH, 600 U/mL catalase 
and 200 U/mL superoxide dismutase. All measurements were performed in duplicate. N.D.: not 
determined; E: estimated.  
 
 
 
Exploring CYP154C5’s specificity by substrate and protein engineering 
 
C
h
a
p
te
r 
4
: 
R
e
s
u
lt
s
 
118 
 
4.4.3 Characterization of CYP154C5 wild type by substrate engineering 
 Based on the knowledge obtained from the crystal structure of CYP154C5-steroid 
complexes with substrates 1 to 6, five new steroid substrates were chosen in order to 
investigate if the P450’s selectivity could be changed by substrate engineering. As shown in 
Figure 4.7.A, a hydrophobic “tube” with polar-regions at both ends forms the active site of 
CYP154C5. Thus, it perfectly fits to the polarity of the steroid structure (1-6), which is formed 
by a hydrophobic core composed of four fused rings and two polar functional groups at 
positions C3 and C17. Furthermore, these oxyfunctionlisations were shown to form hydrogen 
bond interactions with residues Q239 and Q398 (in the first case via water molecules), 
respectively. Therefore, steroid substrates lacking one (10 and 11) or both (9) functional 
groups, as well as steroids containing a larger side chain at position C17 (7 and 8) were 
chosen to be tested in conversions with CYP154C5 wild–type (Figure 4.7.B). Additionally, 
also smaller non-steroidal substrates (12 and 13) were included in this test. 
 
Figure 4.7 New model substrates. A: The active-site structure of the CYP154C5-progesterone 
complex is shown. Hydrophobic regions (red) interact with the hydrophobic core of the steroid 
substrate, whereas its oxyfunctional groups at positions C3 and C17 are located at the ends of the 
“tube”, in more polar regions (blue). Figure taken from Herzog et al. [23]. B: The chemical structures of 
the seven new model substrates (7-13) are shown.  
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4.4.3.1 Analytical-scale bioconversions of new substrates by CYP154C5 
 Initially, small-scale reactions employing whole cells (WC) or cell free extract (CFE) of 
E. coli C43 (DE3) (pIT2cyp154c5) (pACYCcamAB) were carried out in order to investigate if 
compounds 7-13 are converted by CYP154C5 wild type and to determine which of the two 
catalytic systems would give better results. Reactions with initial steroid concentrations of 1 
mM (7-11) were incubated for 16-24 h at 30°C were applied. Cofactor regeneration was 
supported by glucose addition in whole cell catalyses, whereas formate dehydrogenase 
(FDH) from Candida boidinii and sodium formate were applied in cell free extract catalyses. 
In whole cell catalyses an optical density of 40 (OD600), equivalent to 2.6 µM CYP154C5, and 
a PdR-Pdx activity of 7.1 U/mL (1.3 U/ mg of total protein) were applied. On the other hand, 
3.0 µM CYP154C5 and an ETC activity of 8.4 U/mL (1.3 U/mg of total protein) were applied 
in cell free extract catalyses. Reactions employing whole cells or cell free extract of E. coli 
C43 (DE3) (pIT2cyp154c5) not expressing P450 were used as controls under the same 
reaction conditions. 
As a result, the three-component system composed of CYP154C5, PdR and Pdx did 
not convert steroid substrates 8 and 9 neither employing whole cells nor cell-free extract 
(Figure 4.8). In each case only one product was formed when substrate 7 was converted. In 
contrast, conversion of substrates 10 and 11 led to the formation of several products, 
showing for the first time that the regio- and/or stereoselectivty of CYP154C5 is reduced in 
comparison to conversion of substrates 1 to 6. In all cases, the same number of products 
was obtained using CFE and WC catalysis. However, the obtained overall conversions were 
higher using whole cell catalysis. In particular, the overall conversion of substrates 3-
deoxdehydroepiandrosterone (10) and 5α-androstan-3-one (11) by CYP154C5 increased 
from 40 to 100 % (10) and from 7 to approximately 50 % (11) when WC instead of CFE were 
applied. Only in the case of finasteride (7) conversion by CYP154C5, no product was 
obtained with CFE whereas WC showed product formation (Figure 4.8.A). However, this 
product was only obtained once and could not be reproduced. Thus, no final conclusion can 
be drawn yet but more experiments are needed to analyse if CYP154C5 is able to convert 
substrate 7. 
 
 
Figure 4.8 Analytical-scale conversion of finsteride (7, A), etiadienic acid ethyl ester (8, B), 
ethioallocholane (9, C), 3-deoxydehydroepiandrosterone (10, D), 5-androstan-3-one (11, E), β-
ionone (12, F) and (+)-valencene (13, G) by whole cells of E. coli C43 (DE3) (pACYCcamAB) 
(pIT2CYP154C5). Thin layer chromatography (TLC) results show reactions (R) with P450 and controls 
(C) without CYP154C5. Possible products formed are marked in red.  
 
Exploring CYP154C5’s specificity by substrate and protein engineering 
 
C
h
a
p
te
r 
4
: 
R
e
s
u
lt
s
 
120 
 
Although the TLC result of ethioallocholane (9) conversion by CYP154C5 did not 
clearly show an additional product spot, the raw reaction was injected on GC-MS and results 
revealed an additional peak with retention time of 5.84 min with m/z = 258 ([M]+-2]). A NIST-
library search suggested a steroid-related structure containing a double bond for this product. 
This could suggest that substrate 9 was successfully hydroxylated by CYP154C5 and water 
removal as a result of GC-MS conditions led to the formation of the double bond (this effect 
was already observed for other hydroxylated steroids, see appendix section 4.5.2). Further 
tests will be necessary to identify the formed product. 
Non-steroidal substrates 12 and 13 (Figure 4.2) were also tested in conversions by E. 
coli C43 (DE3) (pIT2cyp154c5) (pACYCcamAB) under the same conditions as for steroids 7-
11. Here, initial substrate concentrations of 10 mM were applied. Due to the small size in 
comparison to the traditional tested steroids and most probably due to lack of polar 
functionalities, (+)-valencene (13) was not converted in WC nor CFE reactions. In contrast, 
β-ionone (12) was converted by CYP154C5 yielding only one hydroxylation product with RT= 
17.6 min and m/z = 208 ([M]++16]). This product could be identified as 4-hydroxy-β-ionone 
(12A), since its analytics fully correspond to the previously isolated and identified product 
obtained in our group by conversion of 12 with CYP154H1 from Thermobifida fusca [24]. 
Thus, even the conversion of small molecules, such as -ionone, can be performed in a high 
regioselective manner by CYP154C5. 
 
4.4.3.2 Steroid conversions on preparative scale 
In order to elucidate the structures of formed products, whole-cell bioconversions 
were performed on preparative scale for substrates 3-deoxydehydroepiandrostendione (10) 
and 5-androstan-3-one (11). Additionally, samples were taken at different points of the 
reactions in order to determine turnover numbers (TON, min-1). For that, E. coli C43 (DE3) 
cells overexpressing CYP154C5, PdR and Pdx were resuspended to an OD600 of ~40 and 
glucose was added to regenerate the cofactor NADH. Initial substrate concentrations of 1 
mM and 500 µM of 10 and 11, respectively, were applied. Samples were taken over time, 
extracted and analyzed by TLC and GC in order to determine substrate consumption. Thus, 
after 22 h of reaction, 83 % and 80 % overall conversions were achieved in the 
transformation of 10 and 11 by CYP154C5, respectively. This corresponds to total turnover 
numbers (TTN, µmol substrate consumed per µmol P450) of 747 and 157, respectively. 
Turnover numbers were calculated based on substrate consumption during the first six hours 
of reaction resulting in 1.8 and 0.4 min-1 for substrates 10 and 11, respectively. Similarly to 
the results obtained in analytical scale reactions, five products were formed when 3-
deoxydehydroepiandrosterone (10) was converted by CYP154C5 (Figure 4.9.A), whereas 
two products were obtained when 5α-androstan-3-one (11) was used as substrate (Figure 
4.9.B). All products were purified by column chromatography and analyzed by GC-MS. 
Although all products 10A1 to 10A5 could be purified, only sufficient amounts of 10A2 (~20 
mg) and 10A5 (<5 mg) could be obtained and analyzed by NMR. Similarly, only product 
11A2 was purified in sufficient amount (~5 mg) in order to elucidate its structure by NMR-
analysis. 
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Figure 4.9 Preparative scale conversion of 10 and 11 by whole cells of E. coli C43 (DE3) 
(pIT2cyp154c5) (pACYCcamAB) . A: Preparative-scale conversion of deoxydehydroepiandrosterone 
(10) [1: sample extracted after 9 h of reaction, R: concentrated reaction after 22 h, 2: remaining 
substrate after purification, 3: purified 10A1, 4: purified 10A2, 5: purified 10A3, 6: purified 10A4 and 7: 
purified 10A5; all products were further purified for NMR analysis]. B: Preparative-scale conversion of 
5-androstan-3-one (11) [R: concentrated reaction after 22 h and 11A2: purified product for NMR 
analysis]. C: µmol substrate consumed µmol
-1
 CYP154C5 determined over time during conversion of 
substrates 10 and 11 by CYP154C5, PdR and Pdx. ON: overnight. 
 
GC-MS analysis of product 10A2 showed a multiple peak with average RT = 6.0 min 
and m/z = 288 corresponding to [M]++16, indicating the introduction of an oxygen atom into 
the substrate (see appendix section 4.5.3). When comparing the 1H-NMR spectra of 
substrate 10 and product 10A2, the latter is lacking the signals corresponding to 16β-H and 
16α-H at 2.48 and 2.14 ppm, respectively (Figure 4.10.B-C). Furthermore, the 1H-NMR 
spectrum of 10A2 shows a signal at 4.21 ppm (dd) coupling to a carbon signal at 70.6 ppm 
as assigned by HSQC-NMR. These signals correspond to a CH-OH structure leading to the 
conclusion that CYP154C5 was able to hydroxylate substrate 10 at position 16. In order to 
determine the orientation of the hydroxyl group, coupling constants (J) between 16-H and its 
neighboring signals 14α-H, 15α-H and 15β-H were analyzed. The signal identified as 15β-H 
by NOESY-NMR is depicted as a doublet of triplet (dt) with coupling constants of Jd= 8.3 and 
Jt= 13.2 Hz (Figure 4.10.D). The larger J corresponds to the coupling with 15α-H and 14α-H, 
both protons known to be in trans position with respect to 15β-H, therefore yielding a large 
coupling constant J. Similarly, 16-H should exhibit approximately the same large coupling 
constant for coupling with 15β-H if it would correspond to 16α-H, indicating hydroxylation with 
β-orientation. However, the signal corresponding to 16-H exhibits only a J of 7.9 Hz. Thus, it 
cannot be 16α-H but should be 16β-H (cis to 15β-H) instead (Figure 4.10.E). Hence, it can 
be concluded that CYP154C5 hydroxylates 10 also at 16-position yielding 16α-hydroxy-3-
deoxydehydroepiandrosterone (10A2) (Figure 4.10.A).  
Exploring CYP154C5’s specificity by substrate and protein engineering 
 
C
h
a
p
te
r 
4
: 
R
e
s
u
lt
s
 
122 
 
 
 
Figure 4.10 NMR analysis of product 10A2. A: Predicted structure of product 10A2 according to 
NMR data. B: 
1
H-NMR spectrum of substrate 10 using CDCl3 as solvent, signals corresponding to 
16β-H and 16α-H are shown in red. C: 
1
H-NMR spectrum of 10A2 missing both proton signals at 
position 16, spectrum taken using DMSO as solvent. D: 
1
H-NMR spectrum of product 10A2 including 
the coupling constants (J) of signal 15β-H (dt) and E: coupling constants (J) of signal 16β-H (dd). 
 
GC-MS results of product 10A5 gave a peak with RT = 8.9 min with a maximum 
molecular ion peak of m/z = 304, equivalent to [M]++32. This result suggests a possible 
double hydroxylation of substrate 10. This is consistent with the obtained 1H-NMR data 
showing two different hydroxylation signals at 4.42 and 4.05 ppm (see appendix section 
4.5.6). Additionally, by HSQC-NMR analysis, these two proton signals were found to couple 
with carbon signals at 71.7 and 66.5 ppm corresponding to CH-OH. Unfortunately, further 
structure elucidation was not possible due to the low amounts of purified product and, hence, 
a low resolution of the NMR spectra.  
Furthermore, GC-MS analysis of product 11A gave a single peak with RT = 7.52 min and 
m/z = 290 ([M]++16) (see appendix section 4.5.7). In the 1H-NMR spectrum a multiplet peak 
at 4.49 ppm was identified coupling with a carbon signal at 71.8 ppm in the HSQC-NMR 
spectrum (Figure 4.11.B). In the COSY-NMR spectrum, this proton signal (4.49 ppm) is 
coupling with signals at 1.18 (H14α), 2.08 (H16α or β) and 1.32 ppm (H16α or β) [signals 
assigned by HSQC-NMR] (Figure 5.11.C). Thus, in this case the hydroxylation probably took 
place at C15. Furthermore, NOESY-NMR results showed no coupling between the remaining 
15-H (CH-OH, 4.49 ppm) and 14α-H, indicating that 15-H is not α orientated. Thus, 15-H can 
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be assigned as 15β-H. In contrast, coupling between 15-H and one signal of 16-H at 1.32 
ppm, now assigned as 16β-H, was observed in the NOESY-NMR spectrum. Furthermore, the 
carbon signals corresponding to C15 and C16 shifted to higher ppm in comparison with 
those observed in the substrate´s 13C-NMR spectrum. This indicates that CYP154C5 
hydroxylated substrate 11 at position 15 with α orientation, yielding 15α-hydroxy-5α-
androstan-3-one (11A) (Figure 4.11.A). This result suggests that the lack of the carbonyl 
group at position C3 of the steroid substrate (11) has a strong influence on the protein-
substrate interaction, affecting its orientation in the active site and changing therefore the 
regioselectivity of CYP154C5 while the stereoselectivity remained constant. 
 
 
Figure 4.11 NMR analysis of product 11A. A: Predicted structure of product 11A according to NMR 
data. B: HSQC spectrum of 11A showing coupling between 15-H and C15. C: COSY spectrum of 11A 
showing coupling of signal 15-H with 14-H, 16α-H and 16β-H (proton signals assigned by HSQC-
NMR spectrum). D: NOESY-NMR spectrum showing coupling between 15-H and 16β-H indicating 
hydroxylation of 11 at position 15 with α orientation. 
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4.4.3.3 Dissociation constant determination 
 
Furthermore, dissociation constants (KD) of CYP154C5 towards substrates 10 and 11 
were determined spectroscopically as previously described in section 4.4.2.1. As a result, 
CYP154C5 showed a rather high affinity towards substrate 11 since a KD of 28 nM was 
calculated. On the other hand, a 4-fold higher KD value of 81 nM was obtained for substrate 
10, resulting in a bit lower affinity in comparison to 11. Nevertheless, these values are in the 
same range (bellow 100 nM) as the KD values determined for substrates pregnenolone (1), 
dehydroepiandrosterone (2), progesterone (3), androstenedione (4), testosterone (5) and 
nandrolone (6) (Table.4.2). This indicates that the lack of one of the two polar regions of the 
steroid molecule (oxyfunctionalisation at positions C3 or C17 of the steroid molecule) does 
not severely affect the steroid binding affinity of CYP154C5. However, CYP154C5’s 
selectivity is significantly affected, especially if the oxyfunctionalisation at position C3 
(substrate 10) is missing, since here five different products are formed. This could indicate 
that substrate 10 can bind in several different orientations in the active site although still with 
high affinity. 
In contrast, addition of substrates 7 and 8 to purified CYP154C5 did not generate a 
change in spin state and thus no spectral shift. Hence, the presence of larger substituents at 
position C17 obviously prevents binding to CYP154C5. Furthermore, CYP154C5 exhibited 
only a partial spin-state shift when substrate 9, lacking both polar substitutents at C3 and 
C17, was added. This result could suggest that substrate 9 may bind in different orientations 
in the active site of CYP154C5 but not all of them are close enough to the heme iron to allow 
a change in spin state. Nevertheless, the dissociation constant of CYP154C5 towards 9 was 
determined as 8.6 ± 0.2 mM (the data was fitted using Hill equation) with a high-spin species 
content of roughly 50 % (see appendix section 4.6). 
 
 
4.5   Discussion 
 
Cytochrome P450 from Nocardia farcinica, CYP154C5, exhibits an impressively high 
regio- and stereoselectivity in the hydroxylation of steroid molecules, in particular when 
oxyfunctionalizations at positions C3 and C17 are present in the substrates (1-6). From 
crystal structure data (chapter 3 of this thesis) all steroid substrates were specifically 
orientated leading only to hydroxylation at position 16 with α orientation. In particular, 
glutamine residues at positions 239 and 398 were shown to form hydrogen bond interactions 
with the oxyfunctionalizations at positions C17 and C3, respectively, of the steroid molecule, 
whereas M84 and F92 are involved in hydrophobic interactions with the hydrophobic steroid 
core (Figure 4.3). Based on these findings, two strategies were designed to study the 
remarkable specificity of CYP154C5. Firstly, a protein engineering approach was used to 
modify single amino acid residues in the catalytic pocket in order to study the key interactions 
between substrate and protein. As a second strategy, substrate engineering was applied 
using steroid substrates in bioconversions with CYP154C5 wild-type that differed significantly 
in their structure from previously employed steroid molecules. In this way, steroids lacking 
one or both oxyfunctionalisations at positions C3 and C17 involved in hydrogen bonding, or 
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carrying a large substituent at C17 and thus possibly hindering the preferred substrate 
binding orientation, were tested.  
 In order to investigate their role in substrate binding, residues M84, F92, Q239 and 
Q398 were replaced by Quik-change® to alanine and the catalytic performance of the P450 
mutants was characterized and compared to the wild-type. In all cases, the four point 
mutations introduced in CYP154C5 negatively affected the overall performance of the 
catalytic system. In general, dissociation constants, overall conversions, turnover numbers, 
NADH oxidation rates and coupling efficiencies of the resulting variants were lower as for 
wild-type CYP154C5.  
The obtained weaker binding of the steroids is reasonable, since the substrate has 
more freedom to move in the catalytic pocket if substrate stabilizing interactions, such as 
hydrophobic interactions or hydrogen bonds, are reduced due to the respective mutations. 
Additionally, in all cases the size of the active site cavity was enlarged by the point mutations 
as depicted in Figure 4.12. Thus, even more substrate movement in the active-site is 
possible and the probability is reduced that substrate binds in a suitable position to displace 
the water ligand at the heme iron, which is required to induce a spin state and thus also 
spectral shift. Efficient substrate-binding is a prerequisite for successful enzyme catalysis. 
However, in P450s substrate binding alone is not a direct indication that the positioning of the 
substrate in the active site will also allow product formation since a minimum distance 
between the heme iron and the substrate is needed for catalysis. Similarly, efficient substrate 
binding is also important for coupling efficiency in P450s because a loose binding results in a 
higher proportion of uncoupling. This means, electrons that are delivered to the heme iron by 
the redox partner are more likely transferred onto alternative acceptors if the substrate 
molecule is not well positioned to allow substrate oxygenation. In this way, also the catalytic 
efficiency of the enzyme is negatively affected. 
 In almost all cases, the wild type P450 exhibited the highest affinity (lowest KD 
values) towards the six substrates with the exception of mutant CYP154C5-Q398A which 
showed similar affinities towards substrates 1 and 3 as the wild-type. The reduction of the 
steric impediments by replacement of glutamine with alanine close to the heme group, could 
explain why these substrates containing a larger substituent at C17 (next to the hydroxylation 
position) are bound to the mutant with similar affinities as to the wild type (Figure 4.12.G-H). 
On the other hand, the formation of a hydrogen bond cannot occur and the hydrophobicity of 
the pocket is increased, which suggests that for these two substrates the formation of such 
interaction is not so crucial for their binding into CYP154C5´s active site. Nevertheless, the 
overall conversion of 1 and 3 as well as TONs and coupling efficiencies were significantly 
reduced with the introduction of mutation Q398A. A possible reason could be that despite the 
effective binding, the distance between C16 and the heme-iron is affected which can have a 
direct influence in the catalytic cycle. Additionally, the affinity for substrates with smaller 
substituents at position C17 decreased which could suggest that the rather small 
enlargement of the active site cavity generates a less “tight” pocket, resulting for “smaller” 
substrates in a higher mobility and thus reducing the affinity. Additionally, the missing 
hydrogen bond with CYP154C5 Q398A will also contribute to the weaker binding. Moreover, 
substrate 5α-androstan-3-one (lacking the functional group at C17, 11) was successfully 
converted by CYP154C5 wild-type with a remarkably low KD, in the same range as for 
substrates 1-6.  
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Figure 4.12 Comparison of the catalytic site of CYP154C5 wild-type (left) and CYP154C5 
mutants (right) with pregnenolone (1) bound in the active site. By the introduction of mutation 
M84A (B) it can be observed that the steric hindrance is reduced close to the heme group, which 
could allow a better binding of steroid substrates with large substituents at position C17 of the steroid 
core. Similarly, by mutations F92A (D), Q239A (F) and Q398A (H) the catalytic pocket of the different 
variants gets significantly enlarged. Red arrows depict the enlarged area and red cruces represent 
water molecules. Images were generated by Pymol® without applying energy minimization after the 
exchange of glutamine by alanine residue. 
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The combination of these results suggests that the hydrogen bond formed between 
residue Q398 and an acetyl group at position C17 (steroids 1 and 3) plays an important role 
in substrate conversion as indicated by the low TON and coupling efficiencies obtained when 
this bond cannot be formed (either due to CYP154C5 mutation or a lack of 
oxyfunctionalization at C17 as in substrate 11). Nevertheless, the dissociation constant 
remains rather unaffected if the hydrogen bond cannot be formed. In contrast, for steroids 
with hydroxyl or keto groups at position C17, the exchange of glutamine by alanine at 
position 398 not only affects the efficiency of the catalytic system as indicated by reduced 
TONs and coupling efficiencies but also the substrate binding.  
The effect of amino acid exchanges in the hydrophobic part of the active site, as with 
mutants M84A and F92A, was different for both steroids possessing a large substituent at 
C17 (1 and 3). In the first case, pregnenolone (1) induced only a partial or not spectral shift 
with variants F92A and M84A, respectively, whereas progesterone (3) resulted in the lowest 
KD value of all mutants with variant F92A and, in contrast, no binding to mutant M84A. 
Structurally, 3 carries a double bond at position C4 (A-ring) whereas pregnenolone (1) has it 
at C5 (B-ring) which gives a more polar character to the B-ring due to the sp2-orbitals of the 
participating carbon atoms. Hereby, static repulsion can occur if hydrophobic amino acids 
such as F92 are close to them (Figure 4.3). Similarly, androstenedione (4) and testosterone 
(5) (double bond in the A-ring) induced a complete shift of mutant M84A towards high spin 
yielding the weakest binding among all investigated steroid, but dehydroepiandrosterone (2) 
(double bond in the B-ring) shifted only a fraction of the employed variant M84A to high-spin 
state at the same steroid concentration. These results suggest that the positioning of the 
double bond in the steroid core directly influences the substrate-enzyme hydrophobic 
interactions.  
In some cases, a relatively low KD did not automatically result in a higher coupling 
efficiency as e.g. observed for testosterone (5) with the mutants M84A and F92A. This 
steroid led to a five times higher KD with mutant M84A as compared to mutant F92A, but 
respective coupling efficiencies are almost identical. This difference could be explained by a 
longer Fe-C16-distance in case of CYP154C5-F92A with 5 in comparison to CYP154C5-
M84A. Thereby, the longer distance would lead to a less efficient radical attack of the 
reactive iron-oxo compound on the substrate and thus hydroxylation is slowed down. In order 
to check this hypothesis, 3D-models of CYP154C5 containing the respective amino acid 
exchanges should be created and substrate docking performed.  
Despite the differences observed between the tested mutants and the wild-type, the 
determined substrate binding affinities are still remarkably high with KD values in the range of 
nano- and micro-molar. As a comparison, the herein found largest dissociation constant 
(lowest affinity) was 5.6 µM obtained for mutant CYP154C5-M84A towards testosterone (5). 
This KD value is in the same range as the dissociation constant (3 µM) determined for 
P450cam from Pseudomonas putida towards its natural substrate D-camphor [25]. However, 
in three cases also no shift to HS species could be spectrophotometrically detected upon 
addition of steroid substrates (Table 4.2). As expected, in two of these cases also no 
conversion of the substrate (nandrolone, 6) by the respective three-component catalytic 
system was observed, suggesting that the substrate is not binding in a catalytically sufficient 
orientation. Interestingly, CYP154C5-M84A converted pregnenolone (1) to a small extent 
although no shift from low to high spin could be detected. This behavior was previously 
observed in the case of cytochrome P450 from Bacillus megaterium, CYP106A2, where no 
change in absorbance was obtained upon addition of deoxycortisone (DOC) although this 
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substrate is converted by this enzyme producing 15β-hydroxydeoxycortisone [26]. Later, 
Simgen et al. proved by FT infrared spectroscopy using the stretch vibration of the heme iron 
CO-ligand that DOC indeed enters the active site and binds the heme prosthetic group 
although no change in the UV/VIS spectrum can be observed [26]. Hence, the inability to 
spectrophotometrically detect a change in spin state upon substrate addition is not directly an 
indication that the enzyme will not be able to convert the substrate. 
In general, nandrolone (6) conversion was affected the most among the tested 
substrates by the introduced mutations. In particular, the separate introduction of mutations 
M84A and Q398A caused a complete loss in conversion of 6 and, as already mentioned, no 
dissociation constant could be determined. Nandrolone (6) exhibits the smallest size among 
the tested steroids, since it is lacking the C19-methyl group which reduces its surface and 
increases its water solubility in comparison to the other substrates. Thus, hydrophobic 
interactions between active-site residues and the steroid core are reduced, causing a looser 
binding of this steroid to the P450. However, dissociation constant of CYP154C5-Q239A 
towards nandrolone (6) could be determined and, more importantly, full conversion was 
obtained after 24 h of reaction in contrast to CYP154C5 wild-type where only a conversion 
70 % was achieved. Mutant Q239A is the only variant, for which all steroids still induced a 
complete absorbance shift; however fitting of the resulting data by quadratic tight-binding 
was not possible. In addition, variant Q239A is the only mutant that yielded in full conversion 
of all tested steroids accompanied by relatively high TONs. This may support the hypothesis 
that Q239 is not as important for substrate-binding as the other investigated amino acids. 
Konrad Herzog already presumed the minor relevance of Q239 for substrate binding, since 
the crystal structures of CYP154C5 revealed that Q239 is not directly involved in enzyme-
substrate interactions. Instead, it was postulated that this residue might rather be important 
for the dynamic binding process of substrate and its guidance through the entry channel than 
in stabilizing the substrate within the active site [23]. 
Although substrates 5 and 6 were converted by CYP154C5-F92A with similar initial 
rates as the wild-type, the overall conversion values obtained after 24 h were significantly 
lower. This could indicate that this mutant is less stable in the conversion of 5 and 6 as wild-
type CYP154C5. To prove this theory, wild-type and mutants were individually incubated for 
several hours and their activity followed over time by CO difference spectra in order to 
determine the residual activity. Results do not show a significant difference in active P450 
amounts among the different variants over time which could have explained the 
hypothesized stability difference (see appendix section 4.5). However, the stability of the 
P450 variants was tested in absence of PdR, Pdx and substrate, thus no final conclusion can 
be drawn regarding the stability of the P450 variants under reaction conditions. The same 
behavior, meaning similar TON but reduced overall conversion in comparison to the wild-
type, was observed in the conversion of progesterone (3) by mutants M84A and Q398A. In 
this case, the conversion stopped after 5 hours of reaction with CYP154C5-M84A whereas 
the conversion value of 3 by CYP154C5-Q398A still increased after 8 h reaction time. 
Another possible reason for the overall lower conversions besides P450 instability could be a 
possible product inhibition. In this way, initial rates can still be the same but after a certain 
product level is reached, inhibition becomes so strong that no further conversion occurs. 
Although full conversion of pregnenolone (1) by CYP154C5-Q239A was obtained with 
the highest TON among the tested mutants, the coupling efficiency was found to be the 
lowest. This could suggest that in case of pregnenolone (1) conversion by this mutant, the 
increased uncoupling does not strongly influence the overall conversion under the tested 
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conditions. In fact, the NADH oxidation rate is still comparable to the wild-type and thus 
higher than for the other mutants, which suggests that, as long as the regeneration system 
supplies electrons, the reaction will efficiently occur. Here, it is important to consider that 
electron transfer rates between Pdx and P450 may also differ due to mutations in the P450´s 
active site as well as due to the presence of the different substrates in the active site. So, in 
this specific case, a much higher P450 reduction rate of this enzyme-substrate couple could 
explain the obtained still high overall conversion despite the observed high uncoupling. 
Interestingly, the regioselectivity of CYP154C5 was changed by the exchange of 
phenylalanine to alanine at position 92 of CYP154C5. In this case, a second hydroxylation 
product besides 16α-hydroxyprogesterone was obtained when 3 was applied as substrate. 
From crystallographic data it was concluded that residue F92 plays an important role in the 
positioning and binding of substrates 1 and 3 with larger substituents at position C17, since 
F92’s side chain mediates important hydrophobic interactions with the steroid core. Thus, the 
exchange of phenylalanine by alanine would not only enlarge the catalytic pocket (Figure 
4.12.C-D) but could also affect the enzyme´s ability to interact and therefore correctly locate 
the steroid substrate in a position where 16α-hydroxylation can occur. In this way, a larger 
catalytic cavity could allow CYP154C5-F92A to orientate the substrate in a second 
successful position for hydroxylation. Since the specific hydroxylation position of this second 
product could not be identified in analytical scale conversions, further experiments in large 
scale should be performed. 
Furthermore, the regioselectivity of CYP154C5 could be also altered by substrate 
engineering. Firstly, the simple lack of oxyfunctionalisation at position C3, as in case of 3-
deoxydehydroepiandrosterone (10), resulted in the formation of four different products (16α-
hydroxylated product, one possibly double-hydroxylated product and two still unknown 
products) by CYP154C5 wild-type in comparison to the conversion of 2, where only 16α-
hydroxydehydroepiandrosterone (2A) was obtained [27]. Docking studies suggested that in 
addition to hydroxylation at position C16, also C4 could be hydroxylated with α or β 
orientation [23]. In general, it was observed that the oxyfunctionalisation at position C3 is 
involved in hydrogen bonding via water molecules with residue Q239, which is located at the 
entrance of the enzyme´s substrate binding channel. This could indicate that the orientation 
of the substrate molecule in the active site could be highly affected by the interaction with this 
residue, since five different products were obtained if this interaction cannot occur as in the 
case of substrate 10. However, when Q239 was exchanged to alanine by site directed 
mutagenesis, no change in selectivity was obtained for any of the tested substrates (1-6). 
Nevertheless, in some cases the TONs and coupling efficiencies were reduced as compared 
to the wild-type. As shown in Figure 4.12.E, the protein cavity surrounding the C3 substituent 
region of the steroid is rather hydrophilic and close to the entrance of the substrate channel 
where several water molecules were found from crystallographic data [23]. Thus, these water 
molecules might still stabilize the substrate´s orientation in the active site by hydrogen 
bonding yielding only one hydroxylation product in case of steroids 1-6. In contrast, hydrogen 
bond formation is completely disabled if the steroid substrate carries not oxygen functional 
group at position C3 as in case of 10.  
 
Secondly, when substrate 5α-androstan-3-one (11) was converted by CYP154C5 
wild-type one main hydroxylation product but with an altered regioselectivity was obtained. In 
this case, the absence of oxyfunctionalisation at position C17 in the substrate affected the 
enzyme-steroid interaction changing the selectivity of CYP154C5 wild-type from 16α- 
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towards 15α-hydroxylation. As previously discussed, the affinity of the enzyme towards 
substrate 11 was found to be remarkably high. A possible reason for the change in 
regioselectivity might be the P450´s inability to form a hydrogen bond between residue Q398 
and the substrate, thus allowing a different positioning in the active site. Additionally to the 
smaller molecule size the lack of double bonds in the substrate may also affect the 
interaction of 11 with the enzyme leading to a different orientation in the active site.  
 
When much larger substituents are present at position C17 of the steroid structure, as 
in the case of etiadienic acid ethyl ester (8), no conversion was observed by CYP154C5 
since the steric hindrance close to the heme prosthetic group increases. Although docking 
studies suggested that etiadienic acid ethyl ester (8) should be hydroxylated at position C16 
by CYP154C5 [23], experimental results demonstrated that CYP154C5 is not able to perform 
the anticipated reaction. Similarly, cholesterol and its plant equivalent β-sitosterol are also 
not converted by this enzyme most probably due to their large aliphatic side chain at position 
C17 (unpublished results). In contrast, finasteride (7) gave no conclusive results since 
product formation could only be observed once by TLC. Docking experiments performed by 
Herzog et al. [23] predicted that, due to the large apolar substituent at C17, the steroid core 
of finasteride (7) cannot bind deeply enough in the active site resulting in a C16-Fe distance 
that is too long for effective hydroxylation at C16. However, possible hydroxylation at position 
C21 and epoxidation at position C2 were suggested by docking as possible targets of 
CYP154C5 wild-type catalysis [23].  
Interestingly, when a steroid lacking both oxyfunctionalisations at positions C3 and C17 
was employed as substrate (ethioallocholane, 9), CYP154C5 wild-type was still able to bind 
and successfully convert this substrate as indicated by GC-MS. Although no information 
regarding the structure of the formed product could be obtained so far, docking analysis 
performed by Konrad Herzog [23] suggested that the increase in motional freedom for 
substrate 9 within the active site, due to its smaller size and the missing polar groups, 
reduces its binding energy so that specific binding in a position that would allow 
hydroxylation at position 16 is unlikely. Thus, a change in regioselectivity of CYP154C5 could 
be expected to occur with substrate 9. Although only a partial shift towards high spin state 
was observed for this enzyme-substrate couple, a dissociation constant in the range of µM 
was calculated for the part that was shifted. Hence, it can be concluded that the affinity of 
CYP154C5 wild type towards 9 is only weak in comparison to other steroid substrates.  
Furthermore, CYP154C5 is also able to hydroxylate smaller substrates in a selective 
fashion. In particular, β-ionone (12) was converted by CYP154C5 to 4-hydroxy-β-ionone 
(12A), however, the stereoselectivity remains unknown. Interestingly, no further oxidation to 
4-keto-β-ionone was observed. This over oxidation is commonly reported by P450s as in the 
case of CYP102A1 from Bacillus megaterium and CYP154H1 from Thermobifida fusca [24, 
28]. Moreover, (+)-valencene (13) was not converted by CYP154C5, indicating that the lack 
of any polar functionality in addition to the small size, prevents conversion by this P450. 
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5.1 Abstract 
 
This chapter contains the work on biocatalytic steroid hydroxylations using bacterial 
cytochrome P450 monooxygenases, which was performed in collaboration with Bayer 
Schering Pharma. The bioconversion of four steroid substrates was studied using three 
different P450 enzymes: CYP154C5 from Nocardia farcinica, CYP106A2 from Bacillus 
megaterium and CYP110D1 from Nostoc sp, which were coexpressed in Escherichia coli 
C43 (DE3) together with putidaredoxin reductase (PdR) and putidaredoxin (Pdx) from 
Pseudomonas putida as electron transfer partners. In order to determine if the selected 
steroids were substrates for the three studied P450s, analytical scale conversions were 
performed employing whole cell catalysis. By varying the initial substrate concentration, 
optimal conditions for preparative scale reactions were identified. Finally, four reactions were 
performed on preparative scale in order to purify the obtained products for structure 
elucidation by one and two dimensional NMR analysis. As novelty, we could show for the first 
time that also 3β-hydroxy-Δ5-steroids such as dehydroepiandrosterone (2) are hydroxylated 
by CYP106A2 in a regioselective manner, producing 7 - and 7β-hydroxy-
dehydroepiandrosterone. Furthermore, CYP110D1 is reported for the first time to hydroxylate 
also other steroid derivatives than testosterone (5), such as dehydroepiandrosterone (2), 
androstenedione (4), androstadienedione (14) and 9α-hydroxyandrostenedione (15). In 
particular androstadienedione (14) was monohydroxylated at positions 7, 11, 15 and 16 with 
a turnover number of about 0.85 min-1.  
 
5.2   Introduction 
 The remarkable ability of cytochrome P450 monooxygenases to catalyze the 
insertion of oxygen into non-activated C–H bonds under mild conditions has attracted the 
interest of researchers for several decades [1–4]. In particular, their application in the 
synthesis of steroid hormones by selective introduction of hydroxyl groups into the steroid 
backbone is a common practice in the pharmaceutical industry. This approach represents an 
advantage over chemical approaches since only very few chemical methods exist that can 
directly hydroxylate aliphatic or aromatic C–H bonds, and most of them are not selective or of 
limited scope. Furthermore, it was demonstrated that the introduction of a hydroxyl group 
with a specific orientation and position in the steroid backbone is related to a particular 
therapeutic activity. For example, the presence of an oxygen functional group at 11β-position 
is crucial for anti-inflammatory activity (example of cortisol), whereas a 17β-hydroxyl function 
determines the androgenic properties and aromatization of ring A results in estrogenic effects 
[1]. Today, steroids represent one of the largest sectors in the pharmaceutical industry with 
worldwide markets of about US$10 billion [3]. A further example for the application of 
cytochrome P450s in the pharmaceutical industry is the production of pravastatin (a potent 
cholesterol lowering agent) using a P450 from Mucor hiemalis by Daiichi Sankyio (Tokyo, 
Japan) and Bristol- Myers Squibb (New York, NU) [2, 5]. 
 
Due to their natural role in steroid synthesis, a larger number of eukaryotic P450s are 
known as compared to prokaryotic ones, but their industrial application is limited due to the 
fact that they are membrane bound and that they exhibit rather low catalytic activities [4]. In 
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general, bacterial P450s are 60 to 100 amino acids shorter than their eukaryotic counterparts 
since they lack the N-terminal hydrophobic portion that causes most eukaryotic P450s to be 
membrane bound [6]. In contrast, bacterial P450s are soluble enzymes and thus allow much 
higher expression levels. As such, they represent especially interesting and valuable 
catalysts for industrial applications.  
 
So far more than 1000 bacterial cytochrome P450 genes have been identified 
(http://drnelson.uthsc.edu/Bacteria.html), but only few of them have been studied in detail. 
One example is the bacterial P450 CYP106A2 from Bacillus megaterium ATCC13368, also 
known as  3-oxo-Δ4-steroid hydroxylase, able to hydroxylate steroids such as progesterone, 
testosterone and 11-deoxycortisol [7]. The biological function and natural electron transfer 
partners of this CYP are unknown but the activity can be supported by adrenal redox 
proteins, adrenodoxin and adrenodoxin reductase (Adx and AdR) from bovine adrenals [8–
10]. CYP106A2 hydroxylates mainly at 15β position [11] as well as 6β, 9α and 11α when 
using progesterone as substrate [12]. On the other hand, it was reported that 3β-hydroxy-Δ5-
steroids are not converted by CYP106A2 [7]. Table 5.1 summarizes some substrates and the 
respective products formed in steroid hydroxylations by CYP106A2 that were reported so far. 
 
Table 5.1 Hydroxylation positions of CYP106A2 from Bacillus megaterium towards 
steroid substrates. Table adapted from Zehentgruber et al. [13]. 
Substrate Products Ref. 
   
progesterone (3) 15β-hydroxyprogesterone [11] 
 11α-hydroxyprogesterone [14],[15] 
 9α-hydroxyprogesterone [14],[15] 
 6β-hydroxyprogesterone [11] 
   
20α-dihydroprogesterone 15β-hydroxy-20α-dihydroprogesterone [11] 
   
11-deoxycorticosterone 15β-hydroxy-11-deoxycorticosterone [11] 
 
testosterone (5) 15β-hydroxytestosterone [11] 
 6β-hydroxytestosterone [16] 
   
11-deoxycortisol 15β-hydroxy-11-deoxycortisol [5] 
   
17α-hydroxyprogesterone 15β-17α-hydroxyprogesterone [11] 
   
corticosterone 15β-hydroxycorticosterone [11] 
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During the past two decades, several articles were published regarding the use of 
CYP106A2 as biocatalyst. In a recent work, Zehentgruber et al. reported the coexpression of 
CYP106A2 and the electron transfer partners AdR and Adx together with an alcohol 
dehydrogenase from Lactobacillus brevis used as cofactor regenerating enzyme. In this way, 
a reaction system was developed by which the productivity of progesterone and testosterone 
hydroxylation could be significantly increased yielding an absolute productivity of 5.5 g L-1 d-1 
[13]. Later on, a combination of directed evolution techniques, such as saturation 
mutagenesis and rational site-directed mutagenesis, were used to change the regioselectivity 
of the enzyme from C15 towards C11 in the hydroxylation of progesterone. Thus, an 
impressive increase in regioselectivity towards C11 from 28 % up to 81 % was achieved [17]. 
Furthermore, the hydroxylation of new substrates was demonstrated in a recent study by 
Bleif et al., where the identification of CYP106A2 as a regioselective allylic bacterial 
diterpene hydroxylase was reported [18], followed by a detailed study on the transformation 
of a pentacyclic triterpene using whole cell catalysis [19]. 
In 2006, Agematu et al. published a study where 213 bacterial P450s were examined 
for their ability to hydroxylate testosterone using PdR and Pdx from Pseudomonas putida as 
electron transfer partners in whole cell catalysis [20]. Of all bacterial P450s tested, 24 were 
found to convert testosterone. In particular, CYP154C5 from Nocardia farcinica was found to 
convert this steroid in a highly regio- and stereoselective manner, producing exclusively 16α-
hydroxytestosterone (a detailed characterization of this enzyme is reported in chapters 2 to 4 
of this thesis). Another P450 described by Agematu et al. was CYP110D1 from Nostoc sp. 
PCC7120 (alr4766), giving 15β-hydroxytestosterone selectively. In literature there are 
several reviews about the microbial transformation of steroids. However, in general a cell 
crude extract or whole cells of the native microorganisms are usually used to study the 
oxyfunctionalization of different steroids [1, 21–25]. Thus, only a few bacterial cytochrome 
P450s monooxygenases are identified, and fully characterized as well as their genes known, 
as e.g. for CYP106A2 from Bacillus megaterium [9, 10]. Hence, the identification and 
characterization of more bacterial P450s able to hydroxylate steroids in a regio- and 
stereoselective manner together with the development of cheaper and greener synthetic 
routes to important steroid hormones is highly demanded by pharmaceutical companies. 
 
The aim of this project was to determine the regio- and stereoselectivity of bacterial 
cytochrome P450 monooxygenases CYP106A2 from Bacillus megaterium and CYP110D1 
from Nostoc sp. towards the hydroxylation of four different steroid derivatives that are 
important for the pharmaceutical industry (Figure 5.1). In addition, also CYP154C5 from 
Nocardia farcinica was tested in the conversion of substrates 14 and 15. 
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Figure 5.1 Structure of tested steroid substrates. Dehydroepiandrosterone (2), androstenedione 
(4), androstadienedione (14), and 9- -OH-androstenedione (15). 
 
 
5.3   Materials and methods 
 
5.3.1 Materials 
Dehydroepiandrosterone (2), androstenedione (4), androstadienedione (14), and 9- -
OH-androstenedione (15) were provided by Bayer Schering Pharma AG. Cytochrome c from 
horse heart, formate dehydrogenase from Candida boidinii and hydroxypropyl β-cyclodextrin 
were purchased from Sigma Aldrich. Roti-quant for Bradford assay was purchased from 
Roth. All solvents and other chemicals necessary for the experiments were obtained from 
Applichem, Roth or Sigma-Aldrich and used without further purification. 
 
5.3.1.1 Bacterial strains and plasmids 
Escherichia coli TOP10 (Invitrogen, Carlsbad, CA, USA) was used for genetic 
manipulations, while E. coli C43 (DE3) (Lucigen, Middleton, WI, USA) was used as 
expression strain.  
 
Plasmid pACYC-Duet1 was purchased from Novagen (EMD Biosciences, San Diego, 
CA, USA) while the broad host-range expression vector pIT2-MCS was prepared as 
described elsewhere [26]. The cloning of vector pIT2cyp154C5 carrying the gene of 
CYP154C5 was already described in chapter 2 (section 2.3.2.1) of this thesis. 
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The gene of cyp106A2 was amplified from vector pJNNcyp106A2camAB(t) (kindly 
provided by Dr. Harald Ruijssenaars, TNO, Delft, Netherlands)[16] using primers BM-P-NdeI-
FW: 5’-GTACCGAACATATGAAAGAAGTTATTGCAG-3’ and BM-P-HindIII-RV: 5’-
TTTATTAAAGCTTACATGCGGCTTGCC-3’. Thereby restriction sites NdeI and HindIII were 
introduced. After gel purification and digestion of the PCR product with NdeI and HindIII, 
cyp106A2 was ligated with vector pIT2-MCS, which was digested with the same set of 
enzymes. The resulting plasmid was named pIT2cyp106A2 (see appendix section 5.1). 
 
The gene of cyp110D1 was amplified by PCR from genomic DNA of Nostoc sp. 
PCC7120 (obtained from Institute Pasteur, France) using primers NS-P-NdeI-FW: 5’-
AAAAAAAACATATGACAGTCACTCAAAACCTACCC-3’ and NS-P-HindIII-RV: 5`-
GGAATTAAGCTTCACGAATTACGCATTC-3’. Thereby restriction sites NdeI and HindIII 
were introduced for subsequent cloning of cyp110D1 into pIT2-MCS.[26]  The resulting 
vector was named pIT2cyp110D1 (see appendix section 5.1). 
 
5.3.2 Methods 
5.3.2.1 Recombinant expression in E. coli 
Expression of CYP154C5 from Nocardia farcinica, CYP106A2 from Bacillus 
megaterium or CYP110D1 from Nostoc sp. together with PdR and Pdx from Pseudomonas 
putida was performed using the strains E. coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB), 
E. coli C43 (DE3) (pIT2cyp106A2) (pACYCcamAB) or E. coli C43 (DE3) (pIT2cyp110D1) 
(pACYCcamAB), respectively. 
 
5.3.2.1.1 Heterologous expression in shake flasks 
Small scale expressions were performed in 2 L flasks. Firstly, 5 mL liquid LB media 
supplemented with tetracycline (10 µg/mL) and chloramphenicol (25 µg/mL) was inoculated 
from a -80°C DMSO stock of Escherichia coli C43 (DE3) harboring the respective P450, PdR 
and Pdx. After incubating overnight at 37°C and 250 rpm, a 500 mL TB culture supplemented 
with tetracycline (10 µg/mL), chloramphenicol (25 µg/mL) and 0.1 % v/v trace element 
solution was inoculated with 1 % v/v from the pre-culture and incubated at 37°C and 250 
rpm. At OD600 around 1 expression was induced with isopropyl β-D-1-thiogalactopyranoside 
(IPTG, 200 µg/mL) and δ-aminolevulinic acid (84 µg/mL) was added as a precursor for heme 
synthesis. After 48 hours of expression at 30°C and 250 rpm the cells were harvested (4424 
x g, 4°C for 15 min), washed with 50 mM potassium phosphate buffer pH 7.4, centrifuged 
again (4424 x g, 4°C for 15 min) and the pellet was directly used for biocatalyses. 
 
5.3.2.1.2 Heterologous expression at fermentor scale 
 A 5 mL liquid LB media preculture (10 g/L tryptone, 5 g/L yeast extract and 10 g/L 
NaCl) supplemented with tetracycline (10 µg/mL final concentration) and chloramphenicol 
(25 µg/mL final conc.) was inoculated from a frozen stock of E. coli C43 (DE3) harboring the 
respective P450, PdR and Pdx. After overnight incubation at 37°C and 250 rpm (Bench top 
shaker Certomat Sartorius, Göttingen, Germany), a 200 mL TB preculture (12 g/L tryptone, 
24 g/L yeast extract, 4 mL glycerol, 2.3 g/L KH2PO4 and 12.9 g/L K2HPO4) supplemented 
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with tetracycline (10 µg/mL) and chloramphenicol (25 µg/mL) was inoculated with 1 % v/v of 
the overnight culture and incubated for 24 h under the same conditions. Finally, a 5 L 
fermentor (Bioreactor Biostat MD Sartorius, Göttingen, Germany) containing 4.8 L of TB 
media supplemented with tetracycline (10 µg/mL), chloramphenicol (25 µg/mL) and 0.1 % v/v 
trace element solution (0.50 g/L of CaCl2.2H2O, 0.18 g/L of ZnSO4.7H2O, 0.10 g/L of 
MnSO4.H2O, 20.10 g/L of Na2-EDTA, 16.70 g/L of FeCl3.6H2O, 0.16 g/L of CuSO4.5H2O and 
0.18 g/L of CoCl2.6H2O) was inoculated with 4 % v/v preculture. The pH was set to 7.0 and 
adjusted during the expression with 5 M KOH and H3PO4 solutions. Dissolved oxygen was 
controlled with a pO2 electrode. Foam formation was controlled using commercial Antifoam 
from Sigma. At an optical density (OD600) of 1 expression was induced with IPTG (200 µg/mL 
final conc.) and δ-aminolevulinic acid (84 µg/mL final conc.) was added as a precursor for 
heme synthesis. After 24 hours of expression at 30°C and 300 rpm the cells were harvested 
by centrifugation (4424 x g, 4°C for 15 min) (Sorvall RC-6 Thermo Fischer Scientific, 
Wilmington, USA), washed with 50 mM potassium phosphate buffer pH 7.4 (6.98 g/L K2HPO4 
and 1,35 g/L KH2PO4), centrifuged again (4424 x g, 4°C for 15 min) (centrifuge 5810 R 
Eppendorf, Hamburg, Germany) and the pellets were stored at -20°C. 
 
5.3.2.1.3 Expression of Escherichia coli C43 (DE3) (pACYCcamAB) 
E. coli C43 (DE3) (pACYCcamAB) harbouring the Pdx (camA) and PdR (camB) 
genes but not the gene of CYP154C5 was used as control strain in bioconversions. In this 
case, expression was performed in shake flasks according to the procedure described before 
with two modifications: only chloramphenicol (25 µg/mL) was used for selective growth and 
δ-aminolevulinic acid was not added during the expression.  
 
5.3.2.2 SDS-PAGE and enzyme assays 
SDS-PAGE was carried out according to Schägger et al. adjusted to the Mini 
PROTEAN® Tetra Cell (Bio-Rad) [27]. Samples were prepared and ran as described in 
chapter 2 (section 2.3.2.3) of this thesis.  
 
All enzyme assays were measured with cell lysate of the respective E. coli C43 (DE3) 
containing P450, PdR and Pdx. Cells were resuspended in 50 mM potassium phosphate 
buffer pH 7.4 in order to reach an optical density of 40 and phenylmethylsulfonyl fluoride 
(PMSF, 17 µg/mL final conc.) was added as protease inhibitor. Cell disruption was performed 
in an EmulsiFlex-Homogenizer (Avestin, Germany) with 5 cycles of 1500 psi. After 
centrifugation (17,696 x g, 4°C for 45 min) (Sorvall RC-6 Thermo Fischer Scientific, 
Wilmington, USA) the resulting CFE was immediately used for the assays. P450 
concentration was determined by CO-difference spectra and calculated based on the 
absorbance maximum of CO-bound P450 at 450 nm (ε450=91 mM
-1 cm-1) using a Cary 50 
(Varian) spectrophotometer [28]. The activity of the electron transfer components (ETC) Pdx 
and PdR in CFE was determined by cytochrome c reduction assay, monitoring the  increase 
in absorbance at 550 nm of reduced cytochrome c (ε450=19.1 mM
-1 cm-1) [29]. Protein 
concentration was determined by Bradford assay [30]. 
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5.3.2.3 Analytical scale bioconversions  
In order to perform whole-cell bioconversions on analytical scale, frozen cells of E. 
coli C43 (DE3) (pIT2cyp154C5) (pACYCcamAB), E. coli C43 (DE3) (pIT2cyp110D1) 
(pACYCcamAB) or E. coli C43 (DE3) (pIT2cyp106A2) (pACYCcamAB), overexpressing Pdx, 
and PdR together with the respective cytochrome P450 (CYP154C5, CYP110D1 or 
CYP106A2, respectively), were resuspended in 50 mM potassium phosphate buffer pH 7.4 
to a final OD600 of approximately 40. All bioconversions were carried out in 1 mL scale at 
30°C and 250 rpm with addition of glucose (0.54 mg/mL final conc.) for cofactor 
regeneration. In case of whole cells coexpressing CYP110D1, PdR and Pdx, an optical 
density of 40 was equivalent to 3.0 µM CYP110D1 (5.8 % of total protein) and an ETC 
activity of 1.4 U/mL (0.2 U/mg of total protein), as determined by CO-difference spectra and 
cytochrome c assay, respectively. The same optical density of cells coexpressing 
CYP106A2, PdR and Pdx resulted in 4.1 µM CYP106A2 (6.7 % of total protein) and 3.4 
U/mL ETC activity (0.3 U/mg of total protein). An OD600 = 40 of cells containing CYP154C5, 
PdR and Pdx corresponded to 3.5 µM CYP154C5 (4.5 % of total protein) and an ETC activity 
of 1.0 U/mL (0.3 U/mg of total protein). All substrate stock solutions of steroids (100 mM 
concentration except for 4 where 50 mM were used) were prepared in 36 % (w/v) 
hydroxypropyl-β-cyclodextrin in ddH2O. Control reactions were carried out in parallel with E. 
coli C43 (DE3) (pACYCcamAB) containing only Pdx and PdR. After 20 to 23 hours of 
reaction, the bioconversions were extracted for subsequent HPLC and GC analysis. For that, 
the complete sample was extracted twice with ethyl acetate (700 µL and 500 µL) and once 
with chloroform (500 µL), the organic phases were combined, dried with sodium sulphate and 
the solvent was removed under reduced pressure.  
 
5.3.2.4 Preparative scale bioconversions and product purification 
Preparative-scale bioconversions were carried out in 200 ml 50 mM potassium 
phosphate buffer pH 7.4 in shake flasks using resting whole cells of E. coli C43 (DE3) 
(pIT2cyp110D1) (pACYCcamAB) or E. coli C43 (DE3) (pIT2cyp106A2) (pACYCcamAB) 
(from frozen stock) at 30°C and 250 rpm with the addition of glucose (0.54 mg/mL) for 
cofactor regeneration. In all cases, resting cells with an optical density of 38-40 were used. In 
case of whole cells coexpressing CYP110D1, PdR and Pdx, an optical density of 40 was 
equivalent to 9.2 µM CYP110D1 (4.4 % of total protein) and an ETC activity of 4.6 U/mL (0.4 
U/mg of total protein), as determined by CO-difference spectroscopy and cytochrome c 
assay, respectively. The same optical density of cells coexpressing CYP106A2, PdR and 
Pdx corresponded to 12.4 µM CYP106A2 (5.5 % of total protein) and 3.7 U/mL activity of the 
ETC (0.4 U/mg of total protein). Substrate stock solutions were prepared in the same way as 
described for analytical scale bioconversions. In general, 1 mM final substrate concentration 
was used, except for the bioconversion of androstenedione (4) with CYP110D1 where 2 mM 
was used. During bioconversions, samples were taken every hour for subsequent HPLC    
analysis. For that, 1 mL of reaction was extracted and the sample prepared for HPLC 
analysis as described in section 5.3.2.7. Turnover numbers were calculated based on 
substrate consumption and for the period of time where the highest substrate consumption 
rate was observed. After 22 to 24 h of reaction, the complete reaction volume was extracted 
twice with ethyl acetate (50 and 40 mL) and once with chloroform (30 mL), the organic 
phases were combined, dried with sodium sulphate and the solvent was removed under 
reduced pressure. Hydroxylated steroid products were afterwards purified by silica gel 
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column chromatography (silica gel 60; 0.2-0.5 mm; Roth) with a gradient of ethyl acetate in 
n-heptane to pure ethyl acetate (starting with ethyl acetate:n-heptane ratios of 9:1 for 
dehydroepiandrosterone (2) and androstenedione (4) and 7:3 for androstadienedione (14) as 
mobile phase.  
 
5.3.2.5 Thin layer chromatography (TLC) 
Bioconversions of all substrates were analyzed by TLC using Polygram Sil G/UV 254 
plates (stationary phase), phosphomolybdic acid solution (25 g/L phosphomolybdic acid, 10 
g/L Ce(SO4)2, 8 % v/v of 98 % H2SO4  in ddH2O) for staining and a mixture of ethyl acetate 
and n-heptane (8:2) as mobile phase.  
 
5.3.2.6 GC and HPLC analyses 
In the case of dehydroepiandrosterone (2) reactions the solid residue after sample 
work up was redissolved in chloroform containing 30 mM cholesterol as internal standard. 
The sample was later analyzed on a GC2010 gas chromatograph (Shimadzu) equipped with 
an OPTIMA-17ms column (Macherey-Nagel, Germany) with a linear temperature gradient 
starting at 250°C and heating with 10°C/min to 300°C. Injector and detector temperature 
were set to 300°C. Substrate and product were detected by FID. Dehydroepiandrosterone 
(2), was detected at a retention time (RT) of 7.99 min, whereas its products followed at 11.67 
(2B1), 11.26 (2B2), 12.80 (2C1), 11.30 (2C2) and 10.20 min (2C3).  
The dried residues of bioconversions with androstenedione (4), androstadienedione 
(14) and 9- -OH-androstenedione (15) were dissolved in acetonitrile: water (60:40) and 
injected on a high performance liquid chromatography (HPLC, Beckmann Coulter) equipped 
with a Nucleosil 100-5 C18, 250 x 4,5 mm column at 50°C. Acetonitrile: water (60:40) was 
used as mobile phase with a flow rate of 1 mL/min. Detection of substrates and their 
respective products was performed by UV absorbance at 245 nm. The substrates were 
eluted at 6.40 (4), 5.58 (12), 7.35 (13) and 4.08 min (14) whereas the main products were 
detected at 4.35 (4B1), 3.0 (4B1*), 4.10 (4C1), 4.32 (4C2), 4.65 (4C3), 4.08 (14A), 4.07 
(14B1 and 14B1*), 4.05 (14C1), 4.62 (14C2), 3.55 (15A), 3.50 (15B1), 3.78 (15B2), 3.53 
(15C1) and 3.82 min (15C2).  
In all cases, conversions were calculated based on substrate consumption using 
respective calibration curves of the substrates.  
 
5.3.2.7 GC-MS and NMR analyses 
Preliminary product identification was performed with a gas chromatograph-mass 
spectrometer (GC-MS-QP2010S, Shimadzu, Germany) equipped with an OPTIMA-17ms 
column (Macherey-Nagel, Germany) using a linear temperature gradient starting at 250°C 
and heating with 10°C/min to 300°C. Injector, interface and ion source temperature were set 
to 300, 300 and 200°C respectively.  
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Structure elucidation of formed products was performed by 1H, 13C, COSY and HSQC 
NMR analysis on a Bruker AV400 instrument (1H-NMR 400MHz and 13C-NMR 100MHz). In 
all cases deuterated chloroform was used as solvent with TMS as internal standard. 
Chemical shifts (δ) are given in ppm and coupling constant (J) in Hz (see appendix section 
5.2.) 
 
5.3.2.7.1 Suggested product: 7β-hydroxydehydroepiandrosterone (2B1) 
1H-NMR (400 MHz, CDCl3): δ 5.25 (1H, s, 6-H), 3.89 (1H, t, J= 7.7, 7α-H), 3.49 (1H, m, 3α-
H), 2.41 (1H, dd, Jd= 8.7 Jd= 19.2, 16-H), 2.33 - 2.17 (3H, m, 4α-H, 4β-H, 15-OH), 2.04 (1H, 
m, 16-H), 1.85-1.73 (4H, m, 1-H, 2-H, 12-H, 15-H), 1.64 (1H, m, 11-H), 1.56 - 1.32 (7H, m, 8-
H, 11-H, 12-H, 14-H), 1.27-1.14 (5H, m, 2-H), 1.09 - 0.96 (5H, m, 1-H, 9-H, 19-CH3), 0.83 
(3H, s, 18-CH3). 
13C-NMR: δ 124.4 (6-C), 71.8 (7-C), 70.3 (3-C), 50.3 (14-C), 47.2 (9-C), 40.6 
(4-C), 39.5 (8-C), 35.9 (1-C), 35.0 (16-C), 30.5 (12-C), 30.2 (2-C), 23.2 (15-C), 19.4 (11-C), 
18.2 (19-C), 12.5 (18-C). 
Molecular weight: 304.4 g/mol, GC-MS: Retention time: 10.1 min, M+: 304, m/z (%): 304 (4), 
286 (100), 271 (18), 253 (6), 105 (26), 91 (37), 79 (30), 67 (21), 55 (31), 41 (37). 
 
5.3.2.7.2 Suggested product: 7α-hydroxydehydroepiandrosterone (2B2) 
1H-NMR (400 MHz, CDCl3): δ 5.66 (1H, d, Jd= 3.8, 6-H), 3.98 (1H, m, 7β-H), 3.59 (1H, m, 3α-
H), 2.41 (1H, dd, Jd= 9.4 Jd= 18.8, 16-H), 2.41-2.07 (5H, m, 4α-H, 4β-H, 15-OH, 16-H), 1.95-
1.43 (9H, m, 1-H, 2-H, 12-H, 15-H 11-H, 8-H, 11-H, 12-H, 14-H), 1.35-1.20 (5H, m, 2-H), 
1.11-1.00 (5H, m, 1-H, 9-H, 19-CH3), 0.89 (3H, s, 18-CH3). 
Molecular weight: 304.4 g/mol, GC-MS: Retention time: 10.1 min, M+: 287, m/z (%): 287 (19), 
286 (100), 105 (25), 93 (22), 91 (33), 79 (29), 67 (19), 55 (29), 43 (22), 41 (36). 
 
5.3.2.7.3 Suggested product: 11α-hydroxyandrostenedione (4B1) 
1H-NMR (400 MHz, CDCl3): δ 5.77 (1H, s, 4-H), 4.34 (1H, t, Jt= 3.1, 15-H), 2.52-2.24 (6H, 
m,1β-H, 2α-H, 2β-H, 6α-H, 6β-H, 16β-H), 2.17-2.88 (4H, m, 1α-H,12β-H, 15α-H, 16α-H), 
1.86-1.37 (5H, m, 7β-H, 8β-H, 15β-H, 14α-H), 1.34 (3H, s, 19-CH3), 1.31-.1.10 (1H, m, 12α-
H), 1.03-0.89 (2H, m, 9α-H, 7α-H), 0.89 (3H, s, 18-CH3).
13C-NMR: δ 125.6 (4-C), 72 (15-C), 
54 (9-C), 53 (14-C), 30 (8-C), 21 (15-C), 17 (19-C), 16 (18-C). 
Molecular weight: 302.4 g/mol, GC-MS: Retention time: 12.1 min, M+: 302, m/z (%): 302 
(100), 287 (51), 152 (91), 110 (40), 93 (35), 91 (44), 79 (47), 67 (42), 55 (52), 41 (54). 
5.3.2.7.4  Suggested product: 15-hydroxyandrostenedione (4B1*) 
1H-NMR (400 MHz, CDCl3): δ 5.70 (1H, s, 4-H), 4.53 (1H, t, Jt= 4.8, 11-H), 2.52-2.24 (5H, m, 
2α-H, 2β-H, 6α-H, 6β-H, 16β-H), 2.17-2.88 (4H, m, 1β-H, 7β-H, 8α-H, 16α-H), 1.86-1.37 (5H, 
m, 1α-H, 11 -H, 11β-H, 12α-H, 12β-H), 1.31 - 1.10 (8H, m, 7α-H, 14 -H, 18-CH3, 19-CH3), 
1.03-0.89 (2H, m, 9α-H).13C-NMR: δ 123.1 (4-C), 66 (11-C), 53 (9-C), 50 (14-C), 28 (8-C), 19 
(19-C), 13 (18-C). 
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Molecular weight: 302.4 g/mol, GC-MS: Retention time: 10.1 min, M+: 302, m/z (%): 302 (64), 
260 (52), 199 (17), 124 (100), 109 (62), 91 (63), 79 (61), 67 (34), 55 (41), 41 (56).  
 
5.3.2.7.5 Suggested product: 15-hydroxyandrostadienedione (14B1 and 14C2) 
1H-NMR (400 MHz, CDCl3): δ 6.98 (1H, d, Jd= 10, 1-H), 6.17 (1H, dd, Jd= 19, Jd= 2, 2-H), 
6.11 (1H, m, 4-H), 4.55-4.48 (1H, m, 15β-H), 2.58-2.34 (3H, m, 6α-H, 6β-H, 16β-H), 2.17-
1.87 (3-H, m, 7β-H, 15α-H, 16α-H), 1.84-1.45 (4H, m, 8β-H, 11α-H, 11β-H, 12-H), 1.30-1.02 
(6-H, m, 7α-H, 9α-H, 14α-H, 19-CH3), 0.91 (3-H, s, 18-CH3).
13C-NMR: δ 208 (3-C), 157 (1-C), 
128 (2-C), 126 (4-C), 74 (15-C), 22 (11-C), 21 (19-C), 14 (18-C). 
Molecular weight: 300.4 g/mol, GC-MS: Retention time: 13.2 min, M+: 300, m/z (%): 300 (15), 
255 (22), 228 (35), 138 (64), 121 (59), 107 (100), 91 (77), 79 (96), 55 (60), 41 (72). 
 
5.3.2.7.6 Suggested product: 11-hydroxyandrostadienedione (14B1* and 14C2*) 
1H-NMR (400 MHz, CDCl3): δ 7.00 (1H, d, Jd= 10, 1-H), 6.15 (1H, dd, Jd= 23, Jd= 2, 2-H), 
6.04 (1H, s, 4-H), 4.55-4.48 (1H, m, 11α-H), 2.58-2.34 (3H, m, 6α-H, 6β-H, 16β-H), 2.21 (1H, 
m, 12-H), 2.28 (1H, t, Jt= 7.6, 8β-H), 2.17-1.87 (3-H, m, 7β-H, 15α-H, 16α-H), 1.84-1.45 (2H, 
m, 12β-H, 15β-H), 1.40 (3-H, s, 19-CH3), 1.30-1.02 (7-H, m, 7α-H, 9α-H, 12α-H, 14α-H, 18-
CH3).
13C-NMR: δ 186 (3-C), 168 (5-C), 155 (1-C), 128 (2-C), 124 (4-C), 67 (11-C), 22 (15-C), 
19 (19-C), 18 (18-C). 
Molecular weight: 300.4 g/mol, GC-MS: Retention time: 14.9 min, M+: 300, m/z (%): 300 (2), 
147 (33), 135 (18), 133 (21), 122 (100), 121 (33), 107 (19), 91 (29), 79 (16), 41 (16). 
 
5.3.2.7.7 Suggested product: 16-hydroxyandrostadienedione (14C1) 
1H-NMR (400 MHz, CDCl3): δ 6.99 (1H, t, Jt= 10.1, 1-H), 6.19 (1H, m, 2-H), 6.04 (1H, s, 4-H), 
3.90 (1H, t, Jt= 8.6, 16-H), 2.53-2.21 (2H, m, 6β-H, 16β-H), 2.14-1.33 (6H, m, 7-H, 11-H, 12-
H, 15-H), 1.25-1.13 (3H, m, 7-H, 9-H, 12-H) (3H, s, 19-CH3), 0.74 (3H, s, 18-CH3). 
13C-NMR: 
δ 215 (17-C), 185 (3-C), 167 (5-C), 154 (1-C), 127 (2-C), 123 (4-C), 74 (16-C), 51 (9-C), 51 
(14-C), 14 (19-C), 10 (18-C). 
Molecular weight: 300.4 g/mol, GC-MS: Retention time: 12.9 min, M+: 300, m/z (%): 300 (3), 
161 (3), 147 (4), 122 (100), 107 (9), 91 (13), 77 (7), 67 (4), 43 (8), 41(10). 
 
5.3.2.7.8 Suggested product:  keto-enol tautomer of product 14C1 (14C1*) 
1H-NMR (400 MHz, CDCl3): δ 6.99 (1H, t, Jt= 10.1, 1-H), 6.19 (1H, m, 2-H), 6.04 (1H, s, 4-H), 
3.69 (1H, s, 17-H), 2.14-1.33 (6H, m, 7-H, 11-H, 12-H, 15-H), 1.25-1.13 (9H, m, 7-H, 9-H, 12-
H, 18-CH3, 19-CH3). 
13C-NMR: δ 215 (17-C), 185 (3-C), 167 (5-C), 154 (1-C), 127 (2-C), 123 
(4-C), 85 (16-C), 51 (9-C), 51 (14-C), 18 (18-C), 18 (19-C). 
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5.3.2.7.9 Suggested product: 7-hydroxyandrostadienedione (14C3) 
1H-NMR (400 MHz, CDCl3): δ 7.04 (1H, d, Jd= 10, 1-H), 6.25 (1H, dd, Jd= 10.1, 1.8, 2-H), 
6.11 (1H, s, 4-H), 3.59 (1H, dt, Jt= 10.6, Jd= 5.5, 7α-H), 2.73-2.56 (2H, m, 6α-H, 6β-H), 2.45 
(1H, m, 16-H), 2.27 (1H, m, 15-H), 2.09 (1H, m, 16-H), 2.02-1.83 (4H, m. 8-H, 11-H, 12-H, 
15-H), 1.74 (1H, m, 11-H), 1.46 (1H, m, 14-H), 1.35-1.22 (4H, m, 12-H, 19-CH3), 1.10 (1H, dt, 
Jt= 12, Jd= 3.5, 9-H), 0.95 (3H, s, 18-CH3). 
13C-NMR: δ 185 (3-C), 164 (5-C), 154 (1-C), 128 
(2-C), 125 (4-C), 75 (7-C), 50 (14-C), 48 (9-C), 48 (10-C), 43 (6-C), 42 (8-C), 36 (16-C), 31 
(12-C), 25 (11-C), 23 (15-C), 19 (19-C), 14 (18-C). 
Molecular weight: 300.4 g/mol, GC-MS: Retention time: 14.9 min, M+: 300, m/z (%): 300 (3), 
282 (4), 150 (32), 132 (26), 122 (100), 107 (23), 91 (35), 77 (21), 41 (27).  
 
 
5.4   Results  
5.4.1 Heterologous expression 
In order to produce sufficient biomass to perform all analytical scale reactions, 
heterologous expression of the three P450 proteins (CYP154C5, CYP106A2 and 
CYP110D1) together with the electron transfer partners (PdR and Pdx) in E. coli were carried 
out in 2 L shake flasks at 30°C for 48h. Furthermore, in order to carry out preparative-scale 
bioconversions, heterologous expressions of CYP106A2 and CYP110D1 were repeated in 5 
L fermentor scale. In all cases, protein expression was induced by IPTG addition and δ–
aminolevulinic acid was added for enhanced heme synthesis. Additionally, trace element 
solution was used to supplement the media especially with iron. Expression results are 
shown in Figure 5.2. 
Protein production at fermentor scale with controlled oxygen supply and pH resulted 
in higher expression levels as compared to shake flasks (Table 5.2). In particular, the 
expression of CYP106A2 and CYP110D1 increased 3-fold in comparison with the shake 
flask experiments. Additionally, specific activities of the electron transfer components (ETC) 
increased as well.  As a result, the ETC activities achieved in shake flask expressions were 
1.9 and 2.9 U per milligram of CYP106A2 and CYP110D1, respectively, whereas 7.3 and 6.4 
U per milligram of CYP106A2 and CYP110D1, respectively, were obtained in fermentor 
scale. 
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Figure 5.2 SDS-PAGE of shake flask expressions of E. coli C43 (DE3) (pIT2cyp154C5) 
(pACYCcamAB), E. coli C43 (DE3) (pIT2cyp106A2) (pACYCcamAB) and E. coli C43 (DE3) 
(pIT2cyp110D1) (pACYCcamAB) [1:marker; 2-3: soluble fraction of control strain E. coli C43 
containing PdR (~45KDa) and Pdx (~11KDa) (without P450); 4-5: soluble fraction of E. coli C43 (DE3) 
containing CYP106A2 (~47KDa), PdR and Pdx; 6-7: soluble fraction of E. coli C43 (DE3) containing 
CYP110D1 (~52KDa), PdR and Pdx; 8: marker and 9: soluble fraction of E. coli C43 (DE3) containing 
CYP154C5 (~45KDa), PdR and Pdx]. All expressions were performed in duplicate. 
 
Table 5.2 Coexpression of P450s (CYP154C5, CYP106A2 or CYP110D1) with Pdx and PdR in E. 
coli C43 (DE3) in shake flasks and on fermentor scale. P450 concentration as well as volumetric 
and specific activity of the electron transfer partners PdR and Pdx of recombinant cells resuspended in 
50 mM potassium phosphate buffer pH 7.4 to a final OD600 of 40 are given. 
 [P450] µM 
Volumetric activity of 
ETC (U/mL) 
Specific activity of ETC 
(U/mg of total protein) 
Protein 
Shake flask* 
(0.5 L) 
Fermentor** 
(5 L) 
Shake flask* 
(0.5 L) 
Fermentor** 
(5 L) 
Shake flask* 
(0.5 L) 
Fermentor** 
(5 L) 
       
CYP154C5 3.5  1.0      0.3  
       
CYP106A2 4.1 12.4 0.4 3.7 0.1 0.4 
       
CYP110D1 3.0 9.2 0.5 4.6 0.2 0.4 
* cells used for analytical scale bioconversions 
** cells used for preparative scale bioconversions 
 
5.4.2 Biocatalyses on analytical scale 
As first step, whole-cell biocatalyses in 1 mL scale were performed in order to study if 
the cytochrome P450s were active towards the tested substrates. In all cases an optical 
density (OD600) of 40 of the resting cells and an initial substrate concentration of 0.5, 1, 2 and 
4 mM were tested. The applied P450 concentrations and ETC activities are given in table 
5.2. After 20 h of reaction at 30°C the samples were extracted and the recovered substrates 
analyzed by high performance liquid chromatography or gas chromatography (HPLC or GC, 
respectively) and thin layer chromatography (TLC). First, TLC analysis of bioconversions 
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demonstrated already the different selectivities of CYP154C5, CYP110D1 and CYP106A2 
towards the tested steroid substrates. In all reactions one, two or even three products visible 
on TLC were obtained (Figure 5.3). Formed products are named starting with the substrate 
number, followed by A, B or C depending on the P450 used as catalyst (CYP154C5, 
CYP106A2 or CYP110D1, respectively) and finishing by a sequential number. As an 
example, product 4B1 was the less polar product (as determined by TLC) obtained in the 
bioconversion of androstenedione (4) using CYP106A2 as catalyst. In general, CYP154C5 
proved once more to be highly regioselective, giving again only one product for the two 
tested substrates (14 and 15). On the other hand, CYP110D1 and CYP106A2 exhibit lower 
regioselectivity, forming two or even three different products for all substrates under the 
tested conditions. In contrast, control reactions without P450 did not show any product 
formation. 
 
Samples were afterwards measured by GC and HPLC and conversions (%) as well 
as total turnover numbers (TTN, µmol of substrate consumed per µmol of P450 applied) were 
determined based on substrate depletion. In all cases, conversions were decreasing with 
increasing initial substrate concentration. In whole cell catalyses containing CYP154C5, PdR 
and Pdx, 14 was fully converted for substrate concentrations up to 4 mM. On the other hand, 
only 60 % conversion of 15 could be achieved using low initial substrate concentration (0.5 
mM). Similarly, CYP106A2 only achieved 100 % conversion when 2, 4 and 14 were applied 
in 0.5 mM initial substrate concentration. In biotransformations containing CYP110D, PdR 
and Pdx, 2 was the only steroid that was fully converted, however, only at low initial substrate 
concentration (Figure 5.4). In all cases, the difference in TTN between the different P450s 
increases with increasing substrate concentrations (Figure 5.5). Transformations using 
CYP154C5 as catalyst showed the highest activities in comparison to CYP106A2 and 
CYP110D1 in the conversion of substrates 14 and 15, since here highest TTN and 
conversions were obtained. Furthermore, among all substrates converted by CYP110D1 
dehydroepiandrosterone (2) appears to be the preferred substrate since here the highest 
TTN for this enzyme could be achieved. Lowest TTNs of all tested reactions were obtained 
for the combination of 14 with CYP106A2 (TTN= 30) and 15 with CYP110D1 (TTN= 50).  
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Figure 5.3 Thin layer chromatography results of whole-cell steroid transformations using 
CYP154C5, CYP106A2 or CYP110D1 as catalysts. Bioconversions of 0.5, 1, 2, and 4 mM of A: 
dehydroepiandrosterone (2), B: androstenedione (4), C: androstadienedione (14), and D: 9-OH-
androstenedione (15) were tested. (S) represents the respective pure substrate; possible products are 
labeled with their assigned name.  A mixture of ethyl acetate: n-heptane (8:2) was used as mobile 
phase. Substrate and product spots were stained with phosphomolybdic acid solution. 
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Figure 5.4 Obtained conversions (%) in whole-cell reactions of steroids 
dehydroepiandrosterone (2), androstenedione (4), androstadienedione (14) and 9-OH-
androstenedione (15) using E. coli C43 (DE3) expressing PdR, Pdx and either of the P450s 
CYP154C5, CYP106A2 and CYP110D1. All reactions were carried out in 50 mM potassium 
phosphate buffer pH 7.4, OD600 of 40 at 30°C for 20 h. Substrates were added from stock solutions in 
36 % (w/v) hydroxypropyl β-cyclodextrin in ddH2O. 
 
 
Figure 5.5 Resulting TTNs (µmol substrate consumed µmol
-1
 P450) in whole-cell reactions of 
steroids dehydroepiandrosterone (2), androstenedione (4), androstadienedione (14) 9-OH-
androstenedione (15) using E. coli C43 (DE3) expressing PdR, Pdx and either of the P450s 
CYP154C5, CYP106A2 and CYP110D1. All reactions were carried out in 50 mM potassium 
phosphate buffer pH 7.4, OD600 of 40 at 30°C for 20 h. Substrates were added from stock solutions in 
36 % (w/v) hydroxypropyl β-cyclodextrin in ddH2O. 
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5.4.3 Preparative scale conversions and determination of hydroxylation products 
Based on the results obtained on analytical scale, selected reactions were chosen to 
be performed on preparative scale in agreement with Bayer Schering Pharma. The selected 
reactions were as follows: conversion of dehydroepiandrosterone (2), androstenedione (4) 
and androstadienedione (14) using CYP106A2 from Bacillus megaterium as well as 
conversion of androstadienedione (14) using CYP110D1 from Nostoc sp. Since it was known 
from our previous studies that CYP154C5 is highly selective for hydroxylation at position C16 
with α orientation, reactions with CYP154C5 were not considered for preparative scale. 
Preparative-scale reactions were carried out each in 200 mL volume in 2 L shake 
flasks for 22-24 h at 30°C. Frozen cells containing the respective P450 together with Pdx and 
PdR were resuspended in 50 mM potassium phosphate buffer pH 7.4 to an optical density of 
40. Generally, substrate concentrations of 1 mM (except for 14, were 2 mM were applied) 
were used and 30 mM glucose was added for cofactor regeneration. In order to determine 
the regioselectivity of the enzymes towards the tested substrates, obtained products were 
purified and analyzed by one- and two-dimensional NMR (1H, 13C, COSY, DEPT135 or 
DEPT45 and HSQC). In all cases, due to the generally low product quantities, two reactions 
were ran in parallel and combined for purification if the same products had been formed as 
judged by TLC analysis. 
 
5.4.3.1 Whole-cell conversion of dehydroepiandrosterone (2) catalyzed by CYP106A2 
together with PdR and Pdx in shake flask 
The preparative scale conversion of 1 mM 2 at 30°C using CYP106A2, PdR and Pdx 
as catalytic system was followed by TLC and HPLC for 23 h. As already obtained in 
analytical-scale reactions, the formation of two different products was observed on TLC. On 
the other hand, the conversion (%) and TTN (µmol substrate consumed µmol-1 CYP106A2) 
obtained after 23 h of reaction were significantly lower than in analytical scale since only 17 
% conversion and a TTN of 12 were reached, respectively (Table 5.3). Furthermore, in order 
to determine the initial reaction rate 1 mL samples were extracted and analyzed every hour 
of reaction and data points during the first four hours were used to calculate the turnover 
number (TON, nmol substrate consumed min-1 µmol-1 CYP106A2) of the catalytic system 
towards 2. Thus, a TON of approximately 20 nmol substrate consumed min-1 µmol-1 
CYP106A2 was estimated. After reaction workup, the products (2B1 and 2B2) were purified 
by column chromatography. Approximately 10 mg of each product (white solid) were isolated 
in a pure form (~17 % combined yield – calculated from the amount of substrate added to the 
reaction) and analyzed by GC-MS and NMR. Hence, a space-time-yield (STY) of 0.15 g L-1 d-
1 for each product could be estimated (Figure 5.6).  
Hydroxylation of industrially valuable steroids by bacterial P450 monooxygenases 
CYP106A2 and CYP110D1 
 
 C
h
a
p
te
r 
5
: 
R
e
s
u
lt
s
 
150 
 
 
Figure 5.6 Whole cell conversion of dehydroepiandrosterone (2) by CYP106A2, PdR and Pdx on 
preparative scale. A: Obtained conversion (%) and TTN (µmol substrate consumed µmol
-1
 
CYP106A2 applied in the reaction) over time. B: TLC of substrate 2 (S), the raw product (R) after 
extraction and C: purified products 2B1 and 2B2 used for NMR measurements. 
GC-MS analysis of product 2B1 gave a single peak with RT = 10.0 min and m/z = 304 
([M]++16). Comparison of the corresponding MS spectrum with the NIST library gave 77 % 
similarity with a similar steroid structure with hydroxylation at C6. In the 1H-NMR spectrum a 
triplet peak at 3.89 ppm (J = 7.3 Hz) corresponding to CH-OH was observed coupling with a 
signal at 70.3 ppm in the corresponding 13C-NMR spectrum. In the COSY NMR spectrum this 
proton signal is coupling with the proton signal of the double bond at 5.25 ppm (s, 1H) which 
was assigned as H6 (Figure 5.7.C). Thus, the hydroxylation probably took place at C7. This 
result is in line with NMR data published by Li et al. [31] and Doller et al. [32]. Li et al. studied 
the synthesis of both enantiomers of 7-hydroxydehydroepiandrosterone. The authors state 
that for the α-enantiomer the proton signal of H6 is a doublet at 5.64 ppm with a coupling 
constant of J = 2.0 Hz, whereas for the β-enantiomer this signal is a singlet at 5.32 ppm. This 
indicates that CYP106A2 converts 2 to 7-hydroxydehydroepiandrosterone (2B1) (Figure 
5.7.A-B). 
GC-MS analysis of product 2B2 gave also a single peak with RT = 9.6 min and m/z = 
286 ([M]+-2). The corresponding MS spectrum showed 75 % similarity to a steroid with 
double bond formation at C7 and 69 % similarity with double bond formation at C14. Due to 
the low amount of pure product 2B2 only 1H and COSY NMR spectra were measured. In the 
COSY spectrum the same coupling of the proton signal of CH-OH with the signal of H6 was 
observed as already described for product 2B1 (Figure 5.8.C). However, this time H6 gave a 
doublet at 5.65 ppm (Figure 5.8.B). Thus, according to Li et al. [31] it can be concluded that 
the α-enantiomer of 7-hydroxydehydroepiandrosterone (2B2) is also formed by CYP106A2 
(Figure 5.8.A). Comparing this result with the obtained molecular mass of [M]+-2 by GC-MS, 
it could be possible that the hydroxyl group at C7 is removed by water elimination during GC-
MS analysis. 
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Figure 5.7 NMR analysis of product 2B1. A: Predicted structure of product 2B1 according to NMR 
data. B: Singlet signal for H6. C: COSY spectrum of 2B1 showing coupling signals of H6 and H7.  
 
                                       
Figure 5.8 NMR analysis of product 2B2. A: Predicted structure of product 2B2 according to NMR 
data. B: Doublet signal of H6. C: COSY spectrum of 2B2 showing coupling of signals H6 and H7. 
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5.4.3.2 Whole cell conversion of androstenedione (4) catalyzed by CYP106A2, PdR and 
Pdx in shake flask 
On preparative scale, one major product (4B1) was formed in the hydroxylation of 1 
mM 4 using whole cells overexpressing CYP106A2, PdR and Pdx. In contrast to what was 
obtained on analytical scale, only traces of products 4B2 and 4B3 were formed this time 
(Figure 5.9.A-C). After 23 hours of reaction, a conversion of 34 % and a TTN of 29 were 
reached (Table 5.3). Again, the TON was determined for the first hours of reaction, yielding 
roughly a value of 75 nmol substrate consumed min-1 µmol-1 CYP106A2 applied in the 
reaction. GC-MS analysis of the isolated product 4B1 gave four peaks with retention times of 
9.4; 12.1; 12.4 and 13.9 min with m/z = [M]+- 2 for the first peak (possible hydroxylation 
product with further water removal during GC-MS analysis) and [M]++16 for the last three 
peaks (Figure 5.9.D). The peak at 12.1 min corresponds to a possible product with 
hydroxylation at C11 or C15 (76 % similarity) or possible hydroxylation at position C6 (73 % 
similarity) according to a NIST library search. The mass spectrum of the second major peak 
(4B1*) also showed a possible hydroxylation at position C6 (71 % similarity) and at positions 
C11 or C15 (65 % similarity). Hence, product 4B1 actually consists of two main compounds 
that could not be separated during purification. Overall, 16 mg of purified 4B1 plus 4B1* were 
obtained with a yield of 26 % (calculated from the amount of substrate added into the 
reaction) and analyzed by NMR. 
 
    
Figure 5.9 Whole-cell conversion of androstenedione (4) by E. coli C43 (DE3) (pIT2CYP106A2) 
(pACYCCamAB) on preparative scale. A: TLC of samples over time (0, 2, 4.5 and 23 h), B: raw 
product (R) after work up and C: purified product for NMR measurements. D: GC-MS chromatogram 
of isolated product 4B1. Four peaks with retention times of 9.4; 12.1; 12.4 and 13.9 min were eluted. 
Traces of the first peak exhibited a m/z of [M]
+
-2, which could result from a possible hydroxylation of 
the substrate with further water removal during GC-MS analysis. Mass spectra showed a m/z of 
[M]
+
+16 for the last three peaks, suggesting the introduction of oxygen into the molecule. 
1H, 13C, COSY, HSQC and DEPT135 NMR spectra were measured for substrate 4 
and purified product. The substrate’s 1H-NMR spectrum was assigned as previously 
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described by Kirk et al.[33]. Analysis of the NMR spectra of the purified product led to the 
same conclusion as the GC-MS result, where two different monohydroxylated products (4B1 
and 4B1*), which could not be separated by silica gel chromatography, were present. This is 
confirmed by the presence of two proton signals at 4.54 (t, J =4.8) and 4.35 ppm (t, J = 3.1) 
corresponding to CH-OH in the ratio of 1:1.3 also found by GC. These proton signals are 
coupling to the signals at 66.08 and 71.84 ppm, respectively, in the corresponding 13C-NMR 
spectrum. Almost all signals were found in duplicate in the 13C-NMR spectrum, except the 
ones at 20.69 and 19.25 ppm. Comparing these signals with the 13C-NMR spectrum of the 
substrate, they very likely correspond to C15 and C11, respectively (Figure 5.10.B and 
5.10.C). In the 13C-NMR spectrum of the product these signals are now shifted to 66.08 and 
71.84 ppm (corresponding to CH-OH). Additionally, the COSY spectrum showed coupling 
between the proton signals assigned as H11 and H15 with their respective neighbors, further 
supporting the presented hypothesis (Figure 5.10.D). All proton signals were assigned based 
on HSQC-NMR data. Thus, it can be assumed that one product was formed by hydroxylation 
of 4 at position C11 (4B1) and the second product could correspond to 15-
hydroxyandrostenedione (4B1*) (Figure 5.10.A). In case of 4B1, it can be assumed that the 
11α-hydroxyandrostenedione enantiomer is formed since Kirk et al. reported the presence of 
a multiplet at 1.75 ppm for H8 in the α-enantiomer which is also present in the 1H-NMR 
spectrum of 4B1 [33]. In contrast, the corresponding β-enantiomer would show the H8 signal 
at 2.20 ppm [33]. Additionally, the signal corresponding to H12 appears exactly with the 
same chemical shift (2.17 ppm) as the H12 of 11α-hydroxyandrostenedione as described by 
the same authors (Figure 5.10.D) [33]. Furthermore, hydroxylation of 4 with α-orientation at 
position C11 would be in agreement with the known regio- and stereoselectivity of 
CYP106A2 towards progesterone. In contrast, assigning the orientation of the hydroxyl group 
(α or β) in case of 4B1* is very difficult since NMR data are only available for the α-
enantiomer of 15-hydroxyandrostenedione. Despite this fact, hydroxylation of 4 by 
CYP106A2 was already reported by Berg et al. to give 15β-hydroxyandrostenedione [11]. 
However, the authors give only MS data for 15β-hydroxyandrostenedione which does not 
directly agree with the MS data of 4B1* obtained by GC-MS. Therefore, further analyses 
would be necessary to properly assign the orientation of the hydroxyl group for 4B1*.  
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Figure 5.10 NMR analysis of products 4B1 and 4B2. A: Suggested product structures, 11α-
hydroxyandrostenedione (4B1, black) and 15-hydroxyandrostenedione (4B1*, grey). B: 
13
C-NMR 
analysis of substrate 4, where chemical shifts for C15, C11, C19 and C18 are shown as single peaks. 
C: 
13
C-NMR analysis of products 4B1 and 4B1* where duplicated signals of C18 and C19 (assigned 
using DEPT135) and single signals for C11 (4B1) and C15 (4B1*) were found. D: COSY NMR 
analysis that shows coupling between H11-H9 and H11-H12 signal of product 4B1, confirming the 
hydroxylation at position C11. In the same way, coupling between H15-H16 and H15-H14 is found for 
product 4B1*, confirming the hydroxylation at position C15. H signals were assigned by coupling to the 
respective C atom as observed in HSQC-NMR spectrum. 
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5.4.3.3 Whole-cell conversion of androstadienedione (14) catalyzed by CYP106A2, PdR 
and Pdx in shake flask. 
The bioconversion of 2 mM 14 using CYP106A2, PdR and Pdx as catalytic system 
was performed at 30°C for 19 hours and followed by TLC and HPLC (Figure 5.11.A-C). Only 
32 % of substrate was converted into product (14B1) with a TTN of 35 after 19 h reaction 
(Table 5.3). After purification, GC-MS analysis of 14B1 revealed two main peaks most likely 
corresponding to two different products which could not be efficiently separated by silica gel 
chromatography. The two main peaks were detected at 13.1 (14B1) and 14.9 min (assigned 
as 14B1*) both exhibiting m/z = [M]++16  (Figure 5.11.D). Comparison of the corresponding 
MS spectrum of 14B1 with the NIST library revealed high similarity to steroids but no specific 
hydroxylation position. On the other hand, the MS spectrum of 14B1* exhibited 79 % 
similarity with 11-hydroxyandrostadienedione. After purification, 15 mg of 14B1 plus 14B1* 
were isolated with a yield of 13 % (calculated from the amount of substrate added into the 
reaction) and analyzed by NMR. 
 
 
Figure 5.11 Whole-cell conversion of androstadienedione (14) by E. coli C43 (DE3) 
(pIT2CYP106A2) (pACYCCamAB).  A: TLC of samples taken over time after 2.5; 3.5 and 19 h, B: 
raw product (R) after work up and C: 14B1 after purification. The secondary products could not be 
isolated in a pure form for further NMR analysis. D: GC-MS analysis of purified 14B1, two major peaks 
were detected with m/z = [M
+
]+16. 
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1H, 13C, COSY, HSQC and DEPT135 NMR spectra were measured for substrate and 
purified product. NMR spectra of 14B1-14B1* showed no substrate traces and two products 
in 1:1.7 ratio were observed. This is confirmed by the double signals corresponding to the 
protons at C1 and C2 and the presence of a signal for CH-OH in the 1H-NMR which 
integrates for two protons (4.51 ppm). This peak is coupling not only with the signals at 73.6 
and 67.2 ppm (CH-OH) in the corresponding 13C-NMR spectrum but also to signals assigned 
as H14, H16 and H12 in the COSY-NMR. Additionally, all signals in the 13C-NMR spectrum 
were found in duplicate except the ones corresponding to C11 and C15 (Figure 5.12.B). 
Thus, similarly to the conversion of substrate 4 by CYP106A2, it can be hypothesized that 
this P450 hydroxylates 14 at positions C11 and C15. However, it has to be noted that the 
intensity of the signals in the NMR spectra is considerably low since only a low amount of 
product was obtained after purification and the overlap of most signals makes the 
assignment extremely difficult. For that reason, also comparison with published NMR data for 
15α-hydroxyandrostenedione [34], 11β-hydroxyandrostenedione [35] and 11α-hydroxy-
androstene-dione [36] in order to determine the hydroxyl group orientation was complicated. 
Nevertheless, as usually 15β-and 11-hydroxylated steroid products are formed by 
CYP106A2 it could be assumed that also 15β- and 11-hydroxyandrostadienedione are 
formed using 14 as substrate (Table 5.1).  
 
5.4.3.4 Whole-cell conversion of androstadienedione (14) catalyzed by CYP110D1, PdR 
and Pdx in shake flask.  
Bioconversion of 2 mM androstadienedione (14) using whole cells overexpressing 
CYP110D1, PdR and Pdx was performed at 30°C for 23 h. Samples were taken over time in 
order to follow the conversion by HPLC and TLC and to estimate the TON (Figure 5.13.A-B). 
The final conversion after 23 h was 86 % with a TTN of 218 (Table 5.3). The substrate 
consumption rate (TON) could be estimated as 850 nmol substrate consumed min-1 µmol-1 
CYP110D1. Similar to analytical scale reactions, two main products, 14C1 and 14C2, were 
formed according to TLC analysis. However, after reaction workup the presence of a third 
product was observed (Figure 5.13.C). After purification, 22, 8 and 6 mg of products 14C1, 
14C2 and 14C3 could be isolated with a yield of 6, 3 and 3 %, respectively (calculated from 
the amount of substrate added to the reaction). Afterwards, products were analyzed by GC, 
GC-MS and NMR techniques.  
 
The GC-MS result of product 14C1 showed one main peak with a retention time of 
12.8 min and m/z = [M]++16 (Figure 5.14 in black). Although only one spot was observed by 
TLC, the injection of purified 14C2 showed two main peaks with retention times of 13.2 and 
14.9 min (14C2 and 14C2*, respectively), both exhibiting m/z = [M]++16  (Figure 5.14 in 
grey). This suggests that two different monohydroxylated products were present which could 
not be separated by the conditions used during silica gel chromatography. Furthermore, 
injection of purified 14C3 showed a single peak with a retention time of 14.5 min, again 
exhibiting a m/z = [M]++16 (Figure 5.14 in blue). A NIST library search gave for all products 
high similarities to steroid derivatives but no specific hydroxylation position could be 
assigned. 
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Figure 5.12 NMR analyses of product 14B1 and 14B1*. A: Suggested product structures 11-
hydroxyandrostenedione (14B1, black) and 15-hydroxyandrostenedione (14B1*, grey). B: 
13
C-NMR 
analysis of substrate 14, where chemical shifts for C15, C11, C19 and C18 are shown as single 
peaks. C: 
13
C-NMR analysis of products 14B1 and 14B1* where duplicate signals of C18 and C19 
(assigned using DEPT135) and single signals for C15 (14B1) and C11 (14B1*) are shown. D: COSY-
NMR analysis shows coupling between signals H11 and H12 of product 14B1, confirming the 
hydroxylation at position C11. Similarly, the coupling between signal H15 with H16 and H14 is shown 
for product 14B1*, confirming the hydroxylation at position C15. Proton signals were assigned by 
coupling to the respective C-atom as observed in the HSQC-NMR spectrum. 
Hydroxylation of industrially valuable steroids by bacterial P450 monooxygenases 
CYP106A2 and CYP110D1 
 
 C
h
a
p
te
r 
5
: 
R
e
s
u
lt
s
 
158 
 
 
 
Figure 5.13 Whole-cell conversion of androstadienedione (14) by E. coli C43 (DE3) 
(pIT2CYP110D1) (pACYCCamAB). A: Calculated conversion (%) and TTN (µmol substrate 
consumed µmol
-1
 CYP110D1 applied in the reaction) over time. B: TLC of samples taken over time 
after 2, 5 and 19 h), C: raw product (R) after work up and D: products 14C1-3 after purification.  
 
 
 
Figure 5.14 Overlay of the GC-MS chromatograms of purified products 14C1 (black), 14C2 
(grey) and 14C3 (blue). NIST library search for all different products peaks showed m/z = [M]
+
+16.  
 
Although the GC-MS chromatogram of product 14C1 showed only one peak, 
surprisingly the 1H-NMR analysis revealed two hydroxylation products (now called 14C1 and 
14C1*). This is confirmed by the presence of two proton signals at 3.90 ppm (t, J = 8.6 Hz) 
and 3.69 ppm (singlet), both corresponding to CH-OH, which are coupling to signals at 74.0 
and 85.0 ppm, respectively, in the corresponding 13C-NMR spectrum. The signal for CH-OH 
at 3.90 ppm in 1H-NMR is observed as a triplet, whereas the obtained signal at 3.69 ppm is a 
singlet. When comparing the 1H-NMR spectra of product 14C1 and substrate, one of the H16 
signals clearly disappeared in the product spectrum. In addition, COSY-NMR of the product 
showed coupling between CH-OH and signals probably corresponding to H15α and H15β 
(now shifted to higher ppm, Figure 5.15.B). This leads to the conclusion that hydroxylation 
possibly occurred at position C16 (14C1). The presence of a singlet signal for CH-OH at 3.69 
ppm implicates hydroxylation at a carbon with no protons at neighboring carbon atoms. 
Hence, a possible hydroxylation at a methyl group could have occurred. To check this 
hypothesis a DEPT135-NMR analysis was performed. This should show the carbon signal, 
coupling with the proton at 3.69 ppm, as negative in case of a hydroxylated methyl group 
(H2C-OH). However, the DEPT135-NMR spectrum showed a positive signal for this carbon 
atom revealing a CH-OH group. Hence, it can be concluded that the hydroxylation did not 
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+
 +16 
14C3 
[M]
+
 +16 
14C2* 
[M]
+
 +16 
9.0 10.0 11.0 12.0 13.0 14.0 15.0 16.0 17.0 18.0
0.00
0.25
0.50
0.75
1.00
1.25
(x1,000,000)
Hydroxylation of industrially valuable steroids by bacterial P450 monooxygenases 
CYP106A2 and CYP110D1 
 
 C
h
a
p
te
r 
5
: 
R
e
s
u
lt
s
 
159 
 
take place at a methyl group. On the other hand, the NMR result could be also explained by 
rearrangement of the C=O bond at C17 to C16 after hydroxylation at C16. The carbonyl 
group at position C17 could be in equilibrium with its tautomer form (keto-enol tautomerism) 
after hydroxylation at C16 leading to a diol intermediate. This tautomer could rearrange to its 
corresponding isomer with a carbonyl group at position C16 and hydroxyl group at C17 
(14C1*, Figure 5.15.C). In this case, the singlet proton signal at 3.69 ppm would correspond 
to a proton at position C17. However, it has to be stressed that this keto-enol tautomerism 
was not observed for 16-hydroxylated products of dehydroepiandrosterone (2) and 
androstenedione (4) obtained by CYP154C5 catalysis (chapter 2). 
 
 
 
Figure 5.15 NMR analyses of product 14C1. A: Suggested product structure. B: COSY-NMR 
analysis shows coupling between H16 and H15 (proton signals assigned by coupling to the respective 
C-atom as observed in the HSQC-NMR spectrum), confirming the hydroxylation at position C16. C: 
Keto-enol tautomerism of product 14C1 which could explain formation of the second product (14C1*) 
found in NMR analysis of 14C1. 
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The two peaks (products 14C2 and 14C2*) of the second purified product exhibit the 
same retention times in the GC-MS chromatogram as products 14B1 and 14B1* obtained for 
the same substrate using CYP106A2 from Bacillus megaterium as catalyst. Also NMR 
analysis of these products showed exactly the same profile as for products obtained with 
CYP106A2. Therefore, it can be assumed that products 14C2 and 14C2* also correspond to 
11- and 15-hydroxylated androstadienedione, respectively. In contrast to the results obtained 
with CYP106A2, CYP110D1 favored the formation of 11- over 15-hydroxy-
androstadienedione in a ratio of 3:1.  
 
GC-MS analysis of product 14C3 gave one main peak at RT = 14.8 min with m/z= 
[M]++16 corresponding to a monohydroxylated product (Figure 5.14). NMR analysis of this 
product showed also one hydroxylation product with a signal for CH-OH at 3.58 ppm (dd, J= 
10.1, 5.8 Hz) in the 1H-NMR spectrum coupling to a signal at 75.35 ppm in the corresponding 
13C-NMR spectrum. In addition, 1H-NMR showed a shift of the H6 signal to higher ppm as 
compared to the substrate spectrum and the signals corresponding to both protons at C7 
disappeared from the original position in the substrate 1H-NMR spectrum. Furthermore, in the 
COSY spectrum coupling of the CH-OH signal to the protons at position 6 and 8 can be 
observed. For these reasons it can be concluded that product 14C3 corresponds to 7-
hydroxyandrostadienedione (Figure 5.16). Additionally, the proton signal corresponding to 
H15β is shifted to higher ppm in comparison with the signal in the substrate spectrum, 
whereas the chemical shift of the H15α signal remains constant. This effect could be 
explained if 14C3 would be the β-enantiomer, since an interaction between H7β and H15β 
due to spatial proximity could occur. In addition, the obtained NMR and GC-MS data for 
14C3 are in perfect agreement with previously published NMR and MS data for 7β-
hydroxyandrostadienedione.[37, 38] However, since no NMR data for 7α-hydroxy-
androstadienedione are reported in literature, the stereoselectivity of CYP110D1 towards this 
substrate cannot be concluded with certainty. To properly confirm the formation of 7β-
hydroxyandrostadienedione by CYP110D1 a NOESY-NMR spectrum should be measured in 
order to identify a coupling between H7α and H6α as well as no coupling between signals 
H7α and H8β.  
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Figure 5.16 NMR analyses of product 14C3. A: Suggested product structure. B: COSY-NMR 
analysis shows coupling of H7 with H8 and H6 (proton signals assigned by coupling to the respective 
C-atom as observed in the HSQC-NMR spectrum), confirming the hydroxylation at position C7. 
 
Table 5.3 Conversion (%), yield (%), TTN and TON of reactions of 2, 4 and 14 with CYP106A2 
and CYP110D1 in preparative-scale bioconversions. TTN calculated as µmol substrate consumed 
µmol
-1
 P450 and TON as nmol substrate consumed min
-1
 µmol
-1
 P450.  
Substrate Enzyme 
Hydroxylation 
position 
Conversion     
(%) 
Yield** 
(%) 
TTN 
TON 
(min
-1
) 
Dehydroepiandroste- 
rone (2) 
CYP106A2 7β  (2B1) 17 17*** 12 0.023 
7α  (2B2) 
             
Androstenedione  
(4) 
CYP106A2 11α (4B1) 34 26*** 29 0.075 
15   (4B1*) 
             
Androstadienedione 
(14) 
CYP106A2 11   (14B1) 32 13*** 35 - 
15   (12B1*) 
           
CYP110D1 16   (14C1) 80 9 218 0.850 
11   (14C2) 3*** 
15   (14C2*) 
7     (14C3) 3 
 
**   Calculated from the amount of substrate added to the reaction. 
*** Combined yield. 
-    Not determined 
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5.5   Discussion 
The incorporation of hydroxyl groups in the steroid backbone in a regio- and 
stereoselective manner via traditional chemical synthesis is limited or rather impossible due 
to only poor selectivities that can be achieved with chemical catalysts. Therefore, enzymes 
like P450 monooxygenases are an attractive alternative for the introduction of chiral centers 
in a selective manner, facilitating the production of steroid hormones, among other 
compounds, in the pharmaceutical industry. In the present work, the recombinant expression 
and performance of three different bacterial P450s for the regio- and stereoselective 
hydroxylation of different steroids is reported. Cytochrome P450 monooxygenases 
CYP154C5, CYP106A2 and CYP110D1 were recombinantly expressed in soluble and active 
form in E. coli C43 (DE3) with Pdx and PdR as electron transfer partners (Table 5.2) and 
applied in whole-cell biotransformations of five different steroids (2, 4, 14 and 15, Figure 5.1). 
Thus, analytical-scale reactions revealed that almost all tested combinations of P450s and 
steroid substrates resulted in the formation of at least two different monohydroxylated 
products. Furthermore, the remarkable regio- and stereoselectivity of CYP154C5 from 
Nocardia farcinica, as previously reported for substrates 1-6 (see chapter 2), could be 
confirmed, since in each case only one hydroxylation product was found when substrates 14 
and 15 were employed. Most probably hydroxylation of these substrates by CYP154C5 also 
took place at position C16 with α-orientation as observed earlier for other steroids. However, 
structure elucidation of the formed products would be necessary to confirm this hypothesis.  
 
In terms of achieved total turnover numbers of the three catalytic systems in reactions 
of 14 and 15, CYP154C5 showed the highest efficiency in comparison with CYP106A2 and 
CYP110D1. In the conversion of dehydroepiandrosterone (2) and androstenedione (4) using 
CYP106A2 as catalyst, rather low TTNs (3-fold less) were obtained in comparison to the data 
published by Zehentgruber et al.[13]. However, in that paper the authors applied different 
steroids, progesterone and testosterone, as substrates in conversions using crude cell 
extract of E. coli coexpressing CYP106A2, electron transfer components as well as an 
alcohol dehydrogenase from Lactobacillus brevis for improved cofactor regeneration. 
Furthermore, Zehentgruber et al. employed Adx and AdR as redox partners instead of PdR 
and Pdx. It is important to stress that adrenodoxin and adrenodoxin reductase were 
previously reported to be the preferred redox partners for CYP106A2 [8,39].  
 
Interestingly, in our study CYP106A2 even showed conversion in reactions employing 
dehydroepiandrosterone (2), a 3β-hydroxy-Δ5-steroid, although it was reported before that 
this enzyme would not accept sterols as substrates [7, 11]. Structure elucidation of the 
formed products after preparative-scale bioconversion of 2 using CYP106A2 even revealed 
an altered regioselectivity of the enzyme yielding 7β-hydroxydehydroepiandrosterone (2B1) 
and 7α-hydroxydehydroepiandrosterone (2B2) as products as compared to 3-oxo-Δ4-steroids 
where mainly 15β- and 11α-hydroxylated products are formed [12]. Berg et al. claimed 
already in 1976 that cell-free extracts of Bacillus megaterium ATCC 13368, disrupted by 
sonication, were not able to convert ring A-reduced, aromatic and 3β-hydroxy-Δ5-steroids as 
substrates [11]. In their study they also employed pregnenolone (1) and 
dehydroepiandrosterone (2) as substrates. Hence, the question arises why CYP106A2 is 
able to convert sterol 2 in our case. The main difference of both reaction systems lies in the 
applied redox partners. While Berg et al. employed megaredoxin and megaredoxin reductase 
from B. megaterium ATCC 13368, the natural electron transfer components of CYP106A2 [9, 
11], putidaredoxin and puridaredoxin reductase from P. putida ATCC17453 were used as 
Hydroxylation of industrially valuable steroids by bacterial P450 monooxygenases 
CYP106A2 and CYP110D1 
 
 C
h
a
p
te
r 
5
: 
D
is
c
u
s
s
io
n
 
163 
 
surrogate redox partners in our study. Maybe the binding of megaredoxin to CYP106A2 
results in a certain structural conformation of the P450 that does not allow the conversion of 
3β-hydroxy-Δ5-steroids whereas protein-protein interaction between CYP106A2 and 
putidaredoxin does. Additionally, the redox potentials of putidaredoxin and megaredoxin 
might differ leading only to successful electron transfer upon dehydroepiandrosterone 
binding in case of putidaredoxin. Berg et al. already tried to explain the sudden change in 
stereoselectivity of CYP106A2, when NaIO4 and NaClO2
- were applied as reducing agents 
instead of megaredoxin reductase and megaredoxin together with NADPH, by a different 
conformation of the P450 if megaredoxin is not present. The authors could show that not only 
15β-hydroxyprogesterone but also the 15α-enantiomer is formed if NaIO4 and NaClO2
- are 
used to reduce the heme iron of CYP106A2 in progesterone conversions [11, 39]. Moreover, 
it was described previously for the interaction of Pdx with P450cam that binding of the 
ferrodoxin to the P450 results in changes in the substrate binding pocket [40, 41]. Recently, 
Tripathi et al. elucidated the crystal structure of the P450-Pdx complex in the presence of the 
substrate D-camphor bound in the active site of P450cam [42]. In their study the authors 
conclude that binding of Pdx favors the more open conformation of oxy-P450cam. In this 
case, establishment of a water mediated H-bonding network required for proton-coupled 
transfer and oxygen activation in P450cam is enabled. In conclusion, possible differences in 
redox potential as well as structural changes upon putidaredoxin or megaredoxin binding 
might explain why Pdx enables hydroxylation of dehydroepiandrosterone by CYP106A2 
while megaredoxin did not. However, a more detailed study is necessary to elucidate if 
indeed the use of different redox partners (in particular the ferrodoxins) can cause the 
observed changes in substrate specificity of CYP106A2. 
As already reported for other 3-oxo-Δ4-steroids, CYP106A2 also performed 
hydroxylation of substrates 4 and 14 at positions C15 and C11. In 1976, Berg et al. already 
published the formation of 15β-hydroxyandrostenedione by CYP106A2, megaredoxin 
reductase and megaredoxin in conversions of 4 [11]. In contrast to our results, the authors 
did not report the formation of 11α-hydroxyandrostenedione as a byproduct. Again, the use 
of PdR and Pdx as redox partners instead of megaredoxin and megaredoxin reductase might 
cause this difference in regioselectivity of CYP106A2. Furthermore, due to the insufficient 
data that is available for the formed products, the stereoselectivity of CYP106A2 in 
conversions of 4 and 14 still remains uncertain. Further two dimensional NMR analyses 
should be performed in order to elucidate the orientation of the hydroxyl group in each case. 
However, since so far hydroxylation of steroids in 15-position by CYP106A2 was always 
reported to occur with β-orientation, it can be assumed that also steroid 4 and 14  are 
transformed into the corresponding 15β-hydroxylated product. The same applies to 11α-
hydroxylation of 4 and 14 by CYP106A2.  
TTNs and conversions obtained in preparative-scale reactions of substrates 2, 4 and 
14 were remarkably reduced as compared to analytical-scale reactions. This might be mainly 
caused by the scale-up procedure itself, since a different ratio of reaction volume to total 
vessel volume as well as a different reaction vessel geometry were used on preparative 
scale. This will result, e.g., in differences in oxygen input or mass transfer, thus affecting the 
efficiency of the catalytic system. Furthermore, a faster inactivation of one (or more) of the 
three components of the P450 system might have occurred under preparative-scale 
conditions since different cell batches were used as compared to analytical-scale reactions. 
In particular, ferrodoxins are prone to (fast) inactivation by the loss of their iron-sulfur clusters 
[43, 44], thus interrupting the electron transfer to the cytochrome P450 monooxygenases. 
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Furthermore, it is important to stress that in preparative-scale reactions three times more 
P450 was applied as compared to analytical-scale reactions. This will directly result in 
reduced total turnover numbers if not three times higher conversions are achieved at the 
same time.  
The use of E. coli cells overexpressing CYP110D1 together with Pdx and PdR in the 
preparative-scale conversion of androstadienedione (14) led to the formation of four different 
regioisomeric, monohydroxylated products with a rather high conversion (86 %) as compared 
to the other preparative-scale reactions performed in this study. In particular, positions C7, 
C11, C15 and C16 were found to be hydroxylated. However, due the only low amounts of 
purified products and their fast decomposition the stereoselectivity of CYP110D1 could not 
be determined. In contrast, Agematu et al. reported a rather low conversion of testosterone 
(5) by CYP110D1 together with PdR and Pdx using whole cell catalysis [20]. Furthermore, in 
the reaction with testosterone, the so far only reported steroid substrate of CYP110D1, the 
enzyme exhibited a remarkably high regio- and stereoselectivity, since only 15β-
hydroxytestosterone was found as product [20]. Hence, the regioselectivity of CYP110D1 
seems to depend strongly on the applied steroid substrate, a characteristic commonly 
reported for P450 monooxygenases [13, 45]. In the present study, CYP110D1 was also 
found to convert substrates 2, 4 and 15 into several monohydroxylated products as 
confirmed by GC-MS analyses. However, further studies are necessary to determine the 
respective hydroxylation positions of these products. 
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Today, about 300 approved steroid drugs are known and are ranked among the most 
commercialized medical products representing the second largest category next to antibiotics 
[1, 2].  The physiological activity of steroids directly depends on their structure, type, number 
and position of functional groups attached to the core as well as the oxidation state of the 
rings. In fact, the selective introduction of hydroxyl groups at specific locations of the rings 
will lead to hormones drugs with distinct physiological functions [3]. Therefore, the application 
of cytochrome P450 monooxygenases (CYPs) in the synthesis of steroid hormones is of high 
importance for the pharmaceutical industry. In fact, the remarkable ability of CYPs to 
catalyze the hydroxylation of non-activated carbon atoms in a regio- and stereospecific 
manner facilitates the functionalization of steroids avoiding in this way the use of protecting 
groups and several time-consuming chemical steps. Because of their natural role in steroid 
synthesis, today a larger number of eukaryotic P450s (mainly mammalian enzymes) capable 
of steroid hydroxylation are known as compared to prokaryotic ones. However, the 
biotechnological use of eukaryotic P450 monooxygenases is significantly hampered by the 
fact that they are membrane bound within the cells and often show low catalytic activities [4]. 
In contrast, bacterial P450s are soluble enzymes that can usually be overexpressed to very 
high amounts allowing much higher productivities in biotransformations. Although a large 
number of bacterial species are reported in literature to carry out hydroxylation of various 
steroids, the genes coding for the respective CYPs are often not known and the enzymes 
usually have been only poorly characterized [3, 5–7]. Hence, the investigation and detailed 
characterization of bacterial P450 monooxygenases, as performed in this doctoral thesis, will 
highly contribute to their application in the pharmaceutical industry for the synthesis of steroid 
drugs. 
The main focus of this thesis was the characterization of bacterial CYP154C5 from N. 
farcinica since it constitutes a promising catalyst for steroid hydroxylation due to its high 
regio- and stereoselectivity. Agematu et al. already reported the selective hydroxylation of 
testosterone (5) by this enzyme producing 16α-hydroxytestosterone. The authors simply 
used cell free extract containing CYP154C5, as well as Pdx and PdR from Pseudomonas 
putida as electron transfer components (ETCs) [8]. Based on these findings, here a detailed 
study of this P450 was performed in the conversion of various steroids, an efficient whole-cell 
biocatalyst was generated for steroid hydroxylations on preparative scale and the crystal 
structure of this P450 was solved with different steroids bound in the active site. Additionally, 
based on the obtained structural insights, single-site variants of CYP154C5 were generated 
in order to investigate the influence of selected active-site residues on steroid binding as well 
as catalysis. As described in chapter 2 of this thesis, CYP154C5 was able to successfully 
hydroxylate also pregnenolone (1), dehydroepiandrosterone (2), progesterone (3), 
androstenedione (4) and nandrolone (6) at position C16 with α orientation maintaining its 
high regio- and stereoselectivity (Figure 6.1). Thus, various 16-hydroxylated steroids, which 
are important precursors in the synthesis of highly potent glucocorticoids in the 
pharmaceutical industry, could be selectively produced by this enzyme. 
 
The high selectivity of CYP154C5 could be analyzed in detail based on the six crystal 
structures of this P450 with steroids 1-6 bound in the active site, which were solved in 
collaboration with Konrad Herzog and Kurt Hoffmann from the Fraunhofer IME in Aachen 
(chapter 3 of this thesis). In this way, a closer look into the enzyme-substrate interactions 
was possible giving us a better understanding of the enzyme’s functionality in steroid 
hydroxylation. All six x-ray crystallographic CYP154C5-steroid structures exhibited an 
asymmetric unit composed of two protein molecules covalently linked via a disulphide bond. 
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The CYP154C5-substrate complexes showed no significant protein fold changes induced by 
the structural differences of the steroids. CYP154C5 crystals with pregnenolone (1), 
progesterone (3), androstenedione (4) and testosterone (5) gave diffraction patterns of good 
quality, reaching resolutions from 1.9 to 2.4 Å, while crystals with dehydroepiandrosterone 
(2) and nandrolone (6) diffracted rather poorly resulting in structures of only low resolution. 
The CYP154C5-progesterone structure with a resolution of 1.9 Å gave the most detailed 
molecular insights. Thus, it was found that steroids 1-6 bind in the active site of CYP154C5 
with their C16 pointing towards the heme-iron accounting for the remarkably high 
regioselectivity of this enzyme. Furthermore, the steroid molecule in the active site is slightly 
shifted towards the carboxylic acid groups of the heme prosthetic group which explains why 
only α-hydroxylated steroids are produced by this highly stereoselective enzyme. Overall, 21 
amino acids were identified forming the catalytic pocket, but in particular four key residues 
were suspected to play an important role in the enzyme-substrate interaction. Glutamine 
residues at positions 239 and 398 were shown to form hydrogen bonds with the oxygen 
atoms of functional groups at positions C3 and C17 of the steroid molecule, respectively. In 
contrast, residues M84 and F92 seem to be involved in hydrophobic interactions with the 
hydrophobic steroid core. Interestingly, in all cases the affinity of CYP154C5 towards 
substrates 1-6 was found to be remarkably high as indicated by very low dissociation 
constants (KD) in the nanomolar range. 
 
Later on, a broader substrate scope was tested using the same catalytic three-
component system in order to investigate if CYP154C5 would maintain its high regio- and 
stereoselectivity if structurally less related steroids (compared to 1-6) are applied. Thus, 
steroids lacking one or both oxyfunctional groups at positions C3 and C17 (9-11, Figure 6.1) 
as well as steroid molecules with larger substituents at position C17 (7-8, Figure 4.2) were 
tested. The results obtained from this substrate engineering strategy showed that steroids 
bearing large substituents at position C17 of the steroid molecule, as in the case of 
cholesterol, β-sitosterol, finasteride (7) and etiadienic acid ethyl ester (8), are not converted 
by CYP154C5 wild-type. However, it would be interesting to further investigate how big the 
substituent at position C17 can be in order to be still successfully converted by CYP154C5. 
Surprisingly, the lack of any functional group at this position led to a change in the 
regioselectivity of CYP154C5 resulting in 15α-hydroxylation of substrate 5α-androstan-3-one 
(11, Figure 6.1). Hence, the hydrogen bond between the oxyfunctional group at position C17 
of the steroid molecule and residue Q398 of the enzyme’s active site seems to be of great 
importance for substrate positioning and orientation. On the other hand, when glutamine 398 
was exchanged by alanine through site directed mutagenesis, thus not allowing formation of 
the hydrogen bond, the regio- and stereoselectivity of CYP154C5 towards steroids 1-6 
remained unchanged (chapter 4 of this thesis). In conclusion, the presence of a functional 
group at position C17 of the steroid molecule might be important for substrate positioning 
and orientation in the active site irrespective of the possibility of hydrogen bond formation. 
However, it has to be kept in mind that substrate 11 is also lacking a double bond in the 
steroid core compared to 1-6 resulting in a slightly different three-dimensional structure. This 
might also change the enzyme-steroid interactions and thus substrate orientation in the 
active site.  
 
Similarly, oxyfunctional group at position C3 of the steroid molecule led to a change in 
CYP154C5’s regioselectivity and, hence, may play an important role in substrate orientation 
in the active site. As observed in the conversion of substrate 3-
deoxydehydroepiandrosterone (10), four different hydroxylated products were formed, 
Conclusions and future prospects 
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including the 16α-hydroxysteroid, one possibly double-hydroxylated product and two of which 
the structures are still unknown. From crystal structure analysis it was observed that the 
oxyfunctional group at position C3 is involved in hydrogen bonding, via water molecules, with 
residue Q239 located at the entrance of the enzyme´s substrate channel. However, when 
Q239 was exchanged by alanine no change in selectivity was observed for any of the tested 
substrates (1-6). Hence, these results suggest again that a functional group at position C3 
might have a big influence on the substrate´s positioning and orientation in the active site 
irrespective of the possibility to form a hydrogen bond. 
 
Furthermore, substrate 9 bearing any polar functional group was still converted by 
CYP154C5 as indicated by GC-MS analysis of the reaction mixture. This result indicates that 
the absence of polar groups in the steroid molecule does not necessarily lead to 
unproductive substrate binding. Moreover, this fact highlights again the importance of 
hydrophobic enzyme-substrate interactions for steroid binding and positioning in the active 
site. This is further supported by results obtained in chapter 4, when residues located in the 
hydrophobic part of the substrate channel, such as F92 and M84, were exchanged by 
alanine through site directed mutagenesis and tested in the conversion of steroid substrates 
1-6. In this way it was observed that nandrolone (6) was not converted anymore by mutant 
CYP154C5 M84A and pregnenolone (1) resulted in only 5% conversion under the same 
conditions. Interestingly, residue F92 proved to be important for substrate positioning since 
mutant CYP154C5-F92A exhibited a significant change in regioselectivity in the conversion 
of progesterone (3) due to the formation of a secondary hydroxylation product as identified 
by GC-MS. The reaction should be repeated on preparative scale in order to elucidate the 
hydroxylation position of the secondary product. When a steroid substrate containing already 
a polar functional group at the B ring, as in the case of 9-hydroxyandrostenedione (15), was 
applied, CYP154C5 was still able to convert this steroid producing only one hydroxylation 
product as indicated by GC-MS analysis. However, the regio- and stereoselectivity remains 
uncertain until further experiments are carried out to obtain the product in larger amounts for 
NMR analysis.  
 
Additionally, also non-steroidal substrates β-ionone (12) and (+)-valencene (13) were 
tested in conversions using the three-component system consisting of CYP154C5, Pdx and 
PdR. Thus, β-ionone (12) was found to be selectively hydroxylated by CYP154C5 producing 
4-hydroxy-β-ionone (12A). In contrast, (+)-valencene (13) was not converted by CYP154C5. 
This could indicate that a small hydrophobic molecule lacking polar functionalities will not 
bind in a productive way in the active site to allow conversion, whereas 12 contains a keto 
group in the side chain which could form a hydrogen bond with residue Q398 facilitating its 
correct positioning near the heme iron for hydroxylation. 
 
In summary, the regioselectivity of CYP154C5 was proven to change depending on 
the tested substrate, particularly depending on the substituent at positions C3 and C17 of the 
steroid molecule, as well as by the amino acid exchange F92A of the enzyme. In general, as 
long as oxyfunctional groups are present at positions C3 and C17 of the steroid core and if 
the substituent at C17 is not larger than an acetyl group, it can be expected that CYP154C5 
still hydroxylates the substrate selectively at position 16 with α orientation. Such a high 
selectivity in the hydroxylation of various steroids carrying different functional groups and 
differing in the position of double bonds is remarkable since often more than one product is 
formed for the same steroid substrate by a P450 monooxygenase [8–11] and 
regioselectivities even vary with change of the steroid substrate ([9, 11] and Chapter 5 of this 
Conclusions and future prospects 
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thesis). However, testing a broader substrate range could give further insights into the 
enzyme’s selectivity and could lead to the efficient production of other fine chemicals and 
pharmaceuticals in the future. Additionally, based in our results, protein engineering can be 
used to specifically alter CYP154C5’s selectivity in order to create a P450 toolbox that allows 
specific hydroxylation of various steroids at desired positions of the steroid core. Based on 
the crystal structure data, double or even triple mutants could be predicted in order to change 
the enzyme´s selectivity or to create variants which will accept also other substrates, such as 
for example triterpenes that were previously shown not to be hydroxylated by the wild-type 
enzyme (data not shown). 
In chapter 2 of this thesis, steroid conversions were carried out using either resting 
whole cells or cell-free extract of E. coli containing the three-component system composed of 
CYP154C5, Pdx and PdR, whereas in chapter 3 hydroxylation of steroids 1-6 by the purified 
three-component system was studied. This allows now a detailed comparison of the three 
catalytic systems regarding efficiency and productivity. In all cases, steroid substrates were 
solubilized in hydroxypropyl-β-cyclodextrin solution. Furthermore, whole cell (WC) reactions 
were carried out using different optical densities (OD600 from 30, 40 and 60) and different 
initial substrates concentrations ranging from 0.5 up to 15 mM. Additionally, freshly 
expressed cells as well as partially permeabilized (previously frozen and thawed) cells were 
compared. Furthermore, different CYP154C5 concentrations were tested in bioconversions 
using WC and CFE whereas the P450 as well as Pdx and PdR concentrations in reactions 
with purified proteins were fixed to 3, 14 and 3 µM, respectively. In summary, highest 
conversion rates (TONs) were obtained using the purified three-component system if always 
the same P450 concentration (3 µM) is applied. In contrast, respective TONs for the WC 
system were generally by a factor 2 lower. This might be due to a limited substrate uptake in 
WC bioconversions as compared to isolated enzymes. This is further supported by the fact 
that the use of partially permeabilized cells in steroid biotransformations significantly 
increased the initial conversion rate compared to freshly expressed cells since 
permeabilization of the cell wall can improve substrate uptake. The best conversions using 
whole cells were obtained applying an OD600 of 40 (equivalent to 3 µM CYP154C5 and an 
activity of the ETC of 9 U/mL), achieving total turnover numbers (TTNs) up to 2000 and 
turnover numbers (TONs) in the range of 0.8 - 3.3 min-1, depending on the substrate tested. 
However, a re-use of the (partially permeabilized) whole cell catalyst was not successful as 
hardly any conversion was already observed in the second cycle. Thus, the cofactor NADH 
or other required low molecular weight compounds, e.g. from the cofactor-regenerating 
metabolic pathways within the cell, might have been lost during washing steps prior to the 
next catalytic cycle. 
  
On the other hand, reactions employing CFE exhibited a significantly reduced 
efficiency in steroid conversions as compared to WC. In order to obtain the same amount of 
formed product as with WC catalysis, a six times higher P450 was here required. Thus, the 
use of cell lysate under the tested conditions seems not to be the desired approach for the 
synthesis of steroid hormones on an industrial level. Possible reasons could be a reduced 
stability of the different components (CYP154C5, PdR and particularly Pdx) as well as a 
lower probability of the different proteins to meet outside of the (protecting) cell environment.  
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Figure 6.1 Observed selectivity of CYP154C5 in the conversion of different steroids (1-11 and 
14-15) as well as β-ionone (12). Bioconversions were carried out using whole cells containing 
CYP154C5, Pdx and PdR. Product structures (1A-6A, 10A2, 11A and 12A) were determined by one 
and two-dimensional NMR techniques. 
Conclusions and future prospects 
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It should be stressed here that in case of CFE reactions formate dehydrogenase together 
with sodium formate were used as cofactor regeneration system, whereas cofactor 
regeneration in WC was achieved through the cell metabolism by the addition of glucose as 
cosubstrate. However, the different cofactor regeneration systems cannot account for the 
differences in steroid conversion efficiencies of WC and CFE since the addition of more FDH 
and sodium formate in CFE reactions did not improve the performance. Furthermore, FDH 
and sodium formate were also applied as cofactor regeneration system in reactions of the 
purified three-component system resulting here in even higher rates and productivities as 
obtained for the WC system. 
 
In the case of the purified catalytic system, additionally also catalase and superoxide 
dismutase were added into the reaction mixture. Furthermore, although a two times lower 
ETC activity was employed as compared to WC catalysis, the use of purified proteins still 
resulted in increased TONs and thus also higher space time yields (up to 7.7 g of 16α-
hydroxylated steroid per liter a day). In this case, substrate uptake cannot be limiting as in 
whole-cell biotransformations resulting in higher conversion rates and thus overall higher 
catalytic efficiency. Additionally, the use of catalase and superoxide dismutase efficiently 
removes formed active oxygen species, thus preventing the inactivation of CYP154C5. 
 
Despite the high rates and amounts of product obtained by using the purified three 
component system, the resting whole cell approach would be the desired strategy for the 
synthesis of important steroids hormones on an industrial level. Using this enzymatic system, 
16α-hydroxylated steroids can be selectively produced on preparative scale with attractive 
space-time yields of 1 to 4 g L-1 d-1 using only glucose for cofactor regeneration, without the 
need of time consuming protein purification steps and the addition of expensive cofactors. 
However, the WC catalytic system could be further improved by coexpression of an 
additional enzyme for NADH regeneration (FDH or other dehydrogenases) as well as the 
improvement of substrate uptake by cell permeabilization methods or the coexpression of 
specific steroid carriers such as elicitins [12]. 
Although CYP154C5 exhibited a high regio- and stereoselectivity in the hydroxylation of 
steroids 1-6, further biochemical characterization demonstrated that, independently of the 
use of purified proteins or WC, the P450 shows a clear preference for specific steroid 
substrates. Steroids bearing a hydroxyl group at position C17, such as testosterone (5) and 
nandrolone (6), were always converted with the lowest TONs and resulted in lowest coupling 
efficiencies. In particular, CYP154C5 exhibited the weakest affinity towards nandrolone (6) 
and the lowest coupling efficiency (40 %) determined among the tested steroids which might 
be explained by the missing methyl group at C10 as well as the significantly longer O17-
Q398 hydrogen bond. Similarly, the CYP154C5-testosterone crystal structure revealed the 
longest distance between the hydroxylation position C16 and the iron atom of the heme 
prosthetic group. Additionally, CYP154C5 might exhibit also rather high affinity for the 16α-
hydroxylated products (5A and 6A) delaying their release from the active site and thus 
reducing the overall efficiency of catalytic system. These facts could not only explain the 
lower coupling efficiencies but also the inefficient conversion of testosterone (5) and 
nandrolone (6) by CYP154C5 at higher substrate concentrations. In contrast and 
independent of the applied catalytic system, steroids with an acetyl or keto substituent at 
position C17 were preferentially converted by the three-component system as indicated by 
the high TONs and space-time yields obtained. Furthermore, progesterone (3) seems to be 
Conclusions and future prospects 
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the preferred substrate of CYP154C5 among all tested substrates as indicated by a TON of 
5.7 min-1 as well as an impressive coupling efficiency of 84 %.  
 
In summary, CYP154C5 revealed high selectivity, high productivities and in most 
cases high coupling efficiencies in the hydroxylation of steroid molecules. Additionally, the 
enzyme possesses an active site that is perfectly matching the structure of steroid molecules 
resulting in a remarkably tight binding of the steroid molecules. Hence, it can be assumed 
that the natural substrate of this P450 might be similar in structure to the tested steroid 
molecules. 
Finally, with the aim to create a P450 tool box for steroid hydroxylation also other 
bacterial P450s were tested for the conversion of different steroids in a collaborative project 
with Bayer-Schering Pharma (chapter 5 of this thesis). Thus, two additional bacterial 
cytochrome P450 monooxygenases, CYP106A2 from B. megaterium and CYP110D1 from 
Nostoc sp., were applied. Both enzymes were successfully coexpressed in E. coli together 
with PdR and Pdx as electron transfer components. Using WC of these three-component 
systems, conversion of dehydroepiandrosterone (2), androstenedione (4), 
androstadienedione (14) and 9-hydroxyandrostenedione (15) was carried out. As a result, 
the previously reported regioselectivity of CYP106A2 for hydroxylation of other steroids at 
positions C15 and C11 could be also confirmed for the 3-oxo-Δ4-steroids 4 and 14 (Figure 
6.2). Interestingly, the enzyme also exhibited significant activity in the conversion of 
dehydroepiandrosterone (2), a 3β-hydroxy-Δ5-steroid, although CYP106A2 was reported 
before not to be active on 3β-hydroxy-Δ5-steroids [13]. This difference might be explained by 
the use of putidaredoxin and putidaredoxin reductase as redox partners, which had been 
only reported before in combination with CYP106A2 for the hydroxylation of testosterone [8]. 
Additionally, CYP106A2 was also found to exhibit an altered regioselectivity in the 
conversion of 2 yielding 7- and 7-hydroxydehydro-epiandrosterone as products (Figure 
6.2). In the future, a more detailed study is necessary to elucidate if also other 3β-hydroxy-
Δ5-steroids are converted by CYP106A2 and if indeed the use of different redox partners 
(particularly the ferrodoxins) can cause the observed changes in substrate specificity of this 
as well as other P450s. Furthermore, CYP110D1 was shown for the first time to hydroxylate 
also other steroids besides the previously reported testosterone yielding 15β-
hydroxytestosterone [8]. However, the enzyme was found to exhibit a significantly lower 
regioselectivity in the conversion of 2, 4, 14 and 15 as compared to testosterone since in all 
cases several monohydroxylated products were detected by GC-MS. In particular, four 
different products were obtained in the hydroxylation of androstadienedione (14) obtaining 
the 7-, 11-, 15- and 16-hydroxylated products. Hence, the enzyme seems to be less suited 
for the selective hydroxylation of steroids in the pharmaceutical industry.  
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Figure 6.2 Observed selectivity of CYP106A or CYP110D1 in the conversion of steroids 2, 4, 14 
and 15. Bioconversions on preparative scale were carried out using whole cells containing either 
CYP106A2 or CYP110D1 together with Pdx and PdR as redox partners. Product structures were 
determined by one- and two-dimensional NMR techniques. 
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1 Abbreviations 
 
AAS  anabolic androgenic steroids 
ADH  alcohol dehydrogenase 
Adx  adrenodoxin from bovine adrenals 
AdR  adrenodoxin reductase from bovine adrenals 
AR  androgenic receptor 
BVMO  Bayer-Villiger monooxygenase 
CCE  crude cell extract 
CFE  cell free extract 
CPR  cytochrome P450 reductase   
CYD  hydroxypropyl-β-cyclodextrin 
CYP  cytochrome P450 monooxygenase 
ddH2O  double-distillated water 
DH  dehydrogenase 
DMSO  dimethyl sulfoxide 
DTT  dithiothreitol 
HFCS  high-fructose corn syrups 
HPLC  high performance liquid chromatography 
HS  high spin 
HSD  hydroxysteroid dehydrogenase 
IPTG  isopropyl β-D-1-thiogalactopyranoside 
e.g.  exempli gratia (for example) 
eqv  equivalent 
ETC  electron transfer component  
EtOAc  ethyl acetate 
et al.  et alii (and others) 
FAD  flavin adenine dinucleotide 
FDH  formate dehydrogenase 
FID  flame ionization detector 
FMN  flavin mononucleotide 
GC  gas chromatography 
GC-MS gas chromatography- mass spectroscopy 
gwc  gram of wet cell 
KD  Dissociation constant 
mo  microorganism 
MSTFA N-methyl-trimethylsilyltrifluoroacetamide 
NADH  nicotine adenine dinucleotide 
NAD(P)H nicotine adenine dinucleotide phosphate 
LS  low spin 
OD600  optical density at λ = 600 nm 
P450  cytochrome P450 monooxygenase 
PMSF  phenylmethylsulfonyl fluoride  
PPQ  pyrrolquinoline 
PtxD  phosphite dehydrogenase 
Ref.  reference 
RMSD  root mean square derivation 
RT  retention time 
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SOC  super optimal broth with Catabolite repression 
SOD  superoxide dismutase 
STY  space-time yield 
TCA  tricarboxilic cycle 
TCEP  tris (2-carboxyethyl) phosphine 
TDO  toluene diooxygenase 
TLC  thin layer chromatography 
Tm  melting temperature 
TON  turnover number  
TTN  total turnover number 
UFLC  ultra fast liquid chromatography 
WC  whole cells 
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2 Chapter 2 
2.1  Vector map 
 
 
Figure 2.1 Plasmid map of the expression vector pIT2-mcs containing the gene 
encoding for CYP154C5 from Nocardia farcinica. 
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Figure 2.2 Plasmid map of the expression vector pACYC containing the genes 
encoding for the electron transfer components ferredoxin and ferredoxin reductase 
from Pseudomonas putida. 
 
2.2   CO-Difference spectra 
 
 
Figure 2.3 CO difference spectra obtained in the measurement of CYP154C5. Difference 
spectra between the reduced form of CYP154C5 using sodium dithionate and reduced CO-
CYP154C5 complex. A maximum at 449 nm is observed. 
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2.3   Steroid conversions on analytical scale: control reactions  
 
 
Figure 2.4 Representative HPLC chromatograms of steroid bioconversions using E. 
coli C43(DE3) (pIT2cyp154C5) (pACYCcamAB) and E. coli C43(DE3) (pIT2cyp154C5) 
(pACYCcamAB) (control). Shown are chromatograms of testosterone (5) conversions. A: 
Using E. coli containing CYP154C5, Pdx and PdR product formation can be observed at 4.1 
min while no product is formed in control reactions using E. coli only containing Pdx and PdR 
(B).   
 
 
Figure 2.5 Thin layer chromatography results of cell free extract biocatalysis of six 
substrates (S) pregnenolone (1, A), dehydroepiandrosterone (2, B), progesterone (3, 
C), androstenedione (4, D), testosterone (5, E) and nandrolone (6, F). S represents the 
substrate, entries 1 and 2 show the conversion of 1 mM substrate with CFE containing 
CYP154C5-PdR-Pdx (reaction) and PdR-Pdx (control), respectively. 
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2.4   Product elucidation: GC-MS and NMR analyses 
 
2.4.1 Product 16α-hydroxypregnenolone (1A) 
 
 
Figure 2.6 Chemical structure of product 1A.  
 
 
A 
 
B 
 
Figure 2.7 GC-MS results of derivatized A1. A: GC chromatogram. B: MS of peak with 
RT= 16.9 min ([M]++16). 
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Figure 2.8 1H-NMR spectrum of 1A. 
 
 
Figure 2.9 13C-NMR spectrum of 1A. 
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Figure 2.10 DEPT45-NMR spectrum of 1A. 
 
 
Figure 2.11 COSY-NMR spectrum of 1A. 
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Figure 2.12 HSQC-NMR spectrum of 1A. 
 
 
2.4.2 Product 16α-hydroxydehydroepiandrosterone (2A) 
 
 
Figure 2.13 Chemical structure of product 2A. 
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A 
  
B 
 
Figure 2.14 GC-MS results of product 2A. A: Chromatogram of product 2A. B: MS of peak 
with RT= 8.5 min ([M]++16). 
 
 
 
Figure 2.15 1H-NMR spectrum of product 2A. 
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Figure 2.16 13C-NMR spectrum of product 2A. 
 
 
Figure 2.17 DEPT45-NMR spectrum of product 2A. 
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Figure 2.18 COSY-NMR spectrum of product 2A. 
 
 
Figure 2.19 HSQC-NMR spectrum of product 2A. 
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2.4.3 Product 16α-hydroxyprogesterone (3A) 
 
 
Figure 2.20 Chemical structure of product 3A.  
 
A
 
B 
 
Figure 2.21 GC-MS results of 3A. A: Chromatogram of product 3A. B: MS of peak with 
RT= 15.8 min ([M]++16).  
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Figure 2.22 1H-NMR spectrum of product 3A. 
 
 
Figure 2.23 13C-NMR spectrum of product 3A. 
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Figure 2.24 COSY-NMR spectrum of product 3A. 
 
 
Figure 2.25 HSQC-NMR spectrum of product 3A. 
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2.4.4 Product 16α-hydroxyandrostenedione (4A1) 
 
 
 
 
Figure 2.26 Chemical structure of product 4A1. 
 
 
 
A
 
B 
 
Figure 2.27 GC-MS results of 4A1. A: Chromatrogram of product 1A. B: MS of peak with 
RT= 16.4 min ([M]++16). 
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Figure 2.28 1H-NMR spectrum of product 4A1. 
 
 
Figure 2.29 13C-NMR spectrum of product 4A1. 
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Figure 2.30 DEPT45-NMR spectrum of product 4A1. 
 
 
Figure 2.31 COSY-NMR spectrum of product 4A1. 
Appendix 
 
 A
p
p
e
n
d
ix
 
199 
 
 
Figure 2.32 HSQC-NMR spectrum of product 4A1. 
 
 
 
2.4.5 Product 16α-hydroxytestosterone (5A) 
 
 
Figure 2.33 Chemical structure of product 5A. 
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A 
 
B 
 
Figure 3.34 GC-MS results of derivatized 5A. A: Chromatogram of product 5A. B: MS of 
peak with RT= 16.3 min ([M]++16). 
 
Figure 2.35 1H-NMR spectrum of product 5A. 
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2.4.6 Product 16α-hydroxynandrolone (6A1) 
 
 
 
Figure 2.36 Chemical structure of product 6A1. 
 
 
 
 
 
 
A 
 
B 
 
Figure 2.37 GC-MS results of 6A1. A: Chromatogram of product 6A1. B: MS of peak with 
RT= 10.7 min ([M]++16). 
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Figure 2.38 1H-NMR spectrum of product 6A1. 
 
Figure 2.39 13C-NMR spectrum of product 6A1. 
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Figure 2.40 COSY-NMR spectrum of product 6A1. 
 
 
Figure 2.41 HSQC-NMR spectrum of product 6A1. 
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Figure 2.42 NOESY-NMR spectrum of product 6A1. 
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3 Chapter 3 
3.1  Vector maps 
 
 
 
Figure 3.1 Plasmid map of the expression vector pET28a(+) containing the gene 
encoding for CYP154C5 from Nocardia farcinica. 
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Figure 3.2 Plasmid map of the expression vector pACYC containing the gene encoding 
for ferredoxin (CamB) from Pseudomonas putida. 
 
 
Figure 3.3 Plasmid map of the expression vector pACYC containing the gene encoding 
for ferredoxin reductase (CamA) from Pseudomonas putida. 
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3.2  Protein purification 
 
 
Figure 3.4 First step purification of CYP154C5 (~45 KDa) by ion exchange 
chromatography. A: Record of purification performed in Äkta prime of cell free extract from 
overexpressed E.coli C43(DE3) (pET28CYP154C5) cells is shown. The spectrum at 280 nm 
is shown in blue whereas the buffer gradient is depicted in green. B: The SDS-PAGE 
including marker (line 1), pre purified cell free extract (line 2) and eluted fractions (lines from 
3 to13) is shown. Fractions from 4 to 7 were pooled. 
 
Figure 3.5 Second step purification of CYP154C5 (~45 KDa) by affinity 
chromatography. A: Record of two consecutive purifications performed in Äkta prime of 
pooled fractions containing pre purified CYP154C5 is shown. The spectrum at 280 nm is 
shown in blue. B: The SDS-PAGE of the first purification including marker (line 1) and eluted 
fractions (lines from 2 to13) is shown. Fractions from 3 to 10 were pooled. C: The SDS-
PAGE of the second purification including marker (line 1), eluted fractions (lines from 2 to12) 
and final concentrated samples (lines 13 and 14) is shown. Fractions from 2 to 8 were 
pooled. 
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Figure 3.6 First step purification of PdR (~45 KDa) by ion exchange chromatography. 
A: Record of purification performed in Äkta prime of cell free extract from overexpressed 
E.coli C43(DE3) (pACYCCamA) cells is shown. The spectrum at 280 nm is shown in blue 
whereas the buffer gradient and conductivity are depicted in green and red, respectively. B: 
The SDS-PAGE including marker (line 1) and eluted fractions (lines from 2 to14) is shown. 
Fractions from 9 to 12 were pooled. 
 
 
 
 Figure 3.7 Second step purification of PdR (~45 KDa) by hydrophobic intereaction 
chromatography. A: Record of purification performed in Äkta prime of pooled fractions 
containing pre purified PdR is shown. The spectrum at 280 nm is shown in blue whereas the 
buffer gradient and conductivity are depicted in green and red, respectively. B: The SDS-
PAGE including marker (line 1) and eluted fractions (lines from 2 to14) is shown. Fractions 
from 6 to 9 were pooled. 
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Figure 3.8 First step purification of Pdx (~12 KDa) by ion exchange chromatography. 
A: Record of two consecutive purifications performed in Äkta prime of cell free extract from 
overexpressed E.coli C43(DE3) (pACYCCamB) cells is shown. The spectrum at 280 nm is 
shown in blue whereas the buffer gradient and conductivity are depicted in green and red, 
respectively. B: The SDS-PAGE including marker (line 1) and eluted fractions (lines from 2 
to12) are shown. Fractions from 3 to 9 were pooled and further purified. 
 
 
Figure 3.9 SDS-PAG of purified CYP154C5, PdR and Pdx. A: Pure CYP154C5 can be 
observed. B: four different batches of purified Pdx and one batch of purified PdR are 
depicted.  
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3.3  Steroid stock solutions 
 
Table 3.1 Steroid stock solutions with corresponding concentrations of hydroxypropyl-β-
cyclodextrin in ddH2O. 
Steroid 
Steroid Concentration  
(mM) 
hydroxypropyl- 
β-cyclodextrin (% w/v) 
Pregnenolone (1) 40 
10 
5 
1 
0.1 
36 
9.0 
4.5 
0.9 
0.1 
 
Dehydroepiandrosterone (2) 
Testosterone (5) 
100 
10 
5 
1 
0.1 
36 
3.60 
1.80 
0.36 
0.03 
Progesterone (3) 
Androstenedione (4) 
Nandrolone (6) 
50 
10 
5 
1 
0.1 
36 
7.2 
3.6 
0.72 
0.07 
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3.4  Dissociation constants 
 
 
Figure 3.10 Dissociation constant (KD) of CYP154C5 towards the six tested steroids. 
KDs were determined by fitting the data obtained to tight-binding equation. A: Pregnenolone 
(1). B: Dehydroepiandrostetone (2). C: Progesterone (3). D: Androstenedione (4). E: 
Testosterone (5). F: Nandrolone (6). 
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4 Chapter 4 
4.1 Vector map  
 
 
 
Figure 4.1 Plasmid map of the expression vector pET28a(+) containing the gene 
encoding for CYP154C5 mutants from Nocardia farcinica. 
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4.2  Protein expression 
 
 
Figure 4.2 SDS-PAGE of protein expression. M represents the Marker; lines 1, 2 and 3 
indicate the soluble fraction of samples taken just before addition of IPTG, 24h and 48 after 
induction, respectively, whereas lines 4, 5 and 6 indicate the respective pellet fraction. 
Proteins shown correspond to A: CYP154C5 (~45 KDa); B: Pdx (~11 KDa); C: PdR (~45 
KDa); D: CYP154C5-M84A (~45 KDa); E: CYP154C5-F92A (~45 KDa); F: CYP154C5-
Q239A (~45 KDa) and G: CYP154C5-Q398A (~45 KDa). 
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4.3 Protein purification 
 
 
Figure 4.3 First step purification of CYP154C5 M84A (~45 KDa) by ion exchange 
chromatography. A: Record of purification performed in Äkta prime of cell free extract from 
overexpressed E.coli C43(DE3) (pET28CYP154C5 M84A) cells is shown. The spectrum at 
280 nm is shown in blue whereas the buffer gradient is depicted in green. B: The SDS-PAGE 
including marker (line 1), and eluted fractions (lines from 2 to13) is shown. Fractions from 3 
to 9 were pooled. 
 
 
Figure 4.4 Second step purification of CYP154C5 M84A (~45 KDa) by affinity  
chromatography. A: Record of two consecutive purifications performed in Äkta prime of 
pooled fractions containing pre purified CYP154C5 is shown. The spectrum at 280 nm is 
shown in blue. B: The SDS-PAGE of the first purification including marker (line 1) and eluted 
fractions (lines from 2 to 7) is shown. Fractions from 3 to 5 were pooled.  
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Figure 4.5 First step purification of CYP154C5 F92A (~45 KDa) by ion exchange 
chromatography. A: Record of purification performed in Äkta prime of cell free extract from 
overexpressed E.coli C43(DE3) (pET28CYP154C5 F92A) cells is shown. The spectrum at 
280 nm is shown in blue whereas the buffer gradient is depicted in green. B: The SDS-PAGE 
including marker (line 1) and eluted fractions (lines from 2 to15) is shown. Fractions from 4 to 
9 were pooled. 
 
 
Figure 4.6 Second step purification of CYP154C5 F92A (~45 KDa) by affinity  
chromatography. A: Record of two consecutive purifications performed in Äkta prime of 
pooled fractions containing pre purified CYP154C5 is shown. The spectrum at 280 nm is 
shown in blue. B: The SDS-PAGE of the first purification including marker (line 1) and eluted 
fractions (lines from 2 to 6) is shown. Fractions from 3 to 5 were pooled.  
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Figure 4.7 First step purification of CYP154C5 Q239A (~45 KDa) by ion exchange 
chromatography. A: Record of purification performed in Äkta prime of cell free extract from 
overexpressed E.coli C43(DE3) (pET28CYP154C5 Q239A) cells is shown. The spectrum at 
280 nm is shown in blue whereas the buffer gradient is depicted in green. B: The SDS-PAGE 
including marker (line 1), pre purified cell free extract (line 2) and eluted fractions (lines from 
3 to15) is shown. Fractions 8 and 9 were pooled. 
 
 
Figure 4.8 Second step purification of CYP154C5 Q239A (~45 KDa) by affinity 
chromatography. A: Record of two consecutive purifications performed in Äkta prime of 
pooled fractions containing pre purified CYP154C5 is shown. The spectrum at 280 nm is 
shown in blue. B: The SDS-PAGE of the first purification including marker (line 1) and eluted 
fractions (lines from 2 to 6) is shown. Fractions from 2 to 5 were pooled.  
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Figure 4.9 First step purification of CYP154C5 Q398A (~45 KDa) by ion exchange 
chromatography. A: Record of purification performed in Äkta prime of cell free extract from 
overexpressed E.coli C43(DE3) (pET28CYP154C5 Q398A) cells is shown. The spectrum at 
280 nm is shown in blue whereas the buffer gradient is depicted in green. B: The SDS-PAGE 
including marker (line 1) and eluted fractions (lines from 2 to14) is shown. Fractions from 4 
until 7 were pooled. 
 
 
Figure 4.10 Second step purification of CYP154C5 Q398A (~45 KDa) by affinity  
chromatography. A: Record of two consecutive purifications performed in Äkta prime of 
pooled fractions containing pre purified CYP154C5 is shown. The spectrum at 280nm is 
shown in blue. B: The SDS-PAGE of the first purification including marker (line 1) and eluted 
fractions (lines from 2 to 6) is shown. Fractions 3 and 4 were pooled.  
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Figure 4.11 SDS-PAGE of purified proteins. M represents the marker. A: lines 1 to 5 show 
the purity of CYP154C5, CYP154C5-M84A, CYP154C5-Q398A, CYP154C5-Q239A and 
CYP154C5-F92A, respectively.  
 
 
4.4   Residual activity of CYP154C5 and mutants 
 
 
Figure 4.12 Residual amount of active P450. In order to investigate the stability of 
CYP154C5 and its respective single mutants, duplicate reactions were carried out in 50 mL 
closed falcon tubes containing 3 µM CYP154C5 in 5 mL of 50 mM potassium phosphate 
buffer pH 7.4 and incubated at 250 rpm, 30 °C for 24h. Samples (450 µL) were taken during 
the first six hours of analysis and the P450´s ability to bind carbon monoxide was study 
spectrophotometricaly. Taking into account the experimental error, results do not show a 
significative difference in residual activity among the tested variants and wild-type. 
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4.5   Product elucidation: GC-MS and NMR analysis. 
4.5.1 Possible secondary product of hydroxylation of progesterone (3) 
 
A 
 
B 
 
C 
 
 
Figure 4.13 Secondary product formation in the conversion of progesterone (3) by 
CYP154C5-F92A. A: HPLC chromatogram from the conversion or progesterone (RT= 9.7 
min) after 6h of reaction shows the formation of two products, 16α-hydroxyprogesterone (3A, 
RT= 4.3 min) and a secondary product with retention time 8.6 min. B: GC-MS chromatogram 
of same sample shown in A. C: MS spectrum of secondary product with retention time 8.8 
min. 
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4.5.2 Possible product of hydroxylation of ethioallocholane (9) 
 
A 
 
B 
 
Figure 4.14 GC-MS results of product 9A. A: chromatogram of product 9A. B: MS of peak 
at with RT = 6.0 min ([M]+-2). 
 
 
4.5.3 16α-hydroxy-3deoxydehydroepiandrosterone (10A2) 
 
 
Figure 4.15 Chemical structure of 10A2. 
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A 
 
 
 
 
 
 
B 
 
 
 
 
Figure 4.16 GC-MS results of product 10A2. A: chromatogram of product 10A2. B: MS of 
peak at with RT = 6.0 min ([M]+ + 16). 
 
 
 
Figure 4.17 1H-NMR spectrum of product 10A2. 
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Figure 4.18 13C-NMR spectrum of product 10A2. 
 
 
Figure 4.19 DEPT135-NMR spectrum of product 10A2. 
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Figure 4.20 COSY-NMR spectrum of product 10A2. 
 
 
Figure 4.21 HSQC-NMR spectrum of product 10A2. 
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Figure 4.22 NOESY-NMR spectrum of product 10A2. 
 
 
4.5.4 Unknown 3-deoxydehydroepiandrosterone product (10A3) 
 
A 
 
B 
 
Figure 4.23 GC-MS results of product 10A3 A: chromatogram of product 10A3. B: MS of 
peak at with RT = 9.9 min ([M]+ + 76). 
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4.5.5  Unknown 3-deoxydehydroepiandrosterone product (10A4) 
 
A 
 
B 
 
Figure 4.24 GC-MS results of product 10A4 A: chromatogram of product 10A4. B: MS of 
peak at with RT = 8.3 min ([M]+ + 32). 
 
4.5.6 Dihydroxy-3-deoxydehydroepiandrosterone product (10A5) 
 
A 
 
B 
 
Figure 4.25 GC-MS results of product 10A5. A: chromatogram of product 10A5. B: MS of 
peak at with RT = 8.6 min ([M]+ + 32). 
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Figure 4.26 1H-NMR spectrum of product 10A5. 
 
 
Figure 4.27 COSY-NMR spectrum of product 10A5. 
Appendix 
 
 A
p
p
e
n
d
ix
 
227 
 
 
Figure 4.28 HSQC-NMR spectrum of product 10A5. 
 
 
Figure 4.29 NOESY-NMR spectrum of product 10A5. 
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4.5.7 15α-hydroxy-5α-androstan-3-one (11A) 
 
 
 
Figure 4.30 Chemical structure of product 11A 
 
 
 
A 
 
B 
 
Figure 4.31 GC-MS results of product 11A. A: chromatogram of product ….B: MS of peak 
at with RT = 7.52 min ([M]+ + 16). 
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Figure 4.32 1H-NMR spectrum of product 11A. 
 
 
Figure 4.33 13C-NMR spectrum of product 11A. 
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Figure 4.34 COSY-NMR spectrum of product 11A. 
 
 
 
Figure 4.35 HSQC-NMR spectrum of product 11A. 
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Figure 4.36 NOESY-NMR spectrum of product 11A. 
 
 
4.5.8 4-hydroxy-β-ionone (12A) 
 
 
 
 
Figure 4.37 Chemical structure of product 12A. 
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A 
 
B 
 
Figure 4.38 GC-MS results of product 12A. A: chromatogram of product 12A .B: MS of 
peak at with RT = 18.32 min ([M]+ + 16). 
 
 
4.6 Dissociation constant 
 
 
Figure 4.39 Dissociation constant (KD) of CYP154C5_M84A towards the two tested 
steroids. KDs were determined by fitting the data obtained to tight-binding equation. A: 
Androstenedione (4). B: Testosterone (5).  
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Figure 4.40 Dissociation constant (KD) of CYP154C5_F92A towards the four tested 
steroids. KDs were determined by fitting the data obtained to tight-binding equation. A: 
Progesterone (3). B: Dehydroepiandrostetone (2). C: Androstenedione (4). D: Testosterone 
(5).  
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Figure 4.41 Dissociation constant (KD) of CYP154C5_Q239A towards the six tested 
steroids. KDs were determined by fitting the data obtained to Hill equation. “c” represents the 
concentration of the tested substrates: A: Pregnenolone (1). B: Dehydroepiandrostetone (2). 
C: Progesterone (3). D: Androstenedione (4). E: Testosterone (5). F: Nandrolone (6). 
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Figure 4.42 Comparison of KD values of CYP154C5 wild type and CYP154C5-Q239A 
mutant. 
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Figure 4.43 Dissociation constant (KD) of CYP154C5_Q398A towards the five tested 
steroids. KDs were determined by fitting the data obtained to tight-binding equation. A: 
Pregnenolone (1). B: Dehydroepiandrostetone (2). C: Progesterone (3). D: Androstenedione 
(4). E: Testosterone (5). 
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Figure 4.44 Dissociation constant determination of CYP154C5 towards 
ethioallocholane (9). A: CYP154C5´s partial shift from low-spin to high-spin upon addition 
of different concentrations of substrate ethioallocholane (9). B: KD was determined by fitting 
the data obtained to Hill equation.  
 
 
 
Figure 4.45 Dissociation constant (KD) of CYP154C5 towards the two tested steroids. 
KDs were determined by fitting the data obtained to tight-binding equation. A: 3-
deoxydehydroepiandrosterone (10) and B: 5α-androstan-3-one (11).  
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5 Chapter 5 
5.1 Vector maps 
 
 
Figure 5.1 Plasmid map of the expression vector pIT2-mcs containing the gene 
encoding for CYP110D1 from Nostoc sp. 
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Figure 5.2 Plasmid map of the expression vector pIT2-mcs containing the gene 
encoding for CYP106A2 from Bacillus megaterium. 
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5.2   Product elucidation: GC-MS and NMR analysis 
5.2.1 Conversion of dehydroepiandrosterone (2) using CYP106A2 as catalyst 
  
 
Figure 5.3 Chemical structure of product 2B1. 
 
 
A 
 
B 
 
Figure 5.4 GC-MS results of product 2B1. A: chromatogram of product 2B1. B: MS of 
peak at with RT = 10.0 min ([M]+ + 16). 
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Figure 5.5 1H-NMR spectrum of product 2B1. 
 
 
Figure 5.6 13C-NMR spectrum of product 2B1. 
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Figure 5.7 DEPT135-NMR spectrum of product 2B1. 
 
 
 
 
Figure 5.8 HSQC-NMR spectrum of product 2B1. 
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Figure 5.9 HSQC-NMR spectrum of product 2B1. 
 
 
 
 
Figure 5.10 Chemical structure of product 2B2. 
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A 
B  
 
Figure 5.11 NMR results for product 2B2. A: GC-MS analysis of 2B2. B: MS of peak at 
with RT = 9.65 min ([M]+ + 16). 
 
 
Figure 5.12 1H-NMR spectrum of product 2B2. 
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Figure 5.13 COSY-NMR spectrum of product 2B2. 
 
Figure 5.14 HSQC-NMR spectrum of product 2B2. 
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5.2.2 Conversion of androstenedione (4) using CYP106A2 as catalyst  
 
 
Figure 5.15 Chemical structure of products 4B1-1*. 
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B 
 
C 
 
Figure 5.16 NMR results for products 4B1-1*. A: GC-MS analysis of 4B1-1*. B: MS of 
peak with RT = 12.1 min, ([M]++16) (4B1). C: MS of peak with RT = 13.9 min ([M]++16) 
(4B1*). 
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Figure 5.17 1H-NMR spectrum of products 4B1-1*. 
 
5.8.3.2.2  
 
Figure 5.18 13C-NMR spectrum of products 4B1-1*. 
 
Appendix 
 
 A
p
p
e
n
d
ix
 
248 
 
 
Figure 5.19 DEPT135-NMR spectrum of products 4B1-1*. 
 
 
Figure 5.20 COSY-NMR spectrum of products 4B1-1*. 
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Figure 5.21 DEPT45-NMR spectrum of products 4B1-1*. 
 
 
Figure 5.22 HSQC-NMR spectrum of products 4B1-1*. 
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5.2.3 Conversion of androstadienedione (14) using CYP106A2 as catalyst 
 
 
Figure 5.23 Chemical structure of products 14B1-2. 
 
A 
 
 B 
 
C 
 
 
Figure 5.24 NMR results for products 14B1-2. A: GC-MS analysis of products 14B1-2. B: 
MS of peak with RT= 13.1min ([M]++16) (14B1). C: MS of peak with RT= 14.9min ([M]++16) 
(14B1*). 
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Figure 5.25 1H-NMR spectrum of products 14B1-2. 
 
 
Figure 5.26 Zoomed 1H-NMR spectrum of products 14B1-2. 
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Figure 5.27 13C-NMR spectrum of products 14B1-2. 
 
 
Figure 5.28 COSY-NMR spectrum of products 14B1-2. 
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Figure 5.29 HSQC-NMR spectrum of product 14B1-2. 
 
 
 
 
5.2.4 Conversion of androstadienedione (14) using CYP110D1 as catalyst 
 
 
 
Figure 5.30 Chemical structure of product 14C1. 
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A 
 
B 
 
Figure 5.31 NMR results for products 14C1. A: GC-MS analysis of products 14C1. B: MS 
of peak with RT= 12.9 min ([M]++16) (14C1).  
 
 
Figure 5.32 1H-NMR spectrum of product 14C1 (+ tautomer). 
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Figure 5.33 13C-NMR-spectrum of product 14C1 (+ tautomer). 
 
 
Figure 5.34 COSY-NMR spectrum of product 14C1 (+ tautomer). 
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Figure 5.35 DEPT45-NMR spectrum of product 14C1 (+ tautomer). 
 
 
Figure 5.36 HSQC-NMR spectrum of product 14C1 (+ tautomer). 
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Figure 5.37 Chemical structure of products 14C2-2*. 
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C 
 
Figure 5.38 NMR results for products 14C2-2*. A: GC-MS analysis of products 14C2 and 
14C2*. B: MS of peak with RT= 13.2 min ([M]++16) (14C2). C: MS of peak with RT= 14.9 min 
([M]++16) (14C2*). 
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Figure 5.39 1H-NMR spectrum of products 14C2-2*. 
 
 
Figure 5.40 13C-NMR spectrum of products 14C2-2*. 
 
 
Appendix 
 
 A
p
p
e
n
d
ix
 
259 
 
 
Figure 5.41 DEPT45-NMR spectrum of products 14C2-2*. 
 
Figure 5.42 COSY-NMR spectrum of products 14C2-2*. 
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Figure 5.43 Chemical structure of product 14C3. 
 
 
A 
 
B
 
Figure 5.44 NMR results for product 14C3. A: GC-MS analysis of product 14C3. B: MS of 
peak with RT= 14.4 min ([M]++16). 
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Figure 5.45 1H-NMR spectrum of product 14C3. 
 
 
Figure 5.46 13C-NMR spectrum of product 14C3. 
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Figure 5.47 Zoomed 13C-NMR spectrum of product 14C3. 
 
 
Figure 5.48 COSY-NMR spectrum of product 14C3. 
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Figure 5.49 HSQC-NMR spectrum of product 14C3. 
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